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ABSTRACT  
Leprosy is a disease caused by Mycobacterium leprae, an acid-fast bacillus whose 
clinical spectrum correlates with the host immune response. Erythema nodosum leprosum 
(ENL) is an immune-mediated inflammatory complication causing high morbidity in 
affected leprosy patients. A case-control follow-up study was conducted in Ethiopia to test 
the hypothesis that ENL is associated with impaired immune regulation. In 46 patients with 
ENL and 31 lepromatous leprosy (LL) matched controls, the frequency of regulatory T-
cells, memory T-cells and B-cells were analysed by flow cytometry. The in vitro pro-
inflammatory cytokines production by peripheral blood mononuclear cells (PBMCs) to the 
response of M. leprae whole cell sonicate stimulation was determined by Enzyme-linked 
immunosorbent assay.  The gene expression of these cytokines in the blood and skin 
biopsies was determined by quantitative polymerase chain reaction (qPCR) before and after 
treatment. Patients with ENL had lower percentage of CD4+ regulatory T-cells than LL 
controls at recruitment. The percentage of CD3+, CD4+ and CD8+ T-cells expressing 
activated T-cells were significantly higher in the PBMCs of patients with ENL than in LL 
controls before treatment. The in vitro production and gene expression of the cytokines: 
TNF-α, IFN-γ, IL-1β, IL-6, IL-8 and IL-17A were significantly increased in untreated 
patients with ENL. ENL patients had a higher median percentage of tissue-like memory 
(TLM) and activated memory (AM) B-cells than LL controls before treatment while the 
median percentage of total B-cells and resting memory (RM) B-cells  did not significantly 
different in both groups before treatment. The level of anti-PGL-1, LAM and Ag85 
antibodies were not significantly different in patients with ENL before treatment. Patients 
with ENL had significantly lower circulating C1q than LL controls before treatment.  
However, after treatment, the amount of circulating C1q was not significantly different in 
both groups. Our findings suggest that ENL is associated with reduced percentage of 
regulatory T-cells and increased CD4+/CD8+ T-cell ratio and this immune imbalance may 
lead to the initiation of ENL reactions in either permitting productions of antibodies critical 
to an immune-complex formation or as a cell-mediated immune response in patients with 
leprosy. Consequently, this study illuminates the role of T-cell activation in the 
pathogenesis of ENL reaction and challenges the long-standing dogma of immune-
complexes as the sole aetiology of ENL reactions.   
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CHAPTER 1: INTRODUCTION 
1.1. Statement of the problem 
Leprosy is a disease caused by Mycobacterium leprae, an intracellular acid-fast 
bacillus. It mainly infects the skin and peripheral nerves. Leprosy is a spectral 
disease forming a five-point spectrum with the localized tuberculoid leprosy (TT) 
and the generalized lepromatous leprosy (LL) forming the two poles of the 
spectrum. The clinical spectrum of leprosy correlates with the host immune 
response. 
 Leprosy reactions (Reversal reactions and Erythema Nodosum Leprosum) are 
immune-mediated inflammatory complications of the disease which can occur 
before, during or after successful completion of multi-drug treatment.   They are a 
major cause of nerve damage and morbidity in a significant proportion of leprosy 
patients. Erythema Nodosum Leprosum (ENL) is an inflammatory complications 
of leprosy, manifesting as tender erythematous skin lesions and systemic features 
of disease often fever, neuriti s and bone pain.  
Oral prednisolone is the drug of choice for ENL treatment but more than 40% of 
cases do not show clinical improvement.  High recurrent episodes and flare-ups are 
common in these patients. Hence, treatment and management of reactional and post 
reactional episodes of ENL often pose a therapeutic challenge to leprologists. 
The underlying immunologic mechanisms for ENL remain unclear with several 
different hypotheses. The hypothesis of ENL as an immune-complex mediated 
disease proposed in the 1960s has yet to be convincingly demonstrated. The 
involvement of cell mediated immunity in the pathogenesis of ENL has since been 
postulated. The phenotypic and functional roles of these cell-mediated immunity 
(T-cells) are not yet adequately investigated in leprosy reactions particularly in 
patients with ENL reactions. There are conflicting reports from various studies of 
ENL reactions regarding T-cell subpopulations and immune-complex deposition in 
the lesions. However, although these studies draw our attention to the importance 
of T-cells and immune-complexes in the evolution and subsequent course of ENL 
reactions, specific conclusion is not derived as yet. Most information on ENL 
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reactions are derived from routine clinical treatment of the disease and 
comprehensive well-designed studies with large sample size are lacking.  
The difficulties in treating ENL reactions illustrate the importance of understanding 
the mechanisms of the disease. Since the cause(s) and mechanisms of reactions are 
poorly understood, treatment is often suboptimal. Therefore, understanding the 
immunopathogenesis of ENL reaction is important to improve diagnosis and 
treatment. 
1.2. Research hypothesis  
Erythema nodosum leprosum reaction is associated with increased percentage of 
activated T-cells due to decreased frequency of regulatory T-cells.  
1.3. Aims of the study 
The aims of the study were: 
To describe the relative percentages and phenotypes of T-cells in patients with ENL 
before and after treatment compared to lepromatous leprosy patient controls. 
1.4. Specific objectives  
The specific objectives of the study were:  
1. To investigate T- cell phenotypes (regulatory and memory T-cells)  in patients 
with ENL compared to lepromatous leprosy patient controls  
2. To define B- cell phenotypes  in patients with ENL compared to lepromatous 
leprosy patient controls  
3. To describe the kinetics of pro-inflammatory and regulatory cytokines 
production (IL-1β, TNF-α,TGF-β, IFN-γ, IL-6, IL-8  and IL-17) in  patients 
with ENL and LL controls before and after treatment  
4. To determine the level of gene expressions of pro-inflammatory cytokines 
/chemokines  (IL-1β, TNF-α,.TGF-β, IFN-γ, IL-6, IL-8 and IL-17)  in the 
blood and skin lesions of  patients with ENL and LL controls before and after 
treatment  
5. To determine the level of circulating C1q in the plasma of  patients with ENL 
and  LL controls before and after treatment  
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6. To determine the level of C1q gene expression in the blood and skin lesions of 
patients ENL and LL controls before and after treatment.  
7. To determine the levels of anti ND-O-BSA (PGL-1), Ag85 protein and LAM 
antibodies in the plasma samples of patients with ENL and LL controls before 
and after treatment. 
8. To describe the histological characteristics of ENL and LL lesions before and 
after treatment. 
9. To describe the correlation between clinical and immunological profiles of ENL 
reactions.   
1.5. Outline of the thesis  
This thesis addresses the immunopathology of ENL. A case- control follow-up 
study was set-up to investigate the immune profiles of patients with ENL before 
and after treatment. Several immunological factors were investigated in the blood 
as well as in the skin lesions of patients with ENL reactions (cases) and patients 
with non-reactional LL (controls). 
Chapter 1 outlines the rationale for carrying out this research. Chapter 2, presents 
the literature review of leprosy. This chapter gives the general introduction on 
leprosy, global and regional prevalence of the disease, diagnosis, treatment, 
management of leprosy complications and immunological profiles of each clinical 
type in the leprosy spectrum. The role of innate and adaptive immunity in each 
clinical forms of the spectrum has been reviewed and presented in this chapter.  
Chapter 3 covers with the leprosy reactions. Types of leprosy reactions, the 
occurrence of leprosy reactions in leprosy spectrum, epidemiology of leprosy 
reactions (incidence and prevalence), risk factors, pathology, clinical pictures, 
diagnosis and treatment of leprosy reactions are described in this chapter. The 
challenges of diagnosis, treatment and management of leprosy reactions are also 
highlighted in the chapter. Chapter 4 describes gaps of the immunology of leprosy 
reactions. Current information on the role of innate immunity (complements, 
cytokines and neutrophils), adaptive immunity such as effector and memory T cells, 
regulatory T- cells and memory B-cells in the immunopathogenesis of ENL 
reactions are extensively reviewed in this chapter.  Our current knowledge of the 
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underlying causes of leprosy reactions particularly ENL reactions is also reviewed 
and presented in this chapter.  
Chapter 5 describes the materials and methods used in this study. It describes the 
study area, study design, case definitions and strategies used for patient recruitment 
and follow-up. Procedures and processes for the ethical clearance, consenting and 
compensating patients for their lost time are explained. Standard operating 
procedures for sample collection and subsequent processing are described. Detailed 
procedures for the assessment of various pro-inflammatory cytokines, T-cells, B-
cells and complement C1-q in the blood as well as in the skin lesions are described. 
The outcome and explanatory variables of the study are defined. The data analysis 
approach and statistical parameters used in each sub-group analysis is justified. 
Finally, data interpretation and presentation methods are highlighted in this chapter. 
Chapter 6 comprises the findings of the study. It has 9 sections and the contents of 
each section is summarized as follow as:   
Section-1:   In this section the sociodemographic and clinical characteristics of 
study subjects are described.  Study participants age profile, sex proportion, the 
MDT status of each patients at recruitment, HIV screening, bacillary index at 
leprosy diagnosis, the morphology of skin lesions in ENL, anatomical location of 
pain in ENL,  histopathological features of ENL and LL skin lesions  and the lipid 
profiles of cases and controls at enrolment are described in this section.  
Section-2:  This section presents the frequency of regulatory T- cells in the PBMCs 
of patients with ENL and LL controls before, during and after treatment. The 
relative frequency of CD4+ and CD8+ T-cells in the two groups are presented. The 
kinetics of regulatory T-cells before and after prednisolone treatment of patients 
with ENL is covered in this section. 
Section-3:   Section-3 accounts memory and T-cell activation in patients with ENL 
and LL controls before, during and after treatment. The relative frequency of naïve 
T- cells, effector T-cells, central and activated memory T-cells in the PBMCs of 
patients with ENL and LL controls are presented in this section.  Changes in the 
frequency of activated and memory T-cells before and after prednisolone treatment 
of patients with ENL are summarized in this section.  
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Section-4:  In this section the percentages of regulatory and memory T-cells in acute 
and chronic ENL are presented.   
 Section-5:  This section presents the frequency of the sub-population of B-cells 
(resting memory B-cells, activated memory B-cells, tissue like memory B-cells and 
naive B-cells) in patients with ENL and LL controls before and after treatment. 
 Section-6:  In this section, the in vitro production of pro-inflammatory cytokines 
such as IL-1β, IL-6, IL-8, IL-17, IFN-γ and TNF-α and regulatory cytokine (IL-10) 
in PBMCs in response to the stimulation with M.leprae whole cell sonicate in the 
patients with ENL and LL controls before and after treatment are presented.  
Section-7: The gene expression level of the above cytokines in the blood as well as 
in the skin biopsies of ENL and LL is described in section-7. 
 Section-8: Gives preliminary data on the circulating C1q and their genes 
expression level in blood and skin biopsies of patients with ENL and LL controls 
before and after treatment.  
Section 9: This section presents the levels of anti ND-O-BSA (PGL-1), Ag85 
protein and LAM antibodies in the plasma samples of patients with ENL and LL 
controls before and after treatment. 
In chapter-7 the main findings of the study are discussed. Chapter-8 presents 
conclusions, recommendations and future directions for the study of ENL. Finally, 
my roles in this thesis include: writing the grant for the project under the guidance 
of my supervisor, developing laboratory standard operating procedures, obtaining 
ethical clearance, identifying consumable laboratory reagents and antibodies, 
processing procurements of laboratory consumables, obtaining permits and support 
letters from different institutions for shipping the reagents to  Ethiopia, designing 
framework for study subjects recruitment and follow-up, documentation of clinical 
data; laboratory assays (PBMCs isolation, freezing, storage and thawing; RNA 
extraction; ELISA; flow cytometry and qPCR); data entry, analysis and 
interpretation and write-up of the thesis,  controlling financial expenditures at the 
study site (payments for biopsy nurses, runner, compensation for study subjects) 
and others.   
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 CHAPTER 2: LITERATURE REVIEW OF LEPROSY  
2.1. Literature search strategy and search criteria 
To review the Immunopathology of Erythema Nodosum Leprosum (ENL), 
literature published up to May 2016 was searched. The literature review of ENL 
and leprosy was performed using keywords or phrases “Leprosy”, “Hansen’s 
disease”, “lepr”, “leprosy reactions”, “type 1 reaction”, “reversal reaction”,” Type 
II reaction”, “Erythema nodosum leprosum”,”ENL”, “Lepromatous leprosy, ”LL” 
,”Leprosy spectrum” , “MDT”, ”prednisolone”, ”leprosy immunology”, 
”immunopathology”, ”immune-complex”, ” regulatory T cells” ”B cells”, 
“Memory T cells”, “Memory B cells”, “cytokines”, “leprosy treatment”, 
“Mycobacterium leprae”  “M. leprae”. The search was limited to articles published 
in English. Search engines and bibliographic data-base were the main research 
resources used for this thesis.  PubMed and Cochrane were used to obtain   articles 
with wide coverage of health topics and clinical trials related to leprosy 
respectively. Medline was used to obtain subject guided articles in the area of 
medical and biomedical sciences. EMBASE were used to pick recent articles, 
conference papers, and articles which included drugs and pharmacy topics.   World 
Health Organization (WHO) documents on leprosy were checked on the WHO 
websites. Additional references from professional associations, conferences and 
google internet search were also included. ETHOS database was used to search PhD 
doctoral theses available in UK. LSHTM and UCL libraries were also checked for 
relevant information.  Among the 3,789 articles identified for the immunology of 
leprosy, 477 of them were considered for the current review (Table 2.1).  
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Table 2.1.  Summary of the number of articles retrieved on leprosy research from 
database search (1920- 2016).  
Category   No of publications   
All leprosy research articles since 1920 27,162 
Leprosy immunology 8,789 
Leprosy  reactions  4,912 
Immunology of leprosy reactions  2,462 
Erythema Nodosum Leprosum (ENL) 1,986 
Immunology of ENL 890 
All leprosy related studies in Africa  2,168 
All leprosy related studies in Ethiopia  281 
 
2.2. Historical aspects of leprosy  
2.2.1. Global aspect  
Leprosy is generally considered as one of the oldest diseases known to man. 
Understanding the origins of leprosy is important both epidemiologically and 
historically to describe the human interactions as well as the biological and social 
reaction to the disease. However, the origin of leprosy is not precisely known.  It 
has been found that around 600BC an Indian writings describe a disease that 
resembles leprosy as reviewed by Pankhurst (1984). The most ancient evidence of 
leprosy comes from a 4,000-year-old human skeleton uncovered in India in 2009 
which proved that leprosy existed in India before 2000BC (Robbins et al., 2009). 
Symptoms that are used today to describe leprosy were documented in Chinese 
books in 400 BC (Pankhurst, 1984). Greek writers described a disease that may 
have been leprosy in the 2nd century BC(Susannah, 2015) .  
According to the historians, in Europe leprosy first appeared in the records of 
ancient Greece after the army of Alexander the Great came back from India in 4th 
century BC (Browne, 1975) and carried it into the Middle East and then throughout 
the eastern Mediterranean upon their return home from Egypt (Lechat, 1999). It is 
also traditionally believed that Roman soldiers in the  army of Pompey took the 
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disease from Egypt to Italy in 62 BC and that Roman armies  later took the disease 
as far as the British Isles in 60 BC (Browne, 1975, Susannah, 2015).  
Archaeological studies of Egyptian skeleton have shown that leprosy was prevalent 
in Egypt during the 2nd century BC and claimed that leprosy conceivably originated 
in Egypt. Other scholars, suggested that the disease probably originated in India and 
spread to Europe after the 4th century B.C. (Lechat, 1999). Genetic analysis of the 
leprosy bacillus has shown that M. leprae very likely evolved some 100,000 years 
ago in eastern Africa or South-western Asia and then would have speared to other 
areas through human migration and colonization to Europe and North Africa. The 
introduction of leprosy to America is assumed to be the result of colonization by 
Europe or by the slave trade from West Africa in the 18th century (Monot et al., 
2005b). 
2.2.2. Leprosy in Ethiopia  
Historically the existence of leprosy in Ethiopia had been documented by traveller 
literature after the medieval period. It is not known when and where the disease was 
first diagnosed in the country. Pankhurst has mentioned that Ethiopians has suffered 
since time of immemorial from a high burden of leprosy in his article “the history 
of leprosy in Ethiopia to 1935” (Pankhurst, 1984). However, the author did not 
mention the time and the magnitude of the disease.  
In the 16th century, a Portuguese priest, Fransisco Alvares was the first person to 
document the high incidence of ‘lepers’ in Ethiopia.  A British traveller, Nathaniel 
Pearce, had reported in 1831 that leprosy was common in the northern country 
among lower class and thousands of them had lost their fingers and toes. Many 
travellers from France, Germany and Italy had also reported a high prevalence of 
leprosy in north, south and central Ethiopia in the 1840s (Pankhurst, 1984). 
In the past, it was believed that leprosy was hereditary disease or an act of God 
among Christians in Ethiopia.  It was also commonly believed that leprosy was 
caused by the devil, through adultery and or by being possessed by spirits. Affected 
persons would pray at churches to be cured of this disease, wear amulets around 
their necks, take medicated herbal baths and immerse themselves in thermal pools. 
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They also tried using herbal medicines, both internally and externally (Pankhurst, 
1984).  
Leprosy had been known in Ethiopia, since early times, as lamts. Lamts is a word 
found in the Old Testament of the bible which was translated into Ge’ez, one of the 
Semitic languages in Ethiopia. However, leprosy is also often designated by general 
terms which are also applicable to elephantiasis or other serious skin diseases 
(Pankhurst, 1984).  Leprosy is formally known as Sega Dawe in Amharic which 
means ulcerated or diseased sega (body). Frequently leprosy is referred to more 
explicitly as Qumtena, an Amharic word derived from the verb, to amputate. A 
similar concept is used among the Oromos, the most populous ethnic group in 
Ethiopia.   The Oromo people refer leprosy as Kurchi, a word whose origin in the 
verb, to cut or break (Pankhurst, 1984). 
It has been assumed that the legends and beliefs (Christianity) formed the attitude 
of the Ethiopian society towards leprosy. They are considerably more tolerant and 
compassionate towards people affected by leprosy than that of the West, where 
"total exclusion" of people affected by leprosy in the early medieval period had 
been followed by their rigid detention in "houses of Lazarus" as reviewed by 
Pankhurst (1984).  
The Ethiopians attitude toward leprosy has been probably shaped by the country’s 
traditional code, the Fetha Nagast (Law of the Kings) which took a fundamentally 
empirical and humanitarian view of this disabling disease. However, it was declared 
that a person affected by leprosy could not serve as a Priest or Patriarch not because 
of uncleanness but cause priest to be unloved. Similarly, it was declared that a judge 
had to be free of leprosy only because the infection keeps people away who may 
want to see the judge (Pankhurst, 1984). 
 Nevertheless, leprosy patients faced stigma which resulted in physical isolation and 
discrimination in some areas even recently (Tekle-Haimanot et al., 1992).  In some 
places they are forbidden to beg during the day and are forced to move at night from 
house- to- house to request for alms.  They move in group to protect themselves 
from wild animals and dogs. The group is called Hamina and the Hamina group 
practice the Hamina song-mendicant believing that it will ward off from debilitating 
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by the disease and to get relieve from the symptoms of the disease (Kebede, 2010). 
To date the   Hamina descendants firmly believe that they own an inherited right of 
song-mendicancy which they think as their social and traditional duty. They believe 
that they will be stricken with leprosy if they did not sing.  Moving from house- to- 
house and from door-to-door singing the Hamina song, suffering from the chilly 
nights and being attacked by barking dogs is a mandatory ritual ceremony for them 
at least once a year (Kebede, 2010).  
At the beginning of 20th century, information that leprosy was a contagious disease 
arriving in Ethiopia through missionaries and thus, the idea of isolating leprosy 
patients from the community started to be introduced to some extent as a means of 
encumbering the spread of the disease. With this idea the first Ethiopian 
leprosarium was established at Harar named, Ras Makonnen’s Leprosarium, in 
1901. The establishment of Ras Makonnen’s Leprosarium was funded by French 
catholic missionaries and at the beginning it was run entirely by French 
missionaries giving full service for 25 leprosy families. Ras Makonnen’s 
Leprosarium is now called Bisidimo leprosarium. The second was opened in 1934 
at Akaki, just outside Addis Ababa.  In the 1940s and 1950s, a total of 11 leprosaria 
were opened within a few years: Yesilase leprosurium was opened in Borumeda of 
Wollo province, Tibela in Arusi, Kuyera and Gambo in Shashemene, Finoteselam 
in Gojam province, Gindeberet in Shewa province, Hosaina in Shewa province, 
Akaki and Zenabewark in Addis Ababa.  In the 1950s leprosy was identified as a 
major public health problem in Ethiopia. Leprosy control program was started in 
limited areas of Ethiopia in 1956 (Berhe et al., 1990).  
A leprosy community grew around Zenebawark (ALERT) Hospital made 
up of people who had come from all regions of Ethiopia. Many patients stayed 
around ALERT Hospital after they finished their leprosy treatment because they 
felt unable to return home fearing the stigma and social exclusion. This community 
quickly grew with new arrivals and new generations born it to the area and the 
village has got its name Kore. In an attempt to limit the size of the Kore community, 
the government forcibly moved many people with leprosy to remote, isolated areas 
(Addis Hiwot and Tesfa Hiwot)   and to Kuyara in 1954  (Mesele Terecha, 2005). 
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 The people remaining in the Zenebawark area relied heavily on ALERT and 
the facilities it provided, which contributed to the dependency attitude formed with 
local leprosy affected people enjoying access to free, on demand healthcare. 
However, ALERT began change its method of operation advised by the donors to 
restructure its funding arrangements   because the system  in which it was  operating 
was costly and unsustainable but the Kore community did not understand the 
situation. This situation accounted for the establishment of Addis Ababa 
Association of Ex-Leprosy patients now named Ethiopian National Ex-leprosy 
Association (ENAELP) in 1992 (Isabelle, 2005).   
Currently, leprosy treatment is integrated to the general health system in the 
country. Suspected patients are seen at health posts and then referred to the health 
centres. Most clinically confirmed patients with leprosy are treated with MDT at 
health centres or referred to district and zonal hospital for further diagnosis. The 
leprosy referral systems in Ethiopia will be explained in section 2.4.   
2.3. Epidemiology of Leprosy  
2.3.1. Definitions   
Leprosy is a chronic granulomatous infectious disease mainly affecting the skin and 
peripheral nerves. The etiologic agent of leprosy is Mycobacterium leprae, an 
obligate intracellular bacterium  as reviewed by  Lockwood (2004). A case of 
leprosy is defined as a person with one or more of the following features, and who 
has yet to complete a full course of treatment: i). hypopigmented or reddish skin 
lesion(s) with definite loss of sensation ii) damage to the peripheral nerves, as 
demonstrated by loss of sensation and mobility to hand, feet or face iii) positive slit-
skin smears for acid fast bacilli (World Health organization, 1998). This case 
definition does not include cured persons with late leprosy reactions or with residual 
disabilities. 
2.3.2. Global Prevalence of leprosy   
The global prevalence of leprosy has decreased from more than 5 million cases in 
the mid-1980s to less than 200,000 cases in 2015. A total of 175,554 registered 
prevalence of leprosy cases were reported to WHO in the beginning of 2015 with 
213,899 new case detections from 121 countries (WHO, 2015). According to the 
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WHO report, the introduction of multi-drug therapy (MDT) for the treatment of 
leprosy, improved early diagnoses and complete treatment with MDT are among 
the key factors which contributed to the reduction of disease burden.  
The registered prevalence rate in the beginning of 2015 was 0.31 per 10,000 
populations which is less than that of 2014 (0.32 per 10,000 populations). However, 
the number of new cases reported at the end of 2014 (3.78 per 100,000 populations) 
was almost at the same level as in the previous year (3.81 per 100,000 populations). 
Furthermore, a new case detection prediction model by Smith et al. (2015) has 
reported  that over 2.6 million cases are missed during 2000 and 2012 which implies 
that there may be a large accumulation of people with leprosy in the community 
who remain undiagnosed. At the end of 2014, thirteen countries: India, Brazil, 
Indonesia, Ethiopia, Bangladesh, Democratic Republic Congo, Nepal, Myanmar, 
Nigeria, Sir Lanka, Tanzania, Madagascar and the Philippines reported more than 
1,000 new cases  in 2014. These 13 countries together contributed 94% of all new 
leprosy cases worldwide (WHO, 2015).  
From the total new leprosy cases reported, 72% were from South-east Asia, 16% 
from South America and 9% were from Africa. The highest new leprosy cases 
detection was reported from 8 countries. These are: India (125,785 new cases), 
Brazil (31,064), Indonesia (17,025), Ethiopia (3,758), Bangladesh (3,622), 
Democratic Republic Congo (3,272), Nepal (3,046) and Nigeria (2,983). India, 
Brazil and Indonesia reported greater than 10,000 new cases in 2014 and they 
accounted for 81% of new leprosy cases globally.  Ethiopia, Democratic Republic 
of Congo, Madagascar, Nigeria, Tanzania, Bangladesh, Myanmar, Nepal, Sir Lanka 
and Philippines reported between 1000 and 10,000 new cases in 2014 and they 
accounted for 13% of new leprosy cases in the reported year.  The remaining 108 
countries all together contributed only 6% of all new leprosy cases (WHO, 2015).    
It is very difficult to estimate the actual prevalence of leprosy due to the long 
incubation period of M. leprae, delays in diagnosis after onset of the disease, and 
the lack of laboratory tools to detect leprosy in its very early stages (WHO, 1985).  
Instead, the registered prevalence is used. Registered prevalence in leprosy is 
defined as the number of patients registered for MDT treatment during the reported 
year per 10,000 populations. Incidence rate or new case detection rate in leprosy is 
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defined as the number of newly diagnosed leprosy cases per 100,000 populations 
per year. Incidence is the most useful transmission index to monitor the success of 
leprosy control program since it reflects the current risk of developing leprosy 
within a specified population.  New leprosy case detection among children provides 
better information that there is an early and continued transmission of infection in 
the community. The proportion of children under 15 years  among newly diagnosed  
leprosy cases globally in 2014 was 8.8% with a range of 34.5 % in Comoros to 
1.4% in Niger (WHO, 2015).  
According to the WHO report, although the prevalence of leprosy has been 
declining (Figure 2.1) due to the introduction of MDT and reducing the treatment 
time, new cases continue to occur in almost all endemic countries. The “enhanced 
global strategy for further reducing the disease burden due to leprosy from 2011 to 
2015” is being implemented by national programmes in endemic countries. One of 
the aims of the strategy is to reduce the global rate of new cases with grade-2 
disabilities (i.e. visible deformity and damage) per 100,000 population by at least 
35% by the end of 2015, compared with the baseline at the end of 2010. However, 
the trend of new cases with grade-2 disabilities (G2D) and rates per 100,000 
populations did not change significantly from 2005 to 2014 (Figure 2.2). In 2005 
the grade-2 disabilities among the new cases was 0.25 per 100,000 population and 
it was the same in 2014 (0.25). The proportion of new G2D ranges from 28.0% in 
Uganda to 0.0% in Kenya with global average of 6.6% in 2014 (WHO, 2015). 
The level of new G2D cases is the indicator of delayed diagnosis and treatment of 
leprosy. The rate of new cases detected with grade-2 disabilities per 100,000 
population is proposed as the indicator for a global target by WHO since it  is less 
influenced by operational factors; focuses attention on impairments which are 
critical to persons affected by leprosy, and stimulates improvements in case 
detection.  Delayed diagnosis and treatment of leprosy could be happened either 
due to lack of awareness about the early signs of leprosy and the health seeking 
response in the society or lack of the capacity in the health system to diagnose and 
treat leprosy in time before the development of disabilities. 
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Figure 2. 1. Global Registered prevalence and new cases detection rates of leprosy 
per 100,000 population from 1985 to the beginning of 2014. Figures generated 
from WHO data series  
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                                                                                                   Year of diagnosis  
Figure 2.2 Number of new grade-2 disabilities among newly detected leprosy 
cases reported to WHO from 2005-2014.                              
Figures generated from WHO) data series:  http://www.who.int/gho/database/en/ 
2.3.3. Epidemiology of leprosy in Ethiopia 
Registered prevalence of leprosy cases in Ethiopia: The prevalence and the 
incidence of leprosy in Ethiopia are not precisely known because not all regions 
report registered cases to Ministry of Health regularly. According to the reports of 
the Ministry of Health, leprosy notification rate in Ethiopia remained stable over 
the last five years at between 4000 and 5,000 new leprosy cases recorded per year 
(Figure 2.3). 
In 1982, before the introduction of MDT to Ethiopia, 80,927 registered leprosy 
cases were reported to WHO. Following the introduction of MDT in 1983, the 
registered prevalence dropped to 59,822 cases in 1984. The registered prevalence 
declined rapidly and reached 12,041 cases at the end of 1990 and increased to 
16,670 cases in 1991. In 1992 the registered prevalence slightly dropped to 15,673 
cases and reached 12,698 in 1993. However, after 1994 the registered prevalence 
had decreased slightly and dropped to 3,758 registered cases after 2 decades in 
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2014. This means since 1994, the registered prevalence on average had declined by 
293 cases every year (Figure 2.3)   
New case detection of leprosy in Ethiopia: unlike the registered prevalence, figure 
2.3 shows a slow decline in new cases detection rate since 1982.  In 1982, 6,243 
new leprosy cases were diagnosed. This number dropped to 3,758 cases after 3 
decades (Figure 2.3). On average 4,018 new leprosy cases (0.04/100,000 
population) were detected for the last 33 years.  However, it should be noticed that 
there could be more new leprosy cases in Ethiopia than annually reported according 
to “The Missing Millions” predication model of Smith et al (2015).   
                         
                                                                                           Year of registration   
Figure 2.3. Registered prevalence and new cases detection rates of leprosy per 
100,000 population in Ethiopia from 1982-2014.  Figures generated from WHO and 
Ethiopian Federal Ministry of Health (EFMOH) data series   
Multibacillary (MB) and Paucibacillary (PB) cases:  Most leprosy cases reported 
in Ethiopia are MB cases. For the past 15 years (2000-2014), on average 4,410 
(89.5%) registered MB cases has been reported. The overall ratio of registered MB 
to PB cases indicated that MB cases were nearly nine-folds of PB cases during these 
periods. The proportion of MB cases increased from 2000 (82.1%) to 2014 (91.8%) 
among registered cases (EFMOH, 2015).  
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On average 4,308 new leprosy cases were diagnosed per year from 2000-2014 of 
which MB cases accounted for 86%. Similar to the registered leprosy cases, the 
proportion of MB cases in newly diagnosed leprosy cases showed an increasing 
trend over these periods except in 2014.  In 2014 the proportion of MB cases 
strangely dropped to 73.7% among newly diagnosed leprosy cases in the year 
(EFMOH, 2015).  
2.3.4. Treatment outcome, defaulter rate and relapse cases in Ethiopia  
On average 4,815 leprosy patients annually had been treated with MDT from 2000-
2014 (EFMOH, 2015) and the MDT completion rate over these years was 84.4% 
The treatment completion rate increased from 78% in 2000 to 89% in 2014. The 
average annual defaulter rate from 2000-2011 was 3.7%.  Data was not available 
for the years 2012-2014. The defaulter rate had significantly dropped from 4% in 
2000 to 1.5% in 2011. However, the reduction did not occur in a steady state rather 
in two stages (decreasing and increasing trend) over these periods. The increasing 
and then decreasing trends of defaulter rate could be due to several factors.  It could 
be due to underreporting, shortage of MDT during that particular year or some 
districts might not reported at all to the regional health bureau.  On average, 212 
relapse cases per year with an overall rate of 3.8% were reported. Relapse, in MB 
leprosy, is defined as the multiplication of M. leprae, suspected by the marked 
increase (at least 2+ over the previous value) in the BI at any single site, usually 
with evidence of clinical deterioration (new skin patches or nodules and/or new 
nerve damage). The relapse rate had increased from 2.4% in 2000 to 7.4% in 2010 
(EFMOH, 2015) which raises questions about the future effectiveness of MDT. 
However, relapse case is difficult to determine because it should relate to the year 
when MDT was given.  
2.3.5 Childhood leprosy and grade-2 disability in Ethiopia  
Childhood leprosy: The average proportion of childhood leprosy (0-14 years) in 
Ethiopia is 6.3% for the registered leprosy cases and 7.1% for the newly detected 
cases (Baye, 2015). The rate of childhood leprosy among newly diagnosed leprosy 
cases had increased from 8% in 2006 to 12.8% in 2014 (Baye, 2015). The increasing 
rate of childhood leprosy indicates high level of transmission in Ethiopia. Lack of 
technical means of interruption transmission may further intensify the possibility of 
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leprosy transmission in the country. However, the increasing rate of childhood 
leprosy in the country could be also due to the higher coverage of health service 
after the integration of leprosy to the general health service program.  
Total grade- 2 disability rates: In Ethiopia leprosy patients present with either 
grade-1 or grade-2 disabilities at the diagnosis of leprosy (Baye, 2015).  On average 
about 9.8% of leprosy cases had grade-2 disability (G2D) at the time of diagnosis 
of leprosy from 2005 to 2014 (Figure 2.4).  In 2005 about 15% of leprosy cases 
were diagnosed with G2D which declined to about 10% in 2014.  The fall in G2D 
rate, however, seemed to have occurred gradually in different stages; a slight fall in 
the beginning followed by sharp rise in middle and a relatively gradual rise in the 
end (Figure 2.4) which signals the need for improving early case detection system 
in the country.    
         
 
Figure 2.4. Trends of grade-2 disability (G2D) among newly diagnosed leprosy 
cases in Ethiopia from 2006 - 2014.   Data compiled from EFMOH (2015) 
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2.4. The Ethiopian Health system 
Ethiopia has an estimated population of 84.32 million with median age of 18.6 years 
and life expectancy of 64 years (CSE and ICF, 2012). Ethiopia has a federal system 
where power is decentralized to nine regional states and the city administration 
councils of two cities.  The administration hierarchy in each regional states follows 
the regional levels, zonal and woreda (district) and finally the Kebels.  Kebele is 
the smallest administrative level.   
The health system in Ethiopia is a three-tier health system with special attention to 
the health extension program which runs under the primary health care delivery 
(Figure 2.5). The health extension program serves as the primary vehicle for 
implementation of community-centred essential health care packages and as an 
effective referral system from the grass-roots level to broaden access to care at 
secondary and tertiary levels. The first level is the district health system consisting 
of one primary hospital, 5 health centres and 25 health posts. The second level is 
the general hospital serving for one million people and the third level is a special 
led hospital giving service for 5 million people.  Ethiopia has 149 hospitals, 2,953 
Health centres and about 16,000 health posts  (EFMOH et al., 2015). 
 
Figure 2.5. Ethiopian three-tier health system.   Data source: EFMOH (2015).  
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2.4.1. Leprosy treatment situation in Ethiopian health system  
In Ethiopia health care system, leprosy was treated vertically by leprosy specialized 
personnel until the control program was fully integrated into the general health 
services by the end of 2001.  The need for integration was to ensure that patients 
are diagnosed at an early stage and complete the multidrug treatment (MDT) before 
disability ensues. This means that leprosy prevention and control activities became 
the responsibility of the general health service. However, this integration meant that 
patients are seen by general health workers during outpatient visits rather than by 
leprosy specialized personnel in leprosy dedicated clinics. Hence, the diagnosis of 
leprosy might be delayed because of poor recognition of early signs or lack of a 
high index of suspicion (Abeje et al., 2016). In reality, the health staff training on 
leprosy is inadequate and can be easily outstripped by the high prevalence of TB 
and HIV in the country because more attention is given to these diseases.    
 From health posts leprosy suspects are referred to health centres.  Health centres 
diagnose and treat leprosy patients and are the main health facility for initiating 
MDT and follow-up. They are also supposed to treat and manage reactions and refer 
severe reactions and complications to hospitals. In fact, steroids for treatment of 
reactions are only available at hospitals. Leprosy referral hospitals provide referral 
services for diagnosis and treatment and provide in-patient services. These leprosy 
referral hospitals are quite few and deal only with complicated cases such as leprosy 
reactions. Drugs are supplied quarterly to health facilities based on the previous 
quarter registered number of patients. Regular assessment is done at the Woreda, 
zonal, regional and national levels where epidemiological and operational 
indicators for monitoring of the leprosy are calculated and compiled. Quarterly 
reports are completed according to the Ethiopian fiscal year. Tuberculosis (TB), 
Leprosy and TB/HIV collaborative activities eventually integrated into the Health 
Management Information System. 
2.4.2. Leprosy treatment and management at ALERT Centre   
ALERT is a medical facility located in Addis Ababa.  ALERT was originally the 
All Africa Leprosy Rehabilitation and Training Centre (hence the acronym), but the 
official name is now expanded to include tuberculosis: All Africa Leprosy and, 
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Tuberculosis Rehabilitation and Training Centre. It is the main leprosy specialized 
hospital in Ethiopia. The activities of the hospital included diagnosis, treatment and 
rehabilitation of leprosy patients, provides training programs for leprosy personnel 
from around the world, and leprosy control (administration of the Ethiopian 
Ministry of Health’s regional leprosy control program). ALERT is the continuation 
and expansion of the leprosy hospital originally built by Dr Thomas Lambie in 
1922, which was later named the Princess ZenebeWork Hospital, the second 
daughter of Emperor Haile Selassie of Ethiopia. 
 The Armauer Hansen Research Institute (AHRI) is a biomedical research institute 
which was established by the Swedish and Norwegian Save the Children 
organisations in collaboration with the University of Bergen, with the principal 
objective of pursuing basic research in leprosy. AHRI is located in the same 
compound with ALERT. While AHRI was engaged in leprosy research, the ALERT 
hospital was fully involved in leprosy treatment and management until the portfolio 
of the two institutions expanded to include other infectious diseases.  Both ALERT 
and AHRI are managed by the Ethiopian Federal Ministry of Health.     
Leprosy patients are seen at ALERT hospital at Red Medical Clinic. The clinic is 
staffed with a few dermatologists and nurses.  
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Figure 2.6. Pictures of ALERT and AHRI.   (A) ALERT in 1960s, (B) Present 
picture of ALERT, (C)   AHRI, (D) A nurse taking history from leprosy patient at 
Red Medical Clinic (RMC).  For the patient picture, a consent has been obtained  
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2.5. Transmission  
Anthroponotic Transmission: Transmission of leprosy from an infected person to 
a healthy person is the most accepted mode of transmission by scientists.  Untreated 
multibacillary cases, especially lepromatous patients are the most important source 
of infection compared to the other types in the spectrum. This is because 
lepromatous patients harbour significantly higher numbers of bacilli. Various 
investigators have also reported that household contacts are at a greater risk of 
developing leprosy compared to the general population.   
In Northern Malawi, 80,000 initially leprosy free individuals in leprosy endemic 
area were followed for 10 years and 331 of them developed leprosy (Fine et al., 
1997). In this study, it was found that the risk of household contacts of MB patients 
was eight-fold and that of PB patients two-fold compared with individuals not 
living with leprosy indexes. The risk was greatest for those household contacts 
living together than visiting household contacts of MB patients. Such association 
was not found in PB patients suggesting that PB cases may not be the source of 
infection, but rather an indication that households have had contacts with a source 
of infection (Fine et al., 1997). 
In a retrospective study conducted in Indonesia, the relative risk of household and 
neighbourhood contacts was found to be 8 and 4 times, respectively, compared to 
households that had had no such contact with leprosy patients (van Beers et al., 
1999). Similarly, the relative risk of leprosy among household contacts was found 
to be 8 times more than the general population (Vijayakumaran et al., 1998).  Close 
household contacts such as parents, siblings and children have a higher risk of 
contracting leprosy than other type of household contacts (Vijayakumaran et al., 
1998, Deps et al., 2008  ).  A study conducted in the Philippines which included 
2,087 household contacts and 4,750 community contacts, the relative risk of 
household contacts was 26 times that of the community contacts (Cunanan et al., 
1998 ).   
Although the portal of entry and mode of spread of M. leprae in human leprosy is 
not scientifically proven, the nose is considered to be the main portal of exit and 
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entry of M. leprae and hence suggesting an aerosol route of transmission through 
droplet infection. An assessment of the presence of M. leprae on the nasal mucosa 
in general population in leprosy endemic area was conducted in India. They found 
that among 400 healthy inhabitants, about 31% of them showed PCR positivity for 
M .leprae DNA highlighting the aerosol route of transmission of leprosy through 
droplet infection (Lavania et al., 2013). Another larger study which included 444 
leprosy patients and 1,352 healthy household contacts in Brazil, has reported that 
the nasal swab of 4.7% household contacts were positive for M. leprae DNA 
(Araujo et al., 2012). An experimental infection of mice has shown that among the 
30 mice exposed to M. leprae aerosols 33% of then had countable numbers of acid-
fast bacilli (greater than 2 x104 with the characteristics of M. leprae in one or more 
homogenates prepared from ears, foot pads, nose or lungs (Rees and McDougall, 
1977). These authors has shown that from the distribution of M. leprae that the 
infection had arisen from systemic spread of bacilli initially entering the lungs 
rather than from multiplication of organisms locally retained there, or in the nose, 
at the time of airborne infection.  
However, various investigators suggested that skin could also be another source of 
infection. A clinical and bacteriological examination of M. leprae in the epidermis 
and cutaneous appendages of patients with multibacillary leprosy revealed that 11% 
of samples were positive for acid-fast bacilli (AFB) (Hosokawa, 1999).  The author, 
found that the AFB positivity rate was higher in untreated non-ulcerating skin 
lesions with minor inflammation or in lesions with leprosy reactions than typical 
skin lesions such as papules, nodules and infiltrated punched out skin lesions 
indicating that these lesions could be one possible source of infection.   
Similarly, Job et al. (2008) reported that both skin and nasal mucosa could 
contribute to the shading of M. leprae into the environment and hence transmission. 
These authors evaluated M. leprae in the unbroken skin and nasal secretions of 
multibacillary leprosy patients and their contacts at St Thomas Hospital and 
Leprosy Centre Chettupattu, India. About 60% of untreated MB leprosy patients 
examined histopthologically had M. leprae in the keratin layer of the skin. Using 
PCR, M. leprae DNA was detected in the skin washings and nasal swabs in 80% 
and 60% of these patients respectively. They also confirmed the presence of M. 
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leprae DNA in healthy contacts (17% in the skin and 4% in the nasal swabs) before 
initiating treatment of index cases and after treating the index  cases for 2 months 
the contacts tested negative for M. leprae DNA (Job et al., 2008).  Similarly, the 
presence of M. leprae in intact skin of patients with leprosy has been reported by 
Satapathy et al. (2005) and Satapathy et al. (2005). A case-control study in a hyper- 
endemic region of north-eastern Brazil, found that 69.2% (116/185) of leprosy cases 
and 66.9% (91/136) endemic controls without leprosy were positive  for M. leprae 
DNA in the nasal secretions (Lima et al., 2015).   
In view of the above findings, it seems appropriate to consider that the skin is at 
least one of the important routes of transmission of the disease and that infection 
can occur through skin to skin contact with leprosy patients, especially with those 
in the lepromatous leprosy spectrum, in addition to the aerosol spread of nasal 
secretions and uptake through nasal or respiratory mucosa.  
Zoonotic transmission: It was believed that man is the only natural reservoir host 
of M. leprae and the only source of infection is an untreated case of leprosy. 
However, recent investigations have indicated that a nine banded armadillo 
(Dasypus novemcinctus L) is also natural reservoir of M. leprae, reviewed by 
Turman (2005). 
A temporal aspects of leprosy infection in a wild population of nine-banded 
armadillos in Western Mississippi from 2005-2010 reported an annual prevalence 
of infection varied between 4.5–15% (Williams and Loughry, 2012). In this study 
the incidence density estimates calculated over progressively longer time intervals 
generated values ranging from 0.11–0.61 new cases of infection/1000 days  
indicating that a substantial potential for transmission of infection within the 
armadillo  population.  
In the southern region of the Unites States of America, such as in Louisiana and 
Texas, cases of leprosy among native-born Americans with no history of foreign 
exposure has been commonly reported (Truman et al., 2011). In the same region, a 
wild armadillo infected with M. leprae has been confirmed. A comparative genomic 
analysis of M. leprae obtained from 50 patients and 33 wild armadillos from 
southern USA, confirmed that both humans and armadillos were infected with the 
54 
 
same strains of M. leprae (Truman et al., 2011).  These authors isolated nearly 
identical strains of M. leprae from 28 of 33 wild armadillos and from 25 of the 39 
patients who lived in areas of the USA where they could be exposed to armadillos. 
They found different strains in people who were infected in the Philippines and 
Brazil. This finding strengthens the long-held hypothesis that armadillos can be a 
source of infection in humans and that leprosy is probably a zoonotic disease in the 
southern United States. It is important to mention that the risk of getting leprosy 
from armadillo is described as “low” by these investigators.  
A case-control study conducted in Brazil suggested that direct exposure to 
armadillos is a risk factor for leprosy in Brazil (Deps et al., 2008  ).  Deps et al., 
included in their survey, a total of 1,100 peoples (506 cases with active leprosy and 
594 health controls). They assessed the history of direct exposure to armadillos 
through structured questionnaires. The result of the study has shown that direct 
exposure to armadillos is associated with a two-fold increase in the incidence of 
leprosy in the study area.  
2.6. Microbiology of M. leprae 
Mycobacterium leprae is an acid fast, non-motile, Mycobacterium which belongs 
to the class Actinomycetales and the genus Mycobacterium  based on the cell 
structure,  staining properties and chemical composition of the cell wall, presence 
of mycolic acids, antigenic characteristics of mycobacteria and  a lipid-rich cell 
envelope (Monot et al., 2005a, Shinnick, 2006).  Morphologically the bacterium is 
straight or slightly curved bacillus (road shape) having a length of 4 to 8µm and 0.3 
to 0.5µm diameter. M. leprae exists as single or clump of masses.  It does not have 
capsules, flagella and spores (Shinnick, 2006). The cell of M. leprae is bounded by 
unique cell wall which defines the cell shape and provides protection from 
environmental stress. The cell wall of M. leprae is structurally similar to that of 
most Mycobacterium species. The cell wall is composed of two layers, the outer 
and inner layers. The outer layer contains lipopolysaccharide made up of branching 
chains of arabinogalactan esterified with long chain of mycolic acids.  The inner 
layer is made up of peptidoglycan (Figure 2.7). The cell membrane of these bacteria 
is composed of lipids and protein like other bacteria. Within the cytoplasm there 
are few organelles. 
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Figure 2.7. A schematic model of the cell envelope of M. leprae. (Vissa and 
Brennan, 2001) 
2.7. Growth and Metabolism of M. leprae 
Little progress has made in understanding the metabolic properties of M. leprae due 
to the lack of suitable media to culture the bacteria which is very essential to study 
metabolic property of the organism. Although the genus Mycobacteria are found in 
the soil, water and air, the presence of M. leprae in these environment is not 
precisely known. Since M. leprae cannot be cultured on artificial media, it is very 
difficult to investigate if this bacterium inhibit soil, water or air.  The presence of 
M. leprae DNA has been found in soil samples in leprosy endemic areas. However, 
this does not confirm that its replication in these environments. The optimum 
temperature for M. leprae is 30-33oC which may accounts for M. leprae growth in 
the peripheral nerves.  The doubling time for M. leprae is thought to be 14 days.  
Toxin production by M. leprae has not been identified (Wheeler and RC., 1988).   
It has been reported that many of the pseudogenes of M. leprae are in the metabolic 
pathways. Key metabolic pathways have been lost due to this genomic downsizing 
(Scollard et al., 2006).  Catalase enzyme which breaks down peroxides appears to 
be absent in M. leprae. However, it is not known how M. leprae escapes from the 
toxic oxygen metabolites.  M. leprae cannot synthesis purines and hence dependent  
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on the host for purines (Wheeler, 1987, Scollard et al., 2006). M. leprae does not 
have mycobactin, an iron binding compounds and the siderophores, an Iron 
chelating compounds (Wheeler and RC., 1988). Hence, it is dependent on its host 
for iron provision.  Interestingly, M. leprae synthesises its own ATP  and it does 
not depend on its host for ATP (Lee and Colston, 1986).  
2.8. M. leprae genome  
Analysis of a complete genome sequence of M. leprae (TN strain) from Tamil 
Nadu, India has revealed that M. leprae has undergone reductive evolution and 
massive pseudogene formation (Cole et al., 2001). M. leprae genome contains 
3,268.203 base-pairs (pb)   with an average of G + C content of 57.8% in contrast 
to M. tuberculosis whose genome size is 4,411,532bp and G + C content of 65.6% 
(Table 2.2).  The base composition of DNA of M. leprae is different from most 
other Mycobacteria. The G+C content of other Mycobacteria is 65-70%.  Only 49.5 
% of M. leprae genome contains protein coding genes and the corresponding value 
for M. tuberculosis is 90.8% (Cole et al., 2001). From 50.5% of M. leprae genome 
which does not code for proteins, 27% contains pseudogenes and the remaining 
23.5% of the genome seems either regulatory genes or gene remnants mutated 
beyond recognition (Cole et al., 2001).  
From 1,604 protein coding genes of M. leprae, 1,439 genes are also shared by M. 
tuberculosis. If all genes in M. leprae genome were active 3,000 proteins are 
expected compared with the 4,000 proteins predicted in M. tuberculosis. However, 
only 239 and 1800 types of soluble proteins were found in M. leprae and M. 
tuberculosis respectively which shows the inertness of the pseudogenes (Cole et al., 
2001, Monot et al., 2009).  Hence, it is suggested that M. leprae has lost more than 
2000 genes and these genes could include metabolic genes and this might be an 
explanation for why scientists have failed to grow M. leprae in axenic culture.  
Since, M. leprae had undergone genome decay and contains large number of 
pseudogenes, high genetic diversity is expected among M. leprae strains. However, 
comparative genomics revealed genetic diversity is exceptionally rare among the 
strains. The whole genomic sequencing of strain Br4923 from Brazil, Thai53 from 
Thailand and NHDP63 from USA showed that the gene content is essentially 
identical to TN strain (Singh and Cole, 2011).  
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Mycobacterium lepromatosis has been the only other identified pathogen associated 
with diffuse lepromatous leprosy, also known as Lucio leprosy. Mycobacterium 
lepromatosis was first identified from Mexican patient by Han et al. (2008). 
Comparative genomic study has shown that M. leprae and M. lepromatosis are two 
different but closely related mycobacterial species.  It has been speculated that both 
species derived from a common ancestor that underwent genome downsizing and 
gene decay (Singh et al., 2015). The divergence time for the two species is estimated 
to be 14 million years. It was also suggested that both species have continued to 
lose genes but from different regions of the genome.  According to Singh et al. M. 
leprae appears to be more recent. The hemN gene which is present in M. 
lepromatosis but not in M. leprae is the only diagnostic method available to 
differentiate the two species (Singh et al., 2015).  The comparative genomic analysis 
of M. tuberculosis, M. leprae and M.  lepromatosis is presented (Table 2.2). 
Table 2.2. Comparative genomic analysis of M. leprae genome. M. lepromatosis 
and M. tuberculosis (Cole et al., 2001, Monot et al., 2009, Singh and Cole, 2011, 
Singh et al., 2015).  
Features M. tuberculosis M. leprae  M. lepromatosis  
Genome size (bp) 4,411,532 3,268,203 3,206,741 
G +C (%) 65.61 57.79 57.89 
Protein coding genes (%) 90.8 49.5 46.01 
Protein coding genes (no) 3959 1614 1477 
Pseudogenes  (no) 6 1306 1334 
Gene density (bp/gene) 1,114 2037 ? 
Average gene length (pb) 1012 1011 ? 
Average unknown gene 
length (bp) 
653 338 ? 
 
2.9. Antigenic components of M. leprae  
Identification and characterization of M. leprae specific antigens is among the 
major goals to be attained by researchers for accurate and reliable diagnosis of 
leprosy. M. leprae has two groups of antigens. These antigens are classified as 
protein and non-protein antigens.  
 
58 
 
2.9.1. The non-protein antigens  
The non-protein antigens are composed of lipid or carbohydrate moieties. These are 
mainly cell wall associated antigens. The non-protein antigens of M. leprae further 
subdivided into phenolic glycolipid (PGL) and lipoarabinomannan (LAM) 
antigens.  
Phenolic glycolipid-1: Phenolic glycolipid-1 (PGL-1) is the abundant surface 
glycolipids in M. leprae. It is located at the outermost surface of M. leprae and thus 
ideally positioned to interact with host cells components (Figure 2.7).  
PGL-1 consists of trisaccharide linked to a phenol which in turn linked to 
tetramethyl mycocerosic acid. The terminal trisaccharide gives antigenic specificity 
to M. leprae.  PGL-1 of M. leprae binds complement component C3 in serum and 
mediates phagocytosis by human monocytes (Schlesinger and Horwitz, 1991b).  
PGL-I has also been implicated in the tropism of M. leprae for Schwann cells, 
through specific binding to laminin, and to play an important role in down-
regulation of the inflammatory immune response and inhibition of dendritic cell 
maturation and activation, thereby facilitating the persistence of M. leprae (Spencer 
and Brennan, 2011).  
Lipoarabinomannan: Lipoarabinomannan (LAM) is the major component of the 
cell wall of M. leprae (Figure 2.8).  Chemically it is inert i.e. it is stable and 
indigestible. It consists of repeating units of arabinose and mannose attached 
through phosphatidylinositol moiety to the cytoplasmic membrane. LAM has 
diverse biological activities such as scavenging potentially cytotoxic oxygen free 
radicals, inhibit protein kinase C activity and block the transcriptional activation of 
interferon-gamma inducible genes in human macrophage cells (Spencer and 
Brennan, 2011).  It has been described that LAM inhibits macrophage activation 
and hence, used as a virulence factor contributing to the persistence of mycobacteria 
within mononuclear phagocytes (Spencer and Brennan, 2011).   
2.9.2. The protein antigens 
 The protein antigens are mainly display enzymatic properties. They are either cell 
wall associated, cytoplasmic or secreted antigens. Following the complete sequence 
of M. leprae genome, about 200 recombinant protein antigens have been identified 
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although none of them have been found to be qualified for  early diagnosis of 
leprosy (Geluk A. et al., 2011, Wiker et al., 2011, Kumar et al., 2014a).  
Cytoplasmic proteins: cytoplasmic proteins (10, 18, 65, and 70 KD) are heat shock 
or stress related proteins.  Other cytoplasmic proteins include the 28, 36 and 49 KD 
proteins. The 428 KD protein is superoxide dismutase enzyme, homologous with a 
human mitochondrial enzyme (Hunter et al., 1990). 
Cell wall and membrane associated proteins: A wide range of important cell wall 
and cytoplasmic membrane associated proteins in M. leprae has been identified by 
biochemical and recombinant DNA techniques.  Among these proteins, the family 
of 85B complex proteins are the most widely known proteins. It has been suggested 
that these proteins have enzymatic function in the biosynthesis of mycolic acid 
which is a major component of the cell wall of mycobacteria (Melancon-Kaplan et 
al., 1988). 
Secreted proteins: The secreted proteins of M. leprae include the 25 and 27 KD 
proteins. The 25 and 27 KD proteins have been identified by their release into 
culture filtrates from viable mycobacteria.  These proteins are assumed to be the 
first antigens encountered by the immune system and hence have an important role 
in protecting the M. leprae from the host immunity (Wieles et al., 1994, Harboe and 
Wiker, 1998).    
  2.10. Pathology  
Leprosy affects nerves, skin and eyes. It may also affect other body parts such as 
mucosa (mouth, nose, and pharynx), testes, kidney, voluntary or smooth muscles, 
reticulo-endothelial system, and vascular endothelium. The bacillus has low 
pathogenicity and only a small proportion of infected people develop signs of the 
disease and this depends on the immune response of the host. In most people the 
immune system is able to eliminate leprosy during the early infection stage before 
symptoms develop.  After the bacilli get into the body either through the skin or the 
nasal discharge, they are taken up by histiocytes in the skin and by the Schwann 
cells in the nerve upon which they usually provoke an inflammatory response of 
histiocytes and lymphocytes. The mode of the onset of the response is greatly 
variable.  An early lesion may occur as a vague, ill-defined, hypopigmented (in a 
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dark skin) or erythematous (in a light skin) patch with anaesthesia is called 
‘indeterminate” leprosy. The disease can also occur with multiple infiltrated patches 
or just diffuse skin infiltration (Bryceson and Pfaltzgraff, 1990, Kumar and Kumar, 
2010). 
Most indeterminate lesions will restore spontaneously. However, if the host defence 
mechanism fails to control the multiplication of the bacilli, then the condition 
progresses into one of the forms that make up the spectrum of the disease. The 
clinical form and the subsequent outcome of the disease depends on the nature and 
extent of the host’s immune response (Ridley, 1988).   
When the host immunity especially the cell-mediated immunity (CMI) is strong, 
the clinical form of the diseases is that of tuberculoid leprosy (TT). The disease is 
localized to one or few sites in the skin and few in the large peripheral nerves.  It is 
characterized by granulomatous inflammation associated with infiltration and 
destruction of nerve fibres. The lesion is characterized by well-defined margins, 
which is markedly anaesthetic and do not show the presence of acid-fast bacteria. 
Lesion infiltrate primarily consists of foci of well-developed epithelioid 
macrophages, with or without Langhans-type of multi-nucleated giant cells 
surrounded by a cuff of lymphocytes. (Myrvang et al., 1973, Modlin et al., 1983, 
Schlesinger and Horwitz, 1991b, Sampaio et al., 2011). 
If the host immunity is failed to control the bacilli, the disease progress to the 
lepromatous leprosy (LL) form. This form of leprosy is marked by numerous 
bacterial growth both in the skin and in the nerve. In the skin, macrophages fail to 
differentiate and they laden by the bacilli.  Lymphocytes are scanty or absent. Large 
number of bacilli are found in the Schwann cells of cutaneous nerve fibres.  
Clinically the disease is characterized by multiples of lesions all over the body 
which progress to nodules if untreated. It is characterized by symmetrical loss of 
sensation followed by loss of motor nerves. Antibodies to M. leprae are abundant 
in the sera of these patients but are ineffective in controlling the progress of the 
disease (Ridley, 1988, Walker and Lockwood, 2006). 
In-between the two polar leprosy forms are the immunologically unstable 
borderline forms showing clinical and histopathological characteristics 
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intermediate to the polar forms. The formation of small granulomas is typical 
feature of borderline forms. Within these groups, there is a gradual decrease in cell-
mediated immunity from BT to BL and this is inversely correlated with the bacillary 
load (BI) within the lesions(Ridley and Jopling, 1966, Godal and Negassi, 1973b).  
2.1. Genetic Susceptibility  
Genetic studies provides evidence that genetic variation in human populations 
contributes to susceptibility to infectious disease. The genetic susceptibility is 
thought to be of importance not only in predisposing or protection against 
developing clinical disease, but also in determining the clinical futures of the 
disease in individuals.  It has been shown that the host genetic factors influence the 
acquisition of leprosy and the subsequent clinical course of the disease (Bhat and 
Prakash, 2012).   
In a linkage study included 197 Vietnamese leprosy families and 587 Brazilian 
leprosy cases identified the first major polymorphic risk factors in the shared 
promoter region of PARK2 and PACRG (Mira et al 2004). Single-nucleotide 
polymorphism (SNP) association studies in two Vietnamese familial samples 
involved 298 cases showed a low producing  lymphotoxin-a (LTA)+80A allele was 
significantly associated with increased risk of leprosy (Alcais et al., 2007). 
A genome-wide association study included 706 leprosy patients and 1225 healthy 
controls of the Han Chinese family showed variants of genes in the NOD2-mediated 
signalling pathway (which regulates the innate immune response) associated with 
susceptibility to infection with M. leprae (Zhang et al., 2009).   
An Indian study has reported that the human histocompatibility leukocyte antigen 
(HLA)-DR2 was found to be associated with susceptibility to TT compared to LL 
showing the importance of HLA in the leprosy spectrum  (van Eden et al., 1980). 
A case -control study  which involved 32 LL patients with 32 endemic controls in 
Venezuela has shown that the frequency of HLA specificity LB-E12 (MB1, DC1 
and MT1) was significantly increased in lepromatous leprosy patients compared to 
the endemic controls (Ottenhoff et al., 1984). Similarly, in a study of the relation 
between HLA and lepromatous leprosy, the analysis of HLA haplotype segregation 
in 28 families from Venezuela with multiple cases of different types of leprosy has 
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shown that HLA-DR3 was inherited preferentially by children with polar 
tuberculoid leprosy while, HLA-MT1 was inherited preferentially by children with 
lepromatous leprosy (van Eden et al., 1985). HLA class I HLA-A*1102-B*4006-
Cw*1502 haplotype has been reported showing a highly significant association 
with leprosy susceptibility in Indian patients (Shankarkumar et al., 2003). Among 
the class II genes the HLA-DRB1 locus specifically DRB1*15 and DRB1*16 are 
associated with leprosy susceptibility in India, Thailand and Brazil. The HLA-
DQw1 locus was found to be associated with LL patients (Correa Rda et al., 
2012)The vitamin D receptor (VDR) has been shown associated with leprosy in an 
Indian population where a T-C substitution at codon 352 at the 3’ gene region 
resulted in susceptibility to lepromatous leprosy in the presence of genotypes TT 
and tuberculoid leprosy if the genotypes is CC (Roy et al., 1999). Other SNPs to be 
associated with disease and/or the development of reactions in several genes, such 
as TNF-α, IL-10, IFN-γ, HLA genes, and TLR1 are also suggested (Fitness et al., 
2002).   
2.12. Clinical Features of leprosy  
The clinical features of leprosy vary depending on the host repose to M. leprae. 
Leprosy patients usually present with skin lesions, numbness or weakness caused 
by peripheral nerve involvement or more rarely a painless burn or ulcer in an 
anaesthetic hand or foot. A leprosy reaction may be a presenting feature of the 
disease (Walker and Lockwood, 2006).  
2.12.1. Cutaneous features  
Early skin lesions may be rather poorly defined hypo-pigmented or erythematous 
macules. Sensation in these early stages may be unaltered. Tuberculoid (TT) 
leprosy is characterized by a single or few lesions with defined edges. The lesions 
can either macules or plaques. In dark skin hypopigmentation predominates over 
the erythema or copper colour more usually seen in lighter skin. The lesions are 
mostly anaesthetic and involve alopecia (hair loss). Anaesthesia may not be present 
in facial lesions. Lesions can be dry and scaly, hypohidrotic (diminished sweating 
ability), and hairless. Spontaneous resolution can occur in a few years. Progression 
can also occur, leading to borderline-type leprosy (Walker and Lockwood, 2006).  
63 
 
Patients with borderline tuberculoid (BT) have similar lesion forms to those with 
TT leprosy. However, the lesions in BT patients are smaller and tend to be more 
numerous with less demarcated edges. The skin lesions in patients with borderline- 
borderline (BB) can be macular or papular or plaque-like or even the combination. 
Cutaneous lesions consist of numerous, irregularly shaped plaques that are less well 
defined than those in TT or BT.  The lesions are moderately anaesthetic (Guinto et 
al., 1983, Walker and Lockwood, 2006). 
 In borderline lepromatous leprosy (BL) lesions are numerous and widespread 
bilaterally.  The surface of the lesions are mostly smooth and shiny with ill-defined 
edges. Lepromatous leprosy (LL) is characterized by numerous skin lesions that are 
widespread and symmetrical distribution.  Early cutaneous lesions consist mainly 
of pale macules with ill-defined edges. Papular and nodular lesions are seen in 
advanced disease. Early lepromatous leprosy lesions have little or no loss of 
sensation (Guinto et al., 1983, Walker and Lockwood, 2006). 
2.12.2. Neural features  
The neural involvement of leprosy includes damage to the nerve trunks as well as 
to the cutaneous nerve endings. Nerve involvement in leprosy affects sensory, 
motor and autonomic function of peripheral nerves. Sensory clinical presentations 
are the most common and usually open the clinical picture. Leprosy reactions can 
cause further nerve damage. The nerve damage due to leprosy leads to disability 
and deformity such as clawing of the hand. Deformity also occurs through impaired 
sensation leading to trauma and secondary infection which causes tissue damage 
(Grimaud and Vallat, 2003, Nascimento, 2013).  
In TT leprosy, the nerve thickening is usually confined to one nerve and the damage 
to peripheral nerves is limited. In LL the increases in nerve size is symmetrical 
while the nerve enlargement is frequently segmental rather than diffuse and 
uniform. The destruction of dermal nerves leads to a glove and stocking pattern of 
sensory loss.   
Pure neuritic leprosy (PNL) is characterized by neural impairment (neuropathy) 
without evidence or history of typical skin lesions. It manifests as enlargement of 
one or more peripheral nerves, with or without tenderness, sensory motor 
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impairment, and muscular atrophy, particularly of the hand and foot muscles (Payne 
et al., 2015). Pure neuritic leprosy accounts  for about 4% cases of  leprosy in India 
(Kumar et al 2004) while it was 0.5% in in an Ethiopian cohort (Saunderson et al., 
2000b).  
2.12.3. Other features  
Other features of leprosy includes saddle nose deformity; visual loss due to 
lagophthalmos (an inability to close the eyes completely), corneal ulceration, acute 
or chronic iridocyclitis and secondary cataract, testicular atrophy and facial palsy. 
The involvement of nasal mucosa in lepromatous leprosy gives rise to nasal 
stuffiness and epistaxis in advanced cases which eventually lead to saddle nose 
deformity. Nasal deformity contributes significantly to the stigma associated with 
leprosy (Rafferty, 2005). 
2.13. Classification  
The clinical and histological features of leprosy is correlated with the 
immunological state of the host which determines prognosis and constitutes the 
basis for the classification of this disease. There are two approaches to classifying 
leprosy patients: The Ridley-Jopling (RJ) and WHO classification systems. The 
Ridley-Jopling system mainly is used for classification of leprosy for scientific 
purposes and the WHO system is used for operational activities (Figure 2.9).  
2.13.1. The Ridley-Jopling classification 
The bases for the Ridley-Jopling classification system are clinical, histological 
features and bacteriological index. According to this classification scheme, there 
are two poles of spectrum and three borderline forms of leprosy. The two poles of 
the spectrum are lepromatous leprosy and tuberculoid leprosy.  The borderlines are 
designated as  borderline tuberculoid (BT), mid borderline (BB) and  borderline 
lepromatous (BL) (Ridley and Ridley, 1983). 
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Patients with LL have multiple, symmetrically distributed lesions throughout the 
body (skin, nerves, eyes and nasal mucosa). Histopathologically, LL lesions show 
an infiltrate mainly composed of macrophages, showing varying degrees of foamy 
changes, and few, scattered lymphocytes, predominantly of the CD8+ T-cell subset 
(Walker and Lockwood, 2006). Patients with lepromatous leprosy have high 
bacterial index.  Anti-M. leprae antibody titres are  high in the sera of LL patients 
but do not control the multiplication of the bacilli.  
Patients with tuberculoid leprosy (TT) have few lesions with well-defined margins, 
which are markedly anaesthetic and do not show the presence of acid-fast bacteria. 
Lesional infiltrate primarily consists of foci of well-developed epithelioid 
macrophages, with or without Langhans’ type of multi-nucleated giant cells 
surrounded by a cuff of lymphocytes. The T-lymphocyte subsets are predominantly 
of the CD4+ type (Myrvang et al., 1973, Modlin et al., 1983, Sampaio et al., 2011).  
In-between the two polar leprosy forms are the immunologically unstable 
borderline forms including borderline lepromatous (BL), mid-borderline (BB) and 
borderline tuberculoid (BT), showing clinical and histopathological characteristics 
intermediate to the polar forms. Within these groups, there is a gradual decrease in 
cell-mediated immunity (CMI) from BT to BL and this is inversely correlated with 
the bacillary load (BI) within the lesions (Figure 2.8) (Ridley and Jopling, 1966, 
Godal and Negassi, 1973b).   
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BI= Bacillary Index 
Figure 2.8. Ridley and Jopling leprosy classification schemes (Lockwood, 2004)  
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2.13.2. The WHO classification 
The WHO recommended an operational classification to serve as a basis for 
chemotherapy to be used in the field when slit skin smears are not available. The 
WHO classification is based on the number of skin lesions. Patients with 1 to 5 skin 
lesion are classified as paucibacillary (PB) and those with 6 or more skin lesion are 
grouped as multibacillary (MB) type.  
A comparative study from Philippines has reported that about 38-51% of leprosy 
patients were misclassified as PB by WHO classification criteria when 264 leprosy 
cases had been re-classified using the standard histopathological and 
microbiological criteria (Pardillo et al., 2007). Similarly, of 60 PB and 40 MB new 
untreated leprosy patients by WHO classification scheme in India, 19 (37%) of 
them were misclassified as PB and 7 (15%) of them as MB when correctly classified 
using the histology and slit skin smear microscopy (Gupta et al., 2012). The INFIR 
cohort study of Indian patients has shown that MB cases are very heterogeneous 
and encompasses patients with no detectable bacteria and high immunological 
activity through to patients with high bacterial loads (Lockwood et al., 2012). Thus, 
WHO classification schemes may be a risk for under-treatment of MB cases. 
2.14. Diagnosis of leprosy  
The diagnosis of leprosy is mainly based on clinical features.  Silt skin smear (SSS) 
test and histological appearances are frequently used to support the clinical 
diagnosis. Other methods such as serological testing and DNA based PCR detection 
of M. leprae are sometimes used to supplement the clinical findings.  
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The Cardinal Signs of Leprosy  
Three cardinal signs have identified for the clinical diagnosis of leprosy.  
1. Skin lesions with definite sensory loss. The lesion could be raised or flat, 
light or pigmented 
2. Thickened or enlarged peripheral nerve(s) with  loss of sensation and /or 
weakness of the muscles supplied by that nerve 
3. Presence of acid-fast bacilli (AFB) in a slit skin smear  or tissue biopsy 
Any one of these signs has been regarded as sufficient for the diagnosis of leprosy 
(World Health organization, 1998).   
Slit skin smear test (SSS):  The slit skin smear test is the most simple and 
frequently used method to classify leprosy cases into paucibacillary and 
multibacillary cases. .  An incision of the skin (5mm log and 2mm deep) is obtained 
from multiple sites and stained by the Ziehl-Neelsen method also called Acid Fast 
Bacilli stain (AFB). The AFB stained slides are used for determining the bacillary 
index (BI).   BI is a logarithmic scale (1 -6) quantifying the density of M.leprae on 
a silt skin smear under the microscope. 
From a cross-sectional study in India, slit skin smear test confirmed the presence of 
AFB in 59.8% (64/107) of MB and only in 1.8% (1/57) of PB cases (Banerjee et 
al., 2011).  Although this method has high specificity, its sensitivity is as low as 
less than 10% for PB patients since in such patients the bacilli load is very low to 
be detected by this method (Santos et al., 2013). 
Skin Biopsy: Histopathological examination of tissue sections from suspected 
lesions is the gold standard for the diagnosis of leprosy. The use of skin biopsy 
supports the clinical findings and used as confirmatory diagnosis of leprosy. 
However, the procedure demands medical facilities and a histopathologist which 
limits its application in many countries where leprosy is endemic.     
M. leprae specific antigen (PGL-1):  The use of serological assays based on the 
employment of M. leprae specific antigens, mainly phenolic glycolipid (PGL-1) 
has opened new methods of monitoring M. leprae infections, since antibody levels 
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are associated with intensity of exposure and systemic involvement to the bacteria. 
However, serological tests do not detect all clinical infections, since paucibacillary 
patients do not develop significant levels of antibody response. Many studies have 
demonstrated that multibacillary patients have high titers of M. Leprae specific 
antibodies but paucibacillary patients have low or absent titters. The antibody 
response to PGL-1 is primarily IgM and its level gradually rises from TT to LL 
indicating its direct correlation with bacilli index (BI). It was reported that 90 to 
95% multibacillary and 20-40% paucibacillary leprosy patients  have a positive 
antibody in a  PGL-1 based test (Geluk A. et al., 2011).  It has also been shown that 
the false positivity rate of PGL-1 based tests is greater than 10% in leprosy endemic 
area (Duthie et al., 2007). Consequently, PGL-1 based test has not been widely 
implemented in field situations as screening tools.   
ML-Flow test:  The ML- Flow test is a simple and rapid immunochromatographic 
flow test used for the detection of IgM to PGL-I.  It is a simple dipstick assay which 
can be used at field level using whole blood sample. The ML-Flow test has been 
reported to be comparable to the ELISA in its sensitivity (97.4%), being able to 
detect more than 90% of MB patients and 40% of PB patients, with background 
seropositivity in endemic controls at around 10%.  Moreover, this dipstick test was 
reported to be applicable in the field, identifying multibacillary patients without the 
need for a slit-skin smear test (Buhrer-Sekula et al., 2003). However, its low 
sensitivity to PB patients hindered the use of this test as leprosy diagnostic test in 
the leprosy endemic countries.  
 
LID-1 test:  LID-1 (leprosy Infections Disease Research Institute diagnostic 1) is a 
chimeric fusion of two proteins (ML0405 and ML2331) which is used for leprosy 
diagnosis on the   basis of immunoglobulin G (IgG) reactivity. Positive titres of 
antibodies against LID-1 protein were found in 87-92% MB and 7-48% PB patients 
in different populations of Brazilian leprosy patients (de Souza et al., 2016).  It has 
been reported that some household contacts presenting with high titres of antibodies 
against LID-1  were developed clinical symptoms of leprosy after one year 
suggesting a role for this protein in the monitoring of contacts (Duthie et al., 2007).  
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NDO-LID® rapid test (Orange Life®, Rio de Janeiro, Brazil) was developed by 
impregnating nitrocellulose membranes with ND-O-LID-1, a conjugation of the 
ND-O (a synthetic mimetic of PGL-I disaccharide) and the LID-1 protein  (Duthie 
et al., 2014).  In a study conducted among Brazilian leprosy patients, it was found 
that NDO-LID detected 87.0% MB patients and only 20.2% PB patients (Paula Vaz 
Cardoso et al., 2013).   
UCP-LFA test:  The up-converting phosphor (UCP)-Lateral flow assay is a 
combination of UCP reported technology with lateral flow test which is used for 
detection of a variety of analytes such as drugs of abuse, protein and polysaccharide 
antigens from pathogens, bacterial and viral nucleic acids and antibodies against 
several diseases. The phosphorescent reporter utilized in UCP-LFAs is excited with 
infrared light to generate visible light, a process called up-conversion. UCP-based 
assays are highly sensitive since up-conversion does not occur in nature, avoiding 
interference by autofluorescence of other assay components. Importantly, UCP- LF 
test strips can be stored as permanent records allowing re-analysis in a reference 
laboratory (Bobosha et al., 2014a).   In UCP-LF assay can be developed for a single 
cytokine or antibody test or for combination of cytokines or antibodies termed as a 
multiplex UCP-LFA.  Previous studies have shown that INF-Ƴ-UCP-LFA and IP-
10-UCP-LFA can be used to discriminate leprosy infected individuals from  
endemic  controls in Ethiopian population (Bobosha et al., 2014a).  Corstjens et al. 
(2016), have shown by using a UCP-LFA, that IP-10 was significantly increased 
during the onset of T1R reaction than before the onset of reaction and was 
significantly reduced after treatment.  Therefore, unlike the other leprosy diagnostic 
tests, UCP-LFAs may be used for leprosy diagnosis as well as for monitoring 
multiple immune responses markers during the onset and treatment of leprosy 
reactions.  
Molecular based diagnosis: New molecular biology methods have been developed 
as reliable and sensitive diagnostic tools for the identification of pathogens in many 
infectious diseases. The detection of the DNA of the infectious microbe by 
polymerase chain reaction (PCR) is the most widely used method. Following the 
M. leprae genomic sequence many scientists tried to adopt the experience of PCR 
based diagnosis of infectious diseases to leprosy.  
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According to the reports of Martinez et al., a detection rate of 100% among 
multibacillary patients and 62.5% to 79.2% among paucibacillary (PB) patients has 
been attained using both conventional and real time PCR from 69 biopsy samples 
(25 LL, 11 BL, 3 BB, 24 BT and 6 healthy controls) from Brazil (Martinez et al., 
2006). These authors reported that the clinical sensitivity of real time PCR and 
conventional PCR was 91.3% and 82.6% respectively. An Indian study has shown 
that 85.9% MB and 75.5% PB patients were successfully diagnosed by PCR 
(Banerjee et al., 2011).  Hence, although PCR increases the sensitivity of M. leprae 
DNA detection in patient sample over conventional methods, satisfactory result has 
not been achieved with regard to the detection of PB cases (Kurosaki et al., 2015).  
2.15. Diagnosis and grading disability  
The WHO leprosy disability grading system grades leprosy patients based on the 
disabilities of eyes, hands and feet (Table 2.3).  The highest grade of disability of 
any of these body sites is used as an overall indicator of the disability status of a 
person with leprosy (Alberts et al., 2011). 
Table 2.3.   WHO leprosy disability classification   (Alberts et al., 2011). 
Body sites  Grade Criteria  
  
 
Hands and Feet  
0 No anaesthesia, no visible deformity or damage 
1 Anaesthesia present, but no visible deformity or 
damage 
2 Visible deformity or damage present 
 
 
 
Eyes  
0 No eye problem due to leprosy; no evidence of 
visual loss 
1 Eye problems due to leprosy present, but vision not 
severely affected as a result (vision: 6/60 or better; 
can count fingers at 6 metres). 
2 Severe visual impairment (vision worse than 6/60; 
inability to count fingers at 6 metres); also includes 
lagophthalmos, iridocyclitis and corneal opacities. 
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Among the newly diagnosed Indian INFIR cohort study, 40.9% of them had WHO 
disability grade-1 and 9.6% grade-2 at enrolment (Van Brakel et al., 2005b). The 
Bangladesh Acute Nerve Damage Study (BANDS) cohort had a prevalence of  
9.6% grade-1 and 6.0% grade-2 disability in 2,664 leprosy patients at enrolment 
(Croft et al., 1999). However, the rate of grade-1 disability was 28.5% and that of 
grade-2 was 18.2% in MB patients.  A survey of 1,358 Indonesian leprosy patients, 
who had been released from MDT up to 5 years earlier, found that 75% of the 
patients had physical impairment (van Brakel et al., 2012).  
In Brazil about 6.5% of the new cases reported to WHO in 2014 had grade-2 
disabilities at presentation. The rate of grade two disability in new cases of 
Ethiopian leprosy patients reported to WHO in 2014 was 10.2% (WHO, 2015).  
According to WHO 2014 epidemiological data, 6 countries reported the highest rate 
of grade-2 disability in newly diagnosed leprosy cases. These countries include: 
Chad (25.2%), Burkina Faso (23.6%), China (20.0%), Pakistan (17.6%) and 
Tanzania (17.0%) indicating the delay of diagnosis and treatment in these countries 
(WHO, 2015) 
2.16. Differential Diagnosis  
The differential diagnosis of leprosy is broad due to the variability of clinical 
manifestations of leprosy. Patients may have skin lesions occurred by fixed drug 
eruption, morphea (localised scleroderma), dermatophytosis, dermal filariasis, 
eczema, scars, nodular cutaneous leishmaniasis, post-kala azar dermatitis or 
keloids. 
2.17. Treatment of leprosy  
Leprosy is curable if treated with the correct regimen. A successful treatment for 
leprosy was discovered in 1947 with dapsone which remains a component of 
present day multi-drug combination therapy (MDT) (Table 2.4).  
The WHO recommends that patients diagnosed as having leprosy should receive a 
multi-drug combination therapy. Multi-drug combination therapy was introduced 
in 1982 following the emergence of resistance to dapsone-only regimen (WHO, 
1982). The first-line agents are rifampicin, clofazimine and dapsone. Since 1995, 
WHO provides free MDT for all patients in the world provided by the Novartis 
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Foundation for Sustainable Development. Paucibacillary patients are treated with 
rifampicin and dapsone for six months and the recommendation for individuals with 
MB leprosy cases is three drugs: rifampicin, dapsone and Clofazimine for 12 
months (Table 2.6). Between 1985 and 2014, about 16 million individuals received 
MDT (WHO, 2015).  
Rifampicin 
Rifampicin is a bactericidal antibiotic used to treat Mycobacterium infections such 
as tuberculosis and leprosy. Previous studies in untreated multibacillary leprosy 
patients have shown rifampicin administered in single doses of 600mg killed more 
than 99% of M. leprae  within four days (Levy et al., 1976). The mechanism of 
action of rifampicin is through inhibition of DNA-dependent RNA polymerase and 
hence, impairs the bacterial DNA transcription (Wehrli, 1983). Resistance to 
rifampicin has been shown due to clustered mutations in rpoB genes of clinical 
isolates of M. leprae (Nakata et al., 2012).  
Clofazimine  
Clofazimine has been used in the treatment of multibacillary leprosy since 1962.  It 
is a bactericidal drug with both antibacterial and anti-inflammatory activity. The 
anti-inflammatory activity of clofazimine is through its immunosuppressive effects. 
It works through binding to the guanine bases of bacterial DNA, thereby blocking 
the template function of the DNA and inhibiting bacterial proliferation. It also 
increases activity of bacterial phospholipase A2, leading to release and 
accumulation of lysophospholipids, which are toxic and inhibit bacterial 
proliferation. The lipophilic property of clofazimine enables it to accumulate in skin 
and nerves, while its anti-inflammatory activities are potentially useful in 
controlling leprosy reactions (Cholo et al., 2012).  The side effects of clofazimine 
includes increased skin pigmentation, and dryness, which occur as the drug 
becomes clinically effective (Ramu and Iyer, 1976).  
Dapsone 
Dapsone is a sulphur compound with bacteriostatic action, used in the treatment of 
leprosy. Its mode of action is via inhibition of the synthesis of dihydrofolic acid, 
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(Vitamin B9), a precursor of tetrahydrofolic acid which serves as a cofactor in the 
metabolism of amino acids and nucleic acids. By 1951, oral dapsone (100mg daily 
dose) was introduced as the standard treatment of leprosy. However, in the late 
1960s relapse in patients who had previously treated with dapsone and resistance 
in patients who had never been exposed to dapsone was reported. Haemolytic 
anaemia and skin reactions are among the few reported side effects of dapsone 
(Deps et al., 2012).   
Table 2.4. World Health Organization recommended MDT regimens for leprosy 
treatment  
2.18. Relapse in leprosy and drug resistance  
Relapse  in leprosy is defined as  “ A patient who successfully completes an 
adequate course of MDT, but who subsequently develops new signs and symptoms 
of the disease either during the surveillance period (2 years for PB and 5 years for 
MB leprosy) or thereafter” (World Health organization, 1998). Relapse is 
diagnosed by the appearance of definite new skin lesions and/or an increase in 
bacteriological index (BI) of two or more units at any single site compared to BI 
taken from the same site at previous examination.   
The relapse rates following MDT are low.  WHO estimated a risk of relapse of 0.7% 
for MB and 1.07% for PB patients 9 years after stopping MDT (World Health 
Organization, 2006). A retrospective study included 3,248 leprosy patients who 
completed the WHO-MDT during the period of 1987-2003,  in Tamil Nadu, had 
reported an overall relapse rates of 0.84% in MB and 1.9% in PB leprosy (Ali et al., 
Type of 
Leprosy   
        Drug treatment   Duration of 
treatment  
Monthly 
supervised  
Daily self-
administration 
 
Paucibacillary  Rifampicin 
600mg 
Dapsone 100mg 6 months  
Multibacillary Rifampicin 
600mg 
Dapsone 100mg 12 months  
 Clofazimine 
300mg 
Clofazimine 300mg 
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2005). Relapses cases were not found in 502 patients who completed MDT in the 
AMFES (ALERT MDT Field Evaluation Study) cohort, 8 years after completion 
of treatment (Saunderson et al., 2000b). In a long- term follow-up study of up to 16 
years in the Philippines, the relapse rate amongst MB patients was 6.6%) (Balagon 
et al., 2009). Similarly a relapse rate of 1.97% in MB cases and 1.3% in PB was 
reported from Agra field based cohort study in India (Kumar et al., 2013). A 
retrospective cohort study of 11 years in Colombia, had reported a relapse rate of 
20.0% in 165 leprosy patients (Guerrero-guerrero et al., 2012).  
Genetic studies have identified mutations within drug target genes in M. leprae, 
which confer resistance to rifampicin, clofazimine and dapsone. Studies have 
shown that drug resistance in M. leprae is occurred through gene mutations 
encoding drug targets. These mutations occur spontaneously as a result of errors in 
DNA replication and they can be enhanced in a population of susceptible to M. 
leprae by inappropriate drug therapy. Drug resistant M. leprae mutants can be 
obtained during initial infection from the infection sources (primary drug 
resistance) or from inadequate treatment (secondary drug resistance) (Williams and 
Gillis, 2012, Mejí et al., 2014).  
2. 19. Immunology of leprosy   
Intracellular pathogens are a major cause of global morbidity and mortality. These 
pathogens include different species such as Mycobacteria, Leishmania, Listeria, 
Salmonella, Chlamydia, Rickettsia, Trypanosoma and others. Intracellular 
pathogens live inside the host cells where they are protected from the effector cells 
of the immune system. These pathogens prefer the mononuclear phagocytes of the 
host cells, which are also an important component of the innate immune system. In 
principle, the phagocytes have to restrict the intracellular multiplication of the 
pathogen by phagosome lysosome fusion, generation of reactive oxygen and 
nitrogen intermediates or restricting nutrient availability to the pathogen. They also 
produce soluble mediators such as cytokines and chemokines to increase the 
trafficking of T- and B- lymphocytes to the site of infection.  Furthermore, the 
phagocytes along with other specialized antigen-presenting cells guarantee the 
protein and lipid antigens from the pathogens are processed and presented to the 
host T-lymphocytes for further action (Thi et al., 2012, Ribet and Cossart, 2015). 
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Given that these innate immune effector cells are normally programmed to destroy 
ingested pathogens and promote the development of adaptive immunity, these 
pathogens may manipulate the host innate defence mechanism to survive and 
replicate ( Figure 2.9) which ultimately leads to a state of disease (Diacovich and 
Gorvel, 2010).  
It is thought that about 99% of individuals infected by M. leprae do not develop 
leprosy (Singh et al., 2014). This indicates the capacity of the host immune response 
in controlling the disease progression although much of the pathology of leprosy is 
thought to be related to an inappropriate immune response especially in reactional 
sates (Godal and Negassi, 1973a, Baumgart et al., 1993). However, factors which 
regulate the intensity of immune response in leprosy is yet to be investigated. The 
role of various immune cells and their soluble produces in regulation of immune 
response in leprosy has been the current focus of intense investigation and the next 
section reviews some of the new advances in this area.    
Figure 2.9.  Manipulation of host innate immunity by intracellular pathogenic 
bacteria. (Diacovich and Gorvel, 2010). 
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2.19.1. Innate Immunity and Leprosy 
The innate immune response is comprised of mainly of phagocytic cells and is 
capable of immediately recognizing and responding to microbial invasion. 
Macrophages and neutrophils are professional phagocytic cells acting as effector 
cells to resolve the infection. Dendritic cells (the professional antigen-presenting 
cells) and macrophages are also vital for the initiation of adaptive immunity and the 
subsequent generation of specific immunity.  
2.19.1.1. Toll like receptors  
The innate immune system is capable of recognizing a wide spectrum of pathogens 
through various receptors that bind highly conserved structures on the microbial 
components. Cells of the innate immune system are equipped with germline 
encoded pattern recognition receptors (PRRs), which recognize pathogen-
associated molecular patterns (PAMPs), which are shared among groups of 
pathogens (Modlin, 2010).  The family of toll like receptors (TLRs) is the major 
and most extensively studied class of PRRs. TLRs are thought to play a crucial role 
in the recognition of microbes and subsequent induction of the immune responses. 
These receptors are expressed on immune cells, such as monocytes, macrophages, 
dendritic cells (DC), and granulocytes, and at sites of host-pathogen interaction 
such as airway epithelium and skin (McInturff et al., 2005). Signalling through 
TLRs involves myeloid differentiation 88 (myD88), interleukine-1 receptor-
associated kinase (IRAK), and TNF-receptor associated factor (TRAF), followed 
by activation of nuclear factor (NF)-kB (McInturff et al., 2005).     
Activation of TLRs results in upregulation of the production of inflammatory 
mediators such as TNF-α, IL-6 and  IL-12 and microbial killing mechanisms like 
nitric oxide (NO) production  (Dearman et al., 2009).  Toll-like receptor 2 (TLR2) 
is critical in the immune response to mycobacterial infections and the mutations in 
the TLR2 have been shown to confer the susceptibility to severe infection with 
mycobacteria. TLR2 is activated by bacterial lipoproteins including mycobacterial 
antigens (Kang and Chae, 2001).  Initially it has been  shown that TLR2 SNP was 
associated with susceptibility to lepromatous leprosy in Korean population (Kang 
et al., 2002). However, a study involving 286 Indian leprosy patients and 183 
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ethnically matched controls, has identified the SNP as a pseudogene and does not 
encode a TRL2 gene (Malhotra et al., 2005).  
It has been described that TLR1 1602S SNP was associated with decreased risk of 
developing leprosy (Johnson et al., 2007). The association of TLR1 248SS and 
protection against leprosy has been described by (Schuring et al., 2009). Hence, a 
polymorphism that would reduce TLR2/1 signalling would protect against leprosy. 
In a study which included 842 patients with leprosy in Bangladesh, has shown that 
patients who experienced reversal reactions and/or erythema nodosum leprosum 
reactions during the 4-year follow-up had TLR1 N248S-linked trait suggesting that 
the TLR1 N248S SNP may affect the progression from infection to disease as well 
as the disease course and the risk of developing reactional episodes in this 
population (Schuring et al., 2009).  Recently, a study in a Brazilian leprosy patients 
has reported that TLR1 N248S SNP is associated with leprosy risk and regulates 
immune activation during mycobacterial infection (Marques Cde et al., 2013). 
An Ethiopian cohort study which included 441 patients with leprosy and 193 
healthy controls at ALERT hospital has shown that two SNPs in TLR4 (896G →A 
[D299G] and 1196C →T [T399I]) are associated with protection against leprosy 
(Bochud et al., 2009). These authors have also reported that M. leprae 
downregulates TLR4-mediated cytokine production in monocytes. Conversely, a 
case-control study which included 270 Malawi patients with leprosy cases and 490 
healthy controls has shown that having the polymorphism TLR4 D299G does not 
provide protection against leprosy (Fitness et al., 2004) .   
The differing and sometimes conflicting results of genetic studies may be attributed 
to differences in study design and sample size. It is also possible that different 
populations have distinct genetic susceptibilities (Campbell and Tishkoff, 2008). 
2.19.1.2. Macrophages  
The macrophage is the major host cell of M. leprae bacilli. Schwann cells and 
keratinocytes are the others cells of the host  which harbour M. leprae (Kumar et 
al., 2014a). Regardless of the efficient bactericidal mechanisms of macrophages, 
M. leprae may survive in these cells in two ways. Firstly, M. leprae inhibit 
phagosome lysosome fusion and eventually escape from the phagosome and enter 
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the macrophage cytoplasm. Secondly, perhaps due to the failure of macrophage 
activation during the uptake of bacilli. This is further explained by the fact that 
uptake of M. leprae into the macrophages is selectively mediated by the 
complement receptors, CR1 and CR3, which bind to the surface of the bacteria by 
PGL-1 and hence inhibits oxidative burst. PGL-1 has been shown to scavenge 
oxygen radical thereby, M. leprae resist the intracellular digestion (Launois et al., 
1989, Schlesinger and Horwitz, 1991b).   
Lepromatous leprosy is characterized by the accumulation of macrophages which 
are unable to restrict the multiplication of M. leprae.  The macrophages from these 
LL patients failed to activate when stimulated with IFN-γ in vitro showing that these 
macrophages are defective and unable to re-store the normal function. On the other 
hand, within the TT lesion, bacteria are seen rarely in the macrophages which 
implies that the macrophages in patients with TT are capable of controlling the M. 
leprae infection (Parmaswaran et al., 1976, Desai et al., 1989).   Previous studies 
has shown that macrophages from LL lesions expressed high level of DC-SIGN 
which was thought to be associated with a Th2 environment in these lesions 
(Soilleux et al., 2006).  On the other hand, macrophages obtained from patients with 
TT expressed higher level of toll like receptors-1 (TLR1) and 2 (TLR2) compared 
to patients with LL. (Krutzik et al., 2003). Hence, it appears that macrophages in 
LL lesions show a progressive reduction of Th1 activation resulting in a state of 
antigen specific tolerance.  Furthermore, macrophages in LL lesions may down-
regulate cellular immunity by reducing antigen-presenting function and secreting 
Th2 cytokines or by secreting other suppressive factors, such as IL-10 and 
prostaglandin E2 (PGE-2) (Misra et al., 1995). PGE-2 controls chemokine 
production, inhibiting the attraction of pro-inflammatory cells while enhancing 
local accumulation of regulatory T-cells. It also supports activation of dendritic 
cells but suppresses their ability to attract naive, memory, and effector T-cells 
(Kalinski, 2012). Attempts to induce macrophage activation in LL patients by local 
administration of antigens or IFN-γ have not been yet successful (Kaplan et al., 
1987b).    
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2.19.1.3. Neutrophils 
Neutrophils play important roles in host defence against infectious agents but they 
are also involved in the pathology of various inflammatory conditions. Upon 
phagocytosis, they produce oxidative and non-oxidative microbicidals for 
destruction of these agents intracellularly. They also release cytotoxic molecules 
into the extracellular milieu which can damage the host (Smith, 1994).  
Unlike macrophages, the role of neutrophils in the pathogenesis of leprosy has not 
been well investigated.  The role of neutrophils in inflammation and host defence 
had long been thought to be restricted to phagocytosis and bacterial killing. 
However, more recent studies have demonstrated that plymorphonuclear cells 
(PMNs) produce a variety of proteins after being challenged with various stimuli 
(Oliveira et al., 1999). TNF-α, IL-1β and IL-8 are among the cytokines actively 
produced by neutrophils in vitro (Sakaguchi et al., 2008, Bliss et al., 2010). 
Knowledge about the role of neutrophils in inflammation is largely based on mice 
model and translational studies are required to evaluate the clinical importance of 
these observations in human (Phllipson and Kubes , 2011) since  proportion of 
PMNs circulating in mice is 30% compared to 70% in human (Amulic et al., 2012).    
Although neutrophils are generally the first cell type to reach the site of 
inflammation, the chronic course of leprosy is characterized by the absence of 
neutrophils in situ. An in vitro  study on the chemotactic responses of neutrophils 
derived from 52 patients with lepromatous leprosy in Israel and 24 healthy controls 
has shown that patients  with lepromatous leprosy of long-standing had significantly 
reduced chemotactic responses while those with recently acquired disease showed 
normal chemotactic responses (Wahba et al., 1980). The significance of neutrophils 
in leprosy has only been indicated in leprosy reactions particularly in Erythema 
nodosum Leprosum (ENL) (Goihman-Yahr et al., 1978, Hussain et al., 1995, 
Oliveira et al., 1999). 
2.19.1.4. Complements 
The complement system (CS) comprises an assembly of liver-manufactured, 
soluble and cell-bound proteins made up of more than 30 plasma and cell surface 
proteins that play a crucial role in host defence against infection. As the name 
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implies it represents the first line of defence which helps or complements the ability 
of antibodies and phagocytic cells to clear pathogens from the host (Morgan, 1998). 
Activation of CS results in opsonisation of pathogens and immune-complexes, 
recruitment of leukocytes, inflammation, and cell lysis.  
Recently complement system  have been perceived as a central constituent of innate 
immunity, defending the host against pathogens, coordinating various events during 
inflammation, and bridging innate and adaptive immune responses (Ricklin and 
Lambris, 2007). Complement system not only protect the host against infection but 
also contribute to the amplification of inflammation if activated in excess or 
inappropriately controlled (Abe, 2006). 
There are three major pathways of complement system:  i) the classic pathway (CP), 
which is usually initiated by antigen-antibody complexes followed by complement 
C1 activation; ii) the alternative pathway (AP), which is initiated by spontaneous 
hydrolysis of complement component C3; and iii) the mannose-binding lectin 
pathway (MBLP), which is activated by recognition of certain microbial 
polysaccharides. All the three pathways converge at the C3 activation step, leading 
to the generation of opsonins, inflammatory peptides, and formation of the 
membrane attack complex (Klaska and Nowak, 2007, Bao et al., 2015). 
The activation of complement through either the classical, lectin or alternative 
pathway converges on the deposition of C3b on the pathogen surface, a key event 
in complement mediated lysis. The activation of the CS also results in the release 
of small peptides such as C3a and C5a derived from the cleavage of CS proteins 
which have important biological properties such as mast cell degranulation and 
release of vasoactive amines resulting in vasodilatation and also chemotaxis of 
immune cells. Deposition of C3b on the pathogen/target cell initiates a cascade 
resulting in the assembly of the membrane-attack complex (MAC), forming pores 
on the surface of the target cell and its eventual osmotic death (Bao et al., 2015).  
Complements are probably the first immune systems experimentally studied in 
leprosy by  Lweis and Aronson (1923). The possible role of complements in the 
pathogenesis of leprosy was investigated by the increased level of activated C3 in 
the sera of lepromatous leprosy patients compared to the sera of tuberculoid leprosy 
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patients. Petchclai et al. (1973) and  Schlesinger and Horwitz (1990), showed that 
phagocytosis of M. Leprae is mediated by complement receptors CR1 and CR3 on 
human monocytes and macrophages in serum. 
Gomes et al. (2008), investigated on the levels of complement components and the 
total complement haemolytic activity in the sera of 91 patients with different 
clinical forms of leprosy (36 LL, 33 TT, 22 borderlines) and 31 healthy controls. 
Reduced complement haemolytic activity and lower level of C4 was observed in 
the sera of patients with LL as compared to patients with TT and borderlines. 
Furthermore, when a haemolytic assay was used under conditions favouring 
activation of the alternate pathway of complement activation, no significant 
difference was observed among all groups suggesting the importance of either the 
classical or the lectin pathway in leprosy. In the same study, the highest median 
level of mannan-binding lectin (MBL) were observed in the sera of  patients with 
LL which had lower haemolytic activity whereas patients with TT with lower MBL 
levels showed higher haemolytic activity. It has been reported that low level of 
mannan-binding lectin confer partial protection against some intracellular 
pathogens, such as M. leprae  and M. tuberculosis  (Kilpatrick, 2002).  
2.19.1.5. Cytokines and chemokines  
Cytokines are low molecular weight soluble proteins which mediate the cross-talk 
between the different cells of the immune system. They play a central role in the 
recruitment of the immune cells, the clonal development of the lymphocytes, the 
innate immune response and the effector response of most immune cells. The 
complex regulatory network of cytokines often determines the clinical course of 
infections and the outcome.   
In leprosy cytokine research focused mainly on the association of different cytokine 
profile within the spectrum of the disease specifically with the Th1-Th2 cytokine 
profiles (Barnes et al., 1992b, Fink  et al., 1996, Moubasher et al., 1998a). However, 
recent studies have shown that a distinct cytokine profile associated to a specific 
clinical form and reactions has not been attained (Misra et al., I995, Nath et al., 
2000).  
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A serum cytokine profile study in 56 untreated Egyptian leprosy patients has 
reported that IFN-γ and TNF-α were elevated in patients with TT as compared to 
patients with LL and these two cytokines were negatively correlated with the bacilli 
index (BI) in these patients. Patients with LL had a significantly higher serum levels 
of IL-2R, IL-10, and IL-1β and a significant positive correlations with the BI. 
Significantly high level of IFN-γ and TNF-α were reported in PB, and IL-1β and 
IL-10 in MB leprosy among untreated 38 PB and 13 MB Indian leprosy patients 
suggesting the importance of cytokines in classifying the various forms of leprosy 
and monitoring chemotherapy (Madan et al., 2011a). TNF-α has shown to be 
necessary in granuloma formation and mycobacterial elimination through 
stimulating the migration of immune-cells to the infection site (Mohan et al., 2001, 
Ehlers, 2005). Hence, the granuloma formation and M. leprae bacilli elimination in 
PB could be attributed to the high secretion of TNF-α in these clinical forms of 
leprosy.   
The predominance of IL4, IL-5 and IL-10 in patients with LL is associated with the 
immune suppression state of lepromatous leprosy. IL-10 has been demonstrated to 
supress macrophage mediated destruction of intracellular pathogens (Redpath et al., 
2014) and IL-4 has been shown to play a role in the Th2 polarization of CD4+ T-
cells (Cote-Sierra et al., 2004).  
Chemokines are small (8-10 kilo Daltons, kDa) protein molecules that form a 
subfamily of the cell signalling molecules or cytokines. They are potent chemo-
attractants of various leukocyte subsets and play an important role in promoting 
migration of effector cells in inflammatory diseases. Their profile in leprosy has not 
been well investigated unlike in other infectious diseases like tuberculosis and 
leishmaniasis (Oghumu et al., 2010, Slight and Khader, 2013). Kaplan et al. (1987b) 
have reported that although IP-10 was not constitutively expressed in LL lesions, 
administration of PPD or IFN-γ into the lesions resulted in a strong induction of IP-
10 expression especially by keratinocytes followed by monocytes, fibroblasts and 
endothelial cells in 65 lepromatous leprosy patients in India. On the contrary, TT 
lesions showed intense IP-10 expression by keratinocytes and infiltrating cells 
suggesting a differential expression of IP-10 across the leprosy spectrum associated 
with IFN-γ expression (Kaplan et al., 1987a).  IP-10 is an essential chemokine in 
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the migration of monocytes and activated T-lymphocytes and also enhanced T-cell 
adhesion to endothelial cells (Kawaguchi et al., 2015). Monocyte chemoattractant 
protein-1 (MCP-1) and IL-8 are two other chemokines studied in leprosy and they 
were found to be elevated in the sera of patients with LL (Lew et al., 2002, Hasan 
et al., 2004, Hasan et al., 2006).  
2.19.1.6. Phagocytosis and antigen presentation  
In previous sections it has been described that M. Leprae lives in macrophages, 
monocytes and Schwann cells. Phagocytosis of M. leprae by macrophages and 
Langerhans cells in the skin is mediated by complement receptors CR1 and CR4 on 
monocytes and macrophages interacting with complement component C3 fixed to 
the PGL-1 of M.leprae (Schlesinger and Horwitz, 1991a, Schlesinger and Horwitz, 
1991c). Langerhans cells are a subset of dendritic cells (DC) that initiate immune 
responses in the skin. Studies have shown that PGL-1 is involved in the invasion of 
Schwann cells through the basal lamina by binding to laminin-2 and its receptor α-
dystroglycan (Ng et al., 2000).  
M. leprae can resist lysosomal digestion by inhibiting phagosome/lysosome fusion 
inside the macrophage (Sibley et al., 1987, Degang et al., 2014). In addition, lipid 
components form a waxy coating around the bacteria and contribute to the 
resistance to desiccation and exposure to osmotic imbalance and extremes of pH 
(Sibley et al., 1987, Degang et al., 2014). Mechanisms underlying phagosomal 
arrest in mycobacterial phagocytosis have not been identified. Secretion of low 
molecular weight metabolite by bacteria, expression of enzyme capable of 
modifying a host component involved in regulation of endosomal interactions or 
modifications of the phagosomal membrane by lipids present on the mycobacterial 
outer surface are suggested as mechanisms of phagosomal arrest (Russell et al., 
2002).      
M. leprae antigens are presented via MHC class I and II pathways. M. leprae 
antigen presentation through MHC class I to CD8+ T-cells results by lysis of the 
infected cells by catalytic T- cells (CD8+ T-cells).  Presentation via MHC class II 
to CD4+ T-cells results in secretion of IL-2 and IFN-γ  followed by activation of 
macrophage and an influx of cells into the lesion. Human Schwann cells are able to 
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process and present M. leprae antigens through MHC class II to CD4+ T-cells and 
are efficiently killed by activated T-cells which may potentially cause destruction 
of Schwann cells and subsequently distraction of nerves  (Spierings et al., 2000).   
Mycobacterial antigen presentation is not restricted to MHC pathways. Peptide 
antigens are presented vial MHC class I and II.  Lipid and glycolipid mycobacterial 
antigens are presented via CD1 molecule.  It has been shown that CD1 restricted 
CD4+ T-cell lines from the skin lesions of leprosy patients found to produce IFN-γ  
suggesting that CD4+CD1-restricted T-cells in leprosy skin lesions are producing 
Th1-like cytokine pattern. Interestingly, compared to the MHC molecules, many 
different T-cell subsets, including CD4-, CD8- , TCRαβ and TCRγδ recognize 
antigens presented by CD1 in addition to CD4+ and CD8+ T-cells (Young and 
Moody, 2006). 
The antigen delivery mechanism to the CD1 and MHC class 1 pathways are not 
clearly elucidated and there is little information on how M. leprae antigens reach 
the cytoplasm for presentation by MHC-1. In contrast to MHC-II, which picks and 
process peptide antigens from within the endocytic environment, MHC-I is 
traditionally considered the primary mechanism by which cytosolically derived 
antigen can be processed and presented to T-cells. It is likely that M. leprae antigens 
enter the cytosol through pores in the phagosome although there could be other 
possible mechanisms.  It has been shown that Mycobacterium tuberculosis (Mtb) 
escape the phagosome and reside in the cytosol which was postulated as the primary 
mechanism by which Mtb antigens enter the MHC-I processing and presentation 
pathway (Harriff et al., 2012).  
2.19.2. The Adaptive Immune System and Leprosy  
The adaptive, also known as acquired, immune response requires the specific 
recognition of foreign antigens which activates the humoral response, resulting in 
B-cell maturation and antibody production, and the cell-mediated response, 
focussing mainly on T-cell activation. These divergent arms of the host response to 
pathogens are not mutually exclusive as T-cell help is required for antibody 
maturation and isotype switching while B-cells can function as antigen-presenting 
cells in the induction of specific T-cells. 
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2.19.2.1. Humoral immunity 
B-cells within the lymphoid tissue of the body such as bone marrow, spleen and 
lymph nodes, are stimulated by antigenic substances to proliferate and transform 
into plasma cells and the plasma cells in turn produce immunoglobulins (IgA, IgD, 
IgE, IgM and IgG,).  Immunoglobulins are also called antibodies.  
The study of the humoral immunity in leprosy has largely been restricted to 
antibodies. Patients towards lepromatous leprosy pole of the spectrum have higher 
antibody concentration as compared to with the tuberculoid pole.  Elevation of the 
polyclonal isotypes of these classes of antibody types with the highest concentration 
in patients with LL forms compared to the other clinical types of the spectrum (Turk 
and Bryceson., 1971, Touw et al., 1982, Jadhav et al., 2011, Kumar et al., 2014a). 
Although the in-situ presence of plasma cells and B-cells have been reported in 
leprosy by Ayer et al., the role of these cells in the pathology of leprosy lesions is 
unclear. Both Plasma cells and B-cells have been detected in tuberculoid and 
lepromatous leprosy lesions (Iyer  et al., 2007). It was speculated that these lesional 
B-cells could influence T-cell responses and /or play a role in maintaining the 
inflammatory reaction in leprosy partly through the local secretion of antibodies. 
However, data supporting such hypothesis are lacking. It is generally thought that 
antibodies against M. leprae components do not play a significant role in protection 
against leprosy. However, antibodies may play a role in the uptake of M. leprae by 
mononuclear phagocytes and hence the pathogenesis of the diseases (Schlesinger 
and Horwitz, 1990).  
Memory B-cells 
Memory B-cells are B-cell sub-types that are formed within germinal 
centres following primary infection and are important in generating an accelerated 
and more robust antibody-mediated immune response in the case of re-infection 
also known as a secondary immune response.  Recent advances in tracking antigen-
experienced memory B cells have shown the existence of different classes of 
memory B-cells that have considerable functional differences. Currently there are 
three types of memory B-cells: resting, activated and  tissue like memory B cells, 
(Kurosaki et al., 2015).  Activated memory B-cells  have been shown to function as 
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effective APCs to naive T-cells (McAdam et al., 1998). Tissue-like memory B-cells 
(TLM) expressed patterns of homing and inhibitory receptors similar to those 
described for antigen-specific T-cell exhaustion. These tissue like memory B-cells 
proliferate poorly in response to B-cell stimuli, which is consistent with high-level 
expression of multiple inhibitory receptors. Higher percentage of TLM has been 
reported in immunosuppressive diseases such as HIV (Moir et al., 2008, Amu et al., 
2014). During reviewing the literature on B-cell studies, we couldn’t find any 
literature dealing with memory B-cells and leprosy. Hence, memory B cells are 
potential future areas to elucidate the role of B-cells in leprosy and leprosy 
reactions.  
2.19.2.2. Cell-mediated immunity 
T-cells are produced in bone marrow and complete their development in the 
thymus. Once they completed their development, they enter the blood stream.  
When reached a peripheral lymphoid organ, they leave the blood to migrate through 
the lymphoid tissue, returning via the lymphatics to the bloodstream to recirculate 
between blood and peripheral lymphoid tissues. The stimulation and clonal 
expansion of a specific T-cell response occurs mainly in the peripheral lymphoid 
organs, where circulating naïve T-cells from the blood come in contact with 
antigens presented by antigen presenting cells such as macrophages, dendritic cells 
or B-cells depending on the nature of the antigen to be presented (Murphy et al., 
2012).   
On antigen recognition, naive T-cells differentiate into either CD4 or CD8 effector 
T-cells that are specialized for different activities. CD8 T-cells recognize pathogen 
peptide presented by major histocompatibility class one (MHC I) molecules and 
naive CD8 T-cells differentiate into cytotoxic effector T-cells that recognize and 
kill infected cells (Wang et al., 2001) . CD4 T-cells have a wide range of effector 
activities. After recognition of pathogen peptides presented by MHC II molecules, 
naive CD4 T-cells differentiate into district pathways that generate effector subsets 
with different immunological functions. The main CD4+ effector subsets currently 
distinguished are Th1, Th2, Th17, follicular T helper cells (Tfh) and regulatory T- 
cells (Tregs) (Figure 2.11).  Th1, Th2, Th17 and Tfh activate their target cells while 
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Tregs convey an inhibitory activity that limits the extent of immune activation (Kim 
and Cantor, 2014) (Figure 2.10).  
Effector CD8+ T-cells, employ antimicrobial effects either by secretion of cytokines 
such as IFN-γ and TNF-α activating T-cells or by direct mechanisms such as the 
perforin/granzyme pathway-mediated lysis of pathogen-infected cells. However, a 
subset of CD8+ T-cells with regulatory or suppressor activity has been reported by 
several authors (Xystrakis et al., 2004, Wang and Alexander, 2009, Menoret et al., 
2011, Boer et al., 2014). 
 
 
 
Figure 2.10.  Schematic model for helper cell differentiation from naïve CD4 T-
cells  (Leung et al., 2010) 
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 The classification of CD4+T- helper cells into Th1 and Th2 was initially based on 
the type of cytokines produced by these subsets in mice models  (Mosmann and 
Coffman, 1989). Later on, they were also described in human cells with similar 
cytokine profiles to the pervious findings in mice model (Romagnani, 1991). 
Human Th1 cells produces IL-2, a T-cell growth factor; IFN-γ, a main macrophage 
activating factor; and TNF-α which initiates granuloma formation (Romagnani, 
1991, Leung et al., 2010). The Th2 subset of CD4+ T-cells secretes IL-4, which is 
an autocrine growth factor, IL-5 and IL-6 which give signal for the differentiation 
and proliferation of B-cells (Romagnani, 2000).  
 Little is known about the activation and differentiation process of Th1/Th2. It is 
thought to be influenced by the type of antigen presenting cell and by the cytokine 
milieu at activation. It has been shown that antigen presentation by macrophage 
produces a Th1 response, whereas antigen presentation by B-cells induces a Th2 
response in mice model with ovalbumin (Gajewski et al., 1991).  Although the 
balance between Th1 and Th2 is crucial for the successes of the immune response 
in terms of the specificity and magnitude, it has been remained mysterious how the 
Th1/Th2-response profile is matched to district pathogens and to particular affected 
tissues (Pulendran, 2004, Magombedze et al., 2014).  
It has been described that the cytokines secreted by Th1 and Th2 show cross-
regulatory property for the differentiation and effector functions of the mutual 
phenotype. For example, IFN-γ selectively inhibits Th2 cells proliferation, while 
IL-4 and IL-10 inhibits cytokine secretion by Th1 cells (Fishman and Perelson, 
1999, Magombedze et al., 2014). Generally, the induction of Th1 during 
intracellular infection leads to protection while induction of Th2 associated to 
diseases progression.  
2.19.2.2.1. Cell- mediated Immunity and leprosy 
 Leprosy has been studied as a model system to study the Th1/Th2 hypothesis. 
Several independent studies (Ochoa et al., 1996, Moubasher et al., 1998a, Volc-
Platzer et al., 1988, Madan et al., 2011c) have shown that the infiltrating T-cells in 
TT leprosy produced IL-2 and IFN-γ within the lesions. These T-cells were not 
found in lepromatous lesions.  Analysis of gene expressions of IL-2 and IFN-γ also 
demonstrated a difference between TT and LL lesions. The mRNA expression for 
90 
 
IL-2 and IFN-γ was remarkably higher in TT lesions, whereas, IL-4, IL-5 and IL-
10 mRNAs expression were significantly higher within the lesions of LL compared 
with TT lesions (Yamamura et al., 1991, 1992). These finding suggest that the 
cytokines produced by Th1 subset in TT lesions correlated with healing tuberculoid 
lesions, whereas, a Th2 profile correlated with progressive in the lepromatous 
leprosy.  
On the other hand, many investigators reported that majority of patients showed a 
co-expression of IFN-γ and IL-4 irrespective of the  clinical forms of the spectrum 
(Misra et al., I995, Nath et al., 2000). However, it must be noted that when bulk 
PBMCs and mononuclear cells are stimulated with various M. leprae antigens, it 
may not necessarily reflect the situation of cells at the clonal level or within the 
lesion. Although there is some evidence for association of polarized Th1 and Th2 
responses in leprosy spectrum, in  T-cell populations such distinction may be less 
noticeable in vivo due to the complexity of the induced immune response  (Iyer  et 
al., 2007). 
2.19.2.2.2. Helper T-cells and cytotoxic T-cells in leprosy 
 Immunohistochemical studies have shown that CD4+ T-cells are the predominant 
subset in patients with TT whereas the majority of the T-lymphocytes population 
in patients with LL forms are of the CD8+ subtype (Modlin et al., 1983,  1986) . A 
study by Van Voorhis et al. (1982) showed that the T-cell infiltrate in LL lesions 
consisted almost exclusively of OKT8/Leu-2a cells in contrast to the predominance 
of OKT4/Leu-3a helper T-cells in TT lesions. Similar observation were also 
reported in subsequent studies (Narayanan et al., 1983, 1984).   
Moreover, it has been found that CD4+ T-cell clones from TT individuals 
proliferated in response to M. leprae antigens whereas CD8+ T-cell clones from 
lepromatous individuals did not proliferate but suppressed the proliferation of CD4+ 
T-cells (Damle et al., 1984, Modlin et al., 1986, Salgame et al., 1991 ).  However, 
one earlier study by Molloy et al. (1990) reported that the suppression of T-cell 
proliferation by Mycobacterium leprae is monocyte-dependent+ but not CD8+ T-
cells dependent. 
91 
 
2.19.2.2.3. Markers for identification of regulatory T-cells  
Regulatory T-cells (Tregs) formerly called suppressor T-cells are subpopulations 
which modulate the immune system and maintain tolerance to self-antigens.  Tregs 
are either produced in the thymus as a functionally mature subpopulation of T-cells 
and or induced from naive T-cells in the periphery (Oliveira et al., 1999, Shevach, 
2009). Tregs play an important role in the mechanism of host’s failure to control 
pathogen dissemination in severe forms of different chronic granulomatous 
diseases. While Tregs require antigen specific activation to carry out their effector 
function, their suppressive effects are mediated in a non-specific manner inhibiting 
both innate and adaptive immune responses (Martin et al., 2003, Tanriver et al., 
2009, Lehtimäki and Lahesmaa, 2013). 
Despite these reports, the presence and activity of Tregs and their subsets has not 
been conclusively demonstrated due to the lack of an absolute marker for these 
Tregs. Different combinations of cellular markers have been used by different 
researchers but none of them found to be an absolute marker. The difficulty of 
finding the best marker for Tregs may be explained by the complex nature of the 
immune regulation and the plasticity of immune cells which are perhaps controlled 
by the environment in which they are operating.  
Initially it was suggested that CD4+CD25+ T-cells as a good markers for Tregs but 
it was found that upon activation, all T-cells express CD25 (the α-chain of the IL-2 
receptor) (Sakaguchi et al., 1995, Yamazaki et al., 2003).  The concept of using 
CD4+CD25+ as a marker for regulatory T-cells was derived from the results 
obtained from mice model. In mice, CD4+ Tregs are a homogenous population, in 
which all CD4+CD25+ T-cells are regulatory T-cells. In humans, the Tregs are 
heterogeneous population, in which not all CD25+ T-cells are Tregs. This was first 
observed by a detailed analysis of human CD4+CD25+ populations by Baecher-
Allan et al. (2005).  Consequently it was demonstrated that CD25 is highly 
upregulated on T-cells upon stimulation (Corthay, 2009). The concept of 
CD4+CD25high as a marker for Tregs was introduced following the observation of 
the in vitro suppression of CD4+CD25high  in human cells  similar to that described 
in murine  cells while the cells expressing low-to-intermediate levels of CD25 did 
not (Baecher-Allan et al., 2005). However, a consensus on the thresholds of CD25 
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expression needed to delineate Treg cells within the CD25high population is difficult 
to attain, and variations in FoxP3 expression within the CD25high population have 
been observed even in healthy individuals (Miyara et al., 2009). Hence, the CD25 
high and low is highly subjective and it leads to subject bias.  
 It was also suggested that the immune-suppressive function of CD4+CD25+ T-cells 
was dependent on signalling via the down regulation of T-cell activation by 
cytotoxic lymphocyte- associated antigen-4 (CTLA-4) (Read et al., 2000). These 
findings raise the possibility that Tregs function contributes to the immune 
suppression characteristic of CTLA-4 signalling. However, CTLA-4 is also induced 
on CD4+ T-cells upon activation and hence increases the false positivity of Tregs 
measurement (Dhuban and Piccirillo, 2014) .  
The Ikaros family transcription factor Helios, was suggested to be exclusively 
expressed by Treg cells (Thornton et al., 2010), although later studies challenged 
this notion by reporting Helios up-regulation in in vitro-induced Treg cells (iTreg), 
which are thought to be generated from conventional T-cell precursors in the 
presence of TGF-β (Akimova et al., 2011).  
It was shown that low expression levels of CD127, in conjunction with CD25 
expression, provides highly enriched FoxP3+ population that encompasses the 
majority of FoxP3+ T-cells (Liu et al., 2006). But it has been reported that the 
stimulation of human T-cells may down- regulate CD127 (Miyara et al., 2009, Yu 
et al., 2012). FoxP3 remains as a good candidate marker of Tregs although the 
heterogeneity of FoxP3 is also coming to the picture. The concept of natural 
regulatory T-cells (nTregs) and inducible regulatory T-cells (iTregs) further 
complicated the search for reliable biomarker for Tregs. FoxP3+Helios- and 
FoxP3+Helios+ are suggested as a marker for nTregs and iTregs respectively 
(Elkord et al., 2015).  It has also been shown that Tregs are not confined to only 
CD4+ T-cells. CD8+ regulatory T- cells have had a long history in immunology as 
suppressor T-cells.  Like CD4+ Tregs, the concept of natural and induced CD8+ 
Tregs has also recently been introduced (Ndure and Flanagan, 2014). 
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2.19.2.2.4. Regulatory T-cells in leprosy  
Although, studies on the association of regulatory T-cell phenotypes with leprosy 
are lacking, an M. leprae specific suppression of effector response has been 
described before the characterisation of Tregs by several researchers (Sakaguchi, 
2003). The first report was made by  Mehra et al. (1979) when they noticed the 
suppression of proliferative responses to concanavalin A (an immunogenic lectin 
carbohydrate binding protein) in the presence of lepromin in LL and BL patients.  
Quantification of Tregs in the PBMCs stimulated in vitro by M. leprae antigenic 
preparations and phytohemagglutinin (PHA)  by flow cytometry as well as in the 
skin lesions by immunohistochemistry showed that M. leprae antigens induced low 
lymphoproliferative response (low mean cell counts per minute)  but high number 
of Tregs in lepromatous patients than in tuberculoid  patients (Brandt et al., 2000). 
A cell subset analysis and confocal microscopy of skin biopsies in Ethiopian 
leprosy patients showed increased frequencies of Tregs in the blood as well as in 
the  lesions of LL patients compared to TT and borderline leprosy lesions (Bobosha 
et al., 2014b).  Similar result has been reported in Indian patients by Saini et al. 
(2014b) and in Brazilian patients by Parente et al. (2015).   
2.19.2.2.5. Th-17 cells in leprosy 
IL-17-producing T-cells have recently been classified as a new effector T-cell 
subset, termed Th17, which is distinct from Th1, Th2 and Treg sub-sets. The 
differentiation of naïve CD4+ T-cells to IL-17 producing T-cells in the presence of 
IL-6 and TGF-β  by disfavouring Th1 and Th2 was first described by Veldhoen et 
al. (2006). Th-17 cells produce IL-17, IL- 22 and IL-21 effector cytokines. IL-17 is 
a member of a family of cytokines with at least 6 members in the human genome, 
including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17 is 
considered as a pro-inflammatory cytokine because it increases IL-6, IL-8, nitric 
oxide, TNF-α and IL- 1β production by various cell types.  It has been reported that 
IL-17 plays key role for activation and recruitment of neutrophils to the site of 
infection in inflammatory diseases (Miyamoto et al., 2003). The involvement of IL-
17 as pro-inflammatory cytokine in human inflammatory diseases such as 
rheumatoid arthritis, psoriasis, crohn’s diseases, systemic lupus erythematosus, 
inflammatory bowel diseases and multiple sclerosis has been reviewed by Miossec 
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(2009). It has been described that Th17 and Tregs have reciprocal functions. Th17 
induce inflammation in autoimmune diseases while Tregs inhibit autoimmune 
tissue damage (Bettelli et al., 2006). Recently it was reported that Th-17 cells 
transdifferentiate into regulatory T-cells during resolution of inflammation by a change in 
their signature transcriptional profile and the acquisition of potent regulatory 
capacity (Gagliani et al., 2015). 
A decreased mRNA expression of IL-17A in the skin lesions of patients with 
leprosy compared to the endemic healthy controls were reported by da Motta-
Passos et al. (2012) with undetectable IL-17A in the serum of both patients and 
controls. In these leprosy patients, lepromatous leprosy patients had low level of 
IL-17A mRNA expression which had an inverse linear correlation with bacilli index 
(BI). These authors suggested that the low mRNA expression for IL-17A in patients 
may be a constitutive genetic feature of leprosy patients or a circumstantial event 
induced by the local presence of the pathogen, as an escape mechanism. On the 
contrary, another study reported that the level of IL-17A in the serum of untreated 
leprosy patients (TT, BT and LL) was successfully measured by ELISA and the 
lowest amount of IL-17A was measured in LL cases (Abdallah et al., 2013).  
Similarly, IL-17 isoforms (IL17A-F) showed significantly higher expression and 
release in supernatants of antigen stimulated PBMCs cultures and dermal lesions of 
healthy contacts and tuberculoid leprosy as compared to lepromatous leprosy (Saini 
et al., 2013).  
2.19.2.2.6. Memory T- cells  
Adaptive immunity is said to have memory because the immune system learns. 
Some effector cells in both B and T cells differentiate into memory cells following 
infection. However, memory T-cells are extensively studied unlike memory B-
cells. Following infection, some of the activated T-cells become memory cells that 
exist in a state of readiness and have the ability to rapidly expand and fight off 
recurrence of the same disease (Figure 2.11). In a way, these cells learn from their 
experience of fighting a particular infection and so can use the most effective 
strategy to manage the same infection later. This ability to remember and learn is 
exploited during the process of vaccination. 
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Figure 2.11. The generation of memory cells (Farber et al., 2014). 
Memory T-cells have been characterized by their phenotypic and functional profiles 
into T-cell subsets, typically central memory (TCM) and effector memory (TEM) T- 
cells (Table 2.5). TCM and TEM cells phenotypically differ by the presence of lymph 
node homing receptors CD2L (L-selectin) and C-C chemokine receptpr-7 (CCR7) 
on their surface.  CD62-L and CCR7 are present on the surface of TCM but not on 
the TEM cells (Table 2.7). Naïve (NTC) and TCM express CD62L and CCR7 for 
migration to secondary lymphoid organ, and in the absence of these molecules TEM 
and effector T cells (TEC) accumulate in the peripheral tissues. Central memory T- 
cells produce IL-2 whereas, effector memory T-cells have increased secretion of 
effector cytokines such as IFN-γ and IL-4. TCM cells are relatively long-lived 
memory cells, which are able to differentiate into shorter-lived TEM cells upon 
antigen stimulation. In turn, TEM cells differentiate into TEC cells. TEC cells represent 
terminally differentiated TEM cells, and death is the outcome of increased antigen 
exposure and proliferation of TEC cells   (Farber et al., 2014, Flynn and Gorry, 2014). 
Stem memory T-cells (TSCM) have recently been described as sets of memory T-
cells in mice and humans consisting 2-4% of CD4+ and CD8+ T-cells population in 
the periphery. They thought to represent the earliest and long-lasting developmental 
stage of memory T-cells, displaying stem cell-like properties, and exhibiting a gene 
profile between naïve and central memory T-cells (Flynn and Gorry, 2014). 
Memory cells respond very quickly at 
subsequent exposure to antigen  
Once a lymphocyte has recognized a 
foreign antigen it expands to eliminate 
the infection   
Some cells become long lasting, > 20 
years “Memory” cells  
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Table 2.5.  Phenotypic characteristics of T-cell subsets  
Naïve  TSCM TCM TEM EC 
CD45RA+ CD45RA+ CD45RA- CD45RA- CD45RA+ 
CD45RO- CD45RO+ CD45RO+ CD45RO+ CD45RO- 
CCR7+ CCR7+ CCR7+ CCR7- CCR7- 
CD62L+ CD62L+ CD62L+ CD62L- CD62L- 
CD27+ CD27+ CD27+ CD27- CD27- 
CD28+ CD28+ CD28+ CD28+/- CD28- 
CD95- CD95+ CD95+ CD95+ CD95+ 
CD122- CD122+ CD122+ CD122+ CD122+ 
TCM, Central memory; TEM, effector memory; EC= effector T-cells ;TSCM, 
stem memory T-cell (Flynn and Gorry, 2014) 
Memory T-cells in leprosy: Few studies have intended to identify the memory 
T- cell subsets in leprosy. One earlier study has shown that in fresh and 
unstimulated blood leukocytes from leprosy patients, memory T-cells 
predominated in the PB form of the disease and correlated with IFN-γ production 
but such result was not observed in MB patients (Mitra et al., 1999b). However, 
the study did not use an experimental design that allowed discriminating 
identification of memory T-cell subsets.  
The correlation between central memory T-cell expression and pro-inflammatory 
cytokine production with clinical presentation of multibacillary leprosy relapse case 
has been investigated by Esquenazi et al. (2015). Increased frequency of central 
memory T-cells in relapsed patients was strongly correlated with the bacillary index 
and the number of skin lesions was reported by these authors. The study did not 
give attention to the memory subsets in leprosy spectrum rather they focused on 
relapse cases.  Memory T-cells have not been characterized across leprosy spectrum 
as well as in leprosy reactions. In the present study, for the first time we described 
memory-T cell subsets in lepromatous leprosy and ENL reactions. We also 
characterized memory T-cell subsets in other forms of leprosy (data not presented 
in this thesis).  
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CHAPTER 3: LEPROSY REACTIONS  
3.1. Introduction  
Leprosy reactions are immune-mediated incidents of acute or sub-acute 
inflammation and are the main complication of the disease. A significant proportion 
of leprosy patients, especially in the borderline region of the spectrum, develop 
leprosy reactions. Leprosy reactions can occur before MDT, during or after 
successful completion of MDT. There are two types of leprosy reactions:(i) 
Reversal Reactions (RR), also designated as type 1 leprosy reaction, which occurs 
mainly in patients with borderline leprosy  and (ii) Erythema Nodosum Leprosum 
(ENL) or type 2 leprosy reaction, which predominantly occurs in patients on the 
lepromatous side of the spectrum reviewed by Lockwood et al. (1993).   
3.2. Type 1 (Reversal) Reactions  
Type 1 reactions (T1Rs) manifest clinically with erythema and oedema of skin 
lesions and tender peripheral nerves with loss of nerve function. They are 
characterized clinically by acute inflammation of skin and/or nerves leading to 
nerve impairment if not treated rapidly (Walker and Lockwood, 2006). The 
characteristic signs of T1Rs are an erythematous swelling of existing lesions, 
appearance of new lesions and the onset or worsening of neuritis  (Naafs, 2000). 
Histopathologically, T1R is characterized by a shift towards the tuberculoid end of 
the leprosy spectrum with increased infiltrate of lymphocytes, epithelioid cells, 
giant cells, oedema and a decrease in bacterial load. 
3.1.1. Epidemiology  
Type 1 reactions occur in up to 30% of patients with borderline forms of leprosy 
(Walker and Lockwood, 2006). In a study conducted in Brazil, among 122 leprosy 
patients investigated 44 (36.1%) had type one reactions (Motta et al., 2012b).  In a 
retrospective study conducted in India, from 494 leprosy patients a clinical evidence 
of  T1R was found in 44 (10.9%) (Lockwood et al., 1993). The ALERT MDT field 
evaluation study reported that among 594 leprosy patients 16.5% of them had 
developed T1Rs (Saunderson  et al., 2000).  
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In Nepal, 31% (204/658) leprosy patients with borderline spectrum had a T1Rs 
during the MDT treatment (Roche et al., 1991b).  Similarly, about 36% (50/305) of 
a cohort of MB patients in Malawi had developed T1Rs during a three year follow-
up period (Ponnighaus and Boerrigter, 1995). In INFIR Indian cohort study about 
20% (60/303) had T1Rs at recruitment and up to 39% (74/188) had experienced 
T1R or nerve function impairment (NFI) during the two year follow-up  period (Van 
Brakel et al., 2005b).   
3.1.2. Risk factor  
The risk of a patient developing T1Rs is higher in the first six months of MDT 
treatment (Lockwood and Sinha, 1999).  A retrospective study from China has 
indicated that among 159 cases with T1Rs, 66 (41·5%) had occurred during the first 
6 months of MDT treatment and only 15 (9·4%) had occurred after 12 months of 
MDT treatment (Shen et al., 2005). On the other hand, Ethiopian (Saunderson  et 
al., 2000) and Indian (Kumar et al., 2004) cohort studies have shown that patients 
continue to develop T1Rs and neuropathy in the third year after diagnosis and 
beyond, regardless of MDT completion.     
Patients with borderline leprosy are at higher risk of developing T1R (Ranque et 
al., 2007). Individuals who have WHO disability grades 1 and 2 at diagnosis are 
significantly more likely to have severe T1Rs (Schreuder, 1998).  Borderline 
patients with positive slit-skin-smear (SSS) test,  detectable M. leprae DNA by PCR 
and positive for anti-PGL-1 antibodies test  have an increased risk of T1R (Roche 
et al., 1991a).  
In an Ethiopian cohort study of 431 patients with leprosy, a single nucleotide 
polymorphism (SNP) in TLR2 (597C→597T) was found to be associated with 
protection against T1Rs, whereas a 280-bp microsatellite marker was associated 
with an increased risk of T1Rs (Bochud et al., 2008).  In another cohort study of 
441 Ethiopian patients with leprosy, TLR4 SNP (1530G → 1530T) was more 
frequent in individuals with T1R suggesting that TLR4 SNP of G to T as a risk 
factor for T1R and two single nucleotide polymorphisms in TLR4 (896G →A and 
1196C→T were associated with protective effect against T1R (Bochud et al., 2009).  
An in vivo study in Nepalese patients with leprosy has shown an increased TLR2 
and TLR4 gene expression in untreated patients with T1Rs suggesting the 
99 
 
involvement of TLR2 and TLR4 in the pathogenesis of T1Rs (Walker et al., 2012). 
Other host genetic factors such as: HLA-DR B1, nucleotide-binding 
oligomerisation domain containing 2 (NOD2), vitamin D receptor and natural 
resistance-associated macrophage protein-1 have been indicated to be associated 
with T1Rs (Fava et al., 2012).     
3.2.3. Diagnosis of Type 1 (reversal) reactions  
The diagnosis of T1R is usually clinical but sometimes histological finding is used 
to supplement the clinical diagnosis. The important diagnostic features used by 
pathologist in diagnosing T1R include intra-granuloma oedema, giant cell size, 
giant cell numbers, dermal oedema and HLA-DR expression (Walker and 
Lockwood, 2006, Lockwood et al., 2008).  
In a prospective study based in India, skin biopsies were collected from 99 patients 
with clinically diagnosed T1R and 52 non reactional controls, pathologists 
diagnosed  T1R only 50% of clinically diagnosed  reactions ( Lockwood 2007).  
These authors concluded that T1R is under diagnosed by histology compared to 
clinical diagnosis. On the other hand, in INFIR cohort study in India, from a total 
of 265 newly diagnosed leprosy patients, T1R was diagnosed histologically in 
42.4% of  patients but only in 20.8% clinically (Lockwood et al., 2012).  
Explanation for the discrepancy between the two studies is not straight forward. 
However, it clearly indicates the existing challenges for accurate diagnosis of 
reactions. Clinical signs heterogeneity within the reaction, lack of standard criteria 
for histological diagnosis, experience of pathologists and clinicians in leprosy 
reactions diagnosis could be one of the reasons for the observed difference in these 
studies. However, these reasons need to be confirmed by further study.  
3.2.4. Treatment of Type 1 reactions 
The treatment of T1Rs is aimed at resolving the skin lesions and minimizing the 
risk of permanent nerve damage particularly to the peripheral nerve trunks. 
According to WHO recommendation, severe forms of T1Rs should be treated with 
a course of steroids usually for 3-6 months. The usual course begins with 40-60mg 
daily and then gradually reduced weekly or fortnightly and eventually stopped. 
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Most reversal reactions and neuritis are treated successfully with a standard 12-
week course corticosteroid treatment  (World Health Organization, 2006). 
 3.3. ENL (Type II) Reactions 
ENL (Type-2) reaction  is an immune-mediated inflammatory complication, 
occurring in about 50% of LL and 10% BL patients (Van Veen et al., 2009).  Murata 
in 1912 gave the first clinical and histological description of the reactional lesions 
in leprosy which he referred as erythema nodosum leprosum (ENL) (Penna et al., 
2008). However, since the term ENL was descriptive of only the nodular lesion in 
the skin, Jopling in 1959 proposed the name type II reaction because of the 
numerous other systemic symptoms associated with the condition (Bwire and 
Kawuma, 1993). However, ENL is the commonly used terminology in leprosy 
literature and so, we adhere to this in this thesis.   
3.1.1. Epidemiology  
ENL reactions can occur before, during or after treatment (Shen et al., 2005). 
Accurate data on global and regional prevalence of ENL reaction is lacking 
(Voorend and Post, 2013). In Six prospective and five retrospective field-based 
studies the cumulative frequency of ENL varied between 0.2% in an  Indian study 
(Rao et al., 1994)  and 4.6% in a Chinese study (Shen et al., 2009a). Three 
prospective studies from ALERT, leprosy control services in Ethiopia reported a 
cumulative frequency of ENL at 2.5% among MB cases after an average follow-up 
of 2 and a half years, but 5% after 10-years follow-up (Becx-Bleumink and Berhe, 
1992, de Rijk et al., 1994, Saunderson et al., 2000b). In INFIR cohort study  of 303 
newly diagnosed MB  leprosy patients in India, it was found that 17% LL and 7% 
BL had ENL (Lockwood et al., 2012). These authors reported that ENL diagnosis 
was made at baseline and highlighted that a higher rate of ENL reactions would be 
expected if cohort patients were followed-up after treatment.  
The frequency of ENL reaction according to the Ridley- Jopling classification has 
been reported in many studies (Table 3.1 and 3.2).  In field studies, higher frequency 
of ENL is reported in LL patents (15.4%, range: 11.1 to 26%) compared to BL 
patients (4.1%, range: 2.7 to 5.1%) (Table 3.1). In hospital based studies higher 
proportions were reported, in Brazil up to 56.4% and in India from 24.2% to 50.9 
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% (Shen et al., 2009a).   High rate ENL frequency (91%) among LL patients has 
been reported from Brazil showing that ENL is more common in Brazilian LL 
patients (Nery et al., 1998). In a retrospective study of 481 BL and LL patients in 
Hyderabad, ENL occurred in 49.4% of LL and 9.0% of  BL leprosy cases (Pocaterra 
et al., 2006).  
Some authors suggest that since the introduction of MDT, the frequency and 
severity of ENL may have been decreased by the anti-inflammatory action of the 
clofazimine component of MDT (Kahawita and Lockwood, 2008).  A prospective 
cohort study in Philippines reported that among 296 patients treated with MDT for 
12 months and 293 patients for 24 months, ENL was not significantly more 
common, but it was longer-lasting and more severe in patients receiving 
only 12 months of MDT, as compared with those receiving 24 months treatment 
(Balagon et al., 2011). This would be compatible with a protective effect of 
clofazimine.  
Table 3.1.  Incidence of ENL in Field based studies  
country Follow up 
period 
(years) 
Number of 
leprosy of 
cases 
Definition 
of cases 
ENL 
n(%) 
Authors 
Prospective observational cohort studies 
Bangladesh 5 337 MB 8(2.2) (Richardus et al., 2004) 
Thailand >2 133 BL+LL 16(12.0) (Schreuder, 1998) 
Ethiopia 3.5 375 BL+LL 19(5.0) (Becx-Bleumink and 
Berhe, 1992) 
Ethiopia 2.5-4 158 MB 4(2.5) (de Rijk et al., 1994) 
Ethiopia 10 300 MB 16(5.3) (Saunderson et al., 
2000a) 
India 1-7 106 MB 4(3.8) (Rao et al., 1994) 
Retrospective  observational cohort studies 
Bangladesh n/a 471 MB 10(2.1) (Richardus et al., 1996, 
Desikan et al., 2007) 
India 7 1067 BL+LL  (Desikan et al., 2007) 
Cross-sectional studies 
China n/a 726 MB 9(1.2) (Shen et al., 2009a)  
Indonesia n/a 586 MB 13(2.2) (Bernink and Voskens, 
1997) 
Total 
(average) 
 4,279  194(4.5)  
 n/a: data not available 
Source: Table 3.1.and 3.2 adapted from (Voorend and Post, 2013).  
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Table 3.2.  Incidence of ENL cases in hospital populations  
country  follow-
up period 
years 
leprosy 
cases  
(no)  
definition  ENL N 
(%) 
Authors  
  Retrospective  observational cohort studies   
India >2-10 578 BB+BL+LL 164 (28.4) (Kumar et al., 2003) 
India  >1 481 BL+LL 117(24.4) (Pocaterra et al., 2006)  
Philippines  4 296 MB 36 (12.2)  (Balagon et al., 2011) 
Nepal  2 175 BL+LL 10(5.7)  (Van Brakel et al., 1994) 
Brazil  2 169 BB+BL+LL 43(25.4)  (Nery JAC et al., 199) 
Brazil  2 162 BB+BL+LL 51 (31)  (Nery et al., 1998) 
India  2 990 BB+BL+LL 121(12.2)  (Salodkar and Kalla, 1995) 
India  3-13 1494 MB 337(22.5)  (Kumar et al., 2004) 
Brazil  unknown 218 MB 28 (13)  (Katoch et al., 2008) 
  Prospective observational cohort studies   
India  2 303 MB 6(2) (Van Brakel et al., 2005b) 
India  <8 980 MB 2(0.2) (Vijayakumaran et al., 
1995) 
Thailand   3 119 BL+LL 44(37.0)  (Scollard et al., 1994) 
India  6 100 MB 6(6)  (Katoch et al., 2008) 
Philippines  3 169 MB 10 (7.0)  (Balagon et al., 2010) 
 Cross-sectional studies    
Uganda  n/a 2743 MB 18 (0.7)  (Bwire and Kawuma, 
1993) 
India  " 1141 MB 187 (16.4)  (Arora et al., 2008) 
Nepal  " 563 BL+LL 107(`19)  (Manandhar et al., 1999) 
Brazil " 664 MB 192 (28.9)  (Penna et al., 2008) 
Netherlands " 231 BB+BL+LL 17(7.4)  (Post et al., 1994) 
Morocco " 229 MB 76(33)  (Hali F et al., 2009) 
India " 187 BB+BL+LL 25(13.3)  (Sharma et al., 2004) 
Yemen  " 123 BB+BL+LL 33(26.8) (Mekhlafi and al-Qubati, 
1996) 
Brazil " 120 MB 13(10.8)  (Rodrigues et al., 2000) 
 Controlled trails   
Thailand,  
Philippines, 
Korea  
5 358 BL+LL 36 (10)  (Cellona et al., 1990) 
 India 8 304 BB+BL+LL 30 (10)  (Sharma et al., 2004) 
Zaire   3 280 MB 34(12)  (Groenen et al., 1986) 
Brazil  2 140 MB 48 (34.2)  (Gallo et al., 1996) 
  Total  13317   1791(13.4)    
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3.3.2. Risk factors 
Studies have shown that a BI > 4 significantly increases the risk of developing ENL 
and the degree of skin infiltration correlates positively with risk of ENL  
(Manandhar et al., 1999).  For individuals with LL and BL with BI ≥ 6, the odds of 
developing ENL was 8.4 and 5.2 respectively (Pocaterra et al., 2006). Similarly, an 
Ethiopian study reported that the ENL frequency was 9.6 times higher among LL 
patients compared to BL and BB (Becx-Bleumink and Berhe, 1992). In a  
retrospective study of 563 Nepali patients, the greater infiltration of the skin and BI 
> 4 reported as a high risk factor for developing ENL reactions (Manandhar et al., 
1999).  
Pregnancy and lactation suggested as significant triggering factors for severe and 
recurrent ENL(Lockwood and Sinha, 1999). The frequency of ENL among 
Ethiopian pregnant women increased by 59% among LL and 22% among BL 
(Duncan and Pearson, 1984).  An Indian study  reported that among 32 women with  
ENL, 62% were either pregnant or lactating (Arora et al., 2008). Intrecurrent 
infections, vaccination, stress, genetics and age (puberty) have also been implicated 
as a risk factor for ENL (Kahawita and Lockwood, 2008, Motta et al., 2012a).    
The host genetic factors as a risk factors for ENL have not been addressed. Some 
studies have shown the associations of some genes with ENL such as variants in 
vitamin D receptor (VDR) genes, IL-6, Nucleotide-Binding Oligomerization 
Domain Containing-2 (NOD2) and complement C4B. In a cohort of 409 patients 
with leprosy in Brazil, evidence for association between ENL reaction and IL-
6 single-nucleotide polymorphisms rs2069832, rs2069845, rs2069845 and 
rs1800795 which correlates with increased IL-6 plasma production has been 
reported. Such association was not found inT1R (Sousa et al., 2012). Low vitamin 
D receptor expression level has been reported to be correlated with ENL reaction 
in Indian patients (Mandal et al., 2015). A cross-sectional study in Nepalese 
patients, examined polymorphisms in the NOD2 gene region among 124 patients 
with ENL reaction and 428 non-reactional patients with LL/ BL has found that   
NOD2 genetic variants are associated with ENL reaction (Berrington et al., 2010).  
One study which included 72 Brazilian patients with leprosy (43 ENL and 36 non-
reactional LL) has reported that C4B deficiency (C4B*Q0) was significantly higher 
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among patients with ENL compared to LL suggesting that C4B deficiency may 
affect both the phagocytosis during the reactivation of the inflammatory response 
in ENL reaction and the stimulation of cellular immune responses, possibly through 
IP-10-related pathways (de Messias et al., 1993). A Brazilian study consisting of 
201 leprosy cases has shown that the SNP 274T→ C of NRAMP1 as a risk factor 
for T1R while being protective for ENL (Teixeira et al., 2010) .  
3.3.3. Clinical features of ENL reactions  
ENL usually affects multiple organs and causes systemic illness (Walker and 
Lockwood, 2006).  The onset of ENL is acute, but it may pass into a chronic phase 
and can be recurrent.  ENL produces fever and in the skin painful and tender red 
papules or nodules occur in crops often affecting the face and extensor surfaces of 
the limbs. The lesions may be superficial or deep causing a panniculitis. ENL 
reactions may also produce uveitis, neuritis, arthritis, dactylitis, lymphadenitis and 
orchitis. The recurrent inflammation of eyes can lead to blindness and the testes to 
sterility (Walker and Lockwood, 2006). 
Reoccurrence (episode) of reaction is common in patients with ENL population. 
Higher episodes have been reported in hospital based studies. A systematic review 
of epidemiological data of ENL from 1980 to 2013 has reported that the frequency 
of multiples episodes in patients with ENL reactions ranged from 39% to 77.3% 
with an average of 2.6 episodes (range: 1-8 episodes). These patients experienced 
episodes on average at 14.35 days ( range: 8-20 days )  (Voorend and Post, 2013).  
Episodes of active ENL has been reported to last from 14.4  (Hali F et al., 2009) 
days to  26.1 weeks  (Balagon et al., 2010).  In Ethiopia, almost one third of patients 
with ENL reactions develop chronic condition lasting more than 2 years 
(Saunderson et al., 2000c). ENL often has a protracted course with episodes 
occurring over several more years although the majority last 12 to 24 months 
(Kumar et al., 2004, Pocaterra et al., 2006). 
In an 11-year retrospective case record analysis of 481 outpatients with BL/LL at 
the Dhoolpet Leprosy Research Centre in Hyderabad, three patterns of ENL were 
identified: single actuate episodes, recurrent acute episodes and chronic ENL 
(Pocaterra et al., 2006). Acute episodes were defined as single episodes responding 
to steroid treatment and accounted only 6% of ENL cases, acute multiple ENL 
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(32%) included recurrent episodes with periods off treatment, and chronic when 
patients needed steroid treatment for more than six months (62%).  Among 107 
ENL cases identified in retrospective study in Nepal, 45% had more than one 
episode of ENL (Manandhar et al., 1999).  
3.3.4. Pathology  
An intense neutrophilic infiltrate throughout the dermis and sub-cutis is the 
histological feature seen in biopsies of acute ENL skin lesions.  Polymorphs 
infiltrate the granuloma and there is vasculitis and macrophage degeneration 
together with the breakdown of foam cells. Tissue oedema, vessels exhibiting 
fibrinoid necrosis and associated vasculitis may also present. There is a local; 
reduction in bacterial load; most of the organisms are fragmented and granular (Post 
et al., 1994, Kahawita and Lockwood, 2008). As the lesion progress to chronic 
phase, macrophages are substituted by lymphocytes, plasma cells and histiocytes 
representing chronic inflammatory infiltrate. One study has reported that 36% of 
ENL lesions from Pakistani patients had no visible neutrophil infiltration and C-
reactive protein (CRP) was eight-fold lower in these patients (Hussain et al., 1995). 
It has been previously reported that the timing of biopsy samples is important for 
an accurate picture of ENL  (MEN, 1996). 
3.3.5. Diagnosis 
There is no definitive laboratory test for ENL.  ENL is diagnosed clinically. Sudden 
eruptions of erythematous tender (red) papule, nodules, or plaques which may 
ulcerate are used as major criteria for diagnosis of ENL. Other diagnostic criteria 
such as mild fever, tender enlarged nerve and increased loss of sensation, oedema 
of extremities or face are used as supportive diagnostic criteria. Clinical diagnosis 
can be supplemented by histopathological features of the skin lesion. Histologically 
ENL is characterized by infiltration with neutrophil usually surrounding blood 
vessels and invading the walls. For accurate diagnosis of the disease, 
communication between the clinician and the pathologist is necessary as in chronic 
ENL lesions neutrophil infiltration may not be evident.    
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3.3.6. Treatment of ENL reaction  
The treatment of ENL is aimed at to control acute inflammation, easing pain and 
preventing eye and nerve damage. The majority of ENL reactions require 
immunosuppression. The more severe ones require high doses of corticosteroids, 
usually starting with prednisolone 60mg daily (World Health Organization, 2006). 
The recurrent nature of the condition means that steroid-induced side effects may 
become a significant problem. Thalidomide 300-400mg daily has a remarkable 
effect in controlling ENL and preventing recurrences. However, teratogenicity and 
possible neurotoxicity of thalidomide may limit its wide application.  
Steroids have been the main treatment for ENL since 1950s following the use of 4 
to 7 days course of injections with cortisol or adrenocorticotropic hormone (ACTH) 
for treating leprosy reaction (Chaussinand, 1950) . However, it was also noted that 
reactions re-appeared when the treatment was stopped. As a result, the treatment 
duration and dose of corticosteroid was improved.   
World Health Organization recommends a 12-weeks course of prednisolone (daily 
dose not exceeding 1mg/kg body weight) as effective treatment of ENL reaction. 
However, prednisolone it is not efficacious in preventing reoccurrences. Usually an 
ENL flare-up occurs when the prednisolone dose is decreased to 20-30mg per day 
(Sharma et al., 2004). Clinical experience suggests that higher doses of 
prednisolone being needed to control flare-ups. Furthermore, a considerable 
number of patients with ENL may become steroid dependent. The use of potent 
immunosuppressant like prednisolone is also potentially problematic in areas 
endemic for severe infectious diseases such as tuberculosis. High doses of 
corticosteroid treatment of patients with ENL for prolonged time has been 
implicated in steroid induced osteoporosis, diabetes mellitus and infections 
(Kahawita et al., 2008, Papang et al., 2009).    
The investigation of  alternative drugs with less adverse effects such as clofazimine 
(Groenen et al., 1986), pentoxifylline (Mekhlafi and al-Qubati, 1996), methotrexate 
(Gallo et al., 1996), cyclosporine, (Rodrigues et al., 2000, Lambert et al., 2016) 
have shown some promising hopes but not successful yet. Therefore, alternative 
drugs with less adverse effects for treatment of ENL should be explored.    
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CHAPTER 4:  IMMUNOLOGY OF LEPROSY REACTIONS   
4.1. Introduction   
No clinical or laboratory tests can accurately predict who is most likely to develop 
a reaction or when it might occur. The risk factors and mechanisms responsible for 
each type of reactions are not yet well defined. Several studies have reported 
associations between immunological markers and leprosy reactions. However, the 
reports are inconsistent. Most of these studies involved small number of patients.  
Case definitions, controls and the assay methods used were not described in the 
majority of the studies.  The progress and current status of immunological studies 
of leprosy reactions are reviewed in the following sections.  
4.2. Immunology of Type 1 reactions  
T1Rs are delayed hypersensitivity reactions that occur predominantly in borderline 
forms of leprosy (Job, 1994). M. leprae antigens have been demonstrated in the 
nerves and skin of patients experiencing T1Rs. The antigens are localised to 
Schwann cells and macrophages (Lockwood et al., 2002). M. leprae infection may 
lead to the expression of MHC II on the surface of the cells and this may give rise 
to antigen presentation which triggers CD4 lymphocyte killing of the cell mediated 
by cytokines such as TNF-α (Ochoa et al., 2001).  However, the causes and 
mechanisms of the spontaneous enhancement of cellular immunity and delayed 
hypersensitivity to M. leprae antigens is not clearly known (Scollard et al., 2006). 
Increased lymphocyte proliferation in response to M. leprae antigens in vitro during 
type 1 reaction has also been reported (Godal and Negassi, 1973b).  
Immunophenotyping studies of skin lesions  from patients with T1R has shown that 
the number and percentages of CD4+ T-cells are increased in T1R skin lesions  
compared to the skin lesion of  borderlines. An increased TNF-α protein detectable 
in the skin and nerves of 14 Indian patients during T1Rs has been reported by 
counting the proportion of cells positively stained using anti-TNF-α mouse 
antibody. Immunohistochemical results were supported by TNF-α mRNA gene 
expression  which was measured  by in-situ hybridisation method (Khanolkar-
Young et al., 1995). 
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T1Rs appear to be mediated via Th1 type cells and lesions in reaction express the 
pro-inflammatory IFN-γ, IL-12 and the oxygen free radical producer inducible 
nitric oxide synthase (iNOS) (Little et al., 2001, Venturini et al., 211). The INFR 
cohort study has reported  increased levels of TNF-α, TGF-β and iNOS in the 
biopsies of 6  patients with type 1 reactions (Lockwood et al., 2011).  Similarly, 
Madan et al. (2011a) has shown  that  the levels of TNF-α and  IL-1β were  
significantly higher in T1Rs  compared to  PB cases. In this study, the level of IFN-
γ in T1Rs was not significantly different compared to that of PB.  
The cytokine mRNA genes expression  study involving small number of patients  
(8 leprosy patients  with T1Rs)  has shown that IL-β, TNF-α, IL-2, and IFN-γ 
mRNA were significantly increased in the skin lesions of T1Rs compared to in other 
leprosy types (Yamamura et al., 1992). The expression of mRNA of various 
chemokines including IL-8, MCP-1 and CCL5 (or RANTES) were found to be  
higher in the skin lesions during type 1 reactions (Kirkaldy et al., 2003). It has been 
shown that 10 smear negative newly diagnosed BT patients with T1R had 
significantly elevated levels of plasma CXCL10 and IL-6 compared to BT non-
reactional controls. None of these individuals had neuritis (Stefani et al., 2009). 
Longitudinal immune responses and gene expression profiles study in T1Rs 
has shown  increased production of IFN-γ, IP-10, CXCL9, IL-17A and VEGF at 
diagnosis of T1R compared to before T1R, whereas a simultaneous decrease in IL-
10 and G-CSF was observed at T1R (Geluk et al., 2014).  In this study,  RNA 
expression profiles revealed that IFN-induced genes, vascular endothelial growth 
factor (VEGF), and genes associated with cytotoxic T-cell responses (GNLY, 
GZMA/B, PRF1) were upregulated during T1R, whereas expression of T-cell 
regulation-associated genes were decreased. 
A Longitudinal immune profiles analyses of type 1 leprosy reactions in Bangladesh, 
Brazil, Ethiopia and Nepal has shown that IFN-γ-, IP-10-, IL-17- and VEGF-
production by M. leprae (antigen)-stimulated PBMC peaked at diagnosis of type 1 
reactions, compared to when reactions were absent. In contrast, IL-10 production 
decreased during type 1 reaction while increasing after treatment (Khadge et al., 
2015). These authors have also reported that  the circulating IP-10 in sera were 
significantly increased during type 1 reactions while humoral immunity, 
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characterized by M. leprae-specific antibody detection, did not identify the onset of 
type 1 reactions.  
4.3. Immunology of Erythema Nodosum Leprosum  
ENL reactions were initially thought to be due to immune-complex deposition in 
the blood vessels suggestive of Arthus reaction (Wemambu et al., 1969a). However, 
immune-complex deposition is not consistently demonstrable and typical features 
of immune-complex diseases are absent in ENL. Recent data suggest that cell-
mediated immune responses may also play an important role in the pathogenesis of 
the disease (Laal et al., 1985 , Nath et al., 2015). In the following sections, the 
research findings supporting these two hypotheses are reviewed. Following the 
review, the strengths and weakness of these findings are accounted.    
4.3.1. Immune-complex deposition as causes for ENL  
An immune-complex (IC) is formed by the binding of an antibody to soluble 
antigens. Once the immune-complex is formed, a number of responses such as 
complement activation, opsonisation, phagocytosis, or processing by proteases may 
be initiated. Failure to clear the immune-complex results in deposition of the 
complexes in situ or in the circulation and it becomes detrimental to the host.  
Deposition of the antigen-antibody complex in tissues or in the circulation is the 
hallmark of human autoimmune diseases (Schmidt and Gessner, 2005) such as  
vasculitis (serum sickness), Systemic lupus erythematosus (SLE) and Rheumatoid 
arthritis (RA) (Mayadas et al., 2009). 
The immune-complex aetiology of ENL was  first proposed in the late 1960s, by 
Wemambu et al. (1969a). In this study, 17 ENL and 6 uncomplicated LL controls 
were included. Direct immunofluorescence was used in order to demonstrate 
granular deposits of immunoglobulin and complement in a perivascular distribution 
corresponding to the polymorphonuclear infiltration in the dermis of 10 out of 17 
ENL lesions but not in those of uncomplicated LL lesions.  Soluble mycobacterial 
antigen was found in some of (7/17) the immune-complexes. Following the 
observation, these authors suggested ENL as Arthus reaction. This concept was 
supported by the presence of circulating immune-complexes and the demonstration 
of mycobacterial antigens, complement and immunoglobulins around the vessels in 
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some lesions of patients with ENL (Wemambu et al., 1969b, Turk and Waters, 
1971, Drutz and Gutman, 1973). An Arthus reaction involves deposition of 
immune-complexes with vasculitis and plymorphonuclear infiltrate. Others suggest 
that the immune-complexes are extravascular and hence, ENL is different from the 
Arthus  reaction (Ridley and Ridley, 1983, Andreoli et al., 1985). 
Following the Wemambu and his group’s report, a larger number of leprosy patients 
(38 ENL and 13 LL) were studied to confirm the previous findings by Wemambu 
et.al.  In this study, although, the immunoglobulin, complements and mycobacterial 
antigen were not detected in the lesions of LL controls, these substances were 
detected  in less than half of the skin biopsies (21/47) taken from  patients with ENL 
(Waters et al., 1971). In another study, nonspecific immunoglobulin deposits (IgG) 
were demonstrated in the dermis of all  skin lesions of patients with ENL(25 ENL) 
but none of the 10 LL patient controls had such granular deposits (Anthony et al., 
1978). They also reported that serum complement (C3) levels were decreased in 22 
out of 25 patients with ENL and elevated in 8 out of 10 LL patient controls without 
reaction. Immunoglobulin deposits were not consistently seen in all patients with 
ENL in the blood vessels and in cell infiltration. Immunoglobulin deposits were 
seen in the blood vessels (7/25) and in cell infiltration (12/25) of ENL cases.  The 
authors suggested that the negative fluorescence results in the blood vessels and cell 
infiltration in patients with ENL were due to the biopsies being taken when the 
lesion was subsiding.     
The role of immune-complexes in the sera of patients with leprosy had been 
addressed by several studies in the 1970s and 1980s using different methods  such 
as the C1q immunoassay  (Moran et al., 1972), the platelet aggregation test (PAT) 
(Wager et al., 1978, Sehgal and Kumar, 1981), The Rajii cell binding technique and 
radioactive method (Geniteau et al., 1981),  125I-C1q binding activity (Bjorvatn et 
al., 1976), Polyethylene glycol (PEG) (Park et al., 1984, Rojas and Segal-Eiras, 
1997), Phenolic glycolipid-1 (PGL-1) (Andreoli et al., 1985). However, serum 
samples from leprosy with or without reaction showed positivity to these tests.  
The presence of soluble immune-complexes was investigated in the sera of patients 
with LL forms by measuring the reactivity of serum samples  with C1-q  
complement (Rojas-Espinosa et al., 1972). These authors reported that 78% (39/51) 
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of patients with lepromatous leprosy had immune-complexes, while only 33% (3/9) 
patients with BL had detectable immune-complexes. However, it was not 
mentioned in the study whether the patients with LL included to the study had 
reaction.  By using a non-quantitative agarose C1-q precipitation method, Moran et 
al. (1972) confirmed the presence of immune-complexes in the sera of 76% of ENL 
cases.  Bjorvatn et al. (1976) measured the serum binding activity 125I-C1q in 26 
Ethiopian leprosy patients (13 ENL, 7 LL without reaction and 6 TT) and found an 
increased immune-complexes in 80% of ENL and 82% of LL cases which was not 
significantly different between the two groups as opposed  to the previous findings 
by Moran et al. (1972).  However, an increased plasma C3d level was detected in 
70% ENL cases but only in 18% non-reactional LL patients.  This finding led to the 
hypothesis that ENL is caused by the extravascular immune-complexes formation. 
The presence of extravascular complement fixing complexes was also reported by 
Andreoli et al. (1985). These authors reported a remarkable reduction of circulating 
IgM antibodies to phenolic glycolipid-1 (PGL-1) antigen of M. leprae during ENL 
reaction. Hence, these two authors concluded that ENL is characterized by 
complement hypercatabolism since the level of the C3 breakdown product (C3d) in 
the plasma was found increased in the sera of patients with ENL which was rarely 
found in patients with uncomplicated lepromatous leprosy.  
In contrary to the above findings, (de Azevedo and de Melo, 1966, Anthony et al., 
1978) reported that the level of complements particularly C3 was reduced in 
patients with ENL reaction compared to the non-reactional groups. Anthony et al. 
(1978) postulated that the decreased level of C3 in ENL was most likely due to the 
utilization during the course of immune-complex formation. Similar decrease in 
serum complement level has been described in other immune-complex disorders 
such glomerulonephritis (Vernon et al., 2012) and acute lupus erythematous (SLE) 
(Leffler et al., 2014).  
Wager et al analysed sera from 135 (88 LL, 36 TT/BT, 11 ENL)  leprosy patients  
from Brazil and Ethiopia by the platelet aggregation test (PAT), previously 
suggested to be sensitive detector of IgG complexes in other immune-complex 
diseases (Agnello et al., 1976), and concluded that PAT is a sensitive detector of 
IgG  specific to LL compared to TT but  it does not differentiate  ENL and non-
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reactional LL.  The PAT positivity was 54% in LL and 45% in ENL while it was 
3% in TT/BT (Wager et al., 1978).    
The presence of mycobacterial antigens in the immune-complexes from sera of LL 
patients was also demonstrated by other studies (Furukawa et al., 1982, Chakrabarty 
et al., 1983).  A parallel increase of circulating immune-complex (CIC) and BI from 
TT to LL has been reported from Japanese leprosy patients (77L,19 TT and 21 BB) 
(Furukawa et al., 1982). A study by Rojas and Segal-Eiras (1997) precipitated 
immune-complexes  from sera of leprosy patients to identify antibodies against 
PGL-1 and 10KDa heat shock M. leprae protein. According to this study, the 
highest level of IgM anti PGL-1 in CICs were belonged to the ENL patients which 
was  significantly different to the control groups but not to LL/BL groups indicating 
that the presence of  ICs  could be a finding to both lepromatous leprosy and ENL.    
Disrupted M. Leprae was found to activate more complement fixation than the 
intact one (Lahiri et al., 2008a).  These authors suggested that immune-mediated 
events that precipitate erythema nodosum leprosum could be the activation of 
complements by the antibody-antigen complex formation following local 
inflammation. 
Some studies were not focused on the quantity of circulating immune-complexes 
(CICs) in the sera but instead tried to isolate differences in the qualities of these 
isolated CICs. The ability of sera to solubilize immune precipitates in vitro through 
the complement system was studied in 62 leprosy patients (10 BT, 10 LL without 
reaction, 10 T1R and 32 ENL) by Ramanathan et al. (1985). The solubilizing 
capacity of sera from non-reactional patients were comparable with that of healthy 
controls  (> 95% solubilisation) while sera from leprosy patients with T1R and ENL 
had significantly low levels of solubilisation (< 50%) (Ramanathan et al., 1985).  
They also reported that although the circulating immune complexes and serum C3d 
of these patients came down after the subsidence of reaction, their solubilisation 
remained consistently low during a three month follow-up period. However, Tyagi 
et al. (1990) reported that significant differences were not observed between the 
Polyethylene Glycol (PEG) precipitates from reactional and non-reactional TT/BT 
and BL/LL patients in their complement activating ability.   
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A recent study by Dupnik et al., used microarrays in isolated PMBCs from ENL 
cases and leprosy controls and tried to identify gene patterns of expression 
characteristic of ENL. Several components of the classic complement pathway 
showed increased expression in PBMCs from patients with ENL. Complement 
C1qA, B, C and the complement receptor C3AR1 and C5AR1 showed increased 
expression in ENL cases compared to the other leprosy controls. 
Imunohistochemical staining of skin lesions also showed increased fluorescent 
intensity of C1q in 3 ENL and 3 T1R cases (Dupnik et al., 2015).   
In conclusion, Wemambu et al., able to confirmed the presence of immunoglobulin 
and complement in the skin of  only 59% of  patients with ENL (Wemambu et al., 
1969b). They also reported that only 70% of the patients with immunoglobulin 
deposition showed the presence of M. leprae antigens within the immune-
complexes. This study was the first study conceptualizing the aetiology of ENL. It 
is also the only study which attempted to show the co-localization of complement, 
immunoglobulin and M. leprae antigens in skin lesions in leprosy. The association 
of immune-complex deposition and ENL has been described by several studies 
(Table 4.1).   
However, none of them proved immune-complex as the aetiology of ENL. It is still 
unclear if they initiate the pathogenesis of ENL or if they are simply a by-product 
of the real cause of the disorder. The detection of circulating ICs in infectious 
diseases states neither about their origin nor whether they will always elicit harmful 
consequences for the host (Hoiby et al., 1986). In patients with ENL as in any 
infectious disease, the presence of antibodies against the causing pathogen is part 
of the host defence mechanism against the infection. In infectious diseases where 
ICs are present possibly causing immunopathology, the true pathogenic mechanism 
should be the rate of IC clearance by the host and not the mere detection of ICs in 
the tissues. Furthermore, immune-complexes do not explain the synchronous 
(simultaneous) on set reactions at multiple sites in patients with ENL. In conclusion, 
evidence is not good enough to clearly support the long-standing IC pathogenesis 
dogma in ENL, despite the fact that numerous studies tried to address this for many 
years.  
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Table 4.1. Summary of previous immune- complex studies on leprosy   
Author Method  Sample Patient 
definition  
Main Findings  
(de Azevedo and de 
Melo, 1966) 
Complement  
activity   
serum  33 TT,  37 LL, 
18 ENL 
decreased complement activity in 
ENL 
(Wemambu et al., 
1969a) 
Immunofluoresc
ence 
Biopsy 17 ENL Ig and complements deposition in 
10/17 ENL cases and M. leprae 
antigen in 7/17 cases 
(Waters et al., 1971)  Immunofluoresc
ence  
Biopsy  
  
  
38 ENL,13 LL 
  
  
20/38 ENL positive for complements 
(Cs) and Igs. none of LL were 
positive for Cs and Igs   
Bonomo  1971 Immuno-
electrophoresis  
serum 6 LL  The IC in LL patients made up of IgG 
and IgM. Other Ig s were not detected  
(Rojas-Espinosa et al., 
1972)  
C1q assay   Serum 511, LL, 9TT,  
35 HC 
Soluble IC detected in 76% LL, 22% 
TT, 3% HC 
(Anthony et al., 1978)  
  
  
  
Immunofluoresc
ence  
Complement 
assay     
  
Biopsy 
Serum   
  
  
25 ENL 
10 LL 
  
  
Ig deposits seen  in all  dermis of 
ENL but 
Only in 7ENL the vessel wall and in 
12 ENL in perivascular infiltrates. 
Ig deposits were negative for LL 
controls  
(Wager et al., 1978) PAT serum  36TT/BT,88L
L and 11ENL  
PAT test couldn’t differentiate 
between ENL and LL 
(Sehgal and Kumar, 
1981)  
  
  
PAT  
immunofluoresc
ence   
serum  
biopsy  
  
40 LL, 26 BL  
6 ENL, 
118HC  
  
PAT positivity was confirmed in 85% 
LL and none in HC  
 
 (Mshana et al., 1983) 
Enzyme based 
IHC 
  
  
Biopsy 
  
  
26 ENL 
20 LL 
  
3/26 ENL  and 4/20 had  Ig deposits 
2/20 LL and 5/26 ENL had C deposit 
all ENL and LL had  antigen  
(Ramanathan et al., 
1985)  
IC-
solubilisation  
  
serum  
  
10BT,10 LL 
 10 RR,  
32 ENL, 
15HC  
low solubilisation of IC in in RR and 
ENL  
  
(Chakrabarty et al., 
1988)  
IC -
solubilisation  
  
serum  
  
16 LL,  3RR  
8ENL 
  
solubilisation  capacity of sera from 
LL, ENL and RR  reduced  
Solubilisation was not improved after 
ENL remission  
(Rojas and Segal-Eiras, 
1997) 
PEG  
ELISA 
serum  
  
19 EN,13 HC 
10 controls    
IC associated  anti-Anti PGL-1 and 
anti- 10KDa  significantly increased 
in ENL  
 (Tyagi et al., 1990) PEG  
  
serum  
  
9TT,8 BL/LL, 
7RR,8 ENL, 
10 HC 
  
No significant difference between the 
PEG precipitate for all leprosy 
groups. 
PEG precipitate from BL/LL/ENL 
activated both classical and 
alternative pathway while that of 
TT/BT/RR activated only the 
alternative pathway  
(Dupnik et al., 2015) I 
immunofluoresc
ence 
Biopsy  3RR, 3ENL 
and 5BL 
Immunohistochemical staining of 
skin lesions  showed  increased C1q 
in both RR and ENL  
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4.3.2. Neutrophils in ENL 
Histologically, neutrophils are considered the signature cell in ENL lesions 
(Mabalay et al., 1965). Mabalay et.al gave a comprehensive account of the 
histopathology of ENL. They reported that the inflammatory infiltrate is usually 
seen in the deeper layers of the dermis and subcutis of ENL lesions. According to 
these authors, in acute lesions, within 72 hours neutrophils are the predominant cell 
type, whereas between 72-96 hours equal numbers of neutrophils, lymphocytes and 
plasma cells are seen, and along with the presence of mast cells. Chronic lesions 
show fewer neutrophils and eosinophils, but increased numbers of lymphocytes. 
Sehgal et al. (1986b) suggested vasculitis to be a major pathological event in ENL 
reactions, along with interstitial oedema, and degenerative and necrotizing changes 
seen in classical vasculitis. On the other hand, recent findings claimed that the 
classical signs of vasculitis are not always present in ENL (Adhe et al., 2012b).  
In a study in Pakistani patients, neutrophils have been detected in only 64% (29/45) 
of biopsies but the biopsies were done within 7 days of appearance of lesions 
(Hussain et al., 1995). A retrospective study of 64 Indian leprosy patients (22 RR 
and 42 ENL) confirmed the presence of neutrophils within the granuloma in all 
ENL cases (Adhe et al., 2012b). They also reported that neutrophilic panniculitis 
was commonly seen in 66% (30/45) of ENL lesions.  However, a cross-sectional 
study on the histological features of leprosy reactions in Indian patients by Sarita et 
al. (2013) attested the histological evidence of neutrophil infiltration  only  in 57% 
( 8/14) ENL cases and neutrphilic vasculitis in 7% ( 1/14).  
It has also been shown that the apoptosis of neutrophils is significantly increased in 
patients with  ENL which indicates the involvement of neutrophils during ENL 
reactions (Oliveira et al., 1999).  It is postulated that M. leprae and M. leprae 
derived lipoarabinomannan (LAM) could stimulate neutrophils which in turn 
secrete TNF-α and IL-8. IL-8 contribute to the recruitment of lymphocytes to the 
lesional sites which further increases TNF-α production at the site of ENL lesion 
and hence, tissue damage (Oliveira et al., 1999).  However, at present, it is unclear 
if more significant role is associated with neutrophils in the pathogenesis of ENL. 
The mechanisms of neutrophil recruitment at the site of disease was investigated by 
Lee et al. (2010). The gene expression profile of ENL lesions comprised an 
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integrated pathway of TLR2 and Fc receptor activation, neutrophil migration, and 
inflammation. According to these authors the pathway includes: i) FcR or TLR2 
induction of IL-1β release; ii) endothelial activation, including the upregulation of 
E-selectin and subsequent neutrophil binding; iii) upregulation of inflammatory 
mediators associated with both neutrophils and monocytes/macrophages.  
Thalidomide, which is a highly effective drug in the treatment of ENL, is known to 
reduce neutrophil infiltration in lesions and  targeted individual events in this 
inflammatory pathway (Lee et al., 2010). 
4.3.3. The role of B-cells in ENL  
B-cells enable the antigen-specific humoral immunity by forming highly specific 
antibodies during primary immune response. Although B-cells are traditionally 
known as precursors for antibody-secreting plasma cells, they may also act as 
antigen-presenting cells (APC) and play a role in the initiation and regulation of T 
and B cell responses (Martin and Chan, 2006, Hampe, 2012). The pathogenic roles 
of B-cells in autoimmune diseases occur through several mechanistic pathways that 
include autoantibodies, immune-complexes, dendritic and T-cell activation, 
cytokine synthesis, chemokine-mediated functions, and ectopic neolymphogenesis 
(Hampe, 2012).  
B -cells are the least studied immune cells in leprosy and leprosy reactions.  Little 
evidence of an increase in B-lymphocytes in ENL lesions is available.  An increased 
percentage and absolute count of B-cells in the sera from patients with ENL has 
been reported (Sehgal et al., 1986b), but normal numbers of circulating B-cells have 
also been reported (Rao and Rao, 1986). A study looking at T-cell phenotypes in 
ENL lesions showed that there is no increase in B-cells (Narayanan et al., 1984).  
In a prospective cohort study of 13 untreated patients with acute ENL reaction, 
polyclonal IgG1 antibody synthesis was elevated compared to patients with stable 
lepromatous leprosy and decreased after the disease had subsided.  However, the 
concentration of polyclonal IgG2 had revealed the reverse trend: decreased before 
treatment and increased after treatment (Kifayet et al., 1996). These authors also 
investigated the frequency of antibody secreting B-cells in the blood compartment 
of these patients with the Enzyme-Linked ImmunoSpot (ELISPOT) and found that 
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the decrease in M. leprae specific IgG1 antibody was not related to the down-
regulation of B-cell reposes.  
The role of B-cells in the pathogenesis of autoimmune disorders such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) is now being re-examined 
(Martin and Chan, 2006). It would therefore be interesting to examine the role of 
B-cells in the pathogenesis of ENL.  
4.3.4. T- cells in ENL  
There are several pieces of evidence for increased T-cell activity in leprosy patients 
with ENL reactions in comparison with those with non-reactional LL patients. The 
involvement of cell-mediated immunity in the pathogenesis of ENL was first 
postulated by Rea et al. (1972). They noted that patients with ENL reactions have 
apparently normal cell-mediated immunity compared to those with non-reactional 
LL whose cell-mediated immunity is impaired. In 1982, it was hypothesized that 
ENL is precipitated by an imbalance of T-lymphocyte subpopulations (Mshana et 
al., 1982 ). According to the hypothesis, ENL has two phases: initiation, due to an 
imbalance in T-cell subpopulations with decreased suppressor cells and 
perpetuation. The analysis of tissue lesions of  ENL by in situ hybridization 
technique suggested that ENL reactions may be visualized as transient reduction of 
cytotoxic (CD8+) T-cells activity, leading to partial augmentation of Th (CD4+) 
activity perhaps sufficient to result in antibody and immune-complex formation, 
but insufficient to clear bacilli from lesions (Cooper et al., 1989). 
A direct evaluation of thymus-dependent lymphocytes of peripheral blood in 
leprosy patients with ENL reactions by rosette assay method has shown an 
increased percentage and numbers of T-cells in patients with ENL reactions 
compared to non-reactional lepromatous leprosy patients (Lim et al., 1974).   
An evidence for transient enhancement in T- cell functions was also reported during 
the acute phase of ENL reactions in Indian patients (Laal et al., 1985 ).  Laal et al, 
assessed the status of T-cell mediated functions in 13 non-reactional LL and 15 
patients with ENL reactions. They found that all non-reactional LL patients showed 
lack of antigen-induced leukocyte migration inhibition and lymphoproliferative in 
vitro response to soluble and integral M. leprae antigens. These patients were also 
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showed poor mitogen response. However, patients with active ENL reaction had 
strong antigen-induced leukocyte migration inhibition and enhanced mitogen 
induced lymphoproliferation. In the same study, T-cell subsets in PBMCs from 
ENL and LL were characterized by indirect immunofluorescence using monoclonal 
antibodies; OKT3, OKT4 and OKT8. Patients with ENL reactions had lower 
OKT4/OKT8 ratio compared to non-reactional LL patients (Laal et al., 1985 ).  
Rao and Rao (1986) measured the cell-mediated immune responses in 77 Indian 
leprosy patients (44 ENL and 39 LL). Patients with ENL reactions had significantly 
enhanced M. leprae specific immune responses with increased percentage of early 
T-lymphocytes (47.68%) in ENL compared to LL (38.96%) patients. However, 
there was no response to the lepromin skin test in patients  with ENL reactions  in 
contrast to the enhanced in vitro cell-mediated immune responses (Rao and Rao, 
1986). These authors also found that the number of T-lymphocytes in the post-ENL 
remained high (45.66%) compared to the non-reactional LL patients. On the other 
hand, Rea et al, reported that the proportions of T-cell subsets in ENL and LL 
showed no difference in a study involved 122 leprosy patients (43 LL, 23 ENL, 13 
RR, 13 BL and 31 TT);   22 healthy controls and 27 patients with SLE (Rea et al., 
1984 ).  
The numbers and distribution of T-lymphocyte subsets in the lesions of reactional 
states of leprosy (6 RR, 9 ENL and 2 Lucio's reactions)  with those of stable, non-
reactional patients (6 TT, 2BL and 7LL) was investigated using monoclonal 
antibodies and immunoperoxidase technique by Modlin et al. (1983) .  In this study, 
it has been shown that the T-helper/suppressor (CD4+/CD8+) ratio was significantly 
higher in ENL cases (2:1) compared to the non-reactional controls (0.7:1) (Modlin 
et al., 1983).  According to these authors, the increased T-helper cells in ENL 
lesions compared to LL lesions suggests that cell mediated immune response may 
be important in the pathogenesis of ENL in either permitting productions of 
antibodies critical to immune-complex formation or as a cell-mediated immune 
response.  A similar result was  also reported from Indian study by  Narayanan et 
al. (1984). 
 Bhoopat et al. (1991) studied the subsets of T-cells in the cutaneous leprosy lesions 
of 19 patients with acute ENL, 38 chronic ENL and 61 active non reactional LL 
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patients in suction-induced blisters. They found that lesions in chronic ENL had a 
decreased number of CD8+ T-cells and increased helper/cytotoxic (CD4+/CD8+) 
ratio as compared to those in acute ENL and non-reactional LL patients. In the same 
study, systemic administration of corticosteroids was associated with a reduction of 
intralesional CD4+ T-cell population but did not change CD8+ T-cell population. 
The authors concluded that spontaneous lymphocyte activation in situ, primarily of 
decreased CD8+ T-cells and relatively increased CD4+ T-cells, are important 
features of chronic ENL reactions and may be an intermittent or cyclic phenomenon 
during the reaction. Martiniuk et al. (2012)  highlighted that the possibility of up 
regulation of Th1 and Th17 cells during ENL reactions and after thalidomide 
treatment in a study conducted on 7 ENL patients in Nepal. 
In conclusion, there are in consistent reports on the number of helper (CD4+) and 
cytotoxic (CD8+) T-cell phenotypes in patients with ENL reactions (Table 4.2). 
Several studies (Modlin et al., 1983, Bach et al., 1983, Wallach et al., 1982, Mshana 
et al., 1983, Narayanan et al., 1984) have reported increased percentage of CD4+ T-
cells and reduced CD8+ T-cells with an increased CD4+/CD8+ ratio in patients with 
ENL reactions compared to patients with non-reactional lepromatous leprosy. In 
contrast to these findings, Laal et al. has reported  a reduced CD4+/CD8+ ratio and 
increased percentage of CD8+ T-cells in patients with ENL reactions compared to 
patients with LL  (Laal et al., 1985 ). Van Voorhis et al. (1982) and  Rea et al. ( 
1984 ) on the other hand, concluded that there is no significant percentage 
difference between helper and suppressor cells, as well as helper/suppressor ratio 
in patients with ENL reactions and non-reactional LL. 
The phenotypic and functional roles of different subsets of T-cells in the 
pathogenesis of ENL is not clearly delineated. Although several attempts made to 
define the role of T-cells in ENL, they suffer from lack or poor study designs. Case 
definitions and proper controls are not included in most studies.  Most of these 
studies were cross-sectional studies. However, cross-sectional studies provide little 
information on the kinetics of T-cells during the course of ENL reaction. In the 
current study, we included considerably a large number of untreated ENL cases and 
LL patient controls with follow-up of for at least 28 weeks.     
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Table 4.2.  Summary of previous T- cell studies in ENL*  
Authors Description of the study  Number 
of patients 
Methods 
used in the 
study 
Major findings 
(Lim et al., 
1974) 
The absolute number and the 
proportion of T lymphocytes in 
patients with ENL and LL were 
described. 
ENL=7 
Others= 
29 
Rosette assay 
 
High  %T cells 
in ENL than in 
LL 
(Rea et al., 
1984 ) 
The proportion of T lymphocyte 
subsets using monoclonal antibodies 
directed against CD4+ and CD8+ T 
cells in PBMCs of patients with 
ENL and LL were described.   
ENL=19 
Others 
=103 
Flow  
cytometry 
 
The % T cells in 
ENL and  LL is 
the same 
(Modlin et al., 
1983) 
The numbers and distribution of T 
lymphocyte subsets in the tissues of 
ENL, LL and TT patients were 
determined and compared.  
ENL=9 
Others=8 
Immunopero
xidase 
 
Increased 
CD4+/CD8+ 
ratio  in ENL 
compared to LL 
(Laal et al., 
1985 ) 
The antigen -induced leukocyte 
migration inhibition and antigen-
induced lymphoproliferation of 
lymphocytes in stimulated  PBMCs 
of patients with ENL and LL were 
measured 
ENL=15 
LL=13 
Leukocyte 
migration 
inhibition  
and  
Immunofluor
escence 
Decreased  
CD4+/CD8+ 
ratio in ENL 
compared to LL 
(Yamamura et 
al., 1992) 
 Th1 and Th2 associated  mRNA 
expression of cytokines were 
quantified  
ENL=3  
RR=2 
PCR ENL is 
associated with  
Th2 cells  
(Goulart et 
al., 2000) 
Quantified level of TGF-β1 
production in PBMCs of ENL and 
LL cases  
ENL=5  
others=13 
ELISA ENL is  
associated with 
Th2 cells  
(Nath et al., 
2000) 
 Th1 and Th2 associated  cytokines 
production in PBMCs of  patients 
with ENL and LL were measured  
ENL=8  
LL=8 
RT-PCR ENL is  
associated with 
Th1 cells  
*Only representative articles included.  
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4.3.5. Th-17 in ENL 
The inflammatory process of tissue damage is not governed by a single cytokine or 
a subset of T-cells. It is a complex phenomenon that involves the interaction of 
various cells.  During the era of Th1/Th2 functional classification of T- helper cells, 
it was believed that Th1 cells drive cell-mediated immune response leading to tissue 
damage and Th2 cells derive antibody mediated response mainly in allergic 
reaction. However, the mechanisms of T- cell mediated tissue damage could not 
explained fully by the Th1/Th2 hypothesis which led immunologists for further 
investigation of the Th1/Th2 paradigm in inflammation and tissue damage 
(Steinman, 2007). 
Th17 cells have been identified as a new subset of the T- helper cells and as 
potential mediators of inflammation associated with various autoimmune and 
mycobacterial diseases (Pandhi and Chhabra, 2013). Th17 cells are the least studied 
T-cells in leprosy and only two studies have indicated the involvement of Th-17 in 
immunopathogenesis of ENL (Martiniuk et al., 2012, Attia et al., 2014, Saini et al., 
2016).  
4.3.6. Regulatory T cells in ENL   
It has previously described that regulatory T-cells (Tregs) inhibits naïve CD4+ T-
cell proliferation and differentiation, prevent cytotoxic activity of CD8+ T-cells, 
supress the activation and antibody production of B-cells, and limit the stimulatory 
capacity of antigen presenting cells by down regulating the surface expression of 
costimulatory molecules such as CD80 and CD86 (Shevach, 2009) (Figure 4.1).  
Reduced percentage of Tregs has been associated with immune-complex mediated 
autoimmune diseases such as Wegener’s granulomatosis (WG) (Morgan et al., 
2010) and Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(Marinaki et al., 2005, Wilde et al., 2010).  In patients with these diseases, the 
percentage of Tregs is inversely related to the disease relapse and in active patients 
a relatively increased proportion of Tregs is associated with rapid disease remission. 
However, the role of Tregs in leprosy has only been addressed by few studies (Attia 
et al., 2010, Attia et al., 2014, Bobosha et al., 2014b, Saini et al., 2014a, Saini et al., 
2016) and a clear picture has not arrived at yet. 
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Attia et al. investigated the frequency of circulating Tregs in different clinical forms 
of Egyptian leprosy patients (9 TT, 8 LL, 6 ENL, 2 RR and 13 intermediates). The 
analysis of PBMCs by flow cytometry showed that both the absolute count and 
percentage of Tregs were significantly lower in patients with ENL reaction (1.2%) 
compared to patients with LL 2.8% (Attia et al, 2010).  According to these authors 
the median Tregs/Teffs ratio was significantly lower in patients with ENL (0.08) 
compared to patients with LL (0.22). Surprisingly, they also reported that 
significantly higher percentage of Tregs-FoxP3 expression along with higher 
percentage of effector T-cells in patients with ENL compared to the other forms of 
leprosy.  It is logical that effector T-cells (Teffs) and regulatory T- cells have 
inverse relationship. When one is upregulated, the other one is downregulated.  
Hence, one could not expect increased Teffs and Tregs in parallel in ENL reaction.  
Recently, the same authors investigated the levels of IL-17, TGF-β and IL-10 and 
Tregs in 43 untreated Egyptian leprosy patients (6 TT, 5 PNL, 9 BB/BT/BL, 11 LL, 
6 RR, 6 ENL) and 43 healthy controls (Attia et al., 2014). They reported that the 
production of cytokines IL-10, TGF-β, IL-17 were not statistically significantly 
different in the patient groups. Significantly highest percentage of Tregs was 
obtained in patients with TT leprosy (5.8%) compared to LL (2.8%) and ENL 
(1.15%) which contradicts with the findings of 2010 by the same author. It is very 
strange to expect highest percentage of Tregs in TT as compared to LL. Because 
patients with TT leprosy have strong cell-mediated immune response while those 
on the LL pole are characterized by unresponsive cell-mediated immunity.  Several 
independent studies have shown that patients with LL had significantly the highest 
percentage of Tregs compared to the other leprosy forms of the spectrum (Palermo 
et al., 2012, Bobosha et al., 2014b, Saini et al., 2014a, Parente et al., 2015). 
A recent study performed flow cytometry in PBMCs isolated from 6 patients with 
ENL in comparison to 8 LL patient controls, after stimulation with M. leprae 
sonicated antigen (MLSA), and described a significant reduction of percentage of 
CD4+CD25+FoxP3+  Tregs and Mean Fluorescence Intensity of FoxP3 in PBMC of 
ENL patients (Saini et al., 2016). However, the same study also reported an 
increased expression of FoxP3 in the PBMCs of patients with ENL comparted to 
LL controls by qPCR.  Small sample size, in consistent flow cytometry gating or 
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lack of positive and negative template controls during RNA extraction, cDNA 
synthesis and qPCR amplification could contribute to the observed difference.  
The discrepancy in the current study could be due to lack of patient definition, 
confounding effects in statistical tests or lack of appropriate control for each group. 
For example the level of IL-17 production in patients with LL was 12.5pg/ml while 
in patients with ENL it was 20.5pg/ml but statistical test did not performed to 
compare both groups. Furthermore, the definition of effector T-cells and 
information on the cellular markers used to measure effector T-cells were not given 
by the authors for further comment. Sometimes, T-cells other than Tregs may be 
considered as effector T-cells although in fact these non-Treg cells include effector, 
memory and naïve T cells. Particularly naïve T-cells should not be categorized with 
the effector T-cells group as their biology is completely different.  
An immunohistochemical study of 96 patients with leprosy which included 2 ENL, 
8 T1Rs and 86 other clinical forms of leprosy  has shown the expression of FoxP3 
in the skin lesions of all clinical forms of leprosy with an average density of 2.82% 
of the infiltrate (Parente et al., 2015).  FoxP3 positive cells were observed inside 
and around the granulomas in TT and BT lesions where as in ENL and LL lesions 
they were found randomly in the diffuse macrophages infiltrate.  Significantly 
increased percentage of FoxP3 positive staining was found in T1R but significant 
difference was not observed between the other  clinical forms including ENL 
(Parente et al., 2015). 
In conclusion, it seems that both the percentage of Tregs and the balance between 
effector T-cells (Teffs) and Tregs (Teffs/Tregs) ratio may play role whether patients 
with LL remain stable or proceed to ENL reaction. The difference in Tregs and 
Teffs ratio rather than differences in absolute numbers of Tregs and Teffs influence 
the outcome of the infection as reviewed by Belkaid and Rouse (2005). In 
autoimmune diseases, the imbalance of activated T- cells versus Tregs is considered 
as a key factor for the immmunopathogenesis of these diseases (Marinaki et al., 
2005, Morgan et al., 2010).  
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Figure 4 .1.  Differentiation of effector CD4+ T cells and regulatory T (Treg) 
cells   (Cretney et al., 2013).  
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4.3.7. Cytokines in ENL 
In leprosy the cytokines research focused mainly on the association of differential 
cytokine profile with the spectral pathology of the diseases.  However, the results 
from these various studies have been varied and conflicting.  The presence of both 
Th1 and Th2 type cytokines in the pathogenesis of ENL has been detected from the 
lesions and sera of patients with ENL reaction (Sreenivasan et al., 1998, Moraes et 
al., 2000, Teles et al., 2002).  Th1 like cytokine pattern was found in the sera of 
85% of patients with RR and 64% ENL with basal expression of INF-γ (Sreenivasan 
et al., 1998).  The presence of INF-γ and absence of IL-4 was taken as indicative of 
Th1 pattern while the reciprocal pattern as of Th2 by these authors.   
Similarly INF-γ was detected in 84% of ENL and 100% of T1R in the sera of 
Brazilian patients (Moraes et al., 1999b).  The absence of IL-4 in lesions of ENL 
was reported by Nath et al. (2000), which suggests that ENL is associated with Th1 
type reaction than Th2 type.  On the contrary, Goolart et al., reported that ENL 
reaction elicited a Th2 type response with the production of IL-6, IL-8, IL-10 and 
TNF-α whereas T1R showed mainly Th1 type response with the releases of IL-1β, 
TNF-α, IL-12 and INF-γ (Goulart et al., 2000).  Fink et al., suggested that there is 
no clear association of a clinical form of leprosy with either Th1 or Th2 cytokine 
secretion profile in PBMCs of leprosy patients (Fink  et al., 1996).   
High levels of IL-6 was observed  in patients with ENL than in T1R and the levels 
of IL-6 was found  to be positively correlated with  bacilli index (Belgaumkar, 
2007).  Barnes et al., reported that TNF-α production in the PBMCs of patients with 
ENL reaction was significantly  higher compared to patients with T1R and LL 
which  was significantly reduced upon thalidomide administration (Barnes et al., 
1992b). On the other hand, a study in 131 Indonesian leprosy patients among which 
44 ENL, 5T1R and 68 LL/BL included, no significant difference in IL-6 and TNF-
α levels was observed between ENL cases and non-reactional LL patients (Iyer  et 
al., 2007). However, they found that INF-γ and soluble IL-6 (sIL-6) were 
significantly elevated in serum of patients with ENL reaction  compared to patients 
with non-reactional LL which were declined significantly after corticosteroid 
treatment of patients with ENL (Iyer  et al., 2007). On the contrary, a Mexican study 
which included only 9 ENL, 6 non-reactional LL/BL and 4 TT/BT patients reported 
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that serum IFN-γ was significantly lower in patients at the onset of ENL and was 
increased after 1 and 2 months of thalidomide treatment while serum TNF-α was 
significantly higher in the patients that developed ENL compared to those that did 
not develop the reaction (Sanchez et al., 1998).  
In T1Rs IL-1β, TNF-α, IL-2 and INF-γ mRNA were prominent and found to be 
increasing during the course of the reaction parallel with decreasing the expression 
of mRNA for IL-4, IL-5 and IL-10 (Yamamura et al., 1992). On the other hand, in 
ENL reactions selective increase in expression of mRNA for IL-6, IL-8, and IL-10 
was found with persistent expression of IL-4 and IL-5 mRNA (Yamamura et al., 
1992). These authors concluded that T1R and ENL reactions are associated with 
type 1 and type 2 cytokine patterns respectively.  The level of IL-6 and IL-6 mRNA 
expression was found to be higher in patients with ENL compared to in patients 
with LL or BL (Yamamura et al., 1992) which  is not supported by the findings of 
Iyer et al., (2007).  According to cooper et al., highest expression of INF-γ mRNA 
expression was seen in the cells of patients with T1Rs but in few cells of patients 
with ENL (Cooper et al., 1989). However, the INF-γ mRNA expression in the ENL 
lesions was found to be 5 times higher than in the lesion of non-reactional 
lepromatous leprosy patients (Cooper et al., 1989).   
Higher production of TGF- β was found in patients with ENL reaction compared to 
T1R and non-reactional LL patients (Goulart et al., 2000).  The same authors 
proposed that the high production of TGF-β in patients with ENL  mediate a 
suppressive action locally, associated with the presence of PGL-1,or/and induce 
pro-inflammatory effects when secreted systemically by monocytes, thereby acting 
as a modulatory cytokine in the acute inflammatory reactions of ENL and 
associated with the Th2 immune response in multibacillary forms of leprosy.  
IL-6 is an immunosuppressive cytokine which inhibits macrophage mediated 
intracellular pathogens killing. It is also known to promote B-cell responses and 
augment antibody formation, thereby potentiating immune-complex formation 
(Ochoa et al., 2010). IL-6 and type-2 cytokines would be expected to promote 
antibody production and suppress T-cell response. IL-6 is a strong neutrophil 
chemo-attractant that could augment immediate hypersensitivity character of ENL 
whereas IL-10 suppresses T-cell response and macrophage function whose net 
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effect of these cytokines would be to the favour of continuation of infection 
(Yamamura et al., 1992).  The increase of IL-12 in patients with ENL suggests that 
the possibility of upregulation of both Th1 and Th-17 during ENL development. 
This indicates that Th-17 could be involved in the pathogenesis of ENL (Martiniuk 
et al., 2012).  
The slightly elevated levels of INF-γ in patients with ENL reactions as compared 
to patients with non-reactional BL and LL pinpoints the possible role of cell 
mediated immunity in the pathogenesis of ENL according to Moubasher et al. 
(1998a). However, these data were generated from only one patient with ENL 
reaction and hence, needs confirmation in larger sample size.  
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Table 4.3. Summary of previous cytokine studies in ENL 
  
Author Lab 
method  
sampl
e 
Patient 
definition  
Conclusion Comment  
(Madan et 
al., 2011c) 
 
ELSA Serum  Untreated 
61 Leprosy 
cases ( 
38PB, 
13MB,6 
NP,6RR 
and 4ENL)  
Case 
definition: 
not  given  
IFN-γ increased in 
ENL  compared to 
LL 
IL-10, TNF-α and 
IL-1β  same in LL 
and ENL 
IL-10 increased in 
ENL compared to 
RR but IL-1β  and 
IFN-γ similar in 
both groups  
Mean instead of 
median was used for 
statistical test for 
skewed data  and 
type II error most 
likely affected the 
result*  
(Sehgal et 
al., 1986b) 
ELSA serum 11 RR, 
11ENL 
The level of soluble 
IL-2 receptor in 
ENL and RR are not 
significantly 
different  
The analysis is not 
clear. 
P values not given 
in the table. Patient 
treatment status 
unknown.    
(Attia et al., 
2014)  
ELISA, 
Flow- 
cytomet
ry  
Serum  Untreated  
(6TT,5PNL
,11LL,6 RR 
,6 ENL  
and  
9 
Borderline,   
Level of IL-10, TL-
17,TGF-β 
production the same 
in LL and ENL 
IL-22  increased in 
ENL   
Small sample size. 
Chi-square test were 
used and 
mean/median 
comparison was not 
performed  
(Sanchez et 
al., 1998) 
ELISA Serum 9 
ENL,6LL, 
4BT/BL,10
HC 
 
High TNF-α  and 
Low INF-γ  at onset 
of ENL 
TNF-α decreased 
and INF-γ increased 
during thalidomide 
treatment 
 
The duration of 
ENL in patients 
ranging from 1 to 30 
years.  
Patients are 
heterogeneous 
(Belgaumkar, 
2007) 
ELISA serum 1ENL,5RR 
others 94 
 
INF-γ & IL-6 are 
high in T1R and 
ENL respectively 
The conclusion is 
made based on   
only 1 ENL patient 
(Iyer et al., 
2007b)  
ELISA serum 34 
LL,78BL,3
BB, 
6BT,10TT, 
44ENL,5R
R 
High INF-γ and sIL-
6R  produced  in 
ENL than in LL/BL 
IL-4, IL-10, IL-
6,TNF-α  and 
Neopterin  levels 
same between ENL 
and LL/BL 
Conclusion is made 
based on 17 ENL, 1 
T1R and 68 LL.  
Possible bias from 
loss to follow-up.  
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Author Lab 
method  
sample Patient 
definition  
 Conclusion  
(Nath et al., 
2000)   
 RT-
PCR 
PBMCs 8 ENL,1BL  
7LL 
IL-4 and IL-10 
gene expressions 
higher in LL 
compared to LL 
and  that of 12p40 
and INF-γ higher 
in ENL  
Small sample size 
but good 
experimental 
design   
(Moraes et 
al., 1999b) 
RT-PCR PBMCs 
and 
biopsy  
20ENL, 
11RR, 
17LL/BL, 
mRNA for IL-
6,IL-10,IL-
12,TNF-α,IFN-γ 
upregulated both 
in RR and ENL 
while IL-4 down 
regulated in both 
groups  
Statistical 
analysis were not 
done. The 
Presence and 
absence of these 
genes in the 
sample was taken 
as   comparison 
methods.  
(Stefani, 
2009) 
Cytokin
e –array 
kit 
Plasma  10RR,10EN
L, 
10PB,9 MB 
Ip-10  and IL-6 
elevated in RR ; 
IL-7 and IL- 6 
elevated in ENL 
compared to their 
respective 
controls , 
Small sample size 
for nested case- 
control study.  
*The mean of TNF-α for LL was 50pg/ml with Sd 76.78pg/ml for ENL mean 
105.45pg/ml with Sd 56.78pg/ml. However a p value 0.2 was given. In LL cases Sd is 
> mean. Hence the data is not normally distributed.  Using mean for comparison 
increases type II error.   
4.3.8 Conclusion on the immunology of ENL  
Reduced percentage of Tregs has been associated with immune-complex mediated 
autoimmune diseases such as Wegener’s granulomatosis (WG) (Morgan et al., 2010) 
and Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (Marinaki et 
al., 2005, Wilde et al., 2010).  In these patients, the percentage of Tregs is inversely 
related to the disease relapse and in active patients a relatively increased proportion of 
Tregs is associated with rapid disease remission. However, the role of Tregs in leprosy 
has been addressed only by few studies and no definitive conclusions have been made.  
 The generation and the fate of Tregs depend on the type and availability of specific 
cytokines, i.e. their differentiation, expansion and function is directed by the 
microenvironment surrounding them. The development and maintenance of Tregs 
depend on TGF-β (Wang et al., 2011).  IL-2, the receptor for CD25, plays an important 
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double-edged role in both enabling Tregs to suppress to Teffs as well as for the 
activation and clonal expansion of Teffs (Corthay, 2009).  At the onset of ENL 
reaction, high production of TNF-α has been repeatedly reported by various 
investigators (Barnes et al., 1992b, Memon et al., 1997, Sampaio and Sarno, 1998, 
Sampaio et al., 2011). Increased concentration of INF-γ and IL-6 in sera of  patients 
with ENL compared to patients with non-reactional LL were previously reported  
(Belgaumkar, 2007, Iyer  et al., 2007).   
It has been shown that TNF-α downregulates human regulatory T cells (Ehrenstein et 
al., 2004, Valencia et al., 2006) in active Rheumatoid arthritis  (RA) patients which 
was restored by treating these patients with anti-TNF- antibody (infliximab). The 
dysfunction of Tregs by TNF-α correlates with increased expression of IL-17, INF-γ 
and TNF-α controls the balance between Tregs and pathogenic Th17 and Th1 cells in 
the synovium of individuals with rheumatoid arthritis through FoxP3 
dephosphorylation (Nie et al., 2013).  Toll like receptors on antigen presenting cells 
induce IL-6 upon recognition of microbial products and IL-6 suppress Tregs (Pasare 
and Medzhitov, 2003) in favour of the induction of T-cells activation in vivo.  
By applying the same scenario, it is possible to hypothesize that  activation of T-cells 
are likely to initiate ENL reactions which can be further complicated by the induction 
and formation of immune-complexes. This hypothesis is supported by the presence of 
strong antigen induced leukocyte migration inhibition and enhanced mitogen induced 
lymphoproliferation in patients with ENL reactions unlike in patients with non-
reactional LL as previously described. Furthermore, the pro-inflammatory cytokines 
such as TNF-α, INF-γ and IL-6 are frequently elevated in ENL reactions. It has been 
confirmed that these cytokines suppress Tregs in other diseases such as WG, ANCA- 
associated vasculitis, and RA. The detection of these pro-inflammatory cytokines in 
patients with ENL reactions support the proposition that ENL reaction is driven by the 
imbalances between T-lymphocytes. In several immune-complexes mediated diseases 
such as RA, SLE, WG, ANCA-associated vasculitis and others the imbalance between 
Tregs and Teff cells is reported as the underlying causes of these diseases. Therefore, 
since ENL is considered as an immune-complex associated disease it is likely that the 
imbalance between these T-lymphocytes play role for the initiation and progression of 
the disease. 
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However, the immunopathogenesis of ENL is further complicated by the 
heterogeneous condition of the disease (acute, recurrent or chronic). These conditions 
of ENL might be correlated with the varying immune profile in these patients. In 
addition to the limited number of studies available regarding ENL, previous studies 
didn’t consider the possible variation in immune profile between the various clinical 
conditions of ENL. Conclusions in previous studies were drawn from either cross-
sectional studies or case studies and they lack proper study design.  Proper case 
definitions and control selection criteria are not mentioned in most of these previous 
studies. Therefore, we hypothesized that erythema nodosum leprosum reaction is 
associated with increased percentage of activated T-cells due to decreased frequency 
of regulatory T-cells and hence aimed at to describe the relative percentages and 
phenotypes of T-cells in patients with ENL before and after treatment compared to 
lepromatous leprosy patient controls. 
  In our case-control follow-up study, we set criteria for ENL definition and LL patient 
controls with follow-up at least for 28 weeks. Clinical and biological samples were 
obtained three times from each patients. We investigated several immune factors such 
as T- cells, memory T-cells, regulatory T-cells,  B-cells, memory B-cells, pro-
inflammatory cytokines or chemokines ( IL-6, IL-8, IL-17A, IFN-γ, IL-1β, TNF-α, 
TGF-β) and their gene expressions both in the blood and in lesions and anti-
inflammatory cytokine (IL-10). These findings were also supplemented by histological 
and clinical data. Hence, we believe that this comprehensive data together with our 
large sample size, provide strong evidence as to the immune-profiles of ENL reaction 
which can be used as a base line for further studies.  
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CHAPTER 5:  MATERIALS AND METHODS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
OVERVIEW 
This chapter presents a description of the materials and methods used in the study. It 
is presented in 6 sections for clarity since several laboratory procedures are involved. 
In section 1, the patients and the study set-up are discussed. An overview of the study 
design including the description of matched case-control study as a research design 
and its relevance to this study is discussed. Study site description, sample size 
determination, inclusion and exclusion criteria, sampling frame, demographic and 
clinical data recording methods are described in this section. Section 2 deals with 
clinical sample collection and processing. Clinical sample collection and processing 
such as PBMCs isolation, freezing of cells and storage conditions are described in 
section 2.  Section 3 describes flow cytometry. Basic principles of flow cytometry are 
briefed in this section. Panel construction methods for regulatory T-cells, memory T-
cells and B-cells are described in this section.  List of fluorochrome-conjugated 
antibodies for each panel and the sources of each antibody are given. Antibody titration 
method, staining cells for flow cytometry work, flow cytometry settings, data 
acquisition and the gating strategy for each panel are described in this section. Section 
4 deals with ELISA. A brief description of the principles of ELISA is given.  
Lymphocyte stimulation methods, harvesting supernatant for ELISA, ELISA 
procedures and ELISA data recording methods are described.  In section 5, the real-
time PCR assay methods are described.  Protocols for RNA isolation from PAXgene 
Blood RNA Tubes and RNAlater stored skin biopsies are described.  Protocols for 
cDNA synthesis, primer design, choice of the housekeeping gene (control gene), 
optimization of quantitative PCR and methods for obtaining the relative gene 
expression are described in this section.  Section 6 describes all about the statistical 
methods. Data recording and management, data analysis strategy used for each section 
and data presentation methods are described in this section.  
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SECTION 1:  THE PATIENTS AND STUDY SET-UP  
5.1.1. Case definitions  
 Clinical case definitions (Pocaterra et al., 2006) 
The clinical assessment of the patient was used as main diagnostic criteria for cases 
(lepromatous leprosy patients with ENL reaction) and controls (lepromatous leprosy 
patients without ENL reaction).   
1. Erythema Nodosum Leprosum (ENL) 
  ENL was clinically diagnosed when a patient had tender subcutaneous erythematous 
skin lesions and systemic features of disease often fever, neuritis and bone pain 
occurring in patients with lepromatous leprosy or borderline lepromatous leprosy. 
Other accompanying systemic features included neuritis, joint pain, bone tenderness, 
orchitis, iritis, oedema malaise, anorexia and lymphadenopathy.  
2. Lepromatous leprosy (LL) 
Lepromatous leprosy was clinically diagnosed when a patient had widely 
disseminated nodular lesions with ill-defined borders and BI above 2.  
3. Acute ENL 
      Acute ENL was defined as an ENL episode lasting less than 24 weeks of 
prednisolone treatment   
4. Chronic ENL 
Chronic ENL was defined as an ENL occurring for 24 weeks or more during which 
a patient has required ENL treatment either continuously or where any treatment 
free period has been 27 days or less. 
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5. Recurrent ENL 
 Recurrent ENL was defined as a second or subsequent episode of ENL occurring 28 
days or more after stopping or steady decrease of steroid treatment for ENL. 
6. ENL recurrence or flare-up 
ENL recurrence or flare-up was defined as the appearance of new ENL nodules after 
initial control, either whilst on treatment or after 28 days off treatment. 
7. New ENL case 
New ENL case was defined as the occurrence of ENL for the first time in a patient 
with lepromatous leprosy.  
Histological definitions (Lockwood et al., 2011).   
The histological assessment of paraffin-embedded patient biopsy sample was used as 
supplementary confirmation for the definition of cases and controls whenever 
necessary.  
1. ENL 
When a polymorphonuclear neutrophil infiltrates on the background of a macrophage 
granuloma which can be accompanied by oedema, vasculitis and/or panniculitis is seen 
in H & E stained sections of biopsy, it was recorded as erythema nodosum leprosum 
case. 
2. LL 
When macrophages and foamy cell collections are present with numerous bacilli 
interspersed with a sparse number of lymphocytes in H & E stained sections of biopsy, 
it was recorded as lepromatous leprosy case.  
5.1.2. The study area   
This study was conducted at AHRI/ALERT campus, Addis Ababa, Ethiopia.  Patients 
were recruited at Red Medical Clinic (RMC) of ALERT Hospital.  Clinical sample 
processing such as peripheral blood mononuclear cells (PBMCs) isolation, storage, 
flow cytometry staining and reading, ELISA and qPCR have been done at Armauer 
Hanssen Research Institute (AHRI).  
ALERT: It was initially the All Africa Leprosy Rehabilitation and Training Centre 
(hence the acronym), but the official name is now expanded to include tuberculosis: 
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All Africa Leprosy and Tuberculosis Rehabilitation and Training Centre. ALERT is 
the only leprosy referral centre in Ethiopia. It was established by Dr. Thomas Lambie, 
an American missionary doctor in 1922. It was named as the princess Zannaba Wark 
Hospital by the name of the Emperor Haile Selassie’s daughter in 1966. Leprosy 
patients are seen at Red Medical Clinic (RMC). RMC is a special clinic within the 
hospital dedicated for leprosy, diagnosis, treatment and rehabilitation.  
AHRI: Armauer Hansen Research Institute (AHRI) is a biomedical research institute 
located in ALERT campus. The institute was founded in 1970 through the initiative of 
the Norwegian and Swedish Save the Children Organizations. AHRI has got its name 
from the Norwegian physician, Gerhard Henrik Armauer Hansen, who first described 
the leprosy bacillus (Mycobacterium leprae) as a causative agent of leprosy. AHRI 
conducts basic and applied research in the field of leprosy, tuberculosis, leishmaniasis, 
HIV, malaria and other infectious diseases.   Recently, the portfolio of the institute has 
expanded to include non-infectious diseases such as diabetes and cancer.  FACSCanto 
II, Luminex, qPCR machine, ELISA and ELISPOT readers, BACTEC and HLA 
typing instruments are among the main core facilities available at AHRI. 
5.1.3. The study design  
A case-control study design with follow-up was chosen for this study. A case-control 
study is a type of observational study which involves two groups, cases and controls. 
Cases are a group having the desired outcome and controls are a group sharing all 
properties with cases except the desired outcome in a given population. The cases and 
controls should be drawn from the same population.  
In contrast to a cohort study, in a case-control study, we start with well-defined cases 
having the desired outcome variable and another group called controls from the same 
population but doesn’t have the desired outcome. In a cohort study, we begin with one 
group free of the desired outcome and prospectively classify them according to their 
exposure to the putative risk factor. A case-control study is one of the most frequently 
used study designs to investigate the aetiology of diseases. A case-control study is 
often used to identify factors that may contribute to a medical condition by comparing 
subjects who have the condition “the cases”  with patients who do not have the 
condition ”the controls”. It is particularly suitable for the study of diseases having long 
incubation period like leprosy. This is because in a case-control study we start with 
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study subjects who have already developed the condition of interest. The desired 
outcome of this study was a patient with lepromatous leprosy who has ENL reactions.  
Hence, waiting a long time for the condition of interest to occur was not required as in 
a prospective cohort study. Furthermore, a case-control study, is cost-effective and one 
of the best study designs for examining multiple exposures without compromising the 
significance of the result. However, in a case-control study it is very difficult to 
determine the temporal sequence between exposure and outcome and hence usually 
the odds of occurrence is reported but not the odds of incidence.  To avoid selection 
and recall bias in a case -control studies, the use of incident cases than prevalent cases 
is advisable. Incident cases are newly diagnosed cases with the desired interest (desired 
outcome) during a defined time period while prevalent cases are cases who have had 
the outcome under investigation for some time. The temporal sequence of exposure 
and disease is easier to assess among incident cases than among prevalent cases.    
In this study, a nested case-control study was adopted to e ensure that cases (patients 
with ENL reactions) and controls (LL patients without ENL reactions) at the time of 
diagnosis were drawn from the same study population. A three-time case -control 
study design was used to measure the immunological status of cases and controls 
during the course of treatment for the desired outcome (leprosy and leprosy reaction).  
A total of 77 patients with leprosy, of which 46 were patients with ENL and 31 non-
reactional patients with LL were cases and controls respectively. Individuals in each 
groups were followed for 28 weeks. Clinical and laboratory examination were done at 
each visit. Blood samples were obtained three time from each patient, while biopsies were 
obtained twice (at recruitment and after treatment) from each patient.     
We applied a proper and restrictive case definition, well-defined controls, pre-set 
hypothesis, a pre-defined outcome variable, clearly established inclusion and 
exclusion criteria and adequate sample size to arrive at a valid conclusion. 
5.1.4. Source, study and sample population 
The source population is the population from which the study subjects are drawn. It is 
the catchment population. It refers to the totalities of those that share, at least, one 
common factor. In our study, the source population were all patients with leprosy 
visiting ALERT hospital during the study period. The common property of the 
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population was that all of them had diagnosed leprosy, although their clinical forms of 
leprosy in the population varied.  
The study population is the population from which the samples are drawn. It is the 
population to which the results of the study may be extrapolated out to. However, the 
extrapolation depends on the design and objective of the study. Study population 
sometimes referred to as target population. The study population are more uniform 
than the source population. Our definition of the study population was all patients with 
ENL and LL attending Red Medical Clinic at ALERT hospital during the study period. 
The sample population is   the population which comprises of individuals drawn from 
the study population. Study population and sample population share identical 
properties of a subject of interest for the researcher. For example, in our ENL study, 
all patients with ENL cases were new, untreated with corticosteroids or previously 
treated but off corticosteroids at least for 15 days. Hence, all these patients with ENL 
visited RMC during the study period are study population.  For many reasons, it is not 
possible to study all untreated patients with ENL which necessitates the selection of 
some patients with ENL from the group using either probability or non-probability 
sampling methods. Due to the very close nature of study population and sample 
population, most researchers use sample and study population interchangeably. The 
following diagram shows the difference among the three populations schematically 
(Figure 5.1).  
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Figure 5.1. Schematic representation of source, study and sample population  
The following definitions were used for source, study and sample population in our 
ENL study. 
Source population: All patients with leprosy who presented at the leprosy Clinic 
(RMC) at ALERT Hospital during the study period. 
Study Population: Included all patients with ENL reactions and non-reactional LL 
patients.  
Sample population:  All selected and consenting patients who were eligible for the 
study.     
Source Population  
Sample population 
Study population 
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5.1.5. Sample size determination  
Sample size determination is the process of choosing the number of observations or 
replicates required to include to a statistical sample. The sample size is a vital feature 
of any study if drawing inferences about a population from which the samples drawn 
is required. Determining the ideal sample size for a study guarantees an adequate 
power to detect statistical significance. Hence, it is a critical step in the design of a 
planned clinical studies (Suresh and Chandrashekara, 2012). Power is the probability 
of correctly rejecting the null hypothesis.  It is possible to increase power by increasing 
the sample size but as sample size becomes too large, an effect of little scientific 
importance is statistically detectable and leads to a significant difference between 
groups. Considering an appropriate sample size is also important for economic 
reasons. Hence, power and sample size determination are a fundamental step in the 
design of clinical research. A good clinical study design is judged in terms of the 
estimate of the effect size, confidence interval and P-value.  The confidence interval is 
used to indicate the likely range of values for the given effect size in the population 
and P-value explains how likely that the observed effect in the sample is due to chance. 
Although sample size determination is theoretically simple, practically it is one of the 
challenges in a clinical study, particularly in immunology. Immunological studies are 
very expensive and time-consuming. Therefore, it is mandatory to balance the sample 
size and the economics.  
In our study, we calculated the sample size assuming a constant probability of exposure 
throughout the pool of controls. The controls were matched to cases in terms of age, 
gender or duration of the onset of leprosy. To calculate the sample size for each group 
(cases and controls), the percentage of FoxP3 expression on CD4+CD25+ was 
considered. The percentage of FoxP3 expression in CD4+CD25+ T-cells was used for 
sample size calculation since the main goal of the study was describing the relative 
percentage of regulatory T-cells in ENL and LL controls.  As mentioned in the 
preceding sections, FoxP3 is the robust Treg marker reported by several studies. A 
95% confidence interval with 5% level of significance and 80% power was used to 
obtain reasonable sample size. The expected percentage of Tregs (CD4+CD25+ 
FoxP3+) in patients with ENL and LL controls was 1.2% and 2.8% respectively (Attia 
et al., 2010).  Based on this, using STATA 12 the required sample size for each group 
was calculated to be 30. Anticipating 50% defaulter rate in  patients with ENL cases, 
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the total sample size required for this study  was  adjusted to 75 (45 ENL cases and 30 
LL controls).  Group one: 45 patients presenting with ENL (cases),   Group two: 30 
non-reactional LL patients (controls)  
5.1.6. Effect size  
Using the G*power 3.1.7, software, the effect size was calculated as; Input parameters: 
α=0.05, 1-β=0.8., N=75, test criteria: one tail and effect direction: H1 > Ho.  The 
calculated effect size (Se) is 0.198. Interpretation:  when the value of the standard error 
of the mean for the control and experimental group is ≥ 0.198, there is a significant 
difference between the two groups with an effect size of 0.198 (Figure 5.2).  
 
 
Figure 5.2. : Standardized normal distribution for Z score showing critical regions 
for the desired effect size.  
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5.1.7. Inclusion and exclusion criteria  
Inclusion criteria  
Patients with leprosy who fulfilled the following criteria were eligible to participate in 
the study and considered members of the sample population.  
i. Age group: 18-65 years old  
ii. Individuals  who gave consent and  were willing to return for follow-up study 
iii. Individuals diagnosed as having leprosy  with clinical evidence of ENL reaction 
or  
iv. Individuals diagnosed as having leprosy with clinical evidence of non-reactional 
LL and matched with one of the cases at least by age or sex.  
Exclusion criteria  
Any individual characterized by at least one of the following criteria was not eligible 
to participate in the study.   
i. Individuals unwilling to give consent or unwilling to participate in the follow-up 
study  
ii. Leprosy patients with other forms of the clinical spectrum of leprosy (TT, BT, 
BB, BL).  
iii.  Children below 18 and adults above 65 years old. 
iv. Individuals whose weight was below 40kg. 
v. Pregnant and lactating mothers  
vi.  Anaemic patients  
vii.  Patients with a history of concomitant severe conditions such as TB, HIV/AIDS, 
cardiac and renal problems, diabetes mellitus (DM) that potentially might affect 
the evaluation of the patient’s immune profile.  
viii. ENL patients taking prednisolone or completed prednisolone treatment 14 days or less.
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5.1.8. Ethical considerations  
Since our study involves human subjects and human samples, we adhered to the ethical 
principles and code of practice recommended by the World Medical Association 
declaration of Helsinki 1964 and later revisions. Training of transferable skills training 
offered by LSHTM (research ethics) and good laboratory practice (GLP) offered by 
Armauer Hansen Research Institute were obtained prior to the commencement of the 
study. Research ethical approvals were obtained from London School of Hygiene and 
Tropical Medicine Ethics Committee, AHRI/ALERT Ethics Review Committee 
(AAERC) and National Research Ethics Review Committee (NRERC), Ethiopia.  
Support letters were obtained from ALERT Hospital, AHRI, and LSHTM.  
5.1.9. Informing and consenting patients  
Information sheet and consent were prepared in English and translated to Amharic 
(local language) by a native speaker (Appendix 1). The information sheet was written 
in plain words and given to a layperson to verify if the information was easily 
understandable by the participants. The information sheet was given to each participant 
to read or was read for the participant. Then, the participant was requested to notify 
his/her decision.    
We recruited a study coordinator with a public health professional who has been 
trained for research ethics and consenting patients and does not involve in leprosy 
diagnosis and treatment to avoid any discomfort or worries anticipated by patients. 
Candidate participants were informed that they had the right to refuse to participate 
without given reasons. They were also assured that they could withdraw at any time 
from the study without giving reasons and without prejudicing further treatment. 
Participants who were fulfilled the initial assessment were invited to take part in the 
study. For consenting the two main local languages, Afan Oromo and Amharic were 
used for the majority of the participants. For some patients who were unable to speak 
these two languages, a translator was used.  Consent was obtained from each study 
subject by the study coordinator.  If either the treating physician or nurse takes consent, 
patients could give consent irrespective of their voluntariness because they may think 
that it could affect the outcome of their treatment.  
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In Ethiopia donating blood is not encouraged by many societies, probably tied to 
religion or cultural aspects. The challenge is more serious when more volume of blood 
is required (more than 10mL). Hence, we approached the participants carefully and 
explained them the normal volume of blood donated by apparently healthy adults such 
as for blood bank to convince them to donate 40-50mL blood.  
The consent form was signed by all participants before inclusion to the study. For 
participants unable to sign, a thumb print was obtained instead and witnessed by a 
person obtaining the consent. A study code was given for each participant and on the 
participant’s consent form only the code was written to maintain confidentiality. The 
study code and the name of the participant were written on the separate log book and 
accessed only by the principal investigator and the clinical coordinator.  
5.1.10. Study subjects recruitment  
Study subjects were recruited at Red Medical Clinic of ALERT Hospital which is 
dedicated to leprosy diagnosis, treatment, and rehabilitation. There are 5 nurses of 
which 2 are leprosy specialist nurses. There are also 5 dermatologists (2 females and 
3 males) engaged in leprosy diagnosis and treatment. Theoretically, one dermatologist 
is assigned every day to see leprosy patients at the Clinic. However, practically almost 
all patients are seen by nurses.  
 At ALERT Hospital, suspected leprosy cases are sent to Red Medical Clinic from 
central triage or from the department of dermatology after they are seen by a 
dermatologist for further diagnosis and treatment. I had a brief discussion with all 
nurses working in the clinic about the plan and the requirements of the study. There 
were many challenges to reach a consensus.  Low staff morale, shortage of medication, 
incentive and negligence were some among the challenges. We agreed with the nurses 
to direct new and untreated patients with ENL cases to the study coordinator for 
consenting. The study coordinator has been working in occupational therapy 
department. Participants were guided by the assigned porter to donate a sample, collect 
their medication, receive compensation and given the appointment for the second and 
third round visits. Following consenting, clinical data were filled on the pre-structured 
questionnaire at RMC and checked by the coordinator for completeness. Bacillary 
index (BI) and other laboratory examination were done for further confirmation. Then 
patients were guided to the AHRI blood and biopsy sample room to donate blood and 
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skin biopsy sample. After sample collection, each participant was compensated for 
transportation and lunch.  The next appointment date was given in written form on the 
specifically designed participation ID card (Appendix 1). 
5.1.11. Sampling procedure  
 During the study period, 46 patients with ENL and 31 non-reactional LL controls were 
recruited as case and control study subjects respectively. Any measurement and 
assessment information obtained from each group at the beginning was used as a 
baseline data.  Samples from each patient at his/her next episode of ENL were 
collected to look at the consistency of immunological events within the patient. 
Samples were collected at start, 12 and 24 weeks after the start of corticosteroid 
administration. The 12th week was chosen since the steady decrease of steroid 
after12th week reaches less than half of the start dose and after 24th-week steroid 
administration normally off unless the patient experiences a chronic condition (Figure 
5.3). The samples obtained at recruitment were used to analyse the immunological 
profiles (Regulatory and memory T-cells, pro-inflammatory cytokines and regulatory 
cytokines) before treatment. The second time point samples were obtained when ENL 
cases completed half of their corticosteroid treatment time and the samples were used 
to determine these immune profiles while the patient was on the corticosteroid 
treatment. The third time point sample was obtained when an ENL patient completed 
corticosteroid treatment and the free treatment period is 15 days or more.  Skin Biopsy 
samples were obtained at entry and exit only.  
5.1.12. Follow-up 
A single point of contact was set for patients after enrolment to the program. They 
were advised to report any changes regarding their disease condition (leprosy) to the 
person in charge (coordinator). They were also linked to the nearby health stations in 
their village. The health stations were contacted and notified to send the patient to 
ALERT hospital in case they develop reactions (non-reactional LL controls) or for any 
worsening conditions.  The second round sample was collected from each patient when 
the initial prednisolone dose was tapered by half. The third round sample was collected 
after the patient was off prednisolone for 15 days confirming the patient had no 
evidence of new ENL lesions. In those patients who did not show improvement, 
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prednisolone administration continued as prescribed by the physician and samples 
were collected at the pre-set time interval.  
5.1.13. Patient compensation and appointment for next sampling 
Each participant was compensated for transportation and lunch at each visit.  For those 
patients coming from the outsides of the outskirts of Addis Ababa, accommodation 
was provided. The next visiting date was given on the specifically designed ID card. 
Three days before the appointment each participant was reminded by the phone call. 
For individuals who did not have their own phone number, we used either relative’s 
phone number if available or the nearby health post’s contact number.  
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Figure 5.3.  ENL cases sampling and follow-up chart 
  
 
Prednisolone treatment initiated  
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5.1.14. Demographic and clinical data collection 
Structured questionnaire were used for clinical data recording for each participant. The 
ENL International STudy group (ENLIST) format was modified and used for clinical 
data recording. The data collection sheet included the demographic, clinical and 
diagnostic information set following the standard guideline. The clinical information 
included core points such as the clinical feature, skin lesion, nerve functions and 
systemic involvement. Clinical assessment was done three times consecutively. At 
recruitment, the clinical assessment included the socio-demographic and details of 
clinical signs and symptoms and used as a baseline information. During the second 
and third-time visit assessment, socio-demographic data were not recorded to avoid 
unnecessary duplication. 
 The baseline data included   card number, study code number, age, sex, weight, blood 
pressure, time since leprosy symptoms developed, the Ridley-Jopling classification of 
the disease, previous treatment with MDT and reactions. A detailed history of the skin 
examination and nerve symptoms were recorded on the form. The number, size and 
morphology of skin lesions, the presence of erythema or ulceration, the presence of 
peripheral oedema, nerve tenderness, nerve pain or paraesthesia were recorded on the 
clinical data recording form. The physiotherapist performed Sensory Testing (ST) 
using semmes-weinnstein monofilaments (SWMs) at designated test sites on the hands 
and feet and Voluntary Muscle Testing (VMT) result was documented for each 
participant during each visit.  For all participants, basic laboratory tests were obtained. 
These tests included full blood count, haemoglobin concentration, renal function, liver 
function, glucose level and stool specimen for the presence of ova, cysts and parasites. 
Symptomatic screening for TB (a cough longer than 2 weeks, night sweats, weight 
loss) and HIV test were performed for each participant at each visit. Slit-skin smear 
was used from four sites to calculate the BI at the time of enrolment. BI at leprosy 
diagnosis and the current BI were recorded on the form for further analysis. 
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SECTION 2: CLINICAL SAMPLE COLLECTION AND PROCESSING  
Blood and skin punch biopsy samples were obtained from all patients with ENL and 
LL patient controls. Forty to forty-five- millilitre blood was collected in vacutainer test 
tubes for the subsequent use in flow cytometry and ELISA. About 2mL of blood was 
collected in PAXgene Blood RNA Tubes for mRNA isolation.  Blood samples were 
obtained before, during and after treatment of ENL cases and LL controls. Biopsy 
samples were collected in three different preservatives: for histopathology in 10% 
formalin, for mRNA isolation in 1mL RNAlater and for immunohistochemistry 
embedded in optimum cutting temperature (OCT) medium.  Procedures for each 
sample collection and storage are described below.  
5.2.1. Clinical sample collection           
 Blood samples were collected from each patient at each visit. Skin punch biopsies 
were taken at entry and exit only. Blood sample (40-45mL) was collected in sterile BD 
heparinised vacutainer ® tubes (BD, Franklin, Lakes, NJ, USA) and 2mL of blood was 
added into PAXgene® Blood RNA Tubes (PreAnalytix, GmbH, Switzerland) 
following the aseptic technique. The phlebotomists in charge (the nurses) were 
documented the date, study code number, ALERT number, AHRI number, sex, age, 
blood volume, body sites from which biopsy was taken, name and signatures of the 
nurse in charge. The nurses were also instructed to make sure that the patient is the 
correct participant from whom blood and biopsy sample is desired by crosschecking 
with the attached document. Two research nurses who had been trained and have 
experience in leprosy diagnosis and treatment were recruited for drawing blood and to 
take punch biopsy samples.  
A patient was lied down on its back on the bed while drawing blood and taking biopsy 
samples. The heparinised vacutainer was labelled with patient study code and date. For 
skin punch biopsy, three types of preservation media were prepared as described 
before. One 4mm punch biopsy was fixed in 10% formalin and kept at ambient 
temperature to be used for histology. Another 4mm punch biopsy taken from the same 
area was transferred to a Nunc® tube containing 1mL RNAlater® solution (Thermo-
Fisher Scientific) and was kept at -20oC for 48 hours and then transferred to -80 oC 
freezer. The third 4mm punch biopsy sample was placed in tissue-Tek cryomold and 
embedded by optimum cutting temperature compound (Tissue-Tek®, O.C.T. 
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compound, Sakura® Finetek, USA) and then snap-frozen in liquid nitrogen. The 
Frozen biopsy then transferred to -80oC for storage until used for 
immunohistochemistry. The PAXgene Blood RNA Tubes were kept at room 
temperature for 2 hours and then transferred to -80oC for storage until used for RNA 
isolation.  Blood in heparinised vacutainer tubes was brought to PBMCs isolation room 
and kept for 1 hour at room temperature in disinfected sterile safety cabinet and then 
followed by PBMCs isolation.      
5.2.2. Peripheral blood mononuclear cells isolation  
Peripheral blood mononuclear cells (PBMCs) are blood cells such as monocytes and 
lymphocytes with a round shaped nucleus as opposed to granulocytes which have 
lobbed nucleus. The lymphocytes population consist of T- cells, B- cells and natural 
killer (NK) cells.  Lymphocytes are the main component of the immune system, 
playing an essential role in the host’s defence system. The separation of PBMCs from 
whole blood is usually done through density gradient using Ficoll. After the 
centrifugation step, the Ficoll separates blood into layers of plasma, PBMCs, 
granulocytes and red blood cells (RBCs) (Figure 5.4).  
 
 
 
 
 
 
Figure 5.4. PBMCs isolation from whole blood A) Before centrifugation B) After 
centrifugation with Ficoll-paque. 
 
  
A B 
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PBMCs isolation from whole blood is the critical step for the subsequent works. In our 
study, PBMCs isolation was optimized using healthy volunteer blood. The PBMCs 
isolation protocol is briefly described as follows:  Blood samples in heparinised tubes 
brought to safety cabinet and kept for one hour at room temperature (RT). Fifteen 
millilitres of Ficoll-paque™ PLUS (GE Healthcare, UK LTD) kept at RT was added 
to Leucosep™ tubes (Greiner Bio-one, USA) and centrifuged at 1000g for 30 seconds 
to make the ficoll-paque go down beneath the porous barrier (Figure 5.4A). After 
inverting the blood containing tube 2 to 3 times, 25mL of blood from the heparinised 
tube was poured slowly to the Leucosep tube and centrifuged at 800g for 25 minutes 
with break off at RT.  After  the spinning, the plasma (top layer, Figure 6.4) was 
transferred to cryotubes and the PBMC interface was transferred to 50mL of  non-
pyrogenic, and RNase/DNase-free Corning® (BD, UK) centrifuge tube containing 15 
mL of pre-warmed to RT buffered phosphate saline solution (PBS,  Sigma Aldrich®, 
UK). Then the tube was filled with PBS and centrifuged at 800g for 10 minutes at RT 
with a break on low. After the spinning, the supernatant was discarded and the pellet 
was resuspended with 1mL of   Roswell Park Memorial Institute (RMMI medium 1640 
(1x) + GlutaMAX™ + Pen-Strip (GBICO™, Life technologies™, UK) and mixed 
thoroughly and then the volume brought to 10 mL by adding complete RPMI medium 
followed by washing at 600g for 10 minutes at RT with break on low. After this wash, 
the supernatant was discarded and the pellet was resuspended by adding 1mL of 
complete RPMI medium and mixed thoroughly until the pellet dissolve and then the 
volume was adjusted to 2mL.  Ten µl of the sample was mixed with 90µl of 0.4%, 
sterile, filtered Trypan Blue solution (Sigma Aldrich®, UK) to count live cells. Ten µl 
of the mix was mounted on Neubauer Chamber (Figure 6.5).  Cells in the 25 inner 
squares of Neubauer Chamber were counted and the total number of cells/mL was 
obtained by multiplying the counted cell number by the dilution factor (10x), the 
volume of the cell (2mL) and the constant (104).  For example, if 200 cells counted in 
the inner 25 squares of the chamber, the total number of cells in the sample will be: 
200 x 10 x 2 x 104 = 40 x106 cells/mL (Figure 5.5).  
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Figure 5.5. Cell counting chamber. A) Neubauer Chamber B) counting squares  
5.2.3. Freezing cells 
Cells resuspended in a half the final volume of media with 20% Foetal Bovine Serum 
(FBS, heat inactivated, endotoxin tested ≤5 EU/ml, (GIBCO® Life technologies, UK) 
and kept at 40C.  The freezing medium was prepared with pre-cooled RMMI medium 
1640 (1x) + GlutaMAX™ + Pen-Strip containing 20% foetal bovine serum and 20% 
Dimethyl sulfoxide (DMSO) molecular biology grade  (Sigma Aldrich®, UK). Then 
the freezing medium was gently pipetted to the sample and 1mL of the aliquot 
containing 5-10 million cells was pitted to the 2mL volume cryovials quickly. The 
cryovials were transferred to a pre-cooled MRFrosty containing isopropanol (Figure 
5.6). Then, the MRFrosty was kept at -80oC for freezing the cells slowly.  After 24 
hours, the cryovials were transferred to cryobox and stored at -80oC until used.   
 
 
 
                                                     
           
 Figure 5.6.  The freezing can (MRFrosty)  
  
A 
 
B 
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5.2.4. Procedures for thawing frozen PBMCs  
Thawing frozen PBMCs is a critical step for subsequent process. Frozen cells are 
fragile and should be handled gently with maximum care. If PBMCs are not thawed 
properly, viability and cells recovery can be compromised. We optimized the 
procedure for thawing cells and used the optimized protocol for thawing frozen 
PBMCs as described by Thompson et al. (2001). The procedure for thawing frozen 
PBMCs is briefly described as follow as: Thawing media (complete media + 0.01% 
Benzonase) was prepared and incubated in a 37oC water bath. The cryovials from 
liquid nitrogen or -80 oC were transferred to a 37oC water bath and kept 1 to 2 minutes 
until 75% of the cells thawed. Then the surface of cryovials were cleaned with 70% 
alcohol and the cells were transferred to 15mL polypropylene centrifuge tubes 
containing 10mL of pre-warmed thawing media. Then the cells were centrifuged at 
600g for 7 minutes. The supernatant was decanted and the tube was flicked by a finger 
to break the pellet. The pellet was resuspended with 5mL complete media and 
centrifuged at 600g for 5 minutes at RT. After decanting the supernatant, the pellet 
was dissolved in 1mL completed media. Then cells were counted with a 
haematocytometre (Neubauer chamber) and the cell viability was determined with 
trypan blue as previously described.  Cell concentration was adjusted to 106cells/mL.  
Finally, 1mL/well cell suspension was plated on 24 well polystyrene cell culture plate 
(Corning® Costar® cell culture plates) and incubated at 37oC in a 5% carbon dioxide 
incubator overnight. After overnight incubation, cells were brought to flow cytometry 
staining room for staining with fluorochromes conjugated antibodies (described under 
flow cytometry topic, section 3).     
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SECTION 3:  FLOW CYTOMETRY   
5.3.1. Flow cytometry and Fluorochromes 
Flow cytometry: Flow cytometry is a laser-based technique that simultaneously 
measures and then analysis multiple physical characteristics of single cells as they flow 
in a fluid stream through a beam of light. The properties measured include the relative 
size of cells, relative granularity or internal complexity and relative fluorescence 
intensity. Fluorescence-activated cell sorting (FACS) is a specialized type of flow 
cytometry which provides methods for sorting for mixtures of biological cells into 
groups based upon the specific light scattering and fluorescent characteristics of each 
cell. FACS is a trademark and owned by Becton, Dickinson Company.   
Fluorochromes used in flow cytometry:  A fluorochrome is a chemical that can re-
emit light upon light excitation.  Each fluorochrome has specific absorption spectrum, 
extinction coefficient, emission spectrum and quantum efficiency. These 
fluorochromes are conjugated to antibodies for use in flow cytometry. Fluorochromes 
are emitted at blue, green, red or violet laser of the flow cytometer. For example 
Fluorescein Isothiocyanate (FITC), PE-Cyanine 5.5 and PE-Cyanine 7  are among 
fluorochromes which have 488nm excitation and emitted at blue laser while  APC-
eFluor®  (633) 780  fluorochromes are used  for the  red laser of the flow cytometer.   
5.3.2. Panel construction 
Antibody panel design for multicolour flow cytometry involves the process of 
choosing fluorochromes from each channel and setting a panel. The panel construction 
depends on the question to be answered by the panel, knowledge of the flow cytometer, 
antigens, fluorochrome intensity (brightness) and other factors. It also involves the 
choice of the controls to be used.  Such controls include compensation control, isotype 
control, Fluorescence Minus One (FMO) controls, unstained controls and gating 
controls.  FMO controls contain all the fluorochrome markers except the one of 
interest.  For low density or smeared population such as regulatory T-cells, FMO allow 
accurate delimitation of positively versus negatively stained cells.     
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5.3.2.1. Regulatory T cell panel 
To describe Tregs we used 8 markers. The markers used for this panel included anti-
human CD3 (APC 450), anti-human CD4 (eFluoro780), anti-human CD8 (PerCp-
Cy5.5), anti-human CD25 (PE-Cy7), anti-human CD127 (APC), anti-human CD161 
(PE), anti-human FoxP3 (FITC) and a viability stain (Aqua, v500). We used FMO for 
each maker, compensation controls, unstained and Isotype controls whenever 
necessary (Table 5.1).  Cell viability was also checked before the staining using 0.4% 
trypan blue.  
5.3.2.2. Memory T-cell panel  
Six markers were used to determine memory and activated T- cells. These markers 
were: anti-human CD3 (APC 450), anti-human CD4 (eFluoro780), anti-human CD8 
(PerCp-Cy5.5), anti-human CD62L (APC), anti-human CD45RO (PE), and viability 
(Aqua, v500) (Table 5.1).  We used for each maker FMO, compensation controls and 
unstained cells. Unstained cells were used to exclude the autofluorescence of cells. 
Cell viability was also checked before staining using 0.4% trypan blue. 
5.3.2.3. B- cell Panel 
To describe the memory B-cells sub types the following markers were used:  anti-
CD10 (FITC), anti-PD1 (PE), anti-CD19 (PerCp-Cy5.5), anti-CD95 (PE-Cy7), anti-
CD27 (V500), Anti-CD21 (V450), Live/dead (eFluoro 780), and Isotype control 
(IgG1) ( Table 5.1). Compensation controls and unstained cells were used as described 
before.  Cell viability was also checked before staining using 0.4% trypan blue. 
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Table 5.1.  Antibody panels, fluorochromes and sources of antibodies used in the 
study  
Panel name  Antibody  Conjugated 
fluorochrome  
Clone  Source  Reactivity  
Regulatory  
T -cells   
anti- CD3 APC 450  UCHT1 eBioscience  Human  
anti- CD4 eFluoro780 OKT4 eBioscience Human 
anti-CD8 PerCp-Cy5.5 RPA-T8 eBioscience Human 
anti-CD25 PE-Cy7 M-A251 BD Human 
anti-CD127 APC eBioRDR5 eBioscience  Human 
anti-CD161 PE HP-3G10 eBioscience  Human 
anti-FoxP3 FITC PCH101 eBioscience  Human 
Live/dead 
stain 
V500 aqua - Life 
technologies 
- 
Memory 
 T- cells  
anti -CD3 APC 450 UCHT1 eBioscience  Human 
anti-CD4 eFluoro780 OKT4 eBioscience  Human 
anti-CD8 PerCp-Cy5.5 RPA-T8 eBioscience  Human 
anti-CD45RO PE UCHL1 BD Human 
anti-CD62L APC DREG56 BD Human 
Live/dead 
stain 
V500 aqua - Life 
technologies 
Human 
B- cells  anti-CD10 FITC W8E7 BD Human 
anti-PD1 
(CD279) 
PE EH12.1 BD Human 
anti-CD19 PerCp-Cy5.5 HIB19 BD Human 
anti-CD95 PE-Cy7 DX2 BD Human 
anti-CD27 V500  M-T271 BD Human 
Anti-CD21 V450 B-ly4 BD Human 
Live/dead  eFluoro 780 - Life 
technologies 
- 
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5.3.3. Antibody titration  
In flow cytometry, antibody titration is a process of determining the right concentration 
of antibody to obtain an optimum signal. This is related to antibody-antigen kinetics 
since the goal in flow cytometry is saturation of the marker with the antibody. Hence, 
the purpose of titration is to obtain the optimum concentration where binding 
saturation occurs. Low antibody concentration results in dim staining while the use of 
a high antibody concentration will increase false positivity by staining the background. 
The optimal antibody titre is the dilution that produces the maximum signal to noise 
ratio and it is often not the concentration that produces the highest percentage of 
positive cells  (Stewart and Stewart, 1997).  
To determine the optimum antibody titres required to stain of the samples (PBMCs), 
each antibody was titrated in four dilutions by taking the company’s recommendation 
as the top dilution. Cells were used for titrating antibodies. Unstained cells were used 
as a negative control.  A single staining protocol that means each antibody was stained 
individually. The median fluorescent intensity of positive (MFIpos) and negative 
population (MFIneg) was then calculated. The standard deviation for the negative 
population (SDneg) was also obtained. Then the staining index, named as a signal to 
noise ratio (S/N) was calculated for each antibody and a scatter plot was obtained for 
the log antibody concentration versus the staining index. As a rule, the higher the S/N, 
the better is the signal (Maecker and Trotter, 2004). In the following example, (Figure 
5.7) 2.5µl of antibody is the optimal volume to be used for the 100µl final volume of 
staining.  
                        S/N=(MFIpos − MFIneg)/2SDneg 
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 Figure 5.7.  Antibody titration: determination of the optimum amount of antibody 
required for single stain by graphical methods. 
  
158 
   
5.3.4. Nuclear staining (staining for Tregs)  
The staining of Tregs involves two steps: surface staining followed by nuclear staining.  
The nuclear staining involves permeabilization of the cells to facilitate the entrance of 
fluorochromes-conjugated antibody into the nuclear region to stain the marker of 
interest which is FoxP3 in this study. The staining procedure is briefly described in the 
following paragraphs.  
Frozen PBMCs were thawed as described previously. Cells were washed twice with 
RMPI-1640 supplemented with benzonase (10 U/ml, Novagen, Merck4Biosciences, 
Merck KGaA, Darmstadt, Germany). After washing, the pellets were resuspended in 
1mL complete media.  
About 1x106/mL cells were plated on 48 well cell culture plate with plain media 
(without stimulation) overnight for resting cells. Then the cell suspension was 
transferred to round bottomed FACS tubes (Falcon®, BD, UK) followed by  spinning 
at 400g for 5 minutes at RT.  After discarding the supernatant, the pellet was 
resuspended in 1mL phosphate buffered saline solution (PBS, Sigma Aldrich®, UK) 
and centrifuged at 400g for 5 minutes. The supernatant was discarded and the pellet 
was resuspended in 50µl of PBS. Then the cells were incubated in 1mL of 10% human 
AB serum (Sigma Aldrich®, UK)   for 10 minutes in the dark at room temperature to 
block nonspecific Fc-mediated interactions and followed by centrifugation at 400g for 
5 minutes. The supernatant was discarded and the pellet was resuspended in 50µL PBS 
buffer. Life/dead staining was performed at a concentration of 1µl /1mL live/dead stain 
(V500 Aqua, Invitrogen, Life technologies, UK) for 15 minutes at 4oC in the dark.  
Cells were washed once and stained for surface markers directed against CD3- Pacific 
blue, CD4- eFluoro 780, CD8- PerCp-Cy5.5, CD127-APC, CD161-PE (all 
eBioscience, UK) and CD25-PE-Cy7 (BD, Biosciences, UK). The cells were 
incubated with the cocktail for 30 minutes at 4oC.  After 30 minutes of incubation, the 
cells were washed with FACS buffer (PBS, 1% FBS, 0.1% NaN3 sodium azide) and 
followed by intracellular staining. One millilitre of 1xFoxP3 Fixation- 
Permeabilization buffer (eBioscience, UK) was added to each tube, mixed thoroughly 
and incubated at 4oC for 60 minutes.  After 60 minutes incubation, without washing 
2mL of permeabilization buffer was added and centrifuged at 400g for 5 minutes. The 
supernatant was discarded and resuspended in 50µl of buffer followed by staining the 
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permeablized cells with anti-human FoxP3 (FITC, eBioscience) for 30 minutes at 4oC.  
Then cells were washed twice by 2mL of permeabilization buffer.  Finally, the cells 
were re-suspended in 400µl FACS buffer and followed by FACS acquisition.   
5.3.5. Staining for memory T-cells  
Surface staining was performed for the staining of memory T- cells. About 1x106/ml 
cells were plated on 48 well cell culture plates overnight as described above.  Cells 
were transferred to round bottomed FACS tubes (Falcon®, BD, UK) and washed by 
PBS as described above. After blocking the Fc receptor-mediated interaction by 1mL 
of 10% human AB serum, the cells were stained with live/dead stain (V500 Aqua, 
Invitrogen, Life technologies, UK) for 15 minutes at 4oC in the dark and washed once 
followed by staining with anti-human CD3 (APC 450), anti-human CD4 (eFluoro780), 
anti-human CD8 (PerCp-Cy5.5), anti-human CD62L (APC) and anti-human CD45RO 
(PE), and incubated at 4oC for 30 minutes in the dark. After one wash, cells were fixed 
in 4% paraformaldehyde (PFA, Sigma Aldrich®, UK) for 15 minutes at room 
temperature. Finally, cells were washed with FACS buffer twice and re-suspended in 
400µl FACS buffer for FACS acquisition.   
5.3.6. Staining for B-cells 
The surface staining protocol used for B cells was similar to that of the staining of 
memory T-cells except for the different antibody cocktails used. For B-cell staining 
the following fluorochromes conjugated  antibodies were used: anti-CD10 (FITC), 
anti-PD1 (PE), anti-CD19 (PerCp-Cy5.5), anti-CD95 (PE-Cy7), anti-CD27 (V500), 
Anti-CD21 (V450), Live/dead (eFluoro 780), and Isotype control (IgG1).  
5.3.7. Data acquisition using FACSCanto II 
After staining, cells were acquired by flow cytometry. Cell acquisition by flow 
cytometry involves several setups. The flow cytometry setup techniques used in this 
study are briefly described in the following sections.    
5.3.7.1. Cytometer setup and tracking system 
Flow cytometer setup such as laser alignment, laser time delay and sensitivity was 
checked periodically. Quality control test (QCT) beads supplied by BD were routinely 
used to test the cytometer’s performance. Robust standard deviation of electronic noise 
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(rSDEN), relative detection efficiency for each detector (Qr), relative optical 
background (Br), robust coefficient of variation for each setup bead (rCV) and  
Linearity maximum channel  has been checked and monitored by trained system 
engineer during data acquisition.    
5.3.7.2. PMT voltage setting  
The voltages on the photomultipler tubes (PMTs) convert the photons of light emitted 
by the fluorochromes on the cells and convert them to electrons, which eventually 
become the voltage current that is digitized and ultimately stored in the FCS file as the 
data output(Maecker and Trotter, 2006). 
BD FACSCanto II was used for this study and data were acquired on BD 
FACSDiva™ software. BD FACSDiva™ software efficiently controls the setup, 
acquisition, and analysis of flow cytometry data from the BD FACSCanto II 
workstation. It enables to preview and record data from multiple samples within an 
automated acquisition process. An acquisition template, experimental layouts and 
compensation procedures were created at the time of optimization.  Unstained cells 
were used to set optimal electrical voltage for the forward-scattered light (FSC) and 
side- scattered light (SSC) for each fluorochromes. The voltages were adjusted in 
such a way that unstained cells appeared in the first quadrant on the logarithmic scale 
for each fluorochromes. Special attention was given for fluorochromes with longer 
wavelength emissions such as APC, APC-Cy7, PE-Cy7 and PerCP-Cy5.5 since most 
cells emit little auto fluorescence at these wavelengths (Wang et al., 2008). The FSC 
A, H and FSSC A, H were ticked to facilitate the subsequent gating activity.  
5.3.7.3. Setting fluorescence compensation 
Fluorescence compensation is the process of   excluding the spectral overlap when two 
or more fluorescents are used in multicolour FACS experiments.  Spectral overlap is 
an inherent condition in most multicolour experiments and the spectral overlap should 
be excluded to avoid false positivity. For fluorescence compensation either cells or 
beads can be used. However, compensation beads are preferred rather than cells due 
to the fact that when the markers are dim and or found only on rare subsets of cells, 
setting compensation is difficult using cells (Maecker and Trotter, 2006). 
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A single-stained OneComb eBeads (affymetrix, eBioscience, UK) for all fluorescence 
compensation except for the live dead stain were used.  For the viability dye, cells 
were used for fluorescence compensation.  After acquiring the stained compensation 
beads, the positive and negative population was gated for each single-stained beads 
and the spectral overlap was made to be calculated automatically and linked to the 
sample acquisition worksheet (global worksheet) as previously described by 
Herzenberg et al. (2006).  Compensation controls were used for each batch of samples.  
5.3.8. Sample acquisition  
After the PMT voltage and compensation controls setting, the worksheet area was 
switched from the normal worksheet to the global worksheet.  For inspection purpose, 
the plots were produced on worksheet such as FSC-H versus FSC-A (to inspect the 
singlets), FSC-A versus viability marker (to inspect viable cells), SSC-A versus FSC-
A (to inspect populations such as lymphocytes, monocytes, granulocytes etc.). The 
threshold for FSC was set to 5,000.  For each sample, 500,000-1,000,000 cells were 
acquired (Figure 5.8).  
5.3.9. The gating Strategy 
The acquired data were analysed with FlowJo version 10 (Tree Star, USA).   Before 
gating of cell population for analysis, the acquired cells were inspected for the quality 
by looking into cell subpopulations expected in the sample (Figure 6.8).  Then, for all 
panels, singlets were gated based on the forward light scatter (FSC) and side light 
scatter (SSC) properties. Then, the singlets were gated with viability versus SSC-A. 
Viable cells have low SSC and high FSC scatter (Maecker and Trotter, 2006)(Figure 
5.9).    
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Figure 5.8.  SSC-A versus FSC-A of representative frozen PBMCs.  
5.3.9.1. Gating Tregs 
Viable cells were gated on SSC-A versus FSC-A for lymphocytes. Then, lymphocytes 
were gated for CD3. Total CD3+ T cells were selected and used for isolation of T-cell 
subpopulation.  CD3+ T cells were gated for CD4+ and CD8+ T cells. The CD3+CD4+ 
T cells were used for enumeration of CD4+ T-cell subpopulation. CD25+ cells and 
FoxP3+ cells were gated on CD4+ T-cells. The double positive cells (CD25+FoxP3+ 
cells) were gated with CD127. Then CD4+CD25
+FoxP3+CD127lo/- T-cells were 
considered as CD4+regulatory T-cells. Hence, CD4+ Tregs were defined as 
CD3+CD4+CD25+FoxP3+CD127lo/- cells (Shen et al., 2009b).  
  
Granulocytes 
Monocytes 
Lymphocytes  
Debris   
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 For CD8+ Tregs similar gating strategy was used and CD8+ Tregs were defined as 
CD3+CD8+CD25+FoxP3+CD127lo/- cells. In addition, CD25+ and FoxP3+ cells were 
also gated on CD4+ and CD8+ cells individually for all samples. CD161 was used as a 
marker for all IL-17 producing cells. It is previously described that CD161 is a marker 
for all human IL-17-producing T-cell subsets and is induced by RAR-related orphan 
receptor C (RORC) (Maggi et al., 2010).  However, recent findings have indicated that 
CD161 can also be expressed on other lymphocytes such as natural killer cells 
(Fergusson et al., 2014). Therefore, we gated CD161 positive cells on total 
lymphocytes, T-cells (CD3+ T-cells), CD4+ cells and CD8+ cells individually to catch 
any IL-17 producing cells. Furthermore, the Boolean gate platform was used to 
identify all functions within each cell preparation using the full array of possible 
combinations (Figure 5.9)  
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Figure 5.9. Gating for Tregs.  A): SSCA versus FSCA of acquired cells on flow 
cytometry global worksheet, B) Siglets: obtained by gating FSCH versus FSCA. Cells 
with high FSCA are doublets or granulocytes, C): Live cells obtained by gating 
Live/dead aqua V500 vs SSCA. Live cells have low SSCA, D): lymphocytes obtained 
by gating SSCA versus FSCA.  E): CD3 positive cells gated against FSCA, F): CD4+ 
cells gated on CD3+ T-cells, G): FoxP3+ cells gated on CD4+ T-Cells, H): CD25+ cells 
gated on CD4+T-cells, I): CD25 and FoxP3 gated on CD4+ T-cells,  K): CD127 gated 
with CD25+ FoxP3+ cells (Quadrant II of I). Then the CD25+FoxP3+ CD127 lo/- cells 
were taken as CD4+ Tregs (CD4+CD25+FoxP3+CD127 lo/-).   
A C B 
E D F 
G I H K 
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5.3.9.2. Gating Memory T cells  
Viable cells and lymphocytes were obtained as describe above under gating Tregs. The 
CD3+ population were gated for CD4+ and CD8+ T-cells.  On each population (CD3+, 
CD4+ and CD8+ cells) CD45RO and CD62L were gated to classify into subpopulations 
of memory T cells. CD45RO is used to delineate between naïve and memory T-cells 
while CD62L is used to obtain activated T-cells. The combination of CD45RO and 
CD62L categorizes the population into naïve, central memory, activated memory and 
effector T- cells  (Lugli et al., 2013) (Figure 5.10).  
 
 
 
 
 
 
 
 
Figure 5.10.  Gating memory T-cells on different cell types. A)  gated on CD3+ T-
cells, B) gated on CD4+ T-cells, C) gated on CD8+ T-cells    
5.3.9.3. Gating B cells 
Singlets, viable cells and lymphocytes were obtained in the same way as described in 
the above sections. B-cells were separated from other lymphocytes by gating the 
lymphocytes with FSCA versus CD19.  Then CD19+ B-cells were gated with CD10 
and CD10+ B-cells were excluded from further gates since CD10 is expressed on 
immature B-cells. CD19+CD10- B-cells were gated for CD27 versus CD21 to classify 
them into naïve cells, resting memory, activated memory and tissue-like memory B- 
cells (Table 5.2). In each memory B-cells, the degree of cell death (apoptosis) and B 
C 
B A 
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cells activation were measured using PD1 (CD279) and CD95 respectively (Demberg 
et al., 2012).   
 
 
 
 
 
 
 
 
Figure 5.11.  Gating strategy for B-cell sub populations; A) Gating B-lymphocytes by 
FSCA versus CD19, B) gating matured B-cells (CD19+CD10-), C) memory B-cells 
(obtained by gating matured B-cells for CD27 versus CD21).   
Table 5.2.  Memory T cells and their markers 
 Mature B cells  (CD19+CD10- )                         Marker  
CD27 CD21 
Naïve B cells  (NV) - + 
Resting  Memory B cells (RM) + + 
Activated Memory B cells (AM) + - 
Tissue like memory B-cells (TLM)  - - 
 
  
B A C 
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SECTION 4: ENZYME- LINKED IMMUNOSORBENT ASSAY  
5.4.1. Sample preparation  
An enzyme-linked immunosorbent assay (ELISA) is a biochemical technique which 
is typically performed to detect the presence and /or amount of a target protein of 
interest within an experimental sample. A sandwich ELISA was used to measure the 
in vitro production of the cytokines (TNF-α, IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-17A) 
in culture supernatants of PBMCs from patients with ENL reactions and LL controls 
before and after treatment.   
Sandwich ELISA is a special type of ELISA which measures antigens between two 
layers of antibodies (i.e. capture and detection antibody). The advantage of Sandwich 
ELISA is that the sample does not have to be purified before analysis, and the assay 
can be 2 to 5 times more sensitive than conventional ELISA (Gan and Patel, 2013). 
An ELISA well plate is coated with a known quantity of bound antibody to capture the 
desired antigen. After nonspecific binding sites are blocked using bovine serum 
albumin, the antigen-containing sample is applied to the plate. A specific primary 
antibody is then added that “sandwiches” the antigen. Enzyme-linked secondary 
antibodies are applied that bind to the primary antibody. Unbound antibody-enzyme 
conjugates are washed off. The substrate is added and is enzymatically converted to a 
colour that can be quantified using ELISA reader.  
 PBMCs thawing: During thawing, cells were transported in liquid nitrogen to a pre-
adjusted water bath at 37oC for 30 to 40 seconds until thawed half way and 
resuspended in 10% FCS in AIM-V at 37oC containing 1/10,000 benzonase until 
completely thawed, washed 2 times (7 minutes each) and counted as described above.  
Lymphocyte stimulation tests (LST):  Total PBMCs (200,000 cells/well), were 
added in triplicate into 96 well U-bottom tissue culture plates and cultured with M. 
leprae whole cell sonicate (WCS; 10 mg/ml), phytohaemagglutinin (PHA; 1 mg/ml) 
or AIM-V medium at 37oC with 5% CO2 and 70% humidity. After 6 days, supernatants 
were collected and kept frozen until used in ELISA. 
M. leprae whole cell sonicates (WCS): Irradiated armadillo-derived M. leprae whole 
cells were probe sonicated with a Sanyo sonicator to 95% breakage. This material was 
kindly provided by Dr. J.S. Spencer through the NIH/NIAID ‘‘Leprosy Research 
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Support’’ Contract N01 AI- 25469 from Colorado State University (now available 
through the Biodefense and Emerging Infections Research Resources Repository listed 
at (http://www.beiresources.org/TBVTRMResearch materials/tabid/1431/Default.aspx). 
5.4.2. The Cytokine ELISA protocol 
We used a Ready-Set-Go! ® Sandwich ELISA for detection and quantification of the 
cytokines mentioned above in the supernatants obtained by stimulating the PBMCs 
from patients with ENL and LL controls with M. leprae WCS.  A 96-well flat-bottom 
Nunc MaxiSorp® ELISA plates (Affymetrix, eBioscience, UK) were coated with 
100µl/well of capture antibody for each cytokine in 1x coating buffer. The plates were 
sealed and incubated overnight at 4oC. After aspiration, the plates were washed with 
350µl/well-washing buffer three times with 1-minute soaking interval using 
microplate washer (Bio-Tek). Wells were blocked with 200µl/well of 1x ELISA 
diluents (Affymetrix, eBioscience, UK) and incubated for one hour at room 
temperature and followed by washing the plates once. A twofold serial dilution of a 
standard was prepared for each cytokine and 100µl/well of the serially diluted standard 
was pipetted to the first two columns of the plate in duplicates. To the remaining wells 
test samples (100µl/well) were added. A positive and negative control was included to 
each plate and then the plates were sealed and incubated for 2 hours at room 
temperature.  After 2 hours incubation, the plates were aspirated and washed 3 times 
with 1-minute soaking interval as described above. After blotting the plates, a detection 
antibody (100µl/well) was added, sealed and incubated for 1 hour at room temperature. 
After one-hour incubation, the plates were aspirated and washed as described. A 
100µl/well of avidin-horseradish peroxidase (Avidin-HRP) was added to each well 
and followed by incubation for 30 minutes at room temperature. Then the plates were 
aspirated, washed as described. A chromogenic substrate, Tetramethylbenzidine 
(TMB, 100µl /well) was added and incubated for 15 minutes in the dark. After 15 
minutes incubation, 50µl/well stop solution (1 normal phosphoric acid, 1N H3PO4) 
was added to each well and the optical density (OD) at 450 nm was measured using an 
ELISA plate reader (Microplate reader; Bio-Rad, Richmond, CA). A curve fit was 
applied to each standard curve according to the manufacturer’s manual. Sample 
concentrations were interpolated from these standard curves.  Analyte concentrations 
outside the upper or lower limits of quantification were assigned the values of the 
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limits of quantification of the cytokine or chemokine. The standard curve plots are 
given in the Appendix 8.  
Table 5.3. Antibodies used for ELISA  
Cytokine  Assay 
Sensitivity  
Standard 
curve  range 
Sample 
dilution 
ELISA kit 
source   
Cat no. 
IL-6 2pg/mL 2-200pg/mL 1:10 ebioscience  88-7066 
IL-8 2pg/mL 2-250pg/mL 1:10 ebioscience  88-7086 
IL-10 2pg/mL 2-300pg/mL 1:1 ebioscience  88-7106 
IL-17A 2pg/mL 2-200pg/mL 1:1 ebioscience  88-7170 
TNF-α 4pg/mL 4-500pg/mL 1:2 ebioscience  88-7346 
IFN-γ 4pg/mL 4-500pg/mL 1:2 ebioscience  88-7316 
IL-1β 4pg/mL 4-500pg/mL 1:2 ebioscience  88-7010 
 
5.4.3. Circulating Immune complex determination using C1-q ELISA 
The human C1q ELISA is an enzyme-linked immunosorbent assay for the quantitative 
detection of human C1q. Circulating C1q forms together with the proenzymes C1r and 
C1s, the C1 macromolecule, the first component of the classical complement pathway. 
The formation of an antibody-antigen complex (immune-complex) is the principal way 
of activating the classical pathway of the complement system. With the Fc regions of 
IgG and IgM antibodies present in immune-complexes, efficient activation of the 
classical pathway is initiated. In this way, C1q acts to bridge the innate and adaptive 
immune systems (Leffler et al., 2014). 
In C1-q ELISA, an anti-human C1q coating antibody is adsorbed onto microwells and 
human C1q present in the sample binds to the antibodies adsorbed to the microwells. 
After incubation, the unbound biological components are removed during wash step 
and a biotin-conjugated anti-human C1q antibody is added that binds to human C1q 
captured by the first antibody. After incubation with streptavidin-HRP, a coloured 
product is formed in proportion to the amount of C1q present in the sample following 
the addition of substrate solution.  
For quantitative detection of human C1q in the plasma samples of patients with ENL 
and LL controls, we used human C1q platinum ELISA (ready-to-use sandwich 
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ELISA) with a sensitivity of 0.08ng/mL. The procedure is briefly described as follow 
as: The microwell plate coated with monoclonal antibody to human C1q was aspirated 
and washed twice with wash buffer. Then 100µl of serially diluted C1q standard was 
pipetted to the first two columns of the microwell strips. To the remaining strips pre-
diluted to 1:1000 plasma samples (100µl/well) were added and to the last two wells a 
blank (assay buffer) was added as a negative control. The plate was sealed and 
incubated at 22oC for 2hrs on a microplate shaker set at 400 revolutions per minute 
(rpm). After 2 hours incubation, the plate was washed 6 times with wash buffer and 
tapped on the absorbent pad.  To each well, 100µl of biotin-conjugated anti-human 
C1q antibody was added and incubated at 22oC for 1hr on a microplate shaker set at 
400rpm. Then the microplate was washed as described above and followed by the 
addition of 100µl Streptavidin-HRP to all wells. The plate was sealed and incubated 
at 22oC for 1hr on a microplate shaker as described. After six washes 100µl of TMB 
substrate solution was added to all wells and incubated at 22oC for 30 minutes in the 
dark. The colour development on the plate was monitored and the substrate reaction 
was stopped by pipetting 100µl of stop solution (1N H3PO4).  The optical density (OD) 
at 450nm was measured using an ELISA plate reader (Microplate reader; Bio-Rad, 
Richmond, CA). A curve fit was applied to the standard curve according to the 
manufacturer’s manual using Microplate Manager® 6 Software (Bio-Rad, Richmond, 
CA) and the unknown concentration of C1q in each sample was extrapolated from 
these standard curves (Appendix 9).   
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SECTION 5: REAL -TIME PCR ASSAYS  
In the real-time polymerase chain reaction (qPCR) assay, the mRNA gene expression 
levels for pro-inflammatory cytokines/chemokines listed in the previous section have 
been determined in blood and biopsy samples obtained from patients with ENL and 
LL controls before and after treatment. The real-time PCR assay included mRNA 
isolation and quantification, cDNA synthesis and real-time quantitative PCR. 
5.5.1. RNA isolation from PAXgen Blood RNA Tubes  
PAXgene Blood RNA Kit was used to isolate RNA from blood stored in PAXgene 
Blood RNA Tubes. PAXgene Blood RNA tubes were brought to safety cabinet and 
allowed to reach room temperature (18-22oC) for approximately two hours or 
overnight. After thawing, the tubes were carefully inverted 10 times. Then the 
PAXgene Blood RNA Tubes were centrifuged for 10 minutes at 5000g using a swing-
out rotor. The supernatant was removed by decanting and 4ml RNase-free water 
(Qiagen) was added to the pellet and the tube was closed using a fresh secondary 
Hemogard™ (Qiagen) closure followed by vortex until the pellet completely dissolved 
and centrifuged for 10 minutes at 5000g. The supernatant was discarded and 350μl 
Buffer BR1 (Qiagen) was added. Then the sample was pipetted into a 1.5 ml RNase-
free microcentrifuge tube (Star lab, Ltd., UK)  followed by addition of 300μl Buffer 
BR2 and 40μl proteinase K (Qiagen) and mixed by vortex for 5 seconds and then 
incubated at 55oC for 10 minutes on a shaker set at 400rpm. The lysate was directly 
pipetted into a PAXgene Shredder spin column (Qiagen) which was placed in a 2ml 
processing tube. The lysate then centrifuged for 3 minutes at maximum speed 
(20,000g). The entire supernatant of the flow-through was carefully transferred to a 
fresh 1.5ml microcentrifuge tube without disturbing the pellet in the processing tube. 
Then 350μl ethanol (100%, 200 proof, molecular grade, Sigma-Aldrich, UK) was 
added and centrifuged briefly (1-2 seconds at 1000g) to remove drops from the inside 
of the tube lid.  Then, 700μl of the sample (resuspended in 350μl ethanol) was pipetted 
into the PAXgene RNA spin column (red) placed in a 2ml processing tube, and 
centrifuged for 1 minute at 20,000g.  The old processing tube containing flow-through 
was discarded and the spin column was placed in a new 2mL processing tube. Three 
hundred and fifty microliters of Buffer BR3 (Qiagen) was pipetted into the PAXgene 
RNA spin column, centrifuged for 1 minute at 20,000g and the old processing tube 
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containing flow-through was discarded and the spin column was placed in a new 2mL 
processing tube. Then 10μl DNase I stock solution was added to 70μl Buffer RDD in 
a 1.5ml microcentrifuge tube and mixed gently by flicking the tube and centrifuged 
briefly to collect the residual liquid from the sides of the tube. DNase I incubation mix 
(80μl) was pipetted directly onto the PAXgene RNA spin column membrane 
(containing the sample) and placed on the bench-top at 20-300C for 15 minutes. Then 
350μl Buffer BR3 was pipetted into the PAXgene RNA spin column and centrifuged 
for 1 minute at 20,000g. The old processing tube containing flow-through was 
discarded and the spin column was placed in a new 2mL processing tube. Five hundred 
microliter Buffer BR4 was added to the PAXgene RNA spin column and centrifuged 
for 1 minute at 20,000g followed by replacing the old processing tube as described and 
the procedure was repeated once but this time for 3 minutes.  After replacing the old 
processing tube, without adding any buffer, the spin column was centrifuged for 1 
minute at 20,000g. The tube containing the flow-through was discarded and followed 
by addition of 40μl Buffer BR5 directly onto the PAXgene RNA spin column 
membrane, centrifuged for 1 minute at 20,000g to elute the RNA and this step was 
repeated once. Then, the elute RNA was incubated for 5 minutes at 650C and followed 
by immediate chilling. Finally, the RNA yield was determined using a NanoDrop 
2000, spectrophotometer (Thermo Scientific, Epsom, UK). For all samples cDNA was 
synthesized on the same day to avoid the risk of RNA degrades during storage.  
5.5.2. RNA isolation from RNAlater skin biopsy samples  
RNA was isolated from skin biopsy  samples stored in RNAlater™ (Ambion, Austin, 
Texas) using the RNeasy Fibrous Tissue Kit (Qiagen, Crawley, UK) according to the 
manufacturer’s protocol.  Four-millimetre punch skin biopsy (approximately 15mg) 
was disrupted in 300µl buffer RLT (Qiagen, Crawley, UK) using a disposable pellet 
and pestle (Anachem, Luton, UK) and homogenised with a Qiashredder (Qiagen, 
Crawley, UK). DNA was digested with DNase I (Qiagen, Crawley, UK).  After 
homogenization, 590µl RNase-free water and 10µl proteinase K was added to the 
homogenised tissue followed by incubation in a water bath at 55oC for 10 minutes. 
The remaining procedures were similar with the procedures described under RNA 
extraction from PAXgene Blood RNA Tubes. After determining the yield and quality 
of RNA, cDNA was synthesised on the same day and stored at-20oC. 
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5.5.3. cDNA synthesis 
Complementary DNA (cDNA) was synthesised from RNA using High Capacity 
cDNA Reverse Transcriptase Kit (AB Applied Biosystems, UK).  Reactions consisted 
of  1x RT buffer, 0.5 mM dNTP, 1µM Oligo-dT primer, 0.5 units/µl RNase inhibitor 
( all from AB Applied Biosystems, UK), 2.5units/µl reverse transcriptase, 80ng (1µl)  
template RNA and nuclease- free water to a total volume of 20µl. Reactions were 
incubated in an ABI9700 Programmable Thermal Cycler (Applied Biosystems, Foster 
City, California) for 10 minutes at 25ºC followed by 120 minutes at 37oC  and 5 
minutes 85oC  then  and cooling to 4 ºC.  
5.5.4. Primers 
Genomic DNA and mRNA sequences were obtained from the National Centre for the 
Biotechnology Information (NCBI) data bank. Primers between 20-24 nucleotides in 
length were designed across intron/exon boundaries on mRNA sequence to give a 
product of 100-500bp (Table 6.4). These primers could not amplify genomic DNA 
targets and functioned with cDNA templates only as they spanned exon boundaries.  
All primer sequences were blasted on the NCBI data bank to confirm their specificity. 
Custom synthesis of oligonucleotide primers was performed by Sigma-life science and 
provided in desalted form. Primer stock solution was prepared according to the 
manufacturer’s recommendation.  A working stocks of 10.0µM were prepared and 
kept at -20 °C until used (Table 5.4).   
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Table 5.4.  Primer sequences, length, melting temperature, amplicon size, %GC ratio 
and NCBI accession number. 
Primer 
(F, forward; 
R, reverse) Sequence  (5' to 3') Length 
Tm 
(ºC) 
% GC 
ratio  
Amplicon  
size (bp) 
Accession 
number 
IL-10 FW TGAGAACCAAGACCCAGACA 20 63.4 50 182 
NM_000594 IL-10 RV TCATGGCTTTGTAGATGCCT 20 62.2 45 
TNF-a  FW AGCCCATGTTGTAGCAAACC 20 58.74 50.00 104 
NM_172369 TNF-a RV GCTGGTTATCTCTCAGCTCCA 21 59.24 52.38 
IL-17A FW AGACCTCATTGGTGTCACTGC 21 64.2 52.3 238 
NM_002190 IL-17A RV CTCTCAGGGTCCTCATTGCG 20 67.2 60 
IL-6 FW TTCGGTCCAGTTGCCTTCTC 20 66.5 55 193 
NM_000600 IL-6 RV TACATGTCTCCTTTCTCAGGGC 22 64.3 50 
IL-1B FW AGCCCCAGCCAACTCAATTC 20 67.4 55 380 XM_0067124
96 IL-1B RV CATGGAGAACACCACTTGTTGC 22 66.6 50 
Fox P3  FW TGGAGAAGGAGAAGCTGAGTGC 22 61.99 54.55 73 XM_0115439
19 FoxP3  RV ACAGATGAAGCCTTGGTCAGTGC 23 63.24 52.17 
IFN-g  FW GGCTTTTCAGCTCTGCATCG 20 59.90 55.0 172 
NM_000619 INF-g  RV TCTGTCACTCTCCTCTTTCCA 21 57.76 47.62 
IL-8 FW ACCGGAAGGAACCATCTCAC 20 59.39 55.0 104 
NM_000584 IL-8  RV AAACTGCACCTTCACACAGAG 21 58.71 47.62 
HuPO FW GCTTCCTGGAGGGTGTCC 18 59.33 66.67 105 
NM_001002 HuPO RV GGACTCGTTTGTACCCGTTG 20 58.86 55.00 
TGF-β FW ACATCAACGCAGGGTTCACT 20 59.89 50 264 XM_0115272
42 TGF-β RV GAAGTTGGCATGGTAGCCC 20 60.03 55 
C1-qA  FW ATGGTGACCGAGGACTTGTG 20 59.68 55 276 NM_015991 
C1-qA  RV GTCCTTGATGTTTCCTGGGC 20 58.82 55 
C1-qB  FW CAGGTTGAAATCAGCATTGCC 21 58.39 47.62 163 XM_0115420
59 C1-qB  RV CTGTGTCAGACGCCTCCTTTC 21 60.94 57.14 
C1-qC  FW AAGGATGGGTACGACGGACTG 21 61.56 57.14 213 NM_172369 
C1-qC  RV TTTCTGCTTGTATCTGCCCTC 21 58.01 47.62 
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5.5.5. Choice of the control gene (HuPO) 
Human Acidic Ribosomal Protein (HuPO) has been previously described in PCR 
experiments examining the housekeeping gene expression in whole blood and PBMCs 
samples with minimum variability compared to other housekeeping genes such as 
glaceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actin and hypoxanthine 
phosphoribosyltransferase (HPRT) (Dheda et al.,2004). Hence, Human Acidic 
Ribosomal Protein (HuPO) has been chosen as a house-keeping gene in our 
quantitative PCR experiment.     
5.5.6. Real-time quantitative PCR 
Real-time quantitative PCR for  all genes was performed on the Rotor-Gene™ 3000 
programmable thermal cycler (Corbett Life Science (Qiagen), Crawley, UK) using 
Roter-gene® SYBR® Green PCR Kit (Qiagen, Crawley, UK). The Rotor-Gene SYBR 
Green PCR Kit enables rapid and reliable real-time PCR quantification on the Rotor-
Gene Q without the need for optimization of reaction and cycling conditions. In our 
experiment, we optimized the Tm values for each primer pair.  
PCR reactions consisted of 1x Rotor-gene SYBR Green PCR Master Mix, 1µM 
forward primer, 1µM reverse primer, 1µl cDNA (approximately 100ng) and nuclease- 
free water to a total volume of 12.5 µl. The master mix contained HotStarTaq Plus 
DNA polymerase, Rotor-gene SYBR Green PCR buffer, dNTP mix and SYBR Green 
I fluorescent dye. 
The Rotor-Gene conditions were set as follows:  Initial activation step (polymerase 
activation) was achieved by incubating at 95oC for 15 minutes, 40 cycles of 
denaturation at 95oC for 5 seconds, annealing at 60°C for 10 seconds, extension at 
72oC for 20 seconds and fluorescence acquisition for 5 seconds at  72oC.  
The primer-dimer formation was checked by melting curve analysis.  Melting point 
data were obtained by increasing the temperature   from 50oC to 99oC by 1oC on each 
step. The interval between increases in temperature was 30 seconds for the first step 
and then 5 seconds for subsequent steps.  
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An assay control was included from mRNA extraction to the amplification steps. For 
mRNA extraction, one assay control per batch was used. The assay control included 
all buffers except the sample and was processed under identical conditions with the 
samples. The same assay control was used during cDNA synthesis and real-time 
quantitative PCR.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12.  PCR  optimization:  A) shows the optimizationle threshold or house 
keeping gene (HuPO) and TNF-α,  B) shows the optimization cycle threshold for IL-
1β, IL-10 and IL-17A, C) shows the cycle threshold of  house keeping gene for 
multiple samples, D) showe the melt cuve analysis. The peak curve indicates the 
primer amplified the same region  of all samples and primer dimer is not detected as 
there is only one such peak.    
C D 
IL-1β 
 
IL-17A 
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5.5.7. Calculating the relative gene expression  
The relative gene expression was analyzed by using the 2-∆∆ CT  method  (Cikos et al., 
2007).  The CT  value is  the threshold number for the amplification of the target gene. 
Cikos et al. compared  the six different  methods currently used for real-time PCR data 
analysis  and  has shown that the best results were obtained with the relative standard 
curve (∆CT) method and the least coefficient of variation (∆CV).  
The CT values were abtained  for the target gene and control gene (HuPO)  for each 
patient sample at each time point. Then, the difference in CT value was obtained by 
subtracting the CT of the target gene from the CT of the control gene and designated as 
∆CT.  To compare the target  gene expression in patients with ENL and LL controls, 
∆∆CT  was obtained by subtracting the  ∆CT  of LL patient  control from the ∆CT of the 
patient with ENL. Then, the fold change was obatined by using the formula  2-∆∆ CT.   
similarly, for the comparison of the relative target gene expression in patients with 
ENL before and after treatment, ∆∆CT was obtained by ∆CT  (after) minus  ∆CT  
(before). Then the  fold change for target gene expression from the baseline ( before 
treatment) was given by 2-∆∆ CT.    
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SECTION 6: STATISTICAL METHODS  
5.6.1. Data recording and management 
All clinical data were recorded on standardized patient record specifically designed by 
the ENL International STudy Group (ENLIST). The forms were kept in a separate set 
of case notes from the usual clinical records. All study records were kept in a locked 
box accessed only by the principal investigator and the study coordinator.  For follow-
up studies, a special ID card was prepared for each patient with a specific code.  
Patients have been advised to bring these identification cards when coming to the 
hospital for any health complaints and notified to show to the study coordinator. An 
attendance log book was prepared to document any patient complaints. The 
information was reviewed, compiled and used during the write-up of the thesis. 
With regard to the laboratory-based data, all data were recorded on laboratory 
notebook. Information which included the amount of blood obtained from each patient  
per visit, number of PBMCs isolated, percentage of cell viability,  number of frozen 
PBMCs/vial, the number of vials containing frozen PBMCs,  the number of cells 
recovered during thawing,  samples used for staining, and others. A separate laboratory 
notebook were used for flow cytometry, ELISA and qPCR. In addition, all information 
was also recorded on Excel spreadsheet as an electronic data in two copies. One copy 
was used at the study site and the other copy stored on LSHTM data server through 
remote desktop from the field site. Updating data copy has been done every 48 hours.    
5.6.2. Strategy for data analysis 
Clinical Data: An excel spreadsheet double data entry was used for all data.  Data 
cleaning was performed prior to analysis. Clinical data were analysed by SPSS version 
20. Depending on the nature of the variable and the normality of the data, either 
parametric or non-parametric analysis was used.  Categorical variables were analysed 
by non-parametric methods and normally distributed numerical variables with 
parametric methods. Whenever mean is used for comparison, data presentation has 
followed the form of mean ± standard error of the mean (SE).  
Flow cytometry data:  Flow cytometry data analysis involves several steps.  During 
sample acquisition on BD FACSCanto II, preliminary statistical data are displayed by 
the BD FACSDiva™ Software that it is used for monitoring the overall performance 
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of the cytometer during data acquisition. In flow cytometry, the intensity of a 
distribution of the dots can be represented by the position of the “centre” of the 
distribution (usually median) and the spread of the distribution by the coefficient of 
variation (CV).  These dots are gated into sub-populations based on their side scatter 
(SSC) and forward scatter (FSC) and the specific fluorochromes used by using Flowjo.  
For gating FACS data by flowjo version10, into subpopulations logicle (bi-
exponential) method was selected as recommended by Herzenberg et al. (2006).  Then 
the relative percentage of each subpopulation was copied to Excel for each sample and 
finally an excel spreadsheet electronic data was generated and used for subsequent 
statistical analysis.  STATA 14 version 2 software was used for data analysis and Prism 
6 version 4 software to produce graphs. Mann-Whitney and Kruskal-Wallis tests were 
performed depending on the number of variables needed for comparison. Median and 
Hodges–Lehmann estimator were used for result presentation. Hodges–Lehmann is 
used to measure the effect size for non-parametric data (Gail, 2002). 
ELISA Data: The optical density of each sample for each cytokine was obtained by 
the ELISA reader. The OD was converted to concentration (pg/mL) by microplate 
manager 6.  Unpaired t-test was used to compare the relative concentration of the 
cytokines production in patients with ENL and LL controls. For comparing the 
cytokine concentration in patients with ENL before and after treatment, paired t-test 
was used.  Results are presented as mean ± standard error of the mean with P-values.  
Real-time quantitative PCR:  for the mRNA gene expression of target genes, the 
relative threshold cycle value (CT) comparison method was used as previously 
described in section 5.  The fold change of each target gene was used for statistical 
analysis.  Unpaired t-test was used to compare the fold change of each target gene for 
patients with ENL compared to LL patient controls.  To compare the expression level 
of the desired gene in patients with ENL before and after treatment, paired t-test was 
used.  
5.6.3. Data presentation 
Clinical data: The results of clinical data were presented in the form of figures and 
tables depending on the nature of the data. 
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Flow cytometry data:  considering the complexity of flow cytometry data, graphical 
methods of data presentation was preferred to tabular methods. Tables and other flow 
cytometry representative results are annexed.   
Real-time quantitative PCR:  The results of real-time quantitative PCR are presented 
in tables.  Tables are preferred to figures since fold changes and ∆∆CT are best 
presented and easily understandable by tables. If the value ∆∆CT is negative, it 
indicates upregulation of the gene expression whereas positive ∆∆CT value means the 
downregulation of the gene expression for that particular target gene.   
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CHAPTER 6: RESULTS  
An Overview  
The results of this study are presented in chapter 6 and it is divided into nine sections. 
Section one deals with socio-demographic and clinical backgrounds of study subjects. 
Clinical pictures and histopathological features of patients with ENL and LL controls 
are presented in section one. Section two deals with the results for T-cell regulation in 
patients with ENL reaction and LL controls before, during and after treatment as well 
as within ENL cases before and after treatment. These results included in this section 
are: the median percentages of  CD4+ and  CD8+ T-cells, CD4+/CD8+ T-cells ratio, 
CD4+FoxP3+, CD8+FoxP3+, CD4+CD25+, CD8+CD25+, CD4+CD25+FoxP3+, 
CD8+CD25+FoxP3  T-cells, CD4+ and CD8+ Tregs. In section three the results for 
memory T- cells and T-cell activation in the PBMCs from patients with ENL and LL 
controls before, during and after treatment are described. In section four the results of 
regulatory and memory T-cells in acute and chronic ENL are presented.In section five, 
results obtained from B-cell phenotyping are presented.  The proportion of matured B-
cells, naive B-cells, resting memory B-cells, activated memory B-cells and tissue-like 
memory B-cells in the PBMCs from patients with ENL and LL controls are presented 
in this section.  
The cytokine results are presented in section six. The in vitro cytokine production in 
the PBMCs from patients with ENL and LL controls in response to M.leprae whole- 
cell sonicates before and after treatment are presented in this section. In section seven, 
the mRNA gene expression levels of  selected pro-inflammatory cytokines (TNF-α, 
IFN-γ, IL-1β, IL-6,IL-8,IL-17A) and regulatory cytokines ( IL-10, TGF-β)  as well as 
the transcription factor, FOXP3  in whole blood and skin biopsy samples  from patients 
with ENL and LL controls before and after treatment are presented. The results of the 
C1q ELISA is presented in section eight. Results obtained for the gene expression 
levels of C1q are also presented in section eight.  Section nine presents the levels of 
anti-PGL-1, LAM, and Ag85 antibodies in the plasma samples of patients with ENL 
and LL controls before and after treatment. 
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Figure 6.1.1.  Flow diagram for study subjects recruitment and follow-up  
 
  
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assessment for eligibility n= 113 
Excluded (36 ENL cases)  
 Under 18 years  ( n=4)  
 Above 60 years ( n=6)  
 On prednisolone  (n=17) 
 Pregnant ( n=3)  
 Other reason ( n=6)   
Consented and recruited (n=77)    
Group 1: ENL  Group 2:  LL  
N=46  N=31  
Lost due to death (n=1) 
Lost to follow-up (n= 1)  
Second time point clinical 
data obtained  
N=31  
Lost to follow- up 
       (n= 3)  
Third time point clinical 
data obtained  
First time point clinical 
data obtained  
N=44  
N=44  N=28  
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SECTION 1: SOCIO-DEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS  
1.1. Socio-demographic and clinical backgrounds of study subjects  
Clinical data were obtained on 77 patients (46 LL patients with ENL reactions and 31 
non-reactional LL patients) at recruitment (Figure 6.1.1). The male to female ratio was 
2:1 with a median age of 27.5 [range: 18-56] years in patients with ENL and nearly 
3:1 with a median age of 25.0 [range: 18-60] years in patients with non-reactional LL 
controls. The median age was slightly higher in patients with ENL than in LL controls.  
Interestingly, the age range of females in both groups was relatively narrow (18-35 
years) compared to males (18-60). More than half of the patients with ENL were 
previously treated with MDT. Half of the patients with ENL had acute ENL at the time 
of enrolment with mean BI 3.9 ±0.205 SE (standard error).  Recurrent ENL cases had 
the highest mean BI (4.9 ±0.409 SE) at leprosy diagnosis whereas acute and chronic 
cases had comparable mean bacterial index (BI). All patients were negative in the HIV 
test before and after treatment (Table 6.1.1).  
Pain was the most common symptom reported by patients with ENL.  All patients with 
ENL reported that they had pain at the time of enrolment.  About 80% of the patients 
with ENL had reported skin pain and more than 70% had nerve and joint pains during 
enrolment.  Other pain sites reported include bone, digits, eyes, muscles, lymph nodes 
and testes (Figure 6.1.2).  
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Table 6.1.1.  Sociodemographic and clinical characteristics of study subjects at 
enrolment  
Variables   ENL (n=46) 
n (%) 
LL (n=31) 
n (%) 
Sex  Male  31 (67.4) 23 (74.2) 
Female 15 (32.6) 8  (25.8) 
Median age in years (range)  group  27.5 (18-56) 25.0 (18-60) 
Median age in years (range)  Male  28 (18-56) 26.0 (18-60) 
Median age in years (range) Female  26.7 (18-35) 21.0 (18-30) 
 
MDT status  
 No previous 
MDT 
10 (21.7) 23 (74.2) 
Current  9 (19.6)  7 (22.6) 
Completed  27 (58.7) 1 (3.2) 
 
HIV status  
Positive 0 (0.0) 0 (0.0) 
Negative  46 (100.0) 31 (100.0) 
Duration of current ENL symptom  
(Episode)  Mean ± SE [days ] 
 6.8 ±0.491 
(range: 1-15) 
- 
Clinical status at recruitment     
 
ENL type 
Acute 23 (50.0) - 
Recurrent 5 (10.9) - 
Chronic 18 (39.1) - 
 
LL type 
New  - 23 (74.2) 
Relapse  - 5 (16.1) 
Defaulter  - 3 (9.7) 
BI at diagnosis,  Mean ± SE (range)    
 
ENL  
Acute 3.9 ±0.205 (2-6) - 
Recurrent 4.9 ±0.409 (4-6) - 
Chronic 3.7 ±0.103(3-4) - 
 
LL 
Untreated (new)  4.1 ±0.259 (2-6) 
Relapse   4.2 ±0.330 (4-5) 
Defaulter   4.9 ±0.150 (4-5) 
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Fever was reported in 31 (71.7%) patients with ENL while skin lesions were reported 
nearly in all of these patients (95.7%).  Sixteen (34.8%) patients with ENL complained 
depression and 47.8% nasal stuffiness. Other reported symptoms included oedema, 
insomnia, anorexia, weight loss, joint swelling and malaise (Figure 6.1.3).  
The morphology of cutaneous lesions showed that 95.7% individuals had nodular 
lesions, about two-third had subcutaneous nodules and a quarter of patients had scar 
due to ENL. While one-third of the patients had ulcerated lesions, only 4% had necrotic 
lesions.  Eight patients (17.3%) had vesicles, bullae or pustular lesions (Figure 6.1.4).  
 In most patients with ENL (73.9%), the number of skin lesions recorded at the time 
of enrolment was 11-50. Few patients had five or less skin lesions. Almost all patients 
(97.8%) had skin lesions on the upper limbs.  A considerable number of the patients 
also had skin lesions on the lower limbs (95.7%) and on the head and neck (63.0%).  
Half of the patients reported reduced nerve sensation.  Paraesthesia and hyperaesthesia 
were reported by 13% and 23.9% patients respectively (Table 6.1.2). 
More than half (52.2%) of patients with ENL had old nerve function impairment (NFI) 
while 13% had new NFI at the time of enrolment. Facial and limb oedema were the 
most reported organs involved in ENL reactions. Facial oedema was reported in 56.5% 
of the patients with ENL and nearly half (47.8%) of the patients had oedema on their 
lower limbs. Other organs involved in the patients with ENL were small joint arthritis 
(28.3%), large joint arthritis (15.2%), conjunctivitis (4.3%), lagophthalmos (2.2%), 
scleritis (8.7%), lymph node (15.2%) and dactylitis (2.2%) (Table 6.1.2).  
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Figure 6.1.2.  Location of pain in the patients with ENL. *value is among 31 males  
 
 
Figure 6.1.3.  Frequency of the morphology of skin lesions in patients with ENL  
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Figure 6.1.4.  Symptoms other than pain in patients with ENL 
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Table 6.1.2. Other clinical pictures in patients with ENL at enrolment  
 
 
Number of skin lesions    
  
  
  
  number           % 
 <5 3 6.5 
6-10 4 8.7 
11-20 18 39.1 
21-50 16 34.8 
>50 5 10.9 
 
Location of skin lesions  
  
  
 Head/neck  29 63.0 
Trunk  18 39.1 
Upper limbs  45 97.8 
Lower limbs 44 95.7 
 
 
Nerve symptoms   
  
  
Reduced 
Sensation  
23 50.0 
Paraesthesia 6 13.0 
Hyperaesthesia  11 23.9 
Weakness 35 76.1 
 Nerve function impairment 
(NFI)  
Old 24 52.2 
New 6 13.0 
Organs involved in ENL     
 
Oedema    
  
Hand 26 56.5 
Face 16 34.8 
Lower limbs           22 47.8 
Dactylitis    1 2.2 
Large joint Arthritis   7 15.2 
Small joint arthritis    13 28.3 
Conjunctivitis     2 4.3 
Lagophthalmos   1 2.2 
Scleritis    4 8.7 
Lymph node   7 15.2 
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1. 2. Histopathological features of study subjects 
Paraffin- embedded sections of skin biopsy samples from ENL and LL lesions were 
graded by a histopathologist. Before treatment dermal neutrophil infiltration was 
diagnosed in 58.8% of  patients with ENL cases compared to 14.3% in LL patient 
controls and the difference was statistically significant (P=0.004). Lymphocyte 
infiltration was recorded in all ENL and LL lesions. Foamy histiocytes were more 
frequently seen in LL lesions (95.3%) than in ENL lesions but the difference was not 
statistically significant at recruitment.  Panniculitis was diagnosed only in 62.5% of 
lesions from patients with ENL reactions. After treatment, while neutrophils were 
present in 5 biopsies from patients with ENL reactions, lymphocytes were seen in 20 
skin biopsies of patients with ENL (Table 6.1.3). Flat granular PMN infiltration with 
perivascular lymphocyte infiltration and lobar panniculitis were diagnosed as defining 
features of ENL lesions compared to reticular dermal infiltration of lymphocytes and 
flat epidermis for LL lesions (Figure 6.1.5).  
Table 6.1.3.  Histopathological features of study subjects before and after treatment  
                   δ; n=16               ε; n= 8,           * statistical test significant  at P=0.05 
  
   Diagnosis       Before treatment n (%) After treatment n (%) 
 ENL 
  n= 34 )  
LL (n=21)   (P-value)  ENL   
(n=33) 
LL            
(n=21)  
 P-value 
Neutrophil 
infiltration  
 20 (58.8)  3 (14.3) 0.004* 5 (15.2) 7 (33.3) 0.058 
Lymphocytes  34 (100.0)  21 (100.0) 0.984 20 (60.6) 21 (100.0) 0.006* 
Foamy 
histiocytes  
29 ( 85.3) 20 (95.3) 0.627 14 (42.2) 18 (85.7%) 0.001* 
Eosinophils 
and mast cells  
6  (17.6) 5 (23.8) 0.284 1 ( 3.0) 4 (19.0) 0.06 
Vasculitis  5 (14.7) 4 (19.0) 0.079 2 ( 6.1) 2 (9.5) 0.841 
Necrosis   2 (5.9) 2 (9.5) 0.068 2 ( 6.1)  10 (47.6)  0.004* 
Panniculitis  10 (62.5)δ 0 (0) <0.001*  6(75.0%)ε 0 (0) 0.001* 
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Figure 6.1.5.  H &E stained skin biopsies:  A. Histopathology of LL lesion without 
reaction: reticular dermal infiltration of lymphocytes, flat epidermis and foamy 
histiocytes.  B. Histopathology of EN lesion: flat granular PMN infiltration with 
perivascular lymphocytic infiltration and lobar panniculitis. H & E staining x40 
1. 3. Lipid profile at enrolment  
Lipid metabolism during infection is thought to be mediated by cytokines which 
modulate the immune and inflammatory responses. It has been reported that changes 
in lipid and lipoprotein metabolism are part of the acute phase response of leprosy 
reactions. In our study, we analysed the serum lipid profile in patients with ENL and 
LL controls at enrolment.  
The levels of serum triglycerides were low (99.95 ± 6.046 SE mg/dl) in patients with 
ENL reactions compared to LL patient controls (158.7 ± 7.394 SE mg/dl) (P<0.0001). 
Serum total cholesterol (TC) was significantly lower in patients with ENL reactions 
(137.3 ± 7.049 mg/dl) compared to LL patient controls (175.8 ± 8.805 mg/dl) at 
enrolment (P<0.005).   Patients with ENL reactions had 19.20 ± 1.565mg/dl mean total  
serum high-density lipoproteins (HDL) which were significantly lower than the serum 
HDL of  LL patient controls  (29.76 ± 1.491mg/dl) before treatment (P<0.0001). 
Similarly, mean serum low density lipoprotein (LDL) was also considerably lower in 
A B 
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patients with ENL reactions (40.29 ± 3.596 mg/dl) than in LL patient controls (110.8 
± 3.380mg/dl) (P<0.0001) at enrolment (Figure 6.1.6). 
 
 
 
              
Figure 6.1.6.   Lipid profiles of patients with ENL cases (n=46) and LL controls (n=31) 
at enrolment (mean ± standard error of the mean). TG = Triglycerides, TC= total 
cholesterol, LDL= low density lipoprotein, HDL= high density lipoprotein.  ** P≤ 
0.005; **** P≤0.0001.   
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SECTION 2:  REGULATORY T-CELLS  
Figure 6. 2.1. Flowchart showing number of samples used for flow cytometry 
assays 
  
                                            
    LL (n=31)  
Samples used for first time 
point analysis  
Samples used for second time 
point analysis     ENL (n=44)  
Samples used for third time 
point analysis 
    ENL (n=46)  
       Enrolled (n=77)  
    LL (n=31)  
    ENL (n=44)      LL (n=28)  
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2.1. Optimization 
For the analysis of T and B cells on 8 colour BD FACSCanto II was used. Unstained 
cells, fluorescent minus one (FMO) staining, compensation controls and live/dead 
stains were used for quality control.  Antibody titration was performed to determine 
the minimum amount of antibody required to achieve antigen binding saturation as 
described before. The photomultiplier tubes (PMTs) voltage were adjusted for all 
fluorochromes used in this study as follows: SSC-319, FSC- 434, FITC-580, PE- 483, 
PerCP-Cy5.5- 487, PE-Cy7- 620, APC- 620, eFluoro780-620, APC450 (Pacific Blue)- 
508 and live/dead -594.  Fluorescent compensation was done during each date 
acquisition and automatically linked to the global worksheet (Figure 6.2.2).  
Figure 6.2.2.  Data acquisition on cytometer window      
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2.1. Regulatory T cells   in patients with ENL and LL controls  
2.1.1. Introduction  
To investigate the relative percentage of T-lymphocytes before, during and after 
prednisolone treatment of patients with ENL, venous blood samples were collected at 
each time point from patients with ENL and LL controls.  Peripheral blood 
mononuclear cells (PBMCs) were isolated and stained with antibody conjugated 
fluorochromes. Stained cells were acquired on a flow cytometer and the percentage of 
each subset of T-lymphocytes were obtained by gating according to their forward 
(FSC) and sidescatter (SSC) properties. 
The median percentage of T-lymphocytes in patients with ENL and LL controls were 
compared using Mann-Whitney (U) test. We used non-parametric statistical analysis 
since the distribution of flow cytometry data follows non-Gaussian distribution.  
Fluorescent intensity increases logarithmically and the use of an arithmetic mean for 
such data leads to statistical bias. The median is considered as the most robust test 
statistic for a non-Gaussian distribution since it is less influenced by skewed values or 
outliers. The effect size was calculated using Hodges-Lehmann statistic (∆HL) 
estimates of the median of the population. Hodges-Lehmann estimates the differences 
between the populations of the paired random variables drawn respectively from the 
populations and it is less sensitive to the outliers and to the heterogeneity of the data 
(Lunneborg, 2014).  Values for Hodges-Lehmann (∆HL) and the 95% confidence 
interval for the median are given in tables (Appendices 5-7).   
2.1.2. CD4+ and CD8+ T- lymphocytes   
The median percentage of CD4+ and CD8+ T-cells in patients with ENL and LL 
controls are indicated by box-and-whisker plots (Figure 6.2.3). Patients with ENL 
reactions had a significantly higher percentage of median expression for CD4+T-cells 
(61.3%) compared to LL patient controls (49.1%) at enrolment (P < 0.0001; ∆HL= 
12.8 %).  During prednisolone treatment of patients with ENL reaction, the median 
percentage for CD4+ T cells decreased to 54.2% while that of LL patient controls 
increased to 61.4% and the difference was statistically significant (P≤0.05). Although 
the percentage median expression for CD4+ T-cells had slightly increased to 58.1% in 
patients with ENL reactions after treatment, it remained significantly lower than  in 
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LL patient controls (64.7%) and the difference was  statistically significant (P ≤ 0.005) 
( Figure 6.2.3).  
On the other hand, patients with ENL had a significantly lower median percentage of  
CD8+ T-cells (27.0%) before treatment compared to LL patient controls (35.7%) and 
the difference was statistically significant (P<0.0001; ∆HL= 8.2%). Interestingly, 
while patients with ENL are on treatment, unlike CD4+ T-cells the median percentage 
of CD8+ T-cells increased to 34.4% and it was higher than that of LL patient controls 
(28.3%) (P<0.001). After treatment, the corresponding values did not show significant 
changes in patients with ENL (33.5%) and LL controls (27.2%) (Figure 6.2.3).   
The ratio of CD4+ to CD8+ T-cell was also determined before, during and after 
treatment of patients with ENL to see the trends in the balance of the two main T-cell 
types in patients with ENL compared to the LL controls during the follow-up period.  
The CD4+/CD8+ T-cell ratio was higher (2.3: 1) in patients with ENL compared to  LL 
patient controls (1.4:1) before treatment (P<0.001; ∆HL= 0.09).  However, a 
significantly lower CD4+/CD8+ T-cell ratio was seen in patients with ENL (1.7: 1) 
compared to LL patient controls (2.25:1) during treatment (P≤ 0.001). After treatment, 
the ratio of CD4+/CD8+ T- cell was 2.14: 1 and 1.8:1 in patients with ENL and LL 
controls respectively and the difference was not statistically significant (P>0.05) 
(Figure 6.2.3). Hence, this result indicates that patients with ENL reactions and non-
reactional LL controls not only  show significant differences in the percentage of CD4+ 
and CD8+ T-cells  but also in CD4+ / CD8+ T-cell ratio.  Thus, patients with ENL had 
higher median percentages of CD4+ and CD4+/CD8+ T-cell than LL patient controls 
before treatment.  
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Figure 6.2.3. T-lymphocytes in  patients with ENL cases and LL controls:  median 
percentage of CD4+T-cells, CD8+ T-cells and the median percentage ratio of CD4+ to 
CD8+ T- cells in the PBMCs of patients with ENL reaction and LL controls before, 
during  and after treatment of ENL cases. ENL: n (before) =46, n (during) = n (after) 
= 44; LL: n (before) = n (during) = 31, n (after) =28. Statistical test: Mann-Whitney 
unpaired test (U).  * P≤ 0.05; ** P≤ 0. 0.005; *** P≤0.001; **** P<0.0001. Bar graphs 
show median ± interquartile range 
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2.1.3. Expression of CD25 by T-lymphocytes   
Initially, it was thought that cells expressing CD25, the alpha chain of the IL-2 
receptor, had a regulatory function. However, it was found that CD25 is also expressed 
on conventionally activated T cells that are not regulatory type and not all peripheral 
regulatory T-cells express CD25. Nevertheless, many authors still use CD25 as a 
regulatory marker particularly in mycobacterial research including leprosy research. 
We investigated the median percentage of CD25 expression by CD4+ and CD8+ T- 
cells in the PBMCs from patients with ENL and LL controls before, during and after 
treatment of patients with ENL. The median percentage with interquartile range was 
used to plot a bar graph indicating the relative difference of the percentage of CD25 
cells expression by CD4+ and CD8+ T-cells in these patient groups (Figure 6.2.4). 
The median percentage of CD4+ T-cells expressing CD25+ T-cells in the PBMCs of 
ENL and LL patient controls were almost identical (8.9% and 8.8% respectively) 
before treatment. About 2.6% of CD8+ T-cells had expressed CD25 in the PBMCs 
from patients with  ENL and a slightly higher proportion of CD8+ T-cells (3.2%) was 
expressed CD25 in the PBMCs from LL patient controls before treatment (P≤0.05).  
The expression of CD25 on both CD4+ and CD8+ T- cells during and after treatment 
did not change in both patient groups (Figure 2.4). Hence, these results indicate that 
the expression of CD25 by CD4+ T-cells is similar in patients with ENL and LL 
controls and it does not discriminate ENL from LL.      
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  Figure 6.2.4.  The median percentage of CD25 expression on CD4+ and CD8+ T-cells 
in the  PBMCs of patients with ENL and LL patient controls before, during   and after 
treatment. ENL: n (before) =46, n (during) = n (after) = 44; LL: n (before) = n (during) 
= 31, n (after) =28. Statistical test: Mann-Whitney unpaired test (U).  * P≤ 0.05; ** P≤ 
0. 0.005. Bar graphs show median ± interquartile range. 
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2.1.4. FoxP3 Expression in CD4+ and CD8+ T-lymphocytes  
FoxP3 (forkhead box P3), is considered as the key transcription factor controlling the 
differentiation and function of regulatory T-cells (Cretney et al., 2013). FoxP3 has 
been shown to have important implications in various diseases. Studies have shown 
that the overexpression of FoxP3 in T-lymphocytes leads to progression of leprosy by 
downregulating T-cell activation (Kumar et al., 2014b). 
The expression of FoxP3 in CD4+ and CD8+ T-cells were investigated in the PBMCs 
from patients with ENL and LL controls before, during and after prednisolone 
treatment of patients with ENL by flow cytometry.  The median percentage of FoxP3-
expressing CD4+ T-cells in the PBMCs of patients with ENL was lower (2.1%) 
compared to the median percentage expressed in the PBMCs of LL patient controls 
(5.1%) before treatment (P<0.0001). During treatment, the frequency of FoxP3-
expressing CD4+T- cells slightly increased to 3.5% in patients with ENL and decreased 
by half from 5.1% to 2.6% in LL controls and the difference between the two groups 
was statistically significant (p≤0.05).  However, the frequency of FoxP3-experssing 
CD4+ T-cells in the PBMCs from patients with ENL and LL controls did not show 
statistically significant differences after treatment of patients with ENL (Figure 6.2.5) 
implying the possible association of reduced percentage of  CD4+ FoxP3+  T-cells with 
ENL reaction.  This means that after ENL reaction recedes, the percentage of CD4+ 
FoxP3+T-cells in ENL cases and LL controls was not significantly different.     
We also investigated the frequency of CD8+ T-cells expressing FoxP3 in the peripheral 
blood of patients with ENL and compared to the corresponding LL patient controls 
before, during and after treatment. Although the median percentage of FoxP3-
expressing CD8+ T-cells in the PBMCs of patients with ENL was slightly lower 
(0.57%) compared to LL controls (0.71%) before treatment, the difference was not 
statistically significant (P>0.05).  During treatment, patients with ENL had a lower 
frequency of CD8+FoxP3+ T-cells (0.49%) compared to LL patient controls (1.17%) 
(P≤0.05).  After treatment, the frequency of FoxP3 expression in CD8+ T-cells in 
patients with ENL and LL controls was found to be similar (P ≥0.05) (Figure 6.2.5).      
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 Figure 6.2.5.  Median percentage of FoxP3 expression in CD4+ and CD8+ T-cells in 
the PBMCs of patients with ENL and LL controls before during and after prednisolone 
treatment of patients with ENL.  ENL: n (before) =46, n (during) = n (after) = 44; LL: 
n (before) = n (during) = 31, n (after) =28. Statistical test: Mann-Whitney unpaired test 
(U).  * P≤ 0.05; **** P<0.0001.  Error bars show median ± interquartile range.   
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2.1.5. Expression of CD25+ FoxP3+ double positive T-lymphocytes   
The frequency of CD25+FoxP3+ expression in CD4+ and CD8+ T-lymphocytes were 
measured in the PBMCs of patients with ENL and LL controls before, during and after 
treatment. About 1.8% of CD4+ T-cells were expressed  CD25+FoxP3+ in the PBMCs 
of patients with ENL which was significantly lower than  the proportion of 
CD25+FoxP3+ cells expressed by CD4+ T-cells  (3.8%)  in the PBMCs of LL patient 
controls ( P<0.0001).  During treatment, the median percentage of CD4+CD25+FoxP3+ 
T-cells in the PBMCs of patients with ENL was increased to 2.6% while it was 
decreased from 3.8% to 2.5% in LL patient controls. After treatment, the percentage  
of  CD4+CD25+FoxP3+ T-cells in the PBMCs of patients with ENL was further 
increased to 3.3% while it was decreased to 2.2%  in patients with LL controls and the 
difference was statistically significant (P≤0.001) ( Figure 6.2.6).  
A small proportion of CD8+ T- cells in the PBMCs of patients with ENL and LL 
controls expressed CD25+FoxP3+. The percentage of CD8+CD25+FoxP3+ T- cells in 
the PBMCs of patients with ENL and LL controls was 0.4% and 0.6% respectively 
before treatment and slightly decreased in both groups (0.28% in patients with ENL 
and 0.52% in LL controls) during treatment. After treatment, these figures were 
slightly increased in both groups. The frequency of CD8+CD25+FoxP3+ T- cells 
expression in the PBMCs of patients with ENL and LL controls was not significantly 
different before, during and after treatment (Figure 6.2.6). Hence, it appears that 
CD4+CD25+FoxP3+ T- cells are more importantly associated with ENL reaction than 
the CD8+CD25+FoxP3+ T- cells in patients with ENL.  
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Figure 6.2.6.  Median percentage of CD4+ and CD8+ T-cells expressing CD25+ FoxP3+ 
double positives in the  PBMCs of patients with ENL reaction and LL controls before 
during   and after prednisolone treatment of  patients with ENL.  ENL: n (before) =46, 
n (during) = n (after) = 44; LL: n (before) = n (during) = 31, n (after) =28. Statistical 
test: Mann-Whitney unpaired test (U).  *** P≤0.001; **** P<0.0001. Bar graphs 
show median ± interquartile range. 
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2.1.6. CD4+ and CD8+ regulatory T- cells  
Although several markers have been proposed for identification of Tregs in humans, 
none of them found to be an absolute marker and the search for perfect Treg markers 
continues.  In leprosy, CD4+CD25hi and CD4+CD25+FoxP3+ have been used as Treg 
markers by several researchers. However, a consensus on the thresholds of CD25 
expression needed to define Tregs within the CD25 high population is difficult to attain 
and variations in FoxP3 expression within CD25 high T-cells have been shown in 
patients as well as healthy individuals. Some studies have shown that the low 
expression of CD127 (an Interleukin-7 receptor subunit alpha), in conjunction of 
CD25 expression is one of the best strategies  to identify a highly enriched FoxP3+ 
population that encompasses the majority of FoxP3+ T-cells. Based on these 
assumptions,  we used CD4+CD25+FoxP3+ CD127-/lo and CD8+CD25+FoxP3+ CD127-
/lo as CD4+ and CD8+ Treg markers respectively to investigate the relative proportion 
of regulatory T-cells in patients with ENL and LL controls.  
The median percentage expression of CD4+ regulatory T- cells was significantly lower 
(1.67%) in the PBMCs of patients with ENL compared to LL patient controls (3.79%) 
before treatment (P≤0.0001; ∆HL= 1.93%). During treatment, a significant difference 
was not observed with regard to the percentage of CD4+ Tregs in the PBMCs of 
patients with ENL and LL controls. However, the percentage of CD4+ Tregs in the 
PBMCs of patients with ENL was almost doubled (from 1.67% to 3.21%) while it was 
significantly decreased from 3.79% to 2.43% in LL patient controls during treatment 
(Figure 6.2.7 and Appendix 5).  Hence, it appears that treatment of patients with ENL 
reactions with prednisolone increases the expression of CD4+ Tregs and thus suppress 
the immune hyperactivation to resolve the inflammatory process in these patients. 
After treatment, 3.2% of CD4+ T-cells expressed Tregs in patients with ENL while 
only 2.5% of CD4+ T-cells expressed Tregs in patients with LL controls (P≤0.005) 
(Figure 6.2.7).      
The median percentage of CD8+ Tregs was slightly less in the PBMCs of patients with 
ENL (0.37%) compared to LL patient controls (0.54%) but it was not statistically 
significant (P ≥ 0.05).  During treatment, the median percentage of CD8+ Tregs was 
slightly decreased in both groups (0.23% in patients with ENL and 0.42% in LL patient 
controls) (P ≥ 0.05). The median percentage of CD8+ Tregs after treatment of patients 
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with ENL and LL controls was 0.34% and 0.47% respectively (Figure 6.2.6). Hence, 
it appears that prednisolone treatment does not affect the percentage of CD8+ Tregs 
unlike CD4+ Tregs in ENL patients.  
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Figure 6.2.7.  Median percentage of CD4+ and CD8+ regulatory T- cells 
(CD4+CD25+FoxP3+CD127-/lo and CD8+CD25+FoxP3+CD127-/lo respectively) in the   
PBMCs of patients with ENL reaction and LL controls before, during and after 
treatment.  ENL: n (before) =46, n (during) = n (after) = 44; LL: n (before) = n (during) 
= 31, n (after) =28. Statistical test: Mann-Whitney unpaired test (U). ** P≤ 0. 0.005; 
**** P<0.0001. Box and whiskers show median ± interquartile range. 
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2.1.7. IL-17 producing cells  
IL-17 has recently been drawn much attention in host defence and inflammatory 
diseases. While CD4+ and CD8+ T-cells are important sources of this cytokine, recent 
data have suggested that the γδ T cells and a number of families of innate lymphoid 
cells also secrete IL-17.  In this study, the percentage of IL-17 producing lymphocytes 
and T-cells has been analysed. The percentage of IL-17 producing CD4+ and CD8+ T-
cells was further analysed in the PBMCs of patients with ENL and LL controls before, 
during and after prednisolone treatment of patients with ENL.  
Patients with ENL had a significantly higher median percentage of IL-17 producing 
lymphocytes (26.45%) than LL patient controls (20.6%) before treatment (P≤ 0.05; 
∆HL=5.7). Similarly, the proportion of  IL-17 producing T-cells in the PBMCs of 
patients with ENL was considerably higher (23.1%)  than  in LL patient controls 
(18.4%) before treatment and the  difference was statistically significant (P≤ 0.05; 
∆HL=4.5).  In this study, it was found that while patients with ENL had a higher 
percentage of IL-17 producing CD4+ T-cells than LL patient controls before treatment, 
the percentage of IL-17 producing CD8+ T-cells was not significantly different in these 
patient groups. During and after treatment of patients with ENL, none of these cells 
showed a significant difference in patients with ENL and LL patient controls (Figure 
6.2.8).  
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Figure 6.2.8.  IL-17 Producing cells in the PBMCs of patients with ENL and LL 
controls before, during and after treatment. ENL: n (before) =46, n (during) = n (after) 
= 44; LL: n (before) = n (during) = 31, n (after) =28. Statistical test: Mann-Whitney 
unpaired test (U). *P≤0.05; ** P≤ 0. 0.005. Box and whiskers show median ± 
interquartile range 
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Table 6.2.1.  Summary table showing trends of T-cell regulation before and after 
treatment of patients with ENL and LL controls.  
 
T-cell sub population (%) Before treatment  During treatment  After treatment  
ENL LL ENL LL ENL LL 
CD4+ ↑ ↓ ↓ ↑ ↓ ↑ 
CD8+ ↓ ↑ ↑ ↓ ↑ ↓ 
CD4+/CD8+ * ↑ ↓ ↓ ↑ − − 
CD4+CD25+ − − − − − − 
CD8+CD25+ ↓ ↑ − − − − 
CD4+FoxP3+ ↓ ↑ ↑ ↓ − − 
CD8+FoxP3+ − − ↓ ↑ − − 
CD4+CD25+FoxP3+ ↓ ↑ − − ↑ ↓ 
CD8+CD25+FoxP3+ − − − − − − 
CD4+ Tregs  ↑ ↓ − − ↑ ↓ 
 CD8+ Tregs  − − − − − − 
IL-17+ lymphocytes ↑ ↓ − − − − 
IL-17+T-cells  ↑ ↓ − − − − 
CD4+IL-17+  ↑ ↓ − − − − 
CD8+IL-17+  − − − − − − 
*ratio (without unit).   ↑= increased, ↓= decreased, − = no change   
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2.2. Regulatory T- cells   in individual patients with ENL before and after 
treatment  
T-cell subsets in the PBMCs of patients with ENL before, during and after 
prednisolone treatment was analysed to see the trend of each T-cell subset over 
treatment time. Blood samples were obtained from each patient 3 times (before, during 
and after treatment) and used for T-cells immunophenotyping by flow cytometry.  
2.2.1. CD4+ and CD8+ T- lymphocytes   
The median percentage of CD4+ and CD8+ T-lymphocytes in the PBMCs of patients 
with ENL at each time point were determined. The median percentage of CD4+ T-cells 
was significantly higher (61.3%) before treatment than during treatment (54.2%) 
(P≤0.001; ∆HL=6.8%). Similarly, the median percentage of CD4+ T-cells in the 
PBMCs of patients with ENL was lower (57.3%) after prednisolone treatment than 
before treatment (P≤0.05; ∆HL =4.6%).  However, the median percentage of CD4+ T-
cells in these patients was not significantly different during and after treatment 
(P>0.05) (Figure 6.2.9).  
Unlike CD4+ T-cells, patients with ENL reactions had significantly lower frequency 
of CD8+ T-cells (37.0%) before treatment than during treatment (34.4%) (P≤0.0001; 
∆HL =6.8%).  After treatment, the median percentage of CD8+ T-cells remained high 
(34.3%) compared with before treatment (P≤0.005) (Figure 6.2.9). This finding shows 
that while prednisolone treatment decreased the median percentage of CD4+ T-cells, it 
increased the median percentage of CD8+ T-cells in patients with ENL reactions. 
The median percentage ratio of CD4+ to CD8+ T-cells before, during and after 
treatment of patients with ENL was compared to see the trend of CD4+ to CD8+ T-
cells ratio in these individual patients. The CD4+ to CD8+ T-cells ratio before treatment 
was significantly higher (2.23:1) than during treatment (1.8: 1) (P<0.0001; ∆HL=0.6) 
and after treatment (1.7:1) (P≤0.005; ∆H=0.5) in these patients (Figure 6.2.9, 
Appendix 5).     
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Figure 6.2.9. Median percentage of CD4+T-cells, CD8+ T-cells and the median 
percentage ratio of CD4+ to CD8+ T- cells in the PBMCs of patients with ENL 
reactions before, during   and after treatment with prednisolone. n (before) = (during) 
= n (after) = 44; LL: n (before) = n (during) = (after) =28. Statistical test: Wilcoxon 
matched-pairs test. * P≤ 0. 0.05; ** P≤ 0. 0.005; *** P≤0.001; **** P<0.0001.  Error 
bars show median ± interquartile range. 
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2.2.2. Expression of CD25 and FoxP3 in T-lymphocytes    
The expression of CD25 and FoxP3 by CD4+ and CD8+ T- cells in the PBMCs of 
patients with ENL before, during and after prednisolone treatment was investigated to 
see if there was any significant differential expression of CD25 and FoxP3 on T-
lymphocytes at each time point of treatment status.    
The median percentage expression of CD25 in CD4+ T-cells before and during 
treatment was 8.9% and 8.2% respectively. After treatment with prednisolone, about 
9.5% of CD4+ T-cells expressed CD25. The expression of CD25 by CD4+ T-cells 
before, during and after treatment was not statistically significantly different (P> 0.05) 
implying  that prednisolone may not affect the expression of CD25 in CD4+ T-cells 
(Figure 2.10). Similarly, the expression of CD25 in CD8+ T-cells during and after 
prednisolone treatment of patients with ENL did not change (P> 0.05). About 2.6% of 
CD8+ T-cells was found positive for CD25 staining before treatment.  The median 
percentage of CD8+CD25+ T- cells during and after treatment was 3.2% and 2.2% 
respectively (P> 0.05) (Figure 6.2.10).  
The median percentage of CD4+FoxP3+ T-cells was significantly lower (2.1%) than 
the median percentage obtained during treatment (3.5%) (P<0.0001; ∆HL =1.4%) and 
after treatment (4.4%) (P≤0.0001; ∆HL =2.2). The expression of FoxP3 in CD4+ T-
cells was doubled after prednisolone treatment of patients with ENL indicating the 
association of prednisolone and FoxP3 expression unlike the CD25 expression in the 
PBMCs in these patients (Figure 6.2.10). Interestingly, the expression of FoxP3 in 
CD8+ T-cells was not significantly different before (0.59%), during (0.49%) and after 
(0.50%) treatment of these patients. Hence, it appears that prednisolone treatment does 
not affect the expression of FoxP3 in CD8+ T-cells unlike in CD4+T-cells.  
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Figure 6.2.10.  Median percentage of CD4+ and CD8+ T-cells expressing CD25 and 
FoxP3 in the PBMCs of patients with ENL before, during and after treatment with 
prednisolone.  n (before) = (during) = n (after) = 44; LL: n (before) = n (during) = 
(after) =28. Statistical test: Wilcoxon matched-pairs test. * P≤ 0.05; **** P <0.0001. 
Error bars show median ± interquartile range. 
 
 
  
 
0 .0
2 .5
5 .0
7 .5
1 0 .0
1 2 .5
1 5 .0
%
  
C
D
4
+
C
D
2
5
+
B e f o r e
T re a tm e n t
A f te r
T re a tm e n t
D u r in g
T re a tm e n t
0
1
2
3
4
5
6
7
8
9
1 0
%
C
D
8
+
C
D
2
5
+
B e f o r e
T re a tm e n t
D u r in g
T re a tm e n t
A f te r
T re a tm e n t
0
1
2
3
4
5
6
7
8
C
D
4
+
F
o
x
P
3
+
B e f o r e
T re a tm e n t
D u r in g
T re a tm e n t
A f te r
T re a tm e n t
****
****
*
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
%
  
C
D
8
+
F
o
x
P
3
+
B e f o r e
T re a tm e n t
D u r in g
T re a tm e n t
A f te r
T re a tm e n t
212 
   
2.2.3. CD25 FoxP3 double positive T-lymphocytes   
The expression of double positive (CD25+FoxP3+) by CD4+ and CD8+ T-cells were 
investigated in the peripheral blood mononuclear cells of patients with ENL before, 
during and after treatment. The median percentage  of CD4+CD25+FoxP3+ T-cells in 
the PBMCs of patients with ENL was found to be significantly low before treatment 
compared with the median percentage obtained during treatment ( 2.6%;  P<0.0001; 
∆HL=1.04%) and  after treatment (3.3%;  P<0.0001; ∆HL =1.55%). On the other hand, 
the median percentage of CD8+CD25+FoxP3+ T-cells was not significantly different 
before, during and after treatment (Figure 6.2.11).  
 
 
 
 
 
 
 
 
     
                   
 Figure 6.2.11.  Median percentage of CD25+FoxP3+ expression by CD4+ and CD8+ 
T-cells in the PBMCs of patients with ENL before during   and after treatment with 
prednisolone. n (before) = (during) = n (after) = 44; LL: n (before) = n (during) = 
(after) =28. Statistical test: Wilcoxon matched-pairs test.  **** P <0.0001. Error bars 
show median ± interquartile range. 
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2.2.4. CD4+ and CD8+ regulatory T-cells  
Regulatory T-cells expression in CD4+ and CD8+ T- cells were investigated before and 
after prednisone treatment of patients with ENL. The median percentage expression of 
CD4+ regulatory T- cells was significantly lower (1.67%) in the PBMCs of patients 
with ENL reactions before treatment compared with the median percentage of Tregs 
expressed in these cells during treatment (2.5%) (P<0.0001; ∆HL=1.0%). After 
treatment, the median percentage of CD4+ Tregs increased to 3.20% compared with 
the percentage (1. 67%) obtained before treatment (P<0.0001; ∆HL =1.6 %) (Figure 
6.2. 12). Thus, this result suggests that ENL reaction is associated with decreased 
percentage of CD4+ Treg cells.  
In contrast to CD4+ Tregs, the percentage of CD8+ Tregs was not significantly different 
before and after prednisolone treatment of patients with ENL. The median percentage 
of CD8+ Tregs before, during and after treatment was 0.37%, 0.23% and 0.36% 
respectively (P>0.05) (Figure 6.2.12).   
The median percentage of CD4+ and CD8+ Tregs were highly variable when individual 
patients are considered. While, in the majority of patients with ENL, the median 
percentage of CD4+Tregs increased after treatment, in few cases it was decreased after 
treatment. On the other hand, the median percentage of CD8+ Tregs remained stable in 
the majority of patients with ENL cases but in few instances, it was either increased or 
decreased (Figure 6.2.12).  
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Figure 6.2.12. The median percentage of Tregs expression in CD4+ and CD8+ T-cells.   
(A) The median percentage of CD4+ and CD8+ Tregs in the PBMCs of patients with 
ENL before during and after treatment with prednisolone. (B) Trends in the percentage 
of individual CD4+ and CD8+ Tregs in the PBMCs of patients with ENL reaction 
before and after treatment with prednisolone.  n (before) = (during) = n (after) = 44; 
LL: n (before) = n (during) = (after) =28. Statistical test: Wilcoxon matched-pairs test. 
*P≤ 0.05; **** P<0.0001; ns= non-significant. Error bars show median ± interquartile 
range. 
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2.2.5. IL-17 producing cells   
 The median percentage of IL-17 producing cells was compared in patients with ENL 
cases before, during and after treatment to see the trend of these cells during the follow-
up period.  The median percentage of IL-17 producing lymphocytes in the PBMCs of 
patients with ENL reaction was significantly higher before treatment (26.45%) than 
during treatment (15.4%) (P<0.0001, ∆HL=9.5%). After treatment, the median 
percentage of these IL-17 producing lymphocytes was further decreased to 12.7% and 
it was significantly lower than before treatment (P<0.0001, ∆HL=11.855%).  
Similarly, the proportion of IL-17 producing T-cells was substantially higher (23.1%) 
before treatment than during treatment (16.4%) and after treatment (13.2%) 
(P<0.0001) (Figure 6.2.13). 
The median percentage of IL-17 producing CD4+ and CD8+ T-cells were also 
investigated in these patients before and after treatment to see the source of IL-17.  It 
was found that the proportion of IL-17 producing CD4+ T-cells was significantly 
decreased during treatment (P< 0.0001) but again increased after treatment.  Unlike 
IL-17 producing lymphocytes, the median percentage of IL-17 producing CD4+ T-
cells was not significantly different before and after treatment showing that CD4+ T-
cells may not be the main source of IL-17 in these patients. IL-17 producing CD8+ T-
cells did not show any significant difference before, during and after treatment of 
patients with ENL reaction (Figure 6.2.13). Hence, prednisolone treatment of patients 
with ENL reactions does not affect IL-17 producing CD8+T-cells but it could affect 
transiently IL-17 producing CD4+T-cells.    
In conclusion, ENL reaction was associated with decreased frequency of CD4+ 
regulatory T-cells, increased percentage of CD4+FoxP3+ T-cells and increased 
CD4+/CD8+ T-cell ratio.  On the other hand, CD8+ regulatory T-cells, the expression 
level of CD25 by CD4+ and CD8+ T-cells and  the expression  of CD8+FoxP3+ T-cells 
were not associated with ENL reaction.    
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Figure 6.2.13. IL-17 Producing cells in the PBMCs of patients with ENL before, 
during and after treatment. n (before) = (during) = n (after) = 44; LL: n (before) = n 
(during) = (after) =28. Statistical test: Wilcoxon matched-pairs test. *P≤0.05;    
****P<0.0001. Error bars show median ± interquartile range. 
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Table 6.2.2.  Summary table showing trends of T-cell regulation in patients with 
ENL before and after treatment. 
 
 
*ratio (without unit).   ↑= increased, ↓= decreased, − = no change   
T-cell sub population (%) Before  treatment After treatment 
CD4+ ↑ ↓ 
CD8+ ↓ ↑ 
CD4+/CD8+ * ↑ ↓ 
CD4+CD25+ − − 
CD8+CD25+ − − 
CD4+FoxP3+ ↓ ↑ 
CD8+FoxP3+ − − 
CD4+CD25+FoxP3+ ↓ ↑ 
CD8+CD25+FoxP3+ − − 
CD4+ Tregs  ↓ ↑ 
 CD8+ Tregs  − − 
IL-17+ lymphocytes ↑ ↓ 
IL-17+T-cells  ↑ ↓ 
CD4+IL-17+  − − 
CD8+IL-17+  − − 
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SECTION 3: ACTIVATED AND MEMORY T-CELLS   
3.1. Introduction  
Memory is the hallmark of the acquired immune system. It results from the clonal 
expansion and differentiation of antigen-specific lymphocytes that ultimately persist 
for a lifetime. Memory lymphocytes confer immediate protection in peripheral tissues 
and mount recall responses to antigens in secondary lymphoid organs. In the T-cell 
system, these functions are carried out by distinct cell types. Protective memory is 
mediated by effector memory T-cells (TEM) that migrate to inflamed peripheral tissues 
and display immediate effector function, whereas reactive memory is mediated by 
central memory T-cells (TCM) that home to T-cell areas of secondary lymphoid organs. 
Central memory T-cells readily proliferate and differentiate to effector cells in 
response to antigenic stimulation. Memory T- cells are distinguished by the expression 
of CD45RO. Central memory T-cells express CD62L but effector memory T-cells do 
not express this ligand.  While naïve T-cells are characterized by their expression of 
CD62L but not CD45RO, effector T-cells do not express CD62L and CD45RO.  
 In leprosy, only one study tried to identify memory T-cell subsets (Mitra et al., 1999a) 
although, the study did not use an experimental design that allowed to discriminate the 
identification of memory T cell subsets.  The expression level of each memory T-cell 
subsets and naïve T- cells in the PBMCs of patients with ENL and LL controls before 
and after treatment was investigated. 
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Figure 6. 3.1. Flowchart showing the number of samples used for memory T-cell 
assays   
                                            
    LL (n=25)  
Samples used for first time 
point analysis  
Samples used for second time 
point analysis     ENL (n=35)  
Samples used for third time 
point analysis 
    ENL (n=35  
       Enrolled (n=60)  
    LL (n=25)  
    ENL (n=35)      LL (n=25)  
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3.2. Activated and memory T-cells in patients with ENL and LL controls  
3.2.1. Memory T-cells  
About 40% of PBMCs from patients with ENL expressed CD3+ memory T-cell 
(CD3+CD45RO+) compared to 28% of CD3+ CD45RO+ T-cells in LL patient controls 
before treatment, showing that  a significantly higher  proportion of CD3+ T-cells in 
patients with ENL are antigen-experienced cells than in LL patient controls (P≤ 0.005; 
∆HL= 10.5%). However, during treatment,  the proportion  of CD3+ memory T-cells 
in patients with  ENL was decreased to 29.2%  whereas it remained almost at the same 
level in LL patient controls (29.3%) and the difference between the two groups was 
not  statistically significant (P>0.05). Similarly, the  percentage of CD3+ memory T- 
cells after treatment  of patients with ENL and LL controls were 31.2% and 32.7% 
respectively ( P>0.05) ( Figure 6.3.2).  
More than 50% of CD4+ T-cells were CD45RO+ in patients with ENL which was 
significantly higher than in LL patient controls (30.5%) (P < 0.0001; ∆HL=20.3%) 
before treatment. During treatment, the proportion of antigen-experienced CD4+ T-
cells slightly decreased from 52.3% to 43.8% in patients with ENL while it was 
increased from 30.5% to 45.9% in LL patient controls but the difference was not 
statistically significant (P> 0.05). After treatment, the proportion of CD4+ memory 
(CD4+CD45RO+) T-cells were 45.0% and 41.8% in patients with ENL and LL controls 
respectively (P>0.05) (Figure 6.3.2).  
The median percentage of CD8+ memory (CD8+CD45RO+) T-cells in patients with 
ENL (17.5%) and LL controls (15.2%) was not significantly different before treatment 
(P>0.05).  The percentage of CD8+ memory T- cells did not show a significant change 
during and after treatment (figure 6.3.2).   
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Figure 6.3.2.  Median percentage of CD3+, CD4+ and CD8+ T-cells  expressing 
memory T-cells in the PBMCs of patients with ENL  and LL controls before, during 
and after treatment. n (before) = (during) = n (after) = 35; LL: n (before) = n (during) 
= (after) =25. Statistical test: Mann-Whitney unpaired test (U). ** P≤0.005; **** 
P<0.0001.       
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3.2.2. Activated T- cells  
The median percentage of activated T-cells in unstimulated PBMCs of patients with 
ENL reaction and LL controls was measured using CD62L as a T-cell activation 
marker. CD62L is a glycoprotein also known as L-selectin which serves a homing 
receptor for lymphocytes to enter secondary lymphoid tissues via high endothelial 
venules. During T- cell activation, CD62L is shed from the surface, resulting in 
CD62L- effector cells. Hence, effector memory T-lymphocytes do not express L-
selectin, as they circulate in the periphery and have immediate effector functions upon 
encountering antigen.  
A significant proportion of CD3+ T-cells (59.2%) were activated in patients with ENL 
(CD3+CD62L-)  in contrast to in LL patient controls (37.7% ) before treatment (P 
<0.0001; ∆HL= 22.4%). Interestingly, while the proportion of activated CD3+ T-cells 
decreased to 47% in patients with ENL, it was increased to 49% in LL patient controls 
during treatment (P>0.05) showing that prednisolone treatment of patients with  ENL 
is associated with a decreased frequency of activated CD3+ T-cells.  After treatment, 
the proportion of CD3+ T- cells further decreased to 33.9% in patients with ENL 
(Figure 6.3.3). 
Similarly, the median percentage of activated CD4+ T-cells was (CD4+CD62L-) 
significantly higher (50.7%) in PBMCs of patients with ENL than in LL controls 
(27.1%) before treatment (P <0.0001; ∆HL = 19.1%). During treatment, the frequency 
of activated CD4+ T-cells decreased by half to 29.7% in patients with ENL but 
increased to 38.1 % in LL patient controls yet the difference was not statistically 
significant (P > 0.05). After treatment, the proportion of activated CD4+ T- cells in 
both groups remained almost at the same level with that of during treatment (Figure 
6.3.3).    
With regard to CD8+ activated T- cells (CD8+CD62L-), while nearly two third (71.2%) 
was activated in patients with ENL, less than half (45.4%) was activated in LL patient 
controls (P <0.0001; ∆HL= 27.9%).  The median percentage of CD8+ activated T- cells 
in patients with ENL cases (59.5%) and LL controls (49.7%) was not significantly 
different during treatment (P > 0.05). However, after treatment, the frequency of 
activated CD8+ T-cells was significantly decreased to 34.5% in patients with ENL 
compared to 45.2% in LL patient controls (P≤ 0.05; ∆HL= 10.1%) (Figure 6.3.3).  
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Figure 6.3.3. The median percentage of CD3+, CD4+ and CD8+ T-cells expressing   
CD62L  in unstimulated PBMCs of patients with ENL and LL controls before, during 
and after treatment. n (before) = (during) = n (after) = 35; LL: n (before) = n (during) 
= (after) =25. Statistical test: Mann-Whitney unpaired test (U). * P≤0.05; **** P< 
0.0001.  Box and whiskers show median ± interquartile range.    
  
224 
   
3.2.3. Effector memory T-cells  
 Effector memory T-cells (TEM) are memory T-cells which have lost their CD62L 
expression while migrating to the tissue and progressively gain functionality with 
further differentiation to effector T- cells also called terminally differentiated T-
cells(Seder et al., 2008). Measurement of effector memory T- cells is the most 
commonly used method to determine the extent of T-cell activation in a disease state. 
We measured the proportion of effector T- cells in unstimulated PBMCs from patients 
with ENL and LL controls before and after treatment to prove that the hypothesis that 
ENL is associated with T- cell activation.  
 The median percentage of CD3+ effector memory T-cells (CD3+CD45RO+ CD62L-)  
in the PBMCs of patients with ENL was 26.6% which was significantly higher than in 
LL patient controls (8.0%) before treatment (P<0.0001; ∆HL=18.3%). During 
treatment, the median percentage of CD3+TEM   was decreased to 16.5% in patients 
with ENL while it was appreciably increased to 13.0% in LL patient controls but the 
difference was not statistically significant (P>0.05).  The percentage of CD3+ TEM was 
slightly lower in patients with ENL (7.6%) than in LL patient controls (10.4%) after 
treatment (P≤ 0.05; ∆HL= 3.5%) (Figure 6.3.4). 
The  median percentage of CD4+  effector memory T- cells (CD4+CD45RO+CD62L-)  
in the PBMCs of patients with ENL was  nearly three times  (24.6%)  higher than in 
the PBMCs of LL  patient controls (8.9%) before treatment (P<0.0001; ∆HL= 18.4%).  
During treatment, the proportion of CD4+ T-cells expressing TEM cells in patients with 
ENL was decreased to 11.4% while it was significantly increased to 17.6% in LL 
patient controls (P≤ 0.05; ∆HL= 5.8%).  However, after treatment, the proportion of 
CD4+ T-cells expressing TEM in patients with ENL and LL controls were 9.8% and 
13.1% respectively and  the difference was not  statistically significant between the 
two groups ( P>0.05)  ( Figure 6.3.4).  
Similarly, the median percentage expression level of effector memory T-cells in CD8+ 
T-cells (CD8+CD45RO+ CD62L-)  was twice (16.5%) in patients with ENL compared 
to in LL patient controls (7.2%) before treatment (P< 0.001; ∆HL= 6.7%).  However, 
during treatment, the percentage of CD8+ T- cells expressing TEM was reduced by more 
than half in patients with ENL (7.5%) and  nearly remained at the same level in LL 
patient controls (8.3%) but the difference was not significantly different  (P> 0.05).  
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After treatment, the median percentage of CD8+ effector memory T-cells in patients 
with ENL and LL controls did not show a significant difference (Figure 6.3.4).   
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Figure 6.3.4. The median percentage of CD3+, CD4+ and CD8+ T-cells expressing  
effector memory T-cells (CD45RO+CD62L-) in PBMCs of patients with ENL and LL 
controls before, during and after treatment. n (before) = (during) = n (after) = 35; LL: 
n (before) = n (during) = (after) =25. Statistical test: Mann-Whitney unpaired test (U). 
* P ≤0.05; ** P ≤0.005;   **** P < 0.0001.  Box and whiskers show median ± 
interquartile range.  
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3.2.4. Central Memory T-cells  
Human central memory T-cells (TCM) are CD45RO
+ memory cells that constitutively 
express CCR7 and CD62L. Upon proliferation, they differentiate to effector memory 
T- cells.  The relative proportion of central memory T- cells expressing T- lymphocytes 
was measured in the PBMCs from patients with ENL and non-reactional LL controls 
before, during and after treatment to investigate the association of ENL reaction with 
T-cell activation.    
 The median percentages of TCM expressing CD3
+ T-cells in  patients with ENL and 
LL controls before, during and after treatment were not statistically significantly 
different ( P>0.05). However, unlike CD3+TCM, the proportion of CD4
+ TCM was 
significantly higher in patients with ENL (23.5%) than in LL patient controls (14.6%) 
before treatment (P≤ 0.005; ∆HL= 8.13%). Although the median percentage of CD4+ 
TCM decreased from 23.5% to 13.7% in patients with ENL during treatment, a 
statistically significant difference was not arrived at compared to LL patient controls 
(18.1%) (P>0.05). Similarly, the median percentage of CD4+ TCM was not significantly 
different between the two groups after treatment (Figure 6.3.5).  
Interestingly, the median percentage of CD8+ TCM was significantly lower in patients 
with ENL (1.2%) than in LL patient controls (3.5%) before treatment (P ≤ 0.0001; 
∆HL=2.3%). During treatment, the proportion of CD8+ TCM expressing cells in patients 
with ENL remained at  a lower level (1.9%) than in LL patient controls (2.5%) but was 
not statically significantly different (P>0.05). After treatment, the percentage of 
CD8+TCM was slightly higher in patients with ENL (2.7%) than in LL patient controls 
(2.0%) however the difference was not statistically significant (P>0.05) (Figure 6.3.5).  
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Figure 6.3.5.  The median percentage of central memory T-cell  expression in  
CD3+, CD4+ and CD8+ T-cells in PBMCs of patients with  ENL  and LL 
controls before, during and after treatment. n (before) = (during) = n (after) = 
35; LL: n (before) = n (during) = (after) =25. Statistical test: Mann-Whitney 
unpaired test (U). ** P ≤ 0.005;   **** P < 0.0001.  Box and whiskers show 
median ± interquartile range.  
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3.2.5. Effector T-cells   
Effector T-cells (TEC) are relatively short-lived activated T-cells and they express 
neither CD45RO nor CD62L. TEC display
 an immediate response to infection.  In the 
present study, the percentage of effector T- cells in the PBMCs from patients with 
ENL and LL controls were investigated to compare the T-cell activation status in 
patients with ENL reaction and non-reactional LL patient controls before and after 
treatment. 
Nearly one-third (29.3%) of CD3+ T-cells were effector cells in the PBMCs of  patients 
with ENL with the  corresponding value of 20.0%  in  LL patient controls  before 
treatment and the difference was statistically significant (P≤ 0.001; ∆HL=9.0%).  After 
treatment, the median percentage of CD3+ TEC was significantly decreased in patients 
with ENL (24.6%) compared to in LL patient controls (35.3%) (P≤ 0.05); ∆HL=8.6%). 
With regard to the median percentage of CD4+ TEC, a statistically significant difference 
was not obtained between the two groups before, during or after treatment (Figure 
6.3.6).  It worth mentioning that effector memory T-cells are short-lived unlike 
memory T-cells and they shortly undergo apoptosis once they meet their cognate 
antigens. 
The median percentage of TEC expression in CD8
+ T- cells in patients with ENL was 
62.7% which was considerably higher than the value obtained for patients with LL 
controls (39.5%) before treatment (P< 0.0001; ∆HL= 25.8%). Similar to CD3+ TEC, the 
proportion of CD8+ TEC in patients with ENL was significantly decreased (38.9%) 
compared to in LL patient controls (55.2%) after treatment (P≤ 0.005; ∆HL=14.4) 
(Figure 6.3.6).  
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Figure 6.3.6. The median percentage of CD3+, CD4+ and CD8+ T-cells 
expressing CD45RO-CD62L- (TEC) in PBMCs of patients with ENL and LL 
controls before, during and after prednisolone treatment. n (before) = (during) 
= n (after) = 35; LL: n (before) = n (during) = (after) =25. Statistical test: Mann-
Whitney unpaired test (U). * P≤0.05; ** P≤0.005;   **** P< 0.0001.  Box and 
whiskers show median ± interquartile range. 
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3.2.6. Naive T-cells  
A naïve T-cell is a matured differentiated T-cell that has not encountered its cognate 
antigen within the periphery. Naïve T-cells are usually characterized by the surface 
expression of L-selectin (CD62L). They do not express memory markers (CD45RO) 
or activation markers such as CD25, CD44 and CD69. Naïve T-cells do not proliferate 
until they encounter their corresponding antigens. The relative percentage of naïve T- 
cells in patients with ENL and LL controls before and after treatment were compared 
in this study.   
Despite the higher bacterial load in patients with LL patients, the median percentage 
CD3+ naïve T-cells was significantly higher (59.5%) in these patients compared to in 
patients with  ENL (27.7%) before treatment (P<0.0001; ∆HL= 26.5%). During 
treatment, the median percentage of CD3+ naïve T-cells significantly decreased to 
32.9% in LL patient controls while in patients with ENL the proportion was slightly 
increased to 31.8%.  After treatment, the proportion of CD3+ naïve T- cells was further 
increased to 42.9%  in patients with ENL but did not  change in LL patient controls 
(33.0%) and the difference between the two groups was statistically significant (P 
≤0.05) ( Figure 6.3.7).   
The median percentage of CD4+ naïve T- cells in patients with ENL (34.0%) was 
significantly lower than in LL patient controls (61.5%) before treatment (P<0.0001; 
∆HL=25.6%). During treatment the median percentage of CD4+ naïve T- cells was 
increased in patients with ENL to 45.2%  while it was  decreased in LL patient controls 
to 40.0%  but the difference was not statistically significant(P>0.05).  After treatment, 
the median percentage of these cells did not show a significant change (Figure 6.3.7).   
Regarding to CD8+ T- cells, the median percentage naïve T-cells in patients with ENL 
was more than three times lower (15.4%) than in LL patient controls (50.5%) before 
treatment ( P< 0.0001; ∆HL=31.6%).  During treatment, while the median percentage 
of CD8+ naive T-cells increased to 35.5% in patients with ENL, it was decreased to 
38% in LL patient controls. After treatment, the median percentage of CD8+ naïve T-
cells  in patients with  ENL and LL controls was 51.5%  and 32.8% respectively and 
the difference between the two groups was statistically significant ( P≤ 0.05; 
∆HL=14.4%) (Figure 6.3.7).   
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Figure 6.3.7. The median percentage of naïve T-cells expression in CD3+, CD4+ 
and CD8+ T-cells in the PBMCs of patients with ENL and LL controls before, 
during and after treatment. n (before) = (during) = n (after) = 35; LL: n (before) 
= n (during) = (after) =25. Statistical test: Mann-Whitney unpaired test (U). * P 
≤0.05; **** P< 0.000. Box and whiskers show median ± interquartile range.      
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3.2.7. Treg/TEM cells ratio (ENL versus LL)  
The median percentage ratio of regulatory T-cells to effector memory T-cells 
(Treg/TEM cells) were significantly lower in untreated patients with ENL (0.077) than 
in LL controls (0.44) at recruitment (P≤ 0.0001). However, after treatment the median 
percentage ratio of Treg/TEM cells was significantly increased in patients with ENL 
(0.522) compared LL controls (0.255) (P≤0.005) (Figure 6.3.8).  
   
           
 
 
 
 
 
 
 
 
 
Figure 6.3.8. The median percentage ratio of Treg/TEM cells in the PBMCs of 
patients with ENL and LL controls before, during and after prednisolone 
treatment. n (before) = (during) = n (after) = 35; LL: n (before) = n (during) = 
(after) =25. Statistical test: Mann-Whitney unpaired test (U).  ** P ≤ 0.005; **** 
P< 0.0001. Box and whiskers show median ± interquartile range. 
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Table 6.3.1.  Summary table sowing trends of memory T-cells before and after 
treatment of patients with ENL compared to LL controls  
              
 
 TEM = Effector T-cells, TCM= Central memory T-cells, TEC= effector T-cells, 
TNC= naïve T-cells. ↑= increased, ↓= decreased, − = no change   
  
Memory T-cells (%)  Before treatment  
  
During treatment  
  
After treatment  
ENL LL ENL LL ENL LL 
CD3+CD45RO+ ↑ ↓ − − − − 
       
CD4+CD45RO+ ↑ ↓ − − − − 
CD8+CD45RO+ − − − − − − 
CD3+CD62L- ↑ ↓ − − − − 
CD4+ CD62L- ↑ ↓ − − − − 
CD8+CD62L- ↑ ↓ − − ↓ ↑ 
CD3+TEM ↑ ↓ − − ↓ ↑ 
CD4+TEM ↑ ↓ ↓ ↑ − − 
CD8+TEM ↑ ↓ − − − − 
CD3+TCM − − − −     
CD4+TCM ↑ ↓ − − − − 
CD8+TCM ↑ ↓ − − − − 
CD3+TEC ↑ ↓ − − ↓ ↑ 
CD4+TEC − − − − − − 
CD8+TEC ↑ ↓ − − ↓ ↑ 
CD3+TNC ↓ ↑ − − ↑ ↓ 
CD4+TNC ↓ ↑ − − − − 
CD8+TNC ↓ ↑ − − ↑ ↓ 
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3.3. Activated and memory T-cells expression in patients with ENL before and 
after treatment 
The status of activated and memory T- cells in PBMCs of patients with ENL cases 
before, during and after prednisolone treatment was investigated. Blood samples were 
obtained from each patient with ENL reactions before, during and after treatment. 
PBMCs samples were stained with appropriate antibody conjugates as described 
earlier and the immunophenotyping of activated and memory T-cells was performed 
by flow cytometry to investigate the pattern of these immune cells during the follow-
up period.   
3.3.1. Total memory T-cells  
The median percentage of CD3+ total memory T-cells (CD45RO+) in patients with 
ENL was significantly higher (41.1%) before treatment than during treatment (29.2%) 
(P≤0.001; ∆HL=11.2%) and after treatment (31.5%) (P≤0.001; ∆HL=9.8%).  
Similarly, the median percentage of CD4+ total memory T- cells was 52.3% before 
treatment and significantly decreased to  29.2% during treatment  (P<0.0001; 
∆HL=22.1%).  After treatment, the median percentage of CD4+ memory T- cells 
increased to 45.0% but still lower than before treatment (P ≤ 0.05; ∆HL=8.75%). On 
the other hand, unlike CD3+ and CD4+ memory T-cells, the median percentage of 
CD8+ memory T- cells did not change before, during and after treatment (Figure 3.9).  
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Figure 6.3.9. The median percentage of total memory T-cells (CD45RO+)  expression 
in CD3+, CD4+ and CD8+ T-cells in PBMCs of patients with ENL before, during and 
after treatment.  n (before) = (during) = n (after) = 35; LL: n (before) = n (during) = 
(after) =25. Statistical test: Wilcoxon matched-pairs test. * P≤0.05; ** P< 0.005; *** 
P< 0.001;   **** P< 0.0001. .  Error bars show median ± interquartile range.   
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3.3.2. Total activated T-cells   
The median percentage of CD3+ activated T-cells (CD62L-) before starting 
prednisolone treatment was 59.2% and it was higher than the percentage obtained 
during treatment (47.0%)  (P ≤ 0.05). After treatment, the median percentage of 
activated CD3+ T-cells was decreased to 33.9% which was significantly lower 
compared with before treatment (P< 0.0001; ∆HL=25.5%). The median percentage of 
CD4+ activated T-cells before treatment was 50.7% and was decreased to 29.7% 
during treatment which was statistically significantly different (P< 0.0001; 
∆HL=17.75%). After treatment, the proportion of CD4+ activated T-cells remained at 
29.0% (Figure 6.3.10).  
More than two- third of CD8+ T-cells (71.2%) were CD62- before treatment. During 
treatment, the proportion of activated CD8+ T-cells decreased to 59.5% and was lower 
than before treatment (P ≤ 0.05). Unlike activated CD4+ T-cells, the median percentage 
of activated CD8+ T-cells after treatment  was significantly lower (34.5%) than before 
treatment (P< 0.0001; ∆HL=34.2%) (Figure 6.3.10). 
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Figure 6.3.10. The median percentage of activated T-cells in CD3+, CD4+ and CD8+ 
T-cells in PBMCs of patients with ENL before, during and after treatment. n (before) 
= (during) = n (after) = 35; LL: n (before) = n (during) = (after) =25. Statistical test: 
Wilcoxon matched-pairs test.  * P≤0.05; *** P≤ 0.001; **** P < 0.0001.  Error bars 
show median ± interquartile range. 
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3.3.3. Effector memory T-cells expression          
The median percentage of effector (TEM) and central memory T-cells (TCM) before and 
after treatment of patients ENL were investigated based on the expression of CD62L 
(a homing receptor) as previously described. TCM cells express CD62L to localize in 
secondary lymphoid organs. In these secondary lymphoid organs, they are ready to 
proliferate upon re-encountering antigen. TEM cells do not express CD62L as they 
circulate in the periphery and have immediate effector functions upon encountering 
the antigen.   
Patients with ENL reactions had higher CD3+ TEM cells (26.6%) before treatment than 
during treatment (16.8%) (P< 0.0001; ∆HL =11.88%). The percentage of CD3+ T-cells 
expressing TEM cells  (CD3
+CD45RO+CD62L-) was considerably decreased to 7.6% 
after treatment  which was substantially lower than the median percentage of  CD3+ 
TEM cells before treatment (P<0.0001; ∆HL=20.0%).  Likewise, the median percentage 
of CD4+ TEM (CD4
+CD45RO+CD62L-) cells was more than twofold higher (24.6 %) 
before treatment compared to during treatment (11.4%) and the difference was 
statistically significant (P<0.0001; ∆HL=15.54%).  The percentage of CD4+ TEM cells 
was remarkably reduced to 9.6% after treatment indicating the decreasing tendency of 
T-cell activation after prednisolone treatment of patients with ENL (Figure 6.3.11).  
About 16.5% of CD8+ T-cells (CD8+CD45RO+CD62L-) expressed TEM cells before 
treatment. During treatment, the median percentage of CD8+ T-cells expressing TEM 
cells was notably decreased to 7.5% which was significantly low compared to before 
treatment (P≤ 0.005; ∆HL=6.61%). However, unlike CD4+ and CD3+ TEM cells, the 
proportion of CD8+ TEM cells did not show significant change after treatment (6.5%) 
compared to the figure obtained during treatment (Figure 6.3.11).   
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Figure 6.3.11.  The median percentage of effector memory T- cells expression in 
CD3+, CD4+ and CD8+ T-cells in PBMCs of ENL before, during and after treatment. 
n (before) = (during) = n (after) = 35; LL: n (before) = n (during) = (after) =25. 
Statistical test: Wilcoxon matched-pairs test. ** P< 0.005; *** P≤0.001;   **** P < 
0.0001.  Error bars show median ± interquartile range. 
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3.3.4. Central memory T-cells  
Patients with ENL had a higher median percentage of CD3+ TCM cells (13.8%) before 
treatment than during treatment (9.8%) (P≤ 0.005; ∆HL=4.1%). However, the 
proportion of CD3+ T-cells expressing TCM (CD45RO
+CD62L+) was considerably 
increased from 9.8% of during treatment to 13.5% after treatment (P≤ 0.05; ∆HL= 
4.6%). Interestingly, unlike the proportion of CD3+ effector memory T-cells, the 
median percentage of CD3+ central memory T-cells before and after treatment was 
unchanged (Figure 6.3.13). 
Similarly, the proportion of CD4+ TCM was higher (23.5%) before treatment than 
during treatment (13.7%) and the difference was statistically significant (P≤ 0.001; 
∆HL=9.04%). After treatment, the percentage of CD4+ TCM was again increased to 
22.0% which was not significantly different compared to the percentage value obtained 
before treatment (Figure 6.3.13). 
The proportion of CD8+ T-cells expressing central memory (CD45RO+CD62L+) 
showed an opposite trend. Before treatment, about 1.2% of CD8+ T-cells expressed 
TCM cells. During treatment the proportion of CD8
+ T-cells expressing TCM cells was 
increased to 1.9% which was significantly higher than before treatment (P≤ 0.05; 
∆HL=0.66%). The percentage of CD8+ TCM cells further increased to 2.7% after 
treatment and it was higher than the percentage value obtained before treatment (P< 
0.0001; ∆HL=1.32%).  The percentage of CD8+ TCM was not significantly different 
during and after prednisolone treatment (Figure 6.3.13).  
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Figure 6.3.12. The median percentage of central memory T cells expression in CD3+, 
CD4+ and CD8+ T-cells in PBMCs of patients with ENL before, during and after 
treatment. n (before) = (during) = n (after) = 35; LL: n (before) = n (during) = (after) 
=25. Statistical test: Wilcoxon matched-pairs test. * P≤0.05; ** P≤ 0.005;   *** P≤ 
0.001;   **** P< 0.0001.  .Error bars show median ± interquartile range. 
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3.3.5. Effector and naïve T-cells  
Effector T-cells (TEC) are terminally differentiated memory T-cells. They are the 
relatively short-lived activated cells whose functions involve the interaction of an 
armed effector T-cell with a target cell displaying specific antigen. They neither 
display memory marker (CD45RO) nor the homing receptor (CD62L). Naïve T-cells 
display the homing receptor marker but do not display memory marker.   
The median percentage of CD3+ TEC cells was lower before treatment (29.3%) than 
during treatment (43.4%) (P≤ 0.005).  After treatment, the percentage of these cells 
decreased to 24.6%.  Similarly, the median percentage of CD4+ TEC cells was lower 
before treatment (14.0%) than during treatment (22.9%) (P≤ 0.05). After treatment, 
the percentage of CD4+ TEC cells was decreased by half (12.1%) than during treatment 
(P≤ 0.05).  Like CD3+ TEC cells, the percentage of CD4+ TEC cells did not show 
significant difference before and after treatment (Figure 6.3.12). On the other hand, 
the median percentage of CD8+ TEC cells was slightly higher (62.7%) before treatment 
than during treatment (53.4%) (P≤ 0.05). After treatment, the percentage of CD8+ TEC 
cells was considerably decreased to 38.9% compared to the figure obtained during 
treatment (P≤ 0.05) and  before treatment (P< 0.0001) (Figure 6.3.13). 
With regard to naïve T-cells (TNC), about 27.7% and 31.8% of CD3
+T-cells was TNC 
cells before and during treatment respectively and the difference was not statistically 
significant.  However, after treatment, the median percentage of CD3+TNC cells 
noticeably increased to 42.9% compared to during treatment (P≤ 0.005) and after 
treatment (P< 0.0001). Similarly, the percentage of CD4+ TNC cells was lower (34.1%) 
before treatment than during treatment (45.2%) (P≤ 0.005). After treatment, the 
percentage of CD4+TNC cells (40.4%) did not show a statistically significant difference 
compared to the value obtained  during treatment but was significantly higher than that 
of before treatment (P≤ 0.005).  The percentage of CD8+ TNC cells was 15.4% before 
treatment and it was appreciably increased to 35.5% during treatment (P≤ 0.001). The 
percentage of these CD8+TNC cells was further increased to 51.5%, which was 
significantly higher than the value measured (35.5%) during treatment (P≤ 0.05). The 
median percentage of CD8+ TNC cells was significantly higher after treatment than 
before treatment (P< 0.0001) (Figure 6.3.14).   
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Table 6.3.13. The median percentage of effector T-cells expression in CD3+, CD4+ 
and CD8+ T-cells in PBMCs of patients with ENL before, during and after treatment. 
n (before) = (during) = n (after) = 35; LL: n (before) = n (during) = (after) =25. 
Statistical test: Wilcoxon matched-pairs test. * P≤0.05; ** P≤ 0.005;   *** P≤ 0.001;   
**** P< 0.0001.  .  Error bars show median ± interquartile range. 
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Figure 6.3.14.  The median percentage of naïve CD3+, CD4+ and CD8+ T-cells 
expression  in PBMCs of patients with ENL before, during and after treatment. n 
(before) = (during) = n (after) = 35; LL: n (before) = n (during) = (after) =25. Statistical 
test: Wilcoxon matched-pairs test. * P ≤0.05; ** P≤ 0.005; *** P ≤ 0.001;   **** P < 
0.0001.  .  Error bars show median ± interquartile range. 
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3.3.6. Treg/TEM cells ratio in patients with ENL   
Patients with ENL had a significantly lower median percentage of Treg/TEM cells 
(0.077) before treatment than after treatment (0.552) (P< 0.0001).  
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Figure 6.3.15. The median percentage of Treg/TEM cells in the PBMCs of patients 
with ENL before and after prednisolone treatment. n (before) = (during) = n 
(after) = 35; LL: n (before) = n (during) = (after) =25. Statistical test: Wilcoxon 
matched-pairs test. **** P < 0.0001. 
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Table 6.3.2.  Summary table sowing trends of memory T-cells before and after 
treatment of ENL cases  
 TEM = Effector T-cells, TCM= Central memory T-cells, TEC= effector T-
cells, TNC= naïve T-cells. ↑= increased, ↓= decreased, − = no change   
  
Memory T-cells (%)  Before  treatment After  treatment 
CD3+CD45RO+ ↑ ↓ 
CD4+CD45RO+ ↑ ↓ 
CD8+CD45RO+ − − 
CD3+CD62L- ↑ ↓ 
CD4+ CD62L- ↑ ↓ 
CD8+CD62L- ↑ ↓ 
CD3+TEM ↑ ↓ 
CD4+TEM ↑ ↓ 
CD8+TEM ↑ ↓ 
CD3+TCM − − 
CD4+TCM − − 
CD8+TCM ↓ ↑ 
CD3+TEC − − 
CD4+TEC − − 
CD8+TEC ↑ ↓ 
CD3+TNC ↓ ↑ 
CD4+TNC ↓ ↑ 
CD8+TNC ↓ ↑ 
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SECTION 4.  REGULATORY AND MEMORY T-CELLS IN ACUTE AND 
CHRONIC ENL 
 The subgroup analysis between acute and chronic ENL was done to see any significant 
differences with respect to regulatory and memory T-cells.  Although chronic ENL in 
this study was defined as an ENL occurring for 24 weeks or more during which a 
patient has required ENL treatment either continuously or where any treatment free 
period has been 27 days or less, we included only those patients who were off steroid 
treatment for 15 days or more to exclude the confounding effect of steroid on the 
outcome variables as defined previously in the material and methods section.  
4.1. CD4+ and CD8+ T-cells   
The median percentage of CD4+ T cells in acute ENL was slightly higher (64.6%) than 
in chronic ENL (60.1%) (P≤0.05).  In contrast to CD4+ T-cells the median percentage 
of CD8+ T-cells in acute ENL was lower (24.2%) than in chronic ENL (32.3%) (P 
≤0.005). Acute ENL cases had a significantly higher CD4+/CD8+ ratio (2.6) than 
chronic cases (1.9) (P=0.03) (Figure 6.4.1).   
 
 
Figure 6.4.1.  Median percentage of CD4+ and CD8+ T-cells in acute and chronic ENL 
and the CD4+/CD8+ T cell ratio in acute and chronic ENL.  n (acute) =23, n 
(chronic)=18. Statistical test:  non parametric, Mann -Whitney (U) test, α =0.05.  
*P≤0.05, **P≤0.005. Box and error bars show median ± interquartile range. 
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4.2. CD25 and FoxP3 expression in CD4+ and CD8+ T cells  
The median percentage of CD4+ CD25+ T-cells in acute and chronic ENL was 8.9% 
and 8.6% respectively and the difference between the two groups was not statistically 
significant (P≥0.05).  Similarly, the median percentage of CD8+CD25+ T-cells in acute 
ENL was 2.6% while it was 2.6% in chronic ENL (P≥0.05).  The median percentage 
of CD4+ FoxP3+ T cells in acute ENL (2.3%) and in chronic ENL (2.4%) was not 
statically significant in the two groups (Figure 6.4.2).  
0
5
1 0
1 5
%
 C
e
ll
s
C D 4
+
C D 2 5
+
C D 8
+
C D 2 5
+
C h ro n ic  E N L
A c u te  E N L
 
 
0
5
1 0
1 5
%
 c
e
ll
s
C D 4 + F o x P 3 + C D 4 + F o x P 3 +
 A c u te  E N L
 C h ro n ic  E N L
 
 
Figure 6.4.2.  Median percentage of CD25 and FoxP3 expression in CD4+ and 
CD8+ T-cells in acute and chronic ENL.  n (acute) =23, n (chronic)=18. 
Statistical test:  non parametric, Mann -Whitney (U) test, α=0.05.  Bar graphs 
show median ± interquartile range.  
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4.3. CD25FoxP3 double positives in CD4+ and CD8+ T-cells  
 
About 2.1 % of CD4+ T-cells were expressed CD25+FoxP3+  in acute ENL cases and 
1.8% CD4+ T-cells were express CD25+FoxP3+ in chronic ENL and the difference in 
the two groups was not statistically significant (P≥0.05). Similarly, the median 
percentage of CD25FoxP3 double positives expression in CD4+ T-cells was 0.69% 
and 0.27%  in acute and chronic ENL respectively (P≥0.05) (6.4.3).    
 
 
 
 
 
 
 
 
Figure 6.4.3.  Median percentage of CD25 FoxP3 positives in CD4+ and CD8+ 
T-cells in acute and chronic ENL.  n (acute) =23, n (chronic)=18. Statistical test:  
non parametric, Mann -Whitney (U) test, α=0.05. Bar graphs show median ± 
interquartile range.  
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4.4. CD4+ and CD8+ Tregs   
The median percentage expression of CD4+ regulatory T- cells was 1.8% in acute ENL 
and 1.6% in chronic ENL. The median percentage of CD8+ Tregs was slightly less in 
Chronic ENL (0.25%) than in acute (0.60) but was not significantly different (P ≥ 0.05) 
(Figure 6.4.4).  
 
 
 
Figure 6.4.4.  Median percentage of CD4+ and CD8+ Tregs in acute and chronic 
ENL. n (acute) =23, n (chronic) =18. Statistical test:  non parametric, Mann -
Whitney (U) test, α=0.05.  Box and whiskers show median ± interquartile range.  
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4.5.   Effector and central memory T-cells                            
The median percentage of CD3+ effector memory T-cells (TEM) in acute ENL was 
31.4% while it was 25.2% in Chronic ENL.  Acute ENL cases had 24.0% CD4+TEM 
while chronic ENL cases had 31.9% CD4+TEM.  The median percentage of CD8
+ TEM 
in acute and chronic ENL was 17.8% and 15.7% respectively. The median percentage 
of TEM was not significantly different in acute and chronic ENL in all investigated T-
cell subsets (Figure 6.4.5).  Similarly,   acute and chronic ENL had similar median 
percentage of central memory T-cell (TEM) expression in CD3
+, CD4+, and CD4+ T-
cells (Figure 6.4.5).   
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Figure 6.4.5.  Median percentage of TEM and TCM expression in CD3
+,CD4+ and 
CD8+ T-cells  in acute and chronic ENL.  n (acute) =23, n (chronic) =18. 
Statistical test:  non parametric, Mann -Whitney (U) test, α=0.05.  Bar graphs 
show median ± interquartile range.  
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4.6.   Effector and naive T-cells  
 The median percentage of CD3+ effector T-cells (TEC) in acute ENL was significantly 
lower (26.6%) than in chronic ENL (41.1%) (P≤0.00). Similarly, acute ENL cases had 
a significantly lower median percentage of CD8+TEC (58.7%) than chronic ENL 
(73.9%) (P≤0.005). However, the median percentage of CD4+TEC (13.6%) in acute and 
chronic (17.6%) ENL was not significantly different (Figure 6.4.6). The median 
percentage of naïve T- cell expression in CD3+, CD4+ and CD8+ T-cells in acute and 
chronic ENL was not significantly different (Figure 6.4.6).   
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Figure 6.4.6.  Median percentage of TEC and TNC expression in CD3
+,CD4+ and 
CD8+ T-cells  in acute and chronic ENL.  n (acute) =23, n (chronic) =18. 
Statistical test:  non parametric, Mann -Whitney (U) test, α=0.05. * p≤0.05.   Bar 
graphs show median ± interquartile range.  
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SECTION 5:  MEMORY B-CELLS   
5.1. Introduction  
Memory B-lymphocytes are a sub-type of B-cells that are formed within germinal 
centres following infection. They proliferate and differentiate into antibody secreting 
plasma cells also called effector B-cells in response to reinfection. Recent advances in 
tracking antigen-experienced memory B- cells have revealed the importance of distinct 
classes of memory B-cells in the development of vaccines and therapeutics. Although 
in several studies the antibodies production in leprosy have been described, B-cells are 
among the least studied immune cells in leprosy and information is lacking on the role 
of B-cells in the pathogenesis of leprosy particularly leprosy reactions. This study 
provided basic preliminary information with regard to the different classes of B-cells 
for the first time in patients with ENL and LL controls.  
Figure 6.5.1. Flowchart showing the number of samples used for phenotyping of B- 
cells by flow cytometry.  
  
                                           
 
  
    ENL (n=20)  
Samples used for Second 
time point analysis 
Samples used for third 
time point analysis 
    ENL (n=15)      LL (n=15)  
    LL (n=15)  
    LL (n=20)  
Samples used for first time 
point analysis  
    ENL (n=15)  
       Enrolled (n=40)  
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5.2. Total B- lymphocytes and mature B-cells in patients with ENL and LL 
controls    
The proportion of B-lymphocytes in patients with ENL (9.5%) and LL controls 
(11.6%) was not statistically significantly different at recruitment.  During treatment, 
the percentage of B-cells slightly increased to 10% in patients in ENL cases and to 
14% in LL patient controls but did not show a statistically significant difference.  
However, after treatment, the proportion of B-cells appreciably decreased to 5.7% in  
patients with ENL while it was remained at the same level in LL patient controls 
(12.0%) and the difference between the two groups was statistically significantly 
different ( P≤ 0.001; ∆HL= 6.02%) (Figure 6.5.2).  
The median percentage of mature (CD19+CD10-) and immature (CD19+CD10+) B-
cells in patients with ENL and LL controls before and after treatment were also 
measured. A significant difference was not observed with regard to the proportion of 
mature and immature B-cells in patients with ENL cases and LL controls before and 
after treatment (Figure 6.5.2).  
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Figure 6.5.2.  Total B- lymphocytes (CD19+) and mature B -cells (CD19+CD10-
) production in the PBMCs of patients with ENL and LL controls before, during 
and after treatment. ENL: n (before) =20, n (during) = n (after) = 15; LL: n 
(before) = 20, n (during) = (after) =15. Statistical test: Mann-Whitney unpaired 
test (U).  *** P≤ 0.001.  Box and whiskers show median ± interquartile range.  
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5.3. Memory B-cells in patients with ENL and LL controls    
The median percentage expression of memory B-cell subtypes (resting, activated and 
tissue-like memory B-cells) and naïve B-cells in patients with ENL and LL controls 
before and after treatment was analysed.  The median percentage of naïve B-cells (NB) 
was lower in patients with ENL (76.0%) than in LL patient controls (84.6%) before 
treatment (P≤ 0.05; ∆HL=6.75%). The proportion of these cells decreased to nearly 
64% in both cases during treatment and slightly increased to 74.3% in patients with 
ENL and to 71.6% in LL patient controls after treatment but was not statistically 
significantly different (Figure 6.5.3).  
The median percentage of resting memory B-cells (CD19+CD27+CD21+) was 5.8 % 
in patients with ENL and 4.8 % in LL patient controls before treatment and it was not 
significantly different in both groups. However, during treatment it was increased to 
15.2 % in patients with ENL and was higher than in LL patient controls (8.6%) (P≤ 
0.05; ∆HL=6.95%).  The proportion of these memory cells was decreased to below 
5% in both groups after treatment (Figure 6.5.3).  
The median percentage of activated memory B-cells (AM) was slightly higher in 
patients with ENL (2.1%) than in LL patient controls (1.4%) before treatment but the 
difference was not statistically significant.  During treatment, the percentage AM  cells 
in patients with ENL and LL controls increased to 3.8% and 4.4% respectively and the 
difference  was not statistically  significant (P> 0.05). After treatment, the percentage 
of these memory cells did not change (Figure 6.5.4). 
The percentage of tissue-like memory B-cells (TLM) was significantly higher in 
patients with ENL (9.3%) that in LL patient controls (4.8%) before treatment (P≤ 
0.05).  However, during and after treatment, the percentage of TLM in patients with 
ENL and LL controls was not significantly different (Figure 6.5.4). 
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Figure 6.5.3. The median percentage of naïve (NB) B-lymphocytes (CD19+CD10-
CD27-CD21+) and resting memory (RM) B-cells (CD19+CD10-CD27+CD21+) in the 
PBMCs of patients with ENL and LL controls before, during and after treatment. ENL: 
n (before) =20, n (during) = n (after) = 15; LL: n (before) = 20, n (during) = (after) 
=15. Statistical test: Mann-Whitney unpaired test (U). * P≤ 0.05. 
 
 
 
 
 
 
 
Figure 6.5.4. The median percentage of activated memory (AM) B-cells (CD19+CD10-
CD27+CD21-) and tissue like memory (TLM) B-cells (CD19+CD10-CD27-CD21-) in 
the PBMCs of patients with ENL and LL controls before, during and after treatment. 
ENL: n (before) =20, n (during) = n (after) = 15; LL: n (before) = 20, n (during) = 
(after) =15. Statistical test: Mann-Whitney unpaired test (U). * P≤ 0.05. Box and 
whiskers show median ± interquartile range. 
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5.4. Total B- lymphocytes and matured B-cells in patients with ENL before and 
after treatment  
The median percentage of B-lymphocytes before and during treatment of patients with 
ENL was 9.5% and 9.9% respectively. After treatment, the proportion of these cells 
was significantly decreased to (5.7%) compared with before and during treatment (P 
≤ 0.05). However, the percentage of mature B-cells was slightly lower before treatment 
than during treatment (P ≤ 0.05).  The proportion of mature B-cells before and after 
treatment was not statistically significantly different (Figure 6.5.5).  
The median percentage of naïve B-cells among untreated patients with ENL (76.0%) 
was higher than during treatment (64.7%) (P≤ 0.05).  Interestingly, unlike the central 
memory T-cells, the proportion of resting memory B-cells (RM) was considerably 
lower (5.8%) before treatment than during treatment (15.3%) (P≤ 0.001). After 
treatment, the proportion of  these resting memory B-cells was decreased to 3.7% and 
it was significantly lower than before and during treatment (P≤ 0.05) ( Figure 6.5.6).   
The median percentage of activated memory B-cells (AM) was slightly lower (2.1%) 
before treatment than during treatment (3.8%) but was not significantly different. After 
treatment, the percentage of AM did not change.  Similarly, the percentage of tissue-
like memory B-cells (13.2%) was higher before treatment than after treatment (10.0%) 
but was not statistically significantly different (Figure 6.5.6).   
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Figure 6.5.5. Total B-lymphocytes (CD19+) and matured B-cells (CD19+CD10-) 
expression in PBMCs of patients with ENL before, during and after prednisolone 
treatment. ENL: n (before) = (during) = n (after) = 15; LL: n (before) = n (during) = 
(after) =15. Statistical test: Wilcoxon matched-pairs test. * P≤ 0.05;   ** P≤ 0.005. 
Error bars show median ± interquartile range.    
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Figure 6.5.6. Memory B-cells:  Total naive (NB) B-lymphocytes (CD19+CD10-CD27-
CD21+), resting memory (RM) B-cells (CD19+CD10-CD27+CD21+), expression of 
activated memory (AM) B-cells (CD19+CD10-CD27+CD21-) and tissue like memory 
(TLM) B -cells (CD19+CD10-CD27-CD21-) in the PBMCs of patients with ENL 
before, during and after prednisolone treatment.  ENL: n (before) = (during) = n (after) 
= 15; LL: n (before) = n (during) = (after) =15. Statistical test: Wilcoxon matched-
pairs test. * P≤ 0.05; ** P≤ 0.005; *** P≤ 0.001;   **** P< 0.0001. Error bars show 
median ± interquartile range.    
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Table 6.5.1.  Summary tables sowing trends of memory B-cells in patients with 
ENL and LL controls: A. ENL versus LL, B. within ENL  
A. 
B-cells  Before treatment  
  
During treatment  
  
After treatment  
  
ENL LL ENL LL ENL LL 
CD19+  − − − − ↓ ↑ 
CD19+ CD10- − − − − − − 
AM ↑ ↓ − − − − 
RM − − ↑ ↓ − − 
TLM ↑ ↓ − − − − 
NB ↓ ↑ − − − − 
 
 
B.  
 
 
 
 
 
 
 
 
 
CD19+ marker for B-cells, CD19+ CD10-= marker for mature B-cells, AM= 
Activated memory B-cells, RM= Resting memory B-cells, TLM= Tissue- like 
Memory B-cells, NB= naïve B-cells. ↑= increased, ↓= decreased, − = no change   
B-cells  Before and After treatment  
Before  After  
CD19+  ↑ ↓ 
CD19+ CD10- − − 
AM − − 
RM ↑ ↓ 
TLM − − 
NB − − 
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SECTION 6:  IN VITRO CYTOKINE PRODUCTION    
To investigate the in vitro cytokine response to M. leprae, PBMCs from patients with 
ENL and LL controls were cultured with M. leprae whole cell sonicate (MLWCS), 
Phytohaemagglutinin (PHA) or left unstimulated for 6 days. Phytohaemagglutinin 
(PHA) and plain media were used as positive and negative controls respectively. The 
cytokine levels in culture supernatants were determined using sandwich ELISAs 
specific to TNF-α, IFN-γ, IL-β, IL-6, IL-8, IL-17A and IL-10. The assay sensitivity 
for each cytokine is given in materials and methods (Chapter 5). Differences in 
cytokine production in patients with ENL and LL controls were investigated using an 
unpaired t-test while the cytokine production among patients with ENL before and 
after treatment was determined by a paired t-test at 5% level of significance.  
 
Figure 6.6.1:  Flow diagram showing number of samples used for in vitro cytokine 
response to M. leprae antigen stimulation.  
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6.1. In vitro cytokine production in patients with ENL and LL controls   
The in vitro cytokine response of PBMCs from patients with ENL and LL controls to 
M. leprae WCS before, during and after treatment was compared. The results are given 
by mean ± standard error of the mean (SE). SE was chosen since the primary objective 
of the study was to measure how the mean of the sample is related to the mean of the 
underlying population.  SE takes standard deviation and sample size into account.  
The mean production of TNF-α in response to M. leprae WCS stimulation was 
significantly higher (83.6.4 ±18.82 pg/mL) in the culture supernatants of PBMCs from 
patients with ENL than from LL patient controls (19.4pg/mL ±10.44) before treatment 
(t67 =2.629, P≤0.05).  During treatment, the level of TNF-α production decreased to 
10.7pg/mL in patients with ENL while it was increased to 36.9pg/mL in LL patient 
controls. After treatment, TNF-α production was not significantly different between 
the two groups (Figure 6.6.2).  
Patients with ENL reactions had a significantly higher (1361pg/mL ± 309.6) IFN-γ 
production than the LL patient controls (280.1pg/mL ± 309.6) before treatment (t66= 
2.456, P≤ 0.05). However, during treatment, the level of IFN-γ production was 
significantly decreased in patients with ENL to 304.4 pg/mL ± 119.6 while it was 
increased in LL patient  controls to  1158.0 pg/mL ± 549.2  (t62=2.720, P≤ 0.05). The 
level of IFN-γ production was similar in these two groups after treatment (Figure 
6.6.2). 
Although the amount of IL-1β production was similar in patients with ENL and LL 
controls before and during treatment, patients with ENL had much lower production 
of IL-1β than LL patient controls after treatment (t54=2.112, P≤ 0.05).  On the other 
hand, higher production of IL-17A was obtained in patients with ENL cases compared 
to LL patient controls before treatment (t48=3.474.112, P≤ 0.005). Although the in vitro 
production of IL-17A was considerably decreased after treatment in patients with 
ENL, it still remained high compared to the corresponding figure in LL patient controls 
(t48=2.098.112, P≤ 0.05) (Figure 6.6.2).    
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The in vitro response of IL-6 production was higher in patients with ENL than in LL 
controls before treatment (t73=3.853, P≤ 0.005). However, during and after treatment, 
the in vitro   IL-6 production was similar in both groups.  On the other hand, the level 
of IL-8 production was found to be higher in patients with ENL than in LL controls 
throughout the study period (P≤ 0.05) (Figure 6.6.3).     
The response of IL-10 to M. leprae WCS both in patients with ENL and LL controls 
was also investigated. IL-10 production was considerably lower in patients with ENL 
(18.59pg/mL ± 4.05) than in LL patient controls (122.6 pg/mL ± 23.18) before 
treatment (t67=5.277, P<0.0001).  Interestingly, after treatment, the level of IL-10 
production was significantly increased to 87.78pg/mL ± 22.49 in patients with  ENL 
while it was substantially decreased to 4.91pg/mL ± 2.160 in LL patient controls and 
the difference was statistically significant (P ≤ 0.001) (Figure 6.6.3).    
In conclusion, the in vitro production of the cytokines TNF-α, IFN-γ, IL-17A, IL-6 
and IL-8 were higher  in patients with  ENL than in LL patient controls before 
treatment while IL-10 was  significantly lower in patients with ENL than in LL patient 
controls at recruitment.  
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Figure 6.6.2.  Comparison of the levels of in vitro production of TNF-α, IFN-γ, IL-β 
and IL-17A in culture supernatants of PBMCs from patients with ENL and LL controls 
before and after treatment. ENL: n (before) =46, n (during) = 38, n (after) = 35; LL: n 
(before) =31, n (during) = 26, n (after) =25. Statistical test: unpaired t-test, α=0.05.    
*P ≤0.05; ** P ≤0.005.  Bars graphs show mean ± Standard error of the mean.  
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Figure 6.6.3. Comparison of the levels of in vitro IL-6, IL-8 and IL-10 production in 
culture supernatants of PBMCs from patients with ENL and LL controls before and 
after treatment. n (before) =46, n (during) =38, n (after) =35; LL: n (before) =31, n 
(during) = 26, n (after) =25. Statistical test: unpaired t-test, α=0.05. *P ≤0.05; **P 
≤0.005;   ***P < 0.001;    ****P < 0.0001.  Bars graphs show mean ± Standard error 
of the mean.  
A receiver operator characteristic (ROC) curve plot for the accuracy of a single 
cytokine to discriminate between patients with ENL and LL controls was performed. 
The most accurate cytokines that differentiate between patients with ENL and LL 
controls were: TNF-α, IL-6, IL-17A, IL-1β, IL-8, IFN-γ and IL-10 with the 
corresponding of area under the curves (AUCs) of 0.779, 0.763, 0.745, 0.695, 0.667, 
0.557 and 0.710 respectively (Figure 6.6.4). 
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Variables  
  
area under 
the curve  
  
Std error  
  
Asymptotic 
sig 
  
 Asymptotic 95% confidence 
interval  
        lower bound  upper bound  
TNF-α 0.779 0.063 0.000 0.656 0.903 
IL-6 0.763 0.07 0.001 0.625 0.901 
IL-17A 0.745 0.066 0.002 0.615 0.874 
IL-10 0.710 0.078 0.007 0.556 0.863 
IL1-β 0.695 0.074 0.013 0.551 0.839 
IL-8 0.667 0.079 0.033 0.513 0.821 
IFN-γ 0.557 0.079 0.463 0.402 0.713 
 
Figure 6.6.4.  Receiver operator characteristics curves (ROCs) showing the accuracies 
of individual cytokines in discriminating between patients with ENL and LL controls 
before treatment. AUC= area under the curve.  
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6.1.1. Principal component analysis (PCA) 
Principal component analysis (PCA) with varimax rotation was conducted to assess 
the cytokine variables in order to summarize them by reducing the dimension of the 
dataset into principal components. A loading score statistic was used to select the 
principal components most associated with the outcome (ENL). The assumption of 
independent sampling was met. The assumptions of normality, linear relationships 
between pairs of variables, and the variables being correlated at a moderate level were 
checked.  
Figure 6.6.5. Scree plot showing the in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL. A scree plot shows the eigenvalues 
(y-axis) of the principal components (x-axis) for the data set in descending order and 
indicates the relative importance of the PCs. Those PCs with eigenvalues <1 account 
for an increasingly small and insignificant amount of the variance in the data so are 
not used. In this study the first two PCs have eigenvalues >1 so are the most significant 
components explaining variability in the data. 
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The component plot in rotated space (Figure 6.5.6) shows how closely related the 
cytokines are to each other and to the two components. This plot of the component 
loadings shows that IL-6, IL-1β and IL-8 all load highly and positively on the first 
component. IL-10 and TNF-α had near zero on the first component, but load highly 
on the second component. IL-17A loads moderately on the first component while 
IFN-γ loads moderately on component 2.  
Figure 6.6.6: The component plot in rotated space showing visual representation of 
the loadings plotted in a 2-dimensional space.  
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The coefficients shown in table 6.6.1 explain how well each individual cytokine is 
represented within the clusters. The cytokine levels of IL-6, IL-1β, IL-8 and IL-17 
loaded together on the first component, explaining 42.274%of the total variation in 
the cytokine study. Component 2 is determined by three cytokines: IL-10, TNF-α and 
IFN-γ explaining 20.714% of the variation.  
 Table 6.6.1. Individual factor cytokine scores extracted by loading matrix of 
component solution after Varimax rotation  
 
6.2. In vitro cytokine production in ENL before and after treatment  
The levels of IFN-γ, IL-17A, TNF-α, IL-6, IL-8, Il-1β and IL-10 production in 
response to M. leprae WCS before, during and after treatment were compared. The in 
vitro TNF-α production in response to M. leprae WCS stimulation was considerably 
higher (83.6pg/mL ± 18.82) before treatment than during treatment (10.7pg/mL±2.79) 
(t34=3.924, P ≤ 0.001). After treatment, it was slightly increased to 25.4pg/mL±8.88 
but was still lower than the amount obtained before treatment (t24=3.397, P ≤ 0.005). 
Likewise, the in vitro production of IFN-γ in response to M. leprae WCS was 
considerably higher before treatment (1361.0pg/mL ±309.6) than during treatment 
(304.4pg/mL±119.6) (t37=2.957, P ≤ 0.05) and after treatment (328.2pg/mL±190.3) 
(t28=3.027, P ≤ 0.05) (Figure 6.6.7).   
Cytokines component 1 loading  component 2 loading 
IL-6 0.860  
IL-β 0.776  
IL-8 0.704  
IL-17 0.472  
IL-10  0.899 
TNF-α  0.906 
IFN-γ  0.120 
Total variation explained  42.274% 20.714% 
Extraction method:   principal component analysis  
Rotation Method: Varimax with Kaiser Normalization  
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The level of IL-1β and IL-17A production were also found to be higher before 
treatment than during and after prednisolone treatment of patients with ENL. Although 
IL-6 production was appreciably decreased during treatment, it was increased after 
treatment and statistically significant difference was not revealed before or after 
treatment. Unlike IL-6, the production of IL-8 did not show any significant change 
before, during and after treatment (Figure 6.5.7). On the other hand, the level of IL-10 
production was very low before and during treatment but substantially increased after 
treatment (Figure 6.6.7).  
In summary, the in vitro production of IFN-γ, IL-17A, TNF-α and Il-1β  to M. leprae 
WCS  stimulation were higher before treatment and have shown a significant reduction 
after treatment indicating the possible  association of these proinflammatory cytokines 
and ENL reaction. On the other hand, the in vitro production of IL-10 was noticeably 
low before treatment and significantly increased after treatment showing its possible 
regulatory activity. IL-6 and IL-8 did not show significant change before and after 
treatment of patients with ENL.    
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Figure 6.6.7.  Comparison of the levels of in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL before and after treatment. ENL: n 
(before) = (during) = (after) = 35; LL: n (before) =n (during) = n (after) =25. Statistical 
test: paired t-test, α=0.05. *P ≤0.05; **P ≤0.005;   ***P < 0.001;   ****P < 0.0001. 
Error bars show mean ± Standard error of the mean.  
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SECTION 7:  CYTOKINE GENE EXPRESSION  
To investigate the cytokine gene expression, mRNA was isolated from whole blood 
and skin biopsies and then reverse transcribed into cDNA. The mRNA copy numbers 
were quantified on the Corbett Rotor-Gene using real-time PCR assays specific to 
TNF-α, IFN-γ, IL-β, TGF-β, IL-17A, IL-6, IL-8, IL-10 and HUPO as described in the 
materials and methods section. The mRNA expression level of FOXP3 in whole blood 
and biopsy samples was also quantified to supplement the flow cytometry data aimed 
to measure Tregs. Fold change (FC) was used to compare the levels of these gene 
expressions in patients with ENL and LL controls as well as among patients with ENL 
before and after treatment. 
7.1. Comparison of cytokine gene expression in the blood samples from patients 
with ENL and LL controls  
The cytokines gene expression in whole blood samples from patients with ENL before 
and after treatment was compared to LL patient controls. The gene expression levels 
of TNF-α (FC=3.31) and IFN-γ (FC=2.42) were significantly increased in the blood 
samples from patients with ENL compared to LL patient controls before treatment (P≤ 
0.005). However, after treatment, the expression levels of these cytokines were the 
same in both groups. The gene expression levels of IL-6 (FC=6.01), IL-8 (FC=3.19) 
and IL-17A (FC=3.58) were considerably high in the blood samples from patients with 
ENL compared to LL patient controls (P≤0.001) before treatment  but none of them 
showed a statistically significant difference after treatment (Table 6.7.1).      
Although, the fold changes (FC) of mRNA gene expression for IL-1β and TGF-β were 
slightly increased before treatment in the blood samples from patients with ENL 
compared to LL patient controls, statistically a significant difference was not revealed. 
On the other hand, the mRNA gene expression for TGF-β was increased (FC=4.82) in 
patients with ENL compared to LL patient controls after treatment (P ≤ 0.05). The 
level of IL-10 expression was not significantly different in the two groups before and 
after treatment (Table 6.7.1). 
 The mRNA expression level of FOXP3 in the blood samples from patients with ENL 
cases and LL controls did not show a statistically significant difference before 
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treatment. On the other hand, the gene expression of FOXP3 was evidently increased 
(FC=2.07) in patients with ENL cases after treatment compared to LL patient controls 
(Table 6.1). Except IL-10, the result of mRNA gene expression of the other cytokines 
(TNF-α, IFN-γ, IL-β, TGF-β, IL-17A, IL-6 and IL-8) was found to be consistent with 
the result of the corresponding in vitro cytokine production. Unlike the IL-10 cytokine 
production in the culture supernatants in response to M. leprae WCS, its gene 
expression in patients with ENL did not reveal statistically significant difference 
compared to LL patient controls. 
Table 6.7.1. Cytokine mRNA expression in the blood samples from patients with 
ENL and LL controls before and after treatment.  
 
n (before) =46, n (during) = (after) = 44; LL: n (before) = (during) = 31, n (after) 
=28. Statistical test: unpaired t-test, α=0.05.∆∆CT = delta delta CT, FC= fold change, 
* = significant at α=0.05.  
 Gene of 
interest   
Before treatment After treatment 
∆∆CT   FC P- value  ∆∆CT   FC P- value  
TNF-α -1.73 3.31 0.0047* 0.00 1.00 0.9989 
IFN -γ -1.27 2.42 0.0044* 0.08 0.95 0.8804 
IL-1β -1.23 2.34 0.1085 -0.24 1.18 0.7333 
IL-6 -2.59 6.01 0.0003* -0.99 1.99 0.1167 
IL-8 -1.68 3.19 < 0.0001* -0.81 1.75 0.243 
IL-10 0.83 0.56 0.1552 0.28 0.82 0.5882 
IL-17A  -1.84 3.58 0.0002* 1.12 0.46 0.0502 
TGF-β -0.07 1.05 0.8724 -2.27 4.82 0.0119* 
FOXP3 0.33 0.80 0.6812 -1.05 2.07 0.0083* 
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7.2. Comparison of cytokine gene expression in skin biopsy samples from 
patients with ENL and LL controls  
The cytokine gene expression in the skin biopsies from patients with ENL before and 
after treatment was compared to LL patient controls. The expression of mRNA for 
TNF-α (FC=2.04), IFN-γ (FC=4.01), IL-1β (FC=6.35), IL-6 (FC=5.30) and IL-17A 
(FC=2.99) were significantly higher (P≤ 0.005) in the biopsies from patients with ENL 
than in the biopsies from LL patient controls before treatment. However, except IL-6 
(FC=2.07, P ≤ 0.05), statistically, a significant difference was not obtained in terms of 
mRNA gene expression for these cytokines in patients with ENL and LL controls after 
treatment. The mRNA expression for IL-10 was significantly lower (FC= 0.38) in 
patients with ENL than in LL patient controls (P ≤ 0.0001) before treatment. However, 
after treatment, it was significantly increased in patients with ENL (FC=3.5) compared 
to LL patient controls and the difference was statistically significant (P ≤ 0.0001).  The 
mRNA expression for TGF-β and IL-8 in patients with ENL and LL controls did not 
show statistically significant difference after treatment (Table 6.7.2).   
Unlike in the blood sample, the mRNA expression for FOXP3 in tissue samples from 
patients with ENL was significantly lower (FC =0.35) than in LL patient controls 
before treatment (P ≤ 0.005) but statistically a significant difference was not detected 
between the two groups after treatment (Table 6.7.2).  Except for some minor 
differences, the mRNA expression levels for most of these cytokines showed similar 
pattern both in blood and tissue samples. The most interesting difference was seen in 
mRNA expression for IL-1β and FOXP3. No significant difference in expression 
levels of mRNA for IL-1β was detected in blood samples from patients with ENL and 
LL controls but substantially a higher mRNA expression for IL-1β was found in tissue 
samples from patients with ENL than from LL patient controls before treatment. 
Similarly, the mRNA expression for FOXP3 was not significantly different in the 
blood samples from patients with ENL cases and LL controls before treatment but was 
increased by two-fold in patients with ENL after treatment. On the other hand, mRNA 
expression for FOXP3 in tissue samples from patients with ENL was significantly 
decreased before treatment compared to LL controls but statistically significant 
difference was not obtained between the two groups after treatment (Table 6.7.2). 
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Table 6.7.2. Cytokine mRNA expression in the tissue samples from patients with 
ENL and LL controls before and after treatment. 
Gene of 
interest 
Before treatment After treatment 
∆∆CT   FC P -value  ∆∆CT   FC P-value  
TNF-α -1.03 2.04 0.0033* -0.09 1.07 0.89 
IFN -Ƴ -2.01 4.01 0.0058* -0.32 1.25 0.5224 
IL-1β -2.67 6.35 0.0006* -0.24 1.18 0.7333 
IL-6 -2.41 5.30 0.0015* -1.05 2.07 0.0438 * 
IL-8 -0.12 1.09 0.8465 -0.71 1.64 0.2333 
IL-10 1.41 0.38 < 0.0001* -1.81 3.50 < 0.0001* 
IL-17A  -1.58 2.99 0.0035* -0.13 1.10 0.281 
TGF-β 0.31 0.8 0.4876 -0.63 1.55 0.3598 
FOXP3 1.52 0.35 0.0008* 0.23 0.86 0.6845 
 
n (before) =46, n (during) = (after) = 44; LL: n (before) = (during) = 31, n (after) 
=28. Statistical test: unpaired t-test, α=0.05.∆∆CT = delta delta CT, FC= fold change, 
* = significant at α=0.05. 
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7.3. Comparison of cytokine gene expression in the blood samples from patients 
with ENL before and after treatment  
The gene expression levels of the above cytokines were also investigated in blood 
samples from patients with ENL before and after treatment. The ∆∆CT of each pair 
was obtained by subtracting the ∆∆CT before treatment from ∆∆CT after treatment 
(∆∆CT after – ∆∆CT before). Paired t-test was used to compare the two groups at 5 % 
significance level.      
The mRNA expression for IL-8 and TGF-β did not show a statistically significant 
difference before and after treatment. On the other hand, the gene expression levels of 
IFN-γ (P < 0.0001), IL-6 (P ≤ 0.0001), IL-1β (P ≤ 0.005) and TNF- α (P ≤ 0.05)  were 
significantly decreased in the blood samples from patients with ENL after treatment 
while it was significantly increased for IL-10  (P ≤ 0.0001). The mRNA gene 
expression for FOXP3 in these patients was not significantly different before and after 
treatment (Table 6.7.3). 
Table 6.7.3. Cytokine mRNA expression in the blood samples from ENL before and 
after treatment. 
Cytokine  ∆∆CT   FC P Value  Gene expression after treatment 
TNF-α 1.19 0.44 0.0497 Decreased 
IFN -Ƴ 1.61 0.33 < 0.0001 Decreased 
IL-1β 1.56 0.34 0.0043 Decreased 
IL-6 1.60 0.33 < 0.0001 Decreased 
IL-8 0.48 0.72 0.0790 No change 
IL-10 -1.32 2.50 < 0.0001 Increased 
IL-17A  2.34 0.20 < 0.0001 Decreased 
TGF-β 0.24 0.85 0.7160 No change 
FOXP3 0.33 0.80 0.5564 No change 
n (before) = (during) = (after) = 44; LL: n (before) = (during) = (after) =28. 
Statistical test: paired t-test, α=0.05.∆∆CT = delta delta CT, FC= fold change, * = 
significant at α=0.05. 
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7.4. Comparison of cytokine gene expression in the skin biopsy samples from 
patients with ENL before and after treatment  
The cytokine gene expression in the skin biopsy samples from patients with ENL 
before and after treatment was compared. The mRNA expression levels in biopsy 
samples for TNF-α (P≤ 0.0001), IFN-γ (P≤ 0.0001), IL-1β (P≤ 0.0005) and IL-17A 
(P≤ 0.0204) were significantly decreased after treatment.  On the other hand, mRNA 
expression level for IL-10 was considerably increased after treatment (P≤ 0.0001.  The 
mRNA expression for IL-6, IL-8 and TGF-β did not show statistically a significant 
difference before and after treatment (Table 6.7.4). 
Interestingly, unlike the mRNA expression for FOXP3 in the blood samples, the 
expression in the biopsy samples from patients with ENL was significantly increased 
after treatment (P≤ 0.0001) which shows the possibility of local immune regulation at 
the site of reactional lesions in these patients (Table 6.7.4).     
Table 6.7.4. Cytokine mRNA expression in skin biopsy samples from patients with 
ENL before and after treatment. 
Cytokine  ∆∆CT   FC P Value  Gene expression after treatment 
TNF-α 2.34 0.2 < 0.0001* Decreased 
IFN -Ƴ 3.03 0.12 < 0.0001* Decreased 
IL-1β 2.39 0.19 0.0005* Decreased 
IL-6 0.31 0.81 0.6451 No change 
IL-8 0.16 0.90 0.7617 No change 
IL-10 -1.51  2.85 < 0.0001 * Increased 
IL-17A  1.01  0.5 0.0204 * Decreased 
TGF-β 0.09 0.94 0.8337 No change 
FoxP3 -3.07 8.4 < 0.0001* Increased 
n (before) = (during) = (after) = 44; LL: n (before) = (during) = (after) =28. Statistical 
test: paired t-test, α=0.05.∆∆CT = delta delta CT, FC= fold change, * = significant at 
α=0.05. 
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Table 6.7.5.  Summary of the trends in cytokines gene expression and in vitro cytokine 
production to the response of M. leprae stimulation in patients with ENL and LL 
controls before and after treatment  
                     ↑= increased, ↓= decreased, − = no change   
  
Cytokines  Before treatment   After treatment  
  
ENL LL ENL LL 
In vitro cytokine  production          
TNF-α ↑ ↓ − − 
IL-1β − − ↓ ↑ 
IFN-γ ↑ ↓ − − 
IL-6 ↑ ↓ − − 
IL-8 ↑ ↓ ↑ ↓ 
IL-10 ↓ ↑ ↑ ↓ 
IL-17A ↑ ↓ ↑ ↓ 
Gene expression in blood samples         
TNF-α ↑ ↓ − − 
IL-1β − − − − 
IFN-γ ↑ ↓ − − 
IL-6 ↑ ↓ − − 
IL-8 ↑ ↓ − − 
IL-10 − − − − 
IL-17A ↑ ↓ − − 
TGF-β − − ↑ ↓ 
Gene expression in biopsy  samples          
TNF-α ↑ ↓ − − 
IL-1β ↑ ↓ − − 
IFN-γ ↑ ↓ − − 
IL-6 ↑ ↓ ↑ ↓ 
IL-8 − − − − 
IL-10 ↓ ↑ ↑ ↓ 
IL-17A ↑ ↓ − − 
TGF-β − − − − 
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Table 6.7.6.  Summary of the trends in cytokines gene expression and in vitro cytokine 
production to the response of M. leprae stimulation in patients with ENL before and 
after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ↑= increased, ↓= decreased, − = no change    
In vitro  cytokine production  Before treatment  After  treatment  
TNF-α ↑ ↓ 
IL-1β ↑ ↓ 
IFN-γ ↑ ↓ 
IL-6 − − 
IL-8 − − 
IL-10 ↓ ↑ 
IL-17A ↑ ↓ 
Gene expression in blood samples      
TNF-α ↑ ↓ 
IL-1β ↑ ↓ 
IFN-γ ↑ ↓ 
IL-6 ↑ ↓ 
IL-8 − − 
IL-10 ↓ ↑ 
IL-17A ↑ ↓ 
TGF-β − − 
Gene expression in biopsy  samples      
TNF-α ↑ ↓ 
IL-1β ↑ ↓ 
IFN-γ ↑ ↓ 
IL-6 − − 
IL-8 − − 
IL-10 ↓ ↑ 
IL-17A ↑ ↓ 
TGF-β − − 
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SECTION 8:  PLASMA C1Q PRODUCTION AND ITS GENE EXPRESSION  
Complement C1q is the first subcomponent of the C1 complex of the classical pathway 
of complement activation. C1q recognizes and binds to immunoglobulin complexed 
to antigen and initiates the complement cascade. It has been confirmed that C1q 
deficiency or abnormality is associated with increased incidence of immune complex 
diseases such as systemic lupus erythematosus, polymyositis, glomerulonephritis, and 
Henoch-Schonlein purpura.  
In the present study, the circulating C1q in the plasma of patients with ENL and LL 
controls before and after treatment was quantified using a special C1q-ELISA and its 
gene expression by quantitative PCR. The gene expression of C1q in the biopsy 
samples obtained from patients with ENL reactions and LL controls before and after 
treatment was also determined.  
8.1. Plasma C1q production 
The circulating C1q plasma was measured by ready-to-use sandwich ELISA. Mean ± 
standard error of the mean (SE) was used for comparison between cases and controls.  
Patients with ENL reaction had significantly a lower circulating C1q (11698 ± 618.3) 
than LL patient controls (21059 ± 2382.0) before treatment (P≤ 0.001).  However, after 
treatment, the amount of circulating C1q in both groups did not show statistically a 
significant difference (Figure 6.8.1).   
The circulating C1q in patients with ENL before and after prednisolone treatment was 
compared. The mean circulating C1q in the plasma from patients with ENL reaction 
was considerably increased from 11698 pg/mL ±618.3 before treatment  to 
22287pg/mL ±2154.0 after treatment and the difference was statistically significant 
(t33=5.071, P < 0.0001) ( Figure 8.1). This finding indicates that patients with ENL 
reactions do not have genetic defects of C1q since the level of C1q production 
increased after the ENL reactions subside.  
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Figure 6.8.1.  Plasma circulating C1q levels before and after treatment. A): circulating 
C1q in the plasma of patients with ENL and LL controls before and after treatment, 
B): circulating C1q before and after prednisolone treatment of patients with ENL. 
ENL: n (before) = 46, n (after) = 44; LL: n (before) = 31, n (after) =28. Statistical test: 
for ENL versus LL we used unpaired t-test and for comparison within ENL paired t-
test. **** P < 0.0001. Bars graphs show mean ± Standard error of the mean. 
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8.2. C1q gene expression in blood and skin biopsy samples 
C1q is an 18-subunit glycoprotein consisting of 3 subunits: A, B and C which are coded 
by C1qA, C1qB and C1qC genes respectively. It has been shown that C1q is assembled 
in a 1:1:1 ratio from these three different subunits. The three human C1q genes are 
closely located on chromosome 1 and arranged C1qA-C1qC-C1qB orders.  In this 
study, the mRNA expression for these three genes in the blood and biopsy samples 
obtained from patients with ENL and LL controls before and after treatment was 
quantified.  
The gene expression levels for C1q A, B and C in the blood samples from patients with 
ENL and LL controls were similar before treatment. However, the gene expressions 
of these three genes significantly increased in blood samples from patients with ENL 
compared to LL patient controls after treatment (Table 6.8.1).  The mRNA expression 
levels of these genes in biopsy samples from patients with ENL and LL controls were 
not statistically significantly different before treatment similar to the results obtained 
from blood samples. After treatment, the expression of C1qA was significantly 
increased while that of C1qC was significantly decreased in biopsy samples from 
patients with ENL compared to in LL patient controls (Table 6.8.1).  
Table 6.8.1.  C1q mRNA expression in blood and skin biopsy samples from patients 
with ENL and LL controls before and after treatment.  
                   
ENL: n (before) = (after) = 44; LL: n (before) = (after) =28. Statistical test: paired t-
test. ∆∆CT =delta delta CT;   *statistically significant at α=0.05.   
Sample  gene of 
interest  
 Before treatment                          After treatment  
∆∆CT   FC P Value  ∆∆CT   FC P Value  
Blood C1q-A  -0.54 1.45 0.3928 -1.36 2.56 0.0069 * 
C1-B -0.80 1.74 0.3576 -1.39 2.63 0.0402 * 
C1q-C -0.58 1.49 0.4044 -2.19 4.55 0.0018 * 
Tissue C1q-A  0.37 0.78 0.7661 -2.69 6.45 0.0231* 
C1-B 0.89 0.54 0.2072 0.56 0.68 0.3713 
C1q-C 1.13 0.46 0.0737 2.90 0.13 < 0.0001 * 
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The mRNA expression levels for C1q genes in blood and biopsy samples from patients 
with ENL before or after treatment were also compared. The expressions of mRNA 
for all the three genes in blood samples were not statistically significantly different 
before and after treatment of patients with ENL. Interestingly, the mRNA expression 
for C1qA was remarkably increased after treatment (P < 0.0001). On the other hand, 
the gene expression for C1qC was significantly decreased (P < 0.0001) after treatment 
of patients with ENL (Table 6.8.2).  
Table 6.8.2. C1q mRNA expression in blood and skin tissue samples from patients 
with ENL before and after treatment. 
 
ENL: n (before) = (after) = 44; LL: n (before) = (after) =28. Statistical test: 
paired t-test. ∆∆CT =delta delta CT;   *statistically significant at α=0.05. 
 
 
 
 
  
Samples Gene of 
interest 
∆∆CT FC P-value Gene expression after 
treatment 
Blood C1q-A  0.66 0.63 0.1116 No change 
C1-B 0.64 0.64 0.3309 No change 
C1q-C 0.43 0.74 0.4178 No change 
Tissue C1q-A  -10.3 1264.26 < 0.0001 * Increased 
C1-B 0.11 0.92 0.9302 No change 
C1q-C 2.93 0.13 < 0.0001 * Decreased 
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SECTION 9:   LEVELS OF ANTI PGL-1, Ag85 AND LAM ANTIBODIES  
The levels of anti ND-O-BSA (PGL-1), LAM and Ag85 antibodies were measured by 
ELISA in the plasma samples of patients with ENL and LL controls before and after 
treatment.  BSA was used as negative control and all tested samples had an OD value 
less than 0.2 for BSA. An OD value above 1.5 was assigned as high response for PGL-
1 and LAM, and 1.0 for Ag85.  
The level of anti-PGL-1 antibody was not significantly different in patients with ENL 
(OD= 1.430 ± 0.1281) and LL controls (1.341 ± 0.1415) before treatment. Similarly, 
the levels of anti -LAM and anti-Ag85 protein antibody titres were not significantly 
different in patients with ENL and LL controls before treatment. However, after 
treatment, patients with ENL had significantly lower anti-PGL-1 antibody titre (1.183 
± 0.1333) than LL controls (2.091 ± 0.1081) (p < 0.0001). After treatment, anti -LAM 
and anti-Ag85 protein antibody titres were lower in patients with ENL than in LL 
controls (p < 0.0001). Interestingly, patients with acute ENL had significantly higher 
anti-PGL-1 antibody titre than chronic cases before and after treatment (Figure 6.8.1). 
After treatment, only anti-PGL-1 antibody titre was significantly reduced in patients 
with ENL while anti-LAM and Ag85 did not change. (Figure 6.9.2).  
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Figure 6.9.1. Levels of anti PGL-1, LAM and Ag85 antibody titres of patients with 
ENL and LL controls before and after treatment. Values above 1.5 OD for PGL-1 and 
LAM and above 1.0 OD for Ag85 show high response and values below 0.2 OD show 
a negative response.  ENL: n (before) = n (after) =30; LL: n (before) = (after) =22.  
OD=optical density, PGL-1= phenolic glycolipid-1, LAM=Lipoarabinomannan, 
Ag85= Antigen 85 protein. *= P≤ 0.05, ***= P≤ 0.001, ****= P<0.0001.   Error bars 
show median ± interquartile range. 
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                                              *= P≤ 0.05 
Figure 6.9.2.  Levels of anti PGL-1, LAM and Ag85 titres in patients with ENL before 
and after treatment. Values above 1.5 OD for PGL-1 and LAM and above 1 OD for 
Ag85 show high response and values below 0.2 OD show a negative response.   ENL: 
n (before) = n (after) =30. OD=optical density, PGL-1= phenolic glycolipid-1, 
LAM=Lipoarabinomannan, Ag85= Antigen 85 protein. *= P≤ 0.05. 
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CHAPTER 7: DISCUSSION 
Introduction 
This work is the first study involving a large number of patients with ENL and LL 
controls with follow-up for 28 weeks, which obtained clinical data and biological 
samples at three time points from each patient during this follow-up. Well- formulated 
case definitions and controls were applied to get clear representative patients and 
hence, the results can be extrapolated to the underlying population. Several parameters 
which included clinical assessment to sophisticated laboratory investigations were also 
measured. Several immune profiles both in blood and skin biopsy samples from gene 
expression to protein production levels were investigated. We measured several 
subsets of T-cells such as the CD4+/CD8+ balance, regulatory T-cells, activated T-
cells, memory T-cell subtypes. More accurate markers were used to measure the 
frequency of regulatory T-cells. The proportion of mature B-cells and memory B-cell 
subtypes were also measured.  For the first time memory T and B cells in leprosy are 
presented which we believe it will open new insights for leprosy research. For the first 
time the circulating complement, C1q in the plasma and its gene expression in the 
blood and skin biopsy samples of patients with ENL and LL controls were described.  
We also determined the in vitro cytokine response of PBMCs from patients with ENL 
and LL controls to M. leprae whole cell sonicate. We included several pro-
inflammatory cytokines (IFN-γ, IL-17A, TNF-α, IL-6, IL-8, and IL-1β) and regulatory 
cytokines (IL-10 and TGF- β). The gene expression levels of these cytokines were 
measured in blood as well as in skin biopsy samples of each patient.  The levels of anti 
ND-O-BSA (PGL-1), Ag85 protein and LAM antibodies were measured by ELISA in 
the plasma samples of patients with ENL and LL controls before and after treatment. 
The response of PBMCs from patients with ENL and LL controls by the analysis of 
IFN-γ and IL-10 responses to M. leprae before and after depletion of CD25+ cells were 
also measured and confirmed that Tregs are not functionally impaired in ENL patients 
(data not included in this thesis).  
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SECTION 1. SOCIODEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS 
Some of the key findings of socio-demographic and clinical characteristics of the study 
subjects are discussed in the flowing sections.   
Patient recruitment: In this study, a very stringent inclusion criteria were applied. 
We excluded nearly half of patients with ENL reactions (36 ENL cases) from the study 
after they have passed the screening by nurses and physicians. One of the main 
inclusion criteria for patients with ENL was no previous treatment with any 
corticosteroid or completed corticosteroid treatment of 15 days or longer. The 
excluded patients were individuals who disclosed that they had prednisolone tablets 
obtained privately from pharmacies without a prescription or through a prescription at 
local health centres and district primary hospitals. They had denied that they had had 
prednisolone because they were worried that if they disclosed the information to the 
diagnosing physician or nurse they would not get good treatment. The clinical 
coordinator, who was in charge of consenting the study patients was not involved in 
treatment. He spent a longer time in approaching patients than the diagnosing 
physician or nurses did, and was able to get the actual information from patients 
through discussion. It is important to mention that one has to be conscious of this issue 
when consenting patients with ENL and should not only depend on the information 
obtained about the patient through the diagnosing physicians or nurses for the reasons 
mentioned above. The several contradicting research reports on the immunology of 
ENL could be partially due to the lack of stringent inclusion and exclusion criteria and 
the strategies used for consenting patients.  In most studies, patients are consented by 
the diagnosing and treating physician or nurse which may affect the quality of 
information obtained from patients. Therefore, it is advisable that the diagnosing 
(treating) physicians or nurses should not be involved for consenting patients for 
research purposes.   
Socio-demographic data: In this study, we excluded patients under 18 years and 
above 65 years old. The number of male patients with ENL recruited to the study was 
as twice the number of female patients and it was higher than in the report by (Walker 
et al., 2015).  Walker et al. reported that the number of male and female patients with 
ENL was nearly equal (male: female, 1.1:1). These differences could be attributed to 
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several factors such as the case definitions used, the study period, the study design and 
the sample size. However, five-year retrospective data (2008-2013) in the same area 
have shown the number of male to female ratio to be 1.7:1 which is similar to our 
finding. In our study, the median age for male and female patients with ENL was 28.0 
and 26.7 years respectively. Both male and female patients with ENL were relatively 
older than the LL patient controls (median age: male=26 years, female =21 years). The 
slight difference in median age between the two groups could be explained by the 
chronological order of the disease. Patients usually develop ENL reaction after having 
either LL or BL clinical forms for some time during the course of the disease. 
Interestingly, the age range of females in both groups was relatively narrow (18-35 
years) compared to males (18-60 years) indicating that either younger females are 
more likely have access to health institutions for various reasons than older females 
even in low-income countries where health facilities are relatively inadequate (WHO, 
2009) or that ENL is relatively common among younger females of child bearing age  
due to various biological reasons (Duncan and Pearson, 1984, Lockwood and Sinha, 
1999, Motta et al., 2012a).    
Acute, recurrent and chronic ENL:  Our data confirm that many individuals have 
chronic ENL (39%). This implies that these patients require corticosteroid treatment 
for extended periods. High doses of corticosteroids may be required for prolonged 
periods. However, high doses of corticosteroids do not always control the 
inflammation and also pose life-threatening risks for patients (Girdhar, 1990, Walker 
et al., 2007).  Chronic ENL cases also continue to be a burden in referral hospitals in 
these resource poor settings where the disease is prevalent.  A study in rural India has 
shown that families with an ENL case are incurred coasts of more than 40% of total 
household income compared to families without ENL case due to out of pocket 
expenditure for treatment-seeking (direct costs) and loss of income resulting from 
reduced productivity (earning potential) of household members (indirect costs). This 
implies that households affected by ENL face a significant economic burden and are 
at risk of being pushed further into poverty (Chandler et al., 2015).    
Skin lesions morphology, pain symptoms and location: In this study, more diverse 
cutaneous manifestations of ENL were documented than used in ENL case definition.  
Although nodular lesions were present in more than 95% of the cases, it is worth 
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mentioning that looking at a wider differential diagnosis to other lesions during clinical 
assessments for ENL.  Pain was reported in 98% of the patients and was the most 
common symptom indicating the painful nature of ENL. Most patients had skin pain 
(80.4%), nerve pain (73.9%), joint pain (71.7%) and bone pain (69.2%). The most 
frequent site of pain due to ENL in our study was the skin which is explained by the 
fact that 95% of patients with ENL cases had skin lesions. Our finding is in agreement 
with the report of Walker et al (2015).  Bone pain was reported in two-thirds of our 
study patients which is higher than the report of Walker et al (2015). The difference 
between the two studies are likely to be due to the methodological differences 
employed.  
Other symptoms of ENL: Nerve function impairment (NFI) was reported in 65% of 
our study patients, which was higher than the 51.3% NFI in six countries as reported 
by Walker et al (2015).  Among the 65% of ENL patients who reported NFI, 80% had 
old NFI and hence, the majority of patients with ENL studied were at high risk of 
developing a permanent disability. A study by Santos Santos et al. (2013) in northern 
Brazil had identified NFI and leprosy reactions as the main risk factors associated with 
the development of disability in leprosy patients. The same authors reported that 
having NFI was strongly associated with the development of physical disability in 
children under 15 years of age (Santos et al., 2015).  In this study, 50% of patients with 
ENL had WHO disability grade-1 (G1D) while 4.3% had Grade- 2 disability (G2D).  
The proportion of grade 2 disability was lower than the national figure for Ethiopia 
(10.2%) in 2014 (Baye 2015). The lower proportion of G2D in our study can be 
explained by either the failure of correctly classifying into G1D and G2D or patients 
with G2D were excluded by chance at enrolment. 
Histopathological findings:  Paraffin- embedded sections of skin biopsy samples 
from ENL and LL lesions were graded by a histopathologist. Neutrophil infiltration 
was noted in 58.8% of patients with ENL compared to 14.3% in LL controls 
histologically before treatment. Hussain et al. (1995) has reported the absence of 
neutrophil infiltration in 36% of ENL skin lesions in Pakistani patients despite classical 
signs and symptoms of ENL. Similarly, a cross-sectional study on the histological 
features of leprosy reactions in Indian patients by Sarita et al. (2013) showed that 43% 
ENL skin lesions had no histological evidence of neutrophil infiltration. The reports 
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of these two studies are in agreement with our finding.   Contrary to our reports, 
previous studies by (Ridley et al., 1981, Jayalakshmi et al., 1995, Adhe et al., 2012a), 
reported the findings of neutrophil infiltration in all ENL lesions. The varying reports 
of neutrophil infiltration in ENL lesions could be attributed to several factors. For 
example, Aldhe et al (2012) investigated the presence of cellular neutrophil infiltration 
on previously histologically confirmed ENL cases. These authors mentioned that 
diagnosis of ENL was based on clinico-pathological observations, which means that 
in their case definition of ENL, they already included the presence of neutrophils in 
histology. The differences in findings could be also due to a delay between the onset 
of reaction and the timing of obtaining the biopsy in those without neutrophilic 
infiltrates, as dermal oedema may be missed in older reactional lesions.  Discordance 
between pathologists and standard operating procedures (SOPs) of slide preparation 
are also potential areas that should be further investigated to evaluate impact on the 
findings of neutrophil infiltration in tissue sections. It  is important to mention that 
even though previous reports suggested that vasculitis is  part of the ENL reaction  
commonly seen in Indian patients (Sehgal et al., 1986a),   only 5(14.7%)  of our 
patients had evidence of vasculitis. Similar observations have been made by the 
following authors (Adhe et al., 2012b, Sarita et al., 2013).     
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SECTION 2:  REGULATORY T-CELLS 
To describe the relative frequency of Tregs in the PBMCs from patients with ENL and 
LL controls, the markers CD3+CD4+CD25+FoxP3+CD25+CD127-/lo were used for the 
definition of CD4+Tregs and CD3+CD8+CD25+FoxP3+CD25+CD127-/lo for CD8+ 
Tregs. The relative frequency of these Tregs before, during and after prednisolone 
treatment of patients with ENL to see the dynamics of T-cell regulation in association 
with prednisolone treatment were compared. We have shown not only the percentage 
of Tregs but also the relative balance between CD4+ and CD8+ T-cells, in terms of the 
expression of CD25 and FoxP3 on CD4+ and CD8+ T-cells.  
CD4+ and CD8+ T- lymphocytes (ENL versus LL):  The results indicated that 
patients with ENL had a significantly higher median percentage of CD4+ T-cells and 
lower CD8+ T-cells before treatment compared to LL controls. Patients with ENL had 
a higher CD4/CD8 ratio (2.3:1) compared to LL controls (1.4:1). Prednisolone 
treatment significantly reduced the percentage of CD4+ T-cells in patients with ENL 
implying that prednisolone could suppress CD4+ T-cells to resolve the inflammation. 
Other studies elsewhere have shown that prednisolone treatment promotes an 
immunological state that favours immune regulation rather than inflammation through 
regulation of CD4+ T-cell proliferation (Luther et al., 2009). Interestingly, even though 
patients with ENL had a higher percentage of CD4+ and a lower percentage of  CD8+ 
T-cells before treatment, the percentage of these T-cells are within the normal range 
for Ethiopian population (Tsegaye et al., 2003).  However, the CD4/CD8 ratio obtained 
in our study for patients with ENL was higher than the reference value for apparently 
healthy Ethiopian adults (1.5:1). At the same time, the CD4+/CD8+ ratio of LL  patient 
controls was slightly lower than the normal value. Hence, it is logical to conclude that 
rather than the actual percentage of CD4+ and CD8+ T cells, the balance between the 
two T-cell subtypes is indeed associated with ENL reactions. Therefore, the higher the 
CD4+/CD8+ ratio the greater is the risk of developing ENL reactions. Increased CD4+ 
counts and CD4+/CD8+ T-cells ratio in 11 Indian ENL patients has been reported by 
Hussain et al. (2015) which is in agreement with the present finding. However, they 
did not look at the status of CD4+ T-cells count and CD4+/CD8+ ratio during and after 
treatment unlike the present study. Similar results have been reported by several 
studies (Modlin et al., 1983, Bach et al., 1983, Wallach et al., 1982, Mshana et al., 
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1983, Narayanan et al., 1984). Lymphocyte imbalance (CD4+and CD8+) has also been 
indicated in the progression of many other diseases elsewhere (Pichler et al., 2009, Lu 
et al., 2015).    
However, in addition to the CD4+/CD8+ T-cells ratio, other factors such as the 
expression pattern of costimulatory molecules on T-cells (CD28) and on antigen 
presenting cells (CD80/86) in patients with ENL need to be explored. Abnormal T-
cell co-stimulation and T-cell senescence has been indicated in the expansion of 
effector memory T-cells and thought to facilitate the breakdown of tolerance in 
inflammatory diseases such as anti-neutrophil cytoplasmic autoantibodies (ANCA)-
associated vasculitis (Wilde,et al 2010). In ANCA-associated vasculitis, CD28 was 
found to be downregulated on circulating and lesional CD4+ T- cells ( Moosing et al 
1998) and  CD4+CD28- T-cells  have been described as the major source of pro-
inflammatory cytokines (particularly IFN-γ and TNF-α) in Wegener’s Granulomatosis 
( Komocsi et al 2002). These authors have also shown that the severity of the disease 
was positively correlated with the increased proportion of CD4+CD28- T-cells. We 
found that patients with ENL had increased production of TNF-α and IFN-γ. However, 
the source/s of these pro-inflammatory cytokines has not been addressed in this study. 
Therefore, it is important to investigate the sources of these cytokines in patients with 
ENL.  
CD4+ and CD8+ T-cells in patients with ENL before and after treatment: The 
median percentage of CD4+ T-cells was significantly decreased during and after 
prednisolone treatment. On other hand, the median percentage of CD8+ T-cells was 
significantly increased following prednisolone treatment unlike CD4+ T-cells.  
Interestingly, the CD4+/CD8+ T-cells ratio was significantly deceased after 
prednisolone treatment implying the role of prednisolone in re-establishing the 
immune homeostasis by downregulating excessive CD4+ T-cell activation. Studies 
have shown that prednisolone reduces CD4+ T-cells (Shevach, 2009, Kasang et al., 
2016). A reduction of CD4+ to CD8+ T cells ratio in patients with rheumatoid arthritis 
when as little as 2.5mg of prednisone was administered every 6hrs  has been reported 
(Hepburn and Slade, 1987). Mshana et al. (1982 ) were the first to hypothesize that 
ENL is precipitated by an imbalance of T-lymphocyte subpopulations. According to 
this hypothesis, ENL has two phases: initiation, due to an imbalance in T-cell 
subpopulations with decreased suppressor cells and perpetuation.  Hence, the finding 
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of the imbalance of T-lymphocyte subpopulations (CD4+/ CD8+ ratio) in this study 
would support the initiation of ENL reaction in patients with lepromatous leprosy. The 
initiation of ENL reaction by hyper activation of T-cells further explained by the 
findings of the all of the viable bacterial load associated with release of soluble 
antigenic material at the site of bacterial degranulation in ENL patients  compared to 
the intact bacteria observed in non-reactional LL patients (Rees et al., 1965, Lahiri et 
al., 2008b). Hence, it seems that unlike in the LL patients, macrophages in ENL 
patients are activated and process the bacteria and hence fragmented and granular 
bacterial deposits seen in these patients.  The activation of macrophages by T-cells 
(most likely through IFN-Ƴ secretion) may produce inflammatory cytokines such as 
TNF-α and IL-1β (Arango Duque and Descoteaux, 2014) which could amplify the 
immune hyperactivation and hence tissue damage in ENL patients.   
CD25 and FoxP3 expression on CD4 and CD8 T-cells (ENL versus LL): This  
study has shown, that the level of CD25 expression on CD4+ T-cells was not 
significantly different in patients with ENL and LL controls before treatment but the 
relative expression of CD8+CD25+ was lower in patients with ENL than in LL patient 
controls. This could be explained by the fact that CD25 is  not only expressed on Tregs 
but also on activated T-cells as previously described  (Corthay, 2009). Hence, it is not 
appropriate to compare the level of phenotypic expression of CD25 on either CD4+ or 
CD8+ T-cells in patients with ENL and LL controls since the expression of CD25 could 
have different implications in these groups: activation in patients with ENL and 
regulation in non-reactional LL patients. 
Although transient FoxP3 expression in ex-vivo activated human T-cells has been 
reported by Wang et al. (2007), it remains as a good candidate marker for Tregs.  In 
this study, for immunophenotyping of T-cell subtypes, unstimulated PBMCs were 
used and hence our FoxP3 result is less likely to be over represented. The stimulation 
of CD4+CD25– human T-cells have shown to generate CD4+CD25+ T cells which can 
also express FoxP3 (R.Walker et al., 2003). The present result shows that the 
percentage of CD4+FoxP3+ T-cells in the PBMCs from patients with LL controls was 
more than twice the percentage of CD4+FoxP3+ T-cells in the PBMCs from patients 
with ENL before treatment.  However, a similar percentage of CD4+FoxP3+ was 
obtained in both groups after treatment.  On the other hand, the expression of FoxP3 
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in CD8+ T-cells was not significantly different in either groups before or after 
treatment.  To obtain a more characterized  FoxP3 population that has a regulatory 
property, CD127 was used in conjunction with CD25 as an additional marker as 
previously described by Liu et al. (2006). Therefore, the Tregs described here are better 
characterized than previous reports.  
CD25 and FoxP3 expression in patients with ENL before and after treatment: In 
our study, the expression of CD25 by CD4+ and CD8+ T-cells was not significantly 
different before and after prednisolone treatment.  This can be explained by the fact 
that CD25 can be expressed by activated as well as regulatory T-cells as previously 
described (R.Walker et al., 2003). Therefore, although the CD25 expression in CD4+ 
or CD8+ T-cells before and after treatment is comparable, it may not have the same 
role i.e. it could play with activation role before treatment and a regulatory role after 
treatment in the same patient.  
Interestingly, the expression of FoxP3 in CD4+ T-cells was significantly increased 
after prednisolone treatment. Thus, unlike the expression of CD25 in CD4+ T-cells, 
prednisolone upregulates the expression of FoxP3 in CD4+ T-cells and hence increases 
tolerance through immune suppression (Luther et al., 2009, Shevach, 2009). On the 
other hand, the expression of FoxP3 in CD8+ T-cells was not significantly different 
before and after prednisolone treatment. Hence, it appears that prednisolone does not 
affect the expression of FoxP3 in CD8+ T-cells.  
CD4+ and CD8+ Tregs (ENL versus LL):  in this study, the median percentage of 
CD4+ Tregs in patients with ENL was significantly lower (1.7%) than in LL controls 
(3.8%) before treatment. In addition, after treatment, the percentage of CD4+ Tregs in 
patients with ENL was increased to 3.2% while in LL controls it was decreased to 
2.5%. Tregs are the least studied T-cells in patients with ENL. There are only three 
cross-sectional studies by the same authors which had reported the reduced frequency 
of Tregs in patients with ENL compared to other clinical forms of the spectrum. The 
study by Attia et al (2010) has reported 1.2% of Tregs in the whole blood of patients 
with ENL compared to 2.8% in LL controls although the study was included only 6 
patients with ENL and 8 LL controls. Another study by the same group in 2014 
reported 1.15% and 2.8% of Tregs in the whole blood of 6 patients with ENL and 11 
non-reactional LL controls respectively.  Although these two studies are in agreement 
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with the findings here, they reported slightly lower percentages of Tregs in both groups 
than we found. There are several differences between the study of Attia et al and our 
study. Firstly, Attia et al included only 6 patients with ENL in both studies and the 
sample size was too small to draw a valid conclusion. They also obtained blood 
samples only once and they did not test the trend of Tregs at different time points. 
Secondly, case definitions for ENL were not mentioned and therefore, it is not clear 
how patients with ENL were recruited to the study. Thirdly, they used CD4+CD25high 
FoxP3+ as Treg markers. However, a consensus on the thresholds of CD25 expression 
needed to delineate Treg cells within the CD25high population is difficult to attain, and 
variations in FoxP3 expression within the CD25high population have been observed 
even in healthy individuals (Miyara et al., 2009). Hence, the definition of CD25 high 
and low is highly subjective which could lead to biased reports.  In addition, healthy 
individuals and other clinical forms of leprosy such as TT and T1R have also been 
used by many authors as a basis for comparison with ENL which leads to discordant 
results.  Only patients with either BL or LL will develop ENL reactions. However, not 
all patients with BL or LL develop ENL. Hence, for immunological studies either non-
reactional BL or LL patients are the appropriate controls for ENL patients.    
On the other hand, in this study, the median percentage of CD8+ Tregs was not 
significantly different in patients with ENL and LL controls before or after treatment. 
Hence, it appears that the development of ENL in patients with lepromatous leprosy is 
mainly associated with the decreasing frequency of CD4+ Tregs being unable to 
balance the excessive immune activation via CD4+ T-cells. Studies have shown that 
Tregs inhibit naïve CD4+ T-cell proliferation and differentiation and hence, 
downregulate immune activation (Shevach, 2009). Similar findings have also been 
reported elsewhere in immune-complex mediated autoimmune diseases such as 
Wegener’s granulomatosis (WG) (Morgan et al., 2010) and Anti-neutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (Marinaki et al., 2005, Wilde et 
al., 2010). 
CD4+ and CD8+ Tregs in patients with ENL before and after treatment: Our study 
is the first to present longitudinal data on the frequency of circulating CD4+ and CD8+ 
Tregs at different time points in patients with ENL. Furthermore, unlike previous 
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cross-sectional studies, we used more refined Treg defining markers (CD3+CD4+ 
(CD8+) CD25+FoxP3+CD127-/lo).   
Untreated patients with ENL cases had significantly lower percentage of CD4+Tregs 
which was considerably increased after prednisolone treatment.  On the other hand, 
the frequency of CD8+ Tregs did not show any significant difference before and after 
prednisolone treatment. Thus, our finding indicates that CD4+ Tregs are associated 
with ENL reactions but not CD8+ Tregs. Comparison of our finding with previous 
studies was not possible since our study is the first longitudinal study comparing the 
dynamics of Tregs at different time points in individual patients with ENL. However, 
similar findings have been reported in several independent studies elsewhere in 
autoimmune diseases. Nevertheless, it is not reasonable to make comparisons with 
autoimmune diseases since the aetiology of the ENL is different from that of 
autoimmune diseases. Studies in infection models described the significant 
immunosuppressive activity of Tregs for antigen-specific T-cells. Tregs are considered 
critical for suppressing immune responses to self-antigens and preventing 
autoimmunity and for regulating immunity to foreign antigens, especially those 
derived from pathogens that establish persistent infections (Belkaid and Rouse, 2005).  
It has also been shown that Tregs may protect from non-specific memory T-cell 
activation and potential tissue damage (Arram et al., 2014). Hence, the reduced 
frequency of CD4+ Tregs and the increased CD4+/CD8+ T-cells ratio in untreated 
patients with ENL may explain the possibility of induction of excessive immune 
activation owning to the pre-existing high load of bacterial antigens in patients with 
lepromatous leprosy.  
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SECTION 3:  MEMORY T-CELLS 
The ability of inflammatory cells to respond to pathogens is crucial for maintaining 
healthy conditions. In mammals, lymphocytes leave the circulation and migrate to 
secondary lymphoid organs, such as lymph nodes, where antigens are presented. After 
antigen encounter, guided delivery of immune cells to sites of inflammation 
orchestrates host defence. Adhesion molecules control both constitutive and 
inflammatory leukocyte trafficking. The selectins, especially L-selectin, play a pivotal 
role in the initial tethering of leukocytes to the endothelium and to other leukocytes. L 
selectin directs lymphocytes and neutrophils to sites of inflammation. Upon T-cell 
activation L-selectin is shed from the leukocyte surface (Sallusto et al., 2004, Raffler 
et al., 2005).  
In this study, the status of T-cell activation and the different subtypes of memory T-
cells were investigated. In leprosy, the different classes of memory T- cells have not 
been studied.  To my knowledge, it is for the first time that the different subtypes of 
memory T-cells and T-cell activation are phenotypically described in patients with 
ENL and LL. We are the first to study the status of T-cell activation in patients with 
ENL. Not only T-cell activation and the different classes of memory T-cells are 
described but also the changes of these immune cells over time before, during and after 
prednisolone treatment were investigated. Therefore, our present data will provide 
basic information for future studies involving T-cell activation and memory T-cells in 
ENL.  
Activated T-cells (ENL versus LL):  In our study, patients with ENL had 
significantly higher CD3+, CD4+ and CD8+ activated T-cells than LL controls before 
treatment. However, after prednisolone treatment, T-cell activation was not 
significantly different in patients with ENL and LL controls except for the transient 
activation of CD8+ T-cells. This result evidences of T-cell activation in patients with 
ENL reactions.  In vitro stimulation of PBMCs from patients with ENL reaction with 
M. leprae whole-cell sonicate has shown an increased T-cell response as assessed by 
IFN-γ and TNF-α production. Excessive T-cell activation as a cause of tissue damage 
in several inflammatory diseases have been  described in many studies  (Baniyash, 
2004, Park and Kupper, 2015). The result described here evidence of T-cell activation 
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in patients with ENL, implying the involvement of T-cell activation in the 
pathogenesis of ENL.   
Activated T-cells in patients with ENL before and after treatment: In this study 
changes in activated T-cells was also investigated before, during and after 
prednisolone treatment of patients with ENL. The expression of CD3+, CD4+ and 
CD8+ activated T-cells were significantly reduced during and after prednisolone 
treatment. The reduction of activated T-cells following corticosteroid treatment may 
be explained by the immuno-suppressive activity of prednisolone. Although studies 
showing the effect of prednisolone treatment on T-cell response in leprosy reactions is 
lacking, several studies in other inflammatory diseases have shown the suppressive 
effect of prednisolone on the T-cell response (Hepburn and Slade, 1987, Shevach, 
2009, Kasang et al., 2016). Consequently, our present findings provide evidence that 
the effect of prednisolone treatment of patients with ENL could be through supressing 
T-cell responses.   
Effector memory T-cells (ENL versus LL):  The median percentage of CD3+, CD4+ 
and CD8+ T-cells expressing  effector memory T-cells in PBMCs of patients with ENL 
were significantly high compared to LL controls before treatment. Such a difference 
was not observed after prednisolone treatment of patients with ENL. This implies that 
in patients with ENL, there is a continuous activation of T-cells. This continuous T-
cell activation could lead to an excess antibody-antigen complex formation but  
insufficient to clear bacilli from lesions (Cooper et al., 1989). This means the rate of 
immune-complex formation is greater than the rate of immune-complex clearance 
which leads to further tissue damage through recruitment of inflammatory molecules 
to the site of deposition. In lepromatous leprosy, there is high load of bacilli.  The 
macrophages are laden with this intact bacilli but unable to process and present to T-
cells for further action.  LL patients are also characterized by the presence of high 
antibody titre although these antibodies play little or no role to protect the 
multiplication of M. leprae in these patients. As described in the preceding sections, 
spontaneous activation of T-cells could lead to the macrophage activation or B-cell 
activation or both.  Macrophage activation results in the processing of the bacilli and 
releasing the processed bacterial components which further activate other immune 
cells. The activation of B-cells by T-cells could produce functional antibodies which 
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form immune-complex with the already accumulated bacterial antigens. However this 
scenario is less likely as it is confirmed in this study that the different subtypes  of B-
cells did not significantly different  in ENL and LL patients. Whichever the activation 
takes place, if excess immune-complex is formed due to the presence of excess 
antigens in the body, it leads to more immune-complex formation than immune-
complex clearance and hence, some immune-complexes deposit in tissues and often 
induce an inflammatory responses, and can cause tissue damage.  The causes of tissue 
damage could be due to the action of complement cleavages which induces the release 
of tissue damaging granules such as histamine or the recruitment of   inflammatory 
cells such as neutrophils and macrophages into the tissue. However, this assumption 
need further study to give definitive evidence.  Previous studies have suggested that 
human effector memory T-cells (TEM) display characteristic sets of chemokine 
receptors and adhesion molecules that are required for homing to inflamed tissues and 
they have an immediate effector function (Kaech et al., 2002, Sallusto et al., 2004). 
This situation could amplify the immune response and hence further aggravate tissue 
damage in a vicious circle.  
Effector memory T-cells in patients with ENL before and after treatment:  A 
kinetic analysis of the expression of effector memory T-cells in the PBMCs from 
patients with ENL before, during and after prednisolone treatment showed that the 
median percentage of effector memory T-cells was decreased from 27% before 
treatment to 8% after treatment with an effect size of 20%. It has been described in 
previous sections that effector memory T-cells rapidly differentiate to effector T-cells 
upon antigenic stimulation. The consequence of excessive expression of effector 
memory T-cells is detrimental to tissue damage (Farber et al., 2014). In healthy 
individuals, effector T cells do not express CCR7 or CD62L and do not home to lymph 
nodes (Flynn and Gorry, 2014). A breakdown in the compartmentalization of such 
effector T cells is predicted to have detrimental consequences for the immune system. 
Hence, the fact that an increased percentage of effector memory T-cells in patients 
with ENL was percent before treatment suggests that effector T-cells take part in the 
process of tissue damage observed in these patients.     
Naïve T-cells (ENL versus LL):  :  Interestingly, the median percentage of naïve T-
cells expression in CD3+, CD4+ and CD8+ T-cells in the PBMCs of patients with ENL 
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was significantly low compared to LL controls before treatment implying that T-cells 
from patients with ENL have more antigenic exposure than those from LL. It is 
important to note that patients with ENL had LL before they developed ENL during 
which a high percentage of naïve T-cells is expected since higher percentage of naïve 
T-cells were investigated in this study. Following the development of ENL, the 
percentage of naïve T-cells drops to below 30%. This implies that either those 
previously naive T-cells became responsive and able to recognise their cognate antigen 
or the newly produced T-lymphocytes during the onset of ENL reactions are able to 
recognise and respond to the existing M. leprae antigens unlike in lepromatous leprosy.  
It is an established fact that despite the high bacterial load in patients with lepromatous 
leprosy, the cell-mediated immune response is virtually absent (Godal et al., 1971, 
Godal et al., 1972). In addition to a specific loss of cell-mediated immune response 
against M. leprae in these patients, a relative impairment of the ability of lymphocytes 
to react in vitro has also been reported. Furthermore, lymph nodes from patients with 
lepromatous leprosy show a deficiency of these cells in those areas associated with the 
development of cell-mediated immune responses (Godal et al., 1971, Godal et al., 
1972, Myrvang et al., 1973, Kaplan et al., 1985, Bobosha et al., 2014b). Therefore, the 
significantly reduced median percentage of naïve T-cells in blood from patients with 
ENL reaction provides an evidence of T-cell responsiveness in patients with ENL. 
This means that unlike in LL patients, the naïve T-cells in ENL patients are primed in 
recognition of the M. leprae antigen.      
Naive T-cells in patients with ENL before and after treatment: The median 
percentage of naive T-cells were significantly increased after prednisolone treatment 
of patients with ENL. The percentage of naive T-cells in untreated patients with ENL 
reactions was less than 30% and was increased to nearly 50% after treatment.  Previous 
studies have shown that prednisolone treatment increases in a dose-dependent manner 
the percentage of naive T-cells in experimental mice. Hence, the finding of high 
percentages of naïve T-cells after prednisolone treatment of patients with ENL may be 
explained by the fact that prednisolone resolves inflammation at least partly by 
increasing the percentage of naïve T-cells which concurrently reduce the percentage 
of activated T-cells.   
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SECTION 4:  MEMORY B-CELLS   
Memory B-cells are subtypes of B-cells that are formed within germinal centres 
following infection. They proliferate and differentiate into antibody producing plasma 
cells also called effector B-cells in response to re-infection.  Memory B-cells rapidly 
differentiate into plasmablasts that produce class-switched antibodies which are 
capable of clearing the infection far more quickly than naive B-cells (Kurosaki et al., 
2015). The different classes of memory B-cells have been studied in various chronic 
viral infections such as hepatitis and HIV and several autoimmune diseases (Moir and 
Fauci, 2009, Oliviero et al., 2011). The role of B-cells in the pathogenesis of ENL has 
been speculated in several studies but has never been studied.  For the first time, we 
studied B-cells and the memory B-cell sub-types in patients with ENL and LL controls 
at different time points (before, during and after treatment) to investigate the dynamics 
of these cells during the course of prednisolone treatment.  
Total B-cells (ENL versus LL): The percentage of total B-cells was not significantly 
different in the two groups before treatment. However, after treatment, the proportion 
of B-cells was significantly reduced from 9.5% to 5.7% in patients with ENL. The 
reduction of B-cells after prednisolone treatment of patients with ENL could be either 
transitory or associated with the subsiding of the ENL reaction which needs further 
investigation. The success of Rituximab to deplete B-cells for the treatment of 
rheumatoid arthritis has stimulated investigation of its effects in several other immune 
disorders, and considerable interest in the potential of drugs that can modulate B-cell 
function for the treatment of such diseases (Edwards et al., 2004). Thus, the finding of 
reduced B-cells after ENL subsides poses the question whether depleting B-cells could 
be effective in treatment of ENL. Therefore, investigating the role of B-cells in the 
pathogenesis of ENL is needed in the future studies of ENL.  
 Naive B-cells (ENL vs LL):  Patients with ENL had a significantly lower naïve B-
cells 97.6.0%) than LL controls (84.6%) before treatment (P≤0.05; L-H=6.75). The 
percentage of naïve B-cells was not significantly different in the two groups after 
treatment.  This shows that patients with LL not only have high a frequency of naïve 
T-cells but also have a higher frequency of naïve B-cells than patients with ENL.  
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Activated and resting memory B-cells (ENL versus LL):  A significance difference 
was not observed with regard to the frequency of resting memory B cells (RM) in the 
two groups before treatment. However, the median percentage of activated memory 
B-cells (AM) was significantly higher in patients with ENL (2.1%) than in LL controls 
(1.4%) before treatment. Several studies have shown that activated memory B-cells 
are increased in patients with disease flares in systemic lupus erythematosus (SLE) 
(Jacobi et al., 2008) and rheumatoid Arthritis (Adlowitz et al., 2015). However, the 
biology of ENL and autoimmune diseases is different and whether activated memory 
B-cells are undesirable or not in the pathogenesis of ENL should be further 
investigated to arrive at a conclusive evidence.  
Tissue-like memory B-cells (ENL versus LL):  Patients with ENL had higher 
percentage of tissue-like memory (TLM) B-cells (9.3%) than LL controls (4.8%) 
before treatment. Thus, our finding implies that TLM could have a role in the 
pathogenesis of ENL and this is a new exciting area for further investigation. A similar 
increase in the proportion of tissue-like memory B-cells has been reported in other 
chronic infections such as in hepatitis C virus and malaria infections, and in certain 
autoimmune diseases (Weiss et al., 2009, Charles et al., 2011).  Several studies have 
indicated that TLM  B-cells represent the exhausted state of B-cells since they express 
several inhibitory receptors, including the immunoreceptor tyrosine-based inhibitory 
motif (ITIM)-containing inhibitory receptor Fc receptor-like protein 4 (FcRL4) 
(Barber et al., 2006).  TLM B-cells show a reduced tendency to proliferate in response 
to cognate antigen (Moir et al., 2010). The expression of FcRL4 on human B-cell lines 
disrupts immune synapse formation and blocks antigen induced  B-cell receptor (BCR) 
signalling (Amu et al., 2007).  They also express not only FcRL4 but also a number of 
other inhibitory and chemokine receptors that would reduce the likelihood of B and T 
cell interaction according to Moir et al. (2008). Kardava et al. have shown that a 
specific siRNA knockdown of FcRL4 and other inhibitory receptors may lead to a 
rescue of Ig secretion and proliferation in these tissue-like memory B-cells (Kardava 
et al., 2011). Since the identification of an exhausted population of B-cells (TLM) 
phenotypes have been witnessed in other chronic diseases such as malaria and 
hepatitis-C (Weiss et al., 2009, Charles et al., 2011), it appears that the higher 
frequency of TLM B-cells in ENL could alter the B-cell/T-cell interaction in these 
patients through blocking B-cell receptors and this hypothesis could be a fertile area 
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for future investigation. Once, this hypothesis is proved, the search for the B-cell 
immunomodulators that safely overcome this exhaustion phenotype may be necessary 
in order to develop proper immune response to this complicated disease.  
SECTION 5:  IN VITRO CYTOKINES PRODUCTION AND GENE 
EXPRESSION   
To investigate the in vitro cytokine response to M.leprae, PBMCs from patients with 
ENL and LL controls were cultured with M.leprae whole-cell sonicates (MLWCS), 
Phytohaemagglutinin (PHA) or no stimulation for 6 days. The cytokine levels in 
culture supernatants were determined using sandwich ELISA specific to TNF-α, IFN-
γ, IL-β, IL-6, IL-8, IL-17A and IL-10.  The gene expression of these cytokines in whole 
blood and skin biopsies from patients with ENL and LL controls before and after 
treatment was also investigated.   
The in vitro cytokine response of PBMCs from patients with ENL and LL controls to 
M. leprae antigen and its gene expression in blood and skin biopsy samples were 
compared before, during and after treatment using a t-test. Some of the key findings 
are described in the following paragraphs.     
TNF-α :  TNF-α is a cell signalling cytokine involved in systemic inflammation and 
it is one of cytokines that contribute to the acute phase reaction. However, excessive 
production of TNF-α can cause tissue injury. The in vitro response of TNF-α to 
M.leprae whole cell sonicate (MLWCS) in the PBMCs from patients with ENL and 
LL controls was investigated before and after treatment. The mean production of TNF-
α in response to M. leprae antigen was significantly higher (83.6.4 ±18.8, SE pg/mL) 
in the culture supernatants of PBMCs from patients with ENL than from LL patient 
controls (19.4pg/mL ±10.44) before treatment. However, TNF-α production was not 
significantly different in the groups after treatment.  Similar findings have been 
reported by several studies (Barnes et al., 1992a, Santos et al., 1993, Sampaio et al., 
1998b). On the other hand, the detection of TNF-α in plasma or serum samples from 
patients with ENL has not been consistently reported. Some authors did not find a 
significant difference in patients with ENL and LL controls (Lockwood et al., 2011, 
Madan et al., 2011a). Others reported that increased TNF-α production occurred 
during corticosteroid treatment and decreased after treatment (Moubasher et al., 1998a, 
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Haslett et al., 2005, Villahermosa et al., 2005, Stefani, 2009). Interestingly, an 
upregulation of TNF-α production after thalidomide treatment of patients with ENL 
was also reported by Haslett et al. (2005). These authors justified the increasing 
production of TNF-α during thalidomide treatment as an indication of immune 
stimulation. However, thalidomide and prednisolone may have different effect on the 
TNF-α. The variation of the results in various studies can be attributed to several 
factors such as experimental design, sample size, ENL definition, assay sensitivity and 
assay methods.  
In our study, the mRNA gene expression for TNF-α in blood and skin biopsies from 
patients with ENL was significantly upregulated compared to in LL controls before 
treatment. After treatment, the level of gene expression for TNF-α   in blood and skin 
biopsy samples of patients with ENL was significantly decreased. Similar findings 
have been reported by previous studies (Barnes et al., 1992b, Sampaio et al., 1998b, 
Moraes et al., 1999b, Teles et al., 2002). On the other hand, the absence of any 
significant difference regarding the gene expression of TNF-α in the skin biopsies from 
patients with ENL and LL controls was also reported by Yamamura et al. (1992).  
Thus, our present kinetic studies confirmed that TNF-α is certainly increased during 
ENL reactions in the same individual both in vitro (following stimulation of the cells 
with M.leprae whole cell sonicate) and in vivo (increased TNF-α gene expression in 
situ). Hence, our data imply that TNF-α is involved in the pathogenesis of ENL and it 
may be of use for the diagnosis of ENL. Investigating the sources of TNF-α 
(identifying the major immune cells producing TNF-α) in the pathogenies of ENL may 
also be important to explore alternative therapeutics in the future. 
IFN-γ:  IFN-γ is a major macrophage activator and a known inducer of macrophage 
TNF-α. It increases antigen presentation and lysosome activity of macrophages. 
However, over expression of INF-γ has been  associated with the pathogenesis of  a 
number of inflammatory and autoimmune diseases (Lee et al., 2012). 
In the current study, the mean production of IFN-γ in response to M. leprae antigen 
was significantly higher (1361pg/mL ± 309.6) in the culture supernatants of PBMCs 
from patients with ENL than from LL patient controls (280.1pg/mL ± 309.6) before 
treatment (P≤0.05). However, IFN-γ production was not significantly different in the 
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groups after treatment of patients with ENL.  Previous independent studies have also 
reported an increasing in vitro production of IFN-γ in untreated patients with ENL to 
the response of M.leprae stimulation (Cooper et al., 1989, Sreenivasan et al., 1998, 
Iyer  et al., 2007).  IFN-γ mRNA gene expression in the blood and skin biopsies from 
patients with ENL was significantly upregulated compared to in LL controls before 
prednisolone treatment. After treatment, the level of IFN-γ gene expression in the 
blood and skin biopsy samples from patients with ENL was significantly decreased.  
Similar findings have been reported by Moraes et al. (2000) Iyer  et al. (2007).  
It should be noted that although fewer investigations have focused thus far on the role 
of IFN-γ, in contrast to the weight given to TNF-α, the results are more consistent and 
indicate an important role of IFN-γ in the immunopathology and occurrence of ENL. 
It worth to mention that administration of recombinant IFN-γ to patients with 
lepromatous leprosy led to the development of ENL reactions in 60% of the patients 
over a 6-7 months period compared with an incidence of 15% per year with multiple 
drug therapy alone (Sampaio et al., 1992). Previous studies have demonstrated that 
monocyte/macrophage TNF-α production can be enhanced by the synergistic effect of 
IFN-γ  (Billiau, 1996). In addition, IFN-γ priming of peripheral blood monocytes  from 
patients with leprosy has been demonstrated to enhance TNF-α production, both in 
vivo and in vitro (Sampaio et al., 1992). The mechanism by which IFN-γ induces ENL 
reactions in patients with leprosy is suggested to be through priming of monocytes, 
resulting in enhanced TNF-α production (Sampaio and Sarno, 1998).   
IL-6:   In the present study, we found that the in vitro response of IL-6 production was 
substantially higher in patients with ENL than in LL controls before treatment. IL-6 
mRNA gene expression in the blood and skin biopsy samples was also significantly 
upregulated in patients with ENL than in LL controls. The in vitro production and gene 
expression of this cytokine was decreased after prednisolone treatment of patients with 
ENL and a significant difference was not observed in the two groups after treatment. 
However, its gene expression in the skin samples was not appreciably decreased in 
patients with ENL after prednisolone treatment. This suggests that although the 
systemic symptoms of ENL subside after treatment, there could be an ongoing immune 
response locally in the skin lesions which could take a longer time to establish 
immune-homeostasis.  Similar findings have been reported by Yamamura et al. (1992) 
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and  (Moraes et al. (1999b), 2000, 2001).  IL-6 is an interleukin that acts as both a pro-
inflammatory and an anti-inflammatory cytokine which is secreted by T 
cells and macrophages (Scheller et al., 2011). It is an important cytokine mediating 
fever and  the acute phase response through its ability of crossing the blood-brain 
barrier and initiating the synthesis of  prostaglandin E2 (PGE2) in the hypothalamus 
thereby changing the body’s temperature set point (Banks et al., 1994). Hence, it is 
sensible to assume that higher levels of IL-6 production could contribute to the 
development of ENL reactions in non-reactional lepromatous leprosy patients mainly 
owing to the potent pro-inflammatory role of IL-6 and its capacity to stimulate 
antibody production. The increased production of IL-6 in ENL reactions due to 
polymorphisms in the genes encoding the cytokine have been suggested (Sousa et al., 
2012).   Based on the multiple effects of IL-6 on the control of innate and adaptive 
immune responses, its potential contribution to the immunopathogenesis of ENL 
reaction needs to be explored further.  
IL-8:  IL-8 (CXCL8) is a chemokine produced mainly by macrophages and plays a 
key role in inflammation in neutrophil recruitment and inducer of phagocytosis. 
Studies have shown that anti-IL-8 treatment prevent neutrophil-dependent tissue 
damage as well as neutrophil infiltration in several types of acute inflammatory 
reactions, including lipopolysaccharide (LPS)-induced dermatitis, LPS/IL-1-induced 
arthritis and acute immune complex-type glomerulonephritis (Harada et al., 1994).  
In this study, higher in vitro production of IL-8 to the response of PBMCs stimulation 
to M.leprae was obtained in patients with ENL than in LL controls before, during and 
after prednisolone treatment. Unlike the other cytokines studied, IL-8 production did 
not decrease during and after prednisolone treatment of patients with ENL. The mRNA 
gene expression of IL-8 both in the blood and skin biopsy samples was also 
significantly upregulated in patients with ENL before, during and after prednisolone 
treatment. A Few studies have investigated the role for serum IL-8 in the 
immunopathogenesis of ENL by comparing its production and gene expression.  IL-8 
mRNA upregulation in untreated patients with ENL has been reported by few studies 
(Yamamura et al., 1992) and  in vitro production (Goulart et al., 2000) and both studies 
are in agreement with our finding.   
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Thus, the finding of increased IL-8 production as well as IL-8 mRNA gene expression 
in the blood and skin lesions from patients with ENL suggest a potential role for this 
chemokine in the pathogenesis of ENL.  Hence, exploring the potential role of IL-8 in 
the immunopathogenesis of ENL may provide a valuable information in the diagnosis 
and treatment of ENL. 
IL-17:  IL-17A is an immunoregulatory cytokine capable of promoting the generation 
of pro-inflammatory cytokines and chemokines, which leads to the attraction of 
neutrophils and macrophages to the inflammation site (Jin and Dong, 2013). The in 
vitro production of IL-17A in PBMC samples and IL-17 mRNA gene expression in 
the blood and skin biopsy samples from patients with ENL was significantly increased 
before treatment and declined after prednisolone treatment.  The upregulation of IL-
17A before and after thalidomide treatment of ENL was reported by Martiniuk et al. 
(2012).  The number of patients involved and the assay controls (such as the 
housekeeping genes and patient controls) used in that study contribute to the observed 
differences with our results.  Martiniuk et al. performed a gene expression study in 7 
ENL biopsies pre- and post-treatment with thalidomide however, not only was a larger 
group of 46 patients with ENL used here but also IL-17A mRNA gene expression was 
studied in blood and skin biopsy samples before and after prednisolone treatment.  
More importantly, in the Martiniuk et al. study, controls were not included and also 
thalidomide and prednisolone may have different effect on IL-17 production. 
The finding of increased IL-17A production and its mRNA gene expression in patients 
with ENL in the present study shows the involvement of IL-17A in the pathogenesis 
of ENL reaction. Hence, understanding the exact role of this cytokine in ENL reaction 
will benefit the development of novel immune modulators that reduce the 
inflammatory tissue damage occurring in patients with ENL.       
IL-10:   IL-10 is a well-known cytokine involved in downregulating macrophage 
functions.  IL-10 has been shown to inhibit cytokine synthesis by monocytes, namely 
TNF-α, IL-1, IL-6, IL-8, IL-12 (Sampaio et al., 1998b, Sampaio et al., 1998a). Thus, 
the finding of decreased IL-10 production as well as IL-10 gene expression in 
untreated patients with ENL implies the loss of control over the above mentioned pro-
inflammatory cytokines which exacerbates ENL reactions. 
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The in vitro production of IL-10 in response to M.leprae stimulation in the PBMCs of 
patients with ENL was significantly lower than in LL controls before treatment. After 
prednisolone treatment of ENL patients, IL-10 production was significantly increased 
and it was higher than the value obtained in LL controls. The present  result is in 
agreement with (Sampaio et al., 1998b). Although IL-10 mRNA gene expression in 
the blood samples before and after treatment in patients with ENL and LL controls did 
not reveal a statistically significantly different result, the longitudinal comparison in 
patients with ENL has shown significantly increased IL-10 mRNA gene expression 
after prednisolone treatment to similar to the vitro IL-10 production. On the other hand, 
unlike the blood samples, the gene expression in skin biopsy samples was significantly 
decreased before treatment in patients with ENL compared to LL controls and 
considerably increased after prednisolone treatment. Quantitative IL-10 mRNA gene 
expression studies were not available to compare with the results obtained in this study.  
Variable and inconstant reports have been published on serum or plasma IL-10 
production in patients with ENL. An Indian study reported  increased IL-10 production 
in patients with ENL than in patients with T1Rs (Moubasher et al., 1998b). However, 
the authors made a comparison between patients with ENL and T1Rs taking T1Rs as 
the controls. A similar report was made by Madan et al. (2011b). Others studies failed 
to detect any differences in serum IL-10 between patients with ENL and LL controls 
(Iyer et al., 2007a, Stefani et al., 2009, Attia et al., 2014) or in IL-10 mRNA in biopsy 
skin specimens (Moraes et al., 1999a). The variable and inconsistent reports on IL-10 
can be accounted for by several factors such as sample size, case definitions, inclusion 
and exclusion criteria, assay methods, assay specificity and sensitivity and use of 
appropriate case controls.  
.   
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SECTION 6. CIRCULATING C1-Q AND ITS GENE EXPRESSION  
The amount of circulating C1q in the plasma of patients with ENL and LL was 
quantified using a C1q ELISA.  The gene expression of C1q was also quantified in 
blood and skin biopsy samples of these patients before and after treatment.   
Patients with ENL had significantly lower circulating concentrations of C1q than LL 
controls before treatment.  However, after treatment, the amount of circulating C1q 
was not significantly different in both groups. A similar result has been reported in an 
earlier study by de Azevedo and de Melo (1966). The decreased frequency of 
circulating C1q in the sera of patients with ENL could be due to its utilisation by the 
antigen-antibody complex formation. Similar decreased serum complement levels 
have been observed in other immune complex disorders such as acute 
glomerulonephritis (Lange et al., 1960, Lewis et al., 1971, Ohi and Tamano, 2001) and 
acute systemic lupus erythematosus (SLE) (Baatrup et al., 1984, Grevink et al., 2005). 
However, the pathophysiology of autoimmune disorders and infectious diseases are 
different. In autoimmune disorders, the finding of an antigen-antibody complex may 
be conclusive enough since the autoantibodies are formed as part of the pathogenesis. 
However, in any infectious diseases like ENL, the finding of antigen-antibody is part 
of the host defence mechanism against the infection. Circulating immune complexes 
(ICs) are produced continuously in response to infection and immune reactions to 
foreign antigens. In such cases most ICs are of little pathologic significance because 
they are rapidly cleared. This cycle of IC formation and clearance is an important 
component of acquired immunity, ensuring removal or processing of antigens 
(Schifferli and Taylor, 1989, Stokol et al., 2004, Mayadas et al., 2009).  However, the 
failure of immune-complex clearances leads to immune-complex deposition. Immune-
complex deposition initiates a complex cascade of events, which culminate in the 
recruitment and activation of neutrophils and macrophages which in turn produce pro- 
inflammatory cytokines and other inflammatory molecules causing tissue damage.   
Therefore, to conclude the antigen-antibody complex (immune-complex) formation as 
the aetiology of the ENL, one has to prove the failure of antigen-antibody clearance or 
clearly demonstrate immune-complex deposition in the skin lesions.        
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The gene expression levels of C1q A, B and C in the blood and skin biopsy samples 
from patients with ENL and LL controls were not significantly different before 
treatment. However, after treatment, the gene expression levels of C1q A, B and C 
were increased in the blood samples.  C1qA mRNA expression was increased in the 
skin biopsy samples of patients with ENL compared to LL after treatment. On the other 
hand, The C1qC mRNA expression was decreased in skin biopsy samples of patients 
with ENL compared to LL patient controls after treatment. Studies on C1q gene 
expression in leprosy are not available to make comparisons with these results.  
In this study, the increased C1q production in the plasma samples of patients with ENL 
after treatment could be due to increased C1q gene expression in blood samples of 
these patients after treatment. The lower quantity of circulating C1q in the plasma may 
be act as a positive feedback for C1q gene expression. It has been reported that the 
inflammatory cytokines such as IFN-γ and IL-6 increase C1q production by 
macrophages (Lu et al., 2008). Several studies indicated that C1q can modulate 
dendritic cell maturation, pro-inflammatory cytokine production, and T- and B-cell 
responses in addition to its classical function to initiate complement activation (Fraser 
et al., 2006, Castellano et al., 2007, Nayak et al., 2012). Recently, increased circulating 
C1q and C1qC gene expression in patients with active tuberculosis compared to 
healthy controls and individuals with latent TB infection has been reported by Cai et 
al. (2014) indicating its potential as a biomarker to discriminate active TB from latent 
TB cases . Therefore, C1q could be a potential diagnostic marker for ENL in the same 
way, which necessities further investigation.   
  
313 
   
SECTION 7.  THE LEVELS OF ANTI PGL-1, LAM AND AG85 
ANTIBODIES 
The levels of anti ND-O-BSA (PGL-1), LAM and Ag85 antibodies were measured by 
ELISA in the plasma samples of 30 patients with ENL and 22 non-reactional LL 
controls before and after prednisolone treatment of ENL cases. The first sample was 
obtained from each patient before administering MDT in either groups.  The laboratory 
assays were done at John Spencer’s laboratory, Colorado State University, CO, USA.  
PGL-1: The PGL-1 levels were not significantly different in patients with ENL (OD= 
1.430 ± 0.1281) and LL controls (1.341 ± 0.1415) (P>0.05) before treatment. 
However, after treatment the level of PGL-1 was significantly decreased (OD=1.183 
± 0.1333) in patients with ENL compared to LL patient controls (OD= 2.091 ± 0.1081) 
(p < 0.0001).  A study in Brazilian leprosy patients including 5 untreated ENL cases, 
13 non- reactional LL patients and 13 other clinical forms of leprosy has reported that 
the levels of PGL-1 were not significantly different in ENL and LL patients (Silva et 
al 2007) which is in agreement with the present result.  The finding of lower level of 
PGL-1 in ENL cases than in the corresponding LL controls after prednisolone 
treatment of ENL cases in this study could be explained by the effect of prednisolone 
treatment. Previous studies have shown that the level of PGL-1 was  significantly 
decreased in ENL cases treated with prednisolone compared to LL  patients  (Raju et 
al., 2014). In a comparison made between acute and chronic ENL cases, acute ENL 
cases had higher levels of PGL-1 than chronic ENL cases before treatment (P≤0.001).  
The differences in the levels of PGL-1 in acute and chronic cases could be attributed 
to the clinical condition of these patients and their treatment status.  Higher rate of M. 
leprae multiplication is expected in untreated acute ENL cases than in chronic cases.  
PGL-1 is synthesised by viable and actively dividing M. leprae (Lobato et al., 2011, 
Spencer and Brennan, 2011).  Therefore the finding of a higher anti-PGL-1 antibody 
titre in acute ENL than in chronic ENL in this study indicates the higher rate of PGL-
1 synthesis in acute ENL cases than in chronic ENL cases. Similar findings has been 
reported by Bhoopat et al. (1991). After treatment, the levels of PGL-1 still remain 
lower in chronic ENL cases than in acute ENL cases this could be due to the 
continuation of prednisolone treatment in chronic cases as described above.   
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LAM:  Similar to PGL-1, the levels of LAM   were not significantly different in 
patients with ENL (OD=1.191 ± 0.09790) and LL controls (OD= 1.116 ± 0.1183) 
before treatment (P>0.05).  However, after prednisolone treatment of ENL cases the 
levels of LAM were lower in ENL cases (OD= 1.095 ± 0.08101) than in LL controls 
(OD=1.592 ± 0.08426) (P≤0.0001). The reduction of the level of LAM in ENL cases 
could be due to the effect of prednisolone treatment as previously reported by Raju et 
al (2104).  
Ag85 (ML2028): Antigen 85 (Ag85) complex proteins are major secretory products 
of Mycobacterium.  Like LAM, similar level of Ag85 was measured in the plasma 
samples from patients with ENL (OD=1.154 ± 0.1218) and LL controls (OD =1.134 ± 
0.1360). After prednisolone treatment of ENL cases the level of Ag85was lower in 
ENL cases (OD= 0.9713 ± 0.1164) than in LL controls (OD= 1.536 ± 0.1108) 
(P≤0.001).  The differences in the levels of Ag85 after treatment in the two groups 
might be due the effect of prednisolone treatment of ENL cases. However, this 
assumption should be further investigated and supported by definitive evidence.   
In this study, we did not included healthy endemic controls and hence it was not 
possible to extrapolate the results obtained to the general population. The purpose of 
the study was to compare the levels of anti ND-O-BSA (PGL-1), LAM and Ag85 
antibodies obtained from patients with ENL with that of non-reactional LL controls. 
The assumption was at least one of these antibodies could be used to predict who is 
going to develop ENL among those non-reactional LL patients. Nevertheless, the 
exclusion of endemic health controls can be considered as one of the limitations of the 
study.   
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What drives ENL?  A stepwise illustration has been give below to show what drives 
ENL (Figure 7.1A-D)  
 
Figure 7.1A: Naïve T-cells activated and polarized to Th1 through IL-12 production 
by INF-Ƴ dependent Tregs downregulation. Then, Th1 T-cells produce INF-Ƴ and IL-
6 to activate the macrophages which are already Landen by M.leprae. Activated 
macrophages in turn present M.leprae to Th1 cells for further process.  
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Figure 7.1B.   The activation of macrophages and naïve T-cells lead to the activation 
of Th-17 through IL-6 and IL-1β production. Pro-inflammatory cytokines and other 
inflammatory molecules released to the environment by Th1, macrophages and Th17 
produce excessive immune response. Furthermore, macrophages process M.leprae and 
release components of M.leprae to the external environment which could trigger 
antigen-antibody formation.    
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Figure 7.1C:  M.leprae components released from the macrophages form antigen-
antibody binding.  In patients with lepromatous leprosy (LL) excess antibodies are 
produced although these antibodies do not control the multiplication of M.leprae in 
the host cells.  The formation of antigen-antibody binding recruits complement C1-q 
and results in antigen-antibody complex formation which in turn amplify the immune 
activation through IL-4 production by naïve T-cells to activate Th2 cells.  Then, Th2 
cells initiate the production of plasma B-cells through IL-4 and IL-6 cytokines. Plasma 
B-cells trigger continues production of immunoglobulins (Ig) and these 
immunoglobulins are used for the antigen biding which are released from the 
macrophages.   
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Figure 7.1D: The formation of antigen-antibody complex recruits neutrophils 
resulting in immune-complex formation which leads to excessive immune response.  
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Figure 7.1E. Illustration of the possible immunopathogenesis of ENL based on the 
present findings (Figure 71A-D combibed). 
Based on the finding of this study, the immunepthaogenesis of ENL can be illustrated 
using the following key steps:  
1. Spontaneous activation of T-cells leading to activation of macrophages which are 
already loaded with intact M. leprae. Then, the activation of macrophages produce 
three key events: processing M. leprae and releasing of the processed antigens; 
antigen presentation to Th1 and production of pro-inflammatory cytokines such as 
IFN-Ƴ and TNF-α and other inflammatory molecules.  The causes of spontaneous 
T-cell activation should be investigated in the future.  
2.  Antigen presentation to Th1 stimulates Th1 to produce chemokines which recruits 
macrophages to the site of antigen deposition, pro-inflammatory cytokines (IFN-
Ƴ, TNF-α) and other inflammatory mediators which increase expression of 
vascular adhesion molecules. 
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3.  The processed and released antigens are bind to the pre-synthesized antibody 
leading to antigen-antibody complex formation which in turn recruits C1q 
complement and hence immune-complex formation. Following the immune-
complex formation, neutrophils will be recruited to the site of immune-complexes.  
4. Once immune-complex is formed, it amplifies the immune response which leads 
to aggressive antigen presentation, immunoglobulin synthesis and activation of 
other inflammatory T-cells.  
5. The pro-inflammatory cytokines and other inflammatory molecules released from 
macrophages, Th17 and Th1 and the immune-complex formation beyond 
clearance lead to tissue damage as sketched above (Figure 7.1).  
  
321 
   
CHAPTER 8: CONCLUSIONS AND RECOMMENDATION 
8.1. CONCLUSION                                     
Our understanding of the causes of ENL remains poor. The long-standing hypothesis 
of immune complexes as the causes of ENL has not been convincingly supported with 
good evidence. The contribution of cell mediated immunity in the pathogenesis of the 
diseases has been suggested but not yet supported by good evidence. Thus, we have 
hypothesized that ENL reaction is driven by the activation of previously anergic T-
cells following the decreasing frequency of regulatory T-cells.  
By immunophenotyping T-cell subsets by flow cytometry, we found that a significant 
reduction of the percentage of CD4+ regulatory T-cells and an increased percentage of 
CD4+/CD8+ T-cells ratio in untreated patients with ENL compared to the LL controls. 
These findings suggest that ENL is associated with a reduced percentage of regulatory 
T-cells and increased CD4+/CD8+ T-cell ratio. This immune imbalance could lead to 
the initiation of ENL reactions either by permitting increased production of antibodies 
critical to immune-complex formation or as a cell-mediated immune response in 
patients with leprosy.  
The frequency of activated T-cells and memory T-cell subtypes were also assessed to 
see if the reduction of the percentage of regulatory T-cells is associated with T-cell 
activation in patients with ENL. The percentage of activated T-cells, activated and 
central memory T-cells was significantly increased in patients with ENL before 
prednisolone treatment. This is the first study to show T-cell activation and the 
different subsets of memory T-cells in patients with ENL. This study illuminates the 
role of T-cell activation in the pathogenesis of ENL reaction and challenges the dogma 
of immune-complexes as the sole aetiology of ENL reactions. 
To further investigate the kinetics of pro-inflammatory cytokines, the in vitro cytokine 
production of PBMCs to the response of M.leprae whole cell sonicate stimulation and 
the gene expression level in blood and skin biopsies were determined in these patients.  
The in vitro production of the cytokines: TNF-α, IFN-γ, IL-1β and IL-17A were 
significantly increased in untreated patients with ENL at recruitment. However, IL-10 
production was significantly lower in untreated patients with ENL and significantly 
increased after treatment.  The mRNA expression in blood and skin biopsy samples of 
322 
   
TNF-α, IFN-γ, IL-1β, IL-6 and IL-17A significantly reduced in patients with ENL 
after treatment, while mRNA expression for IL-10 was significantly increased both in 
blood and skin biopsy samples after treatment.  This is the first study examining the 
effect of prednisolone on the kinetics of inflammatory cytokines in patients with ENL 
reactions before and after treatment. Our findings suggest that prednisolone modulates 
the pro-inflammatory cytokines studied here either directly or through suppressing the 
immune cells producing these inflammatory cytokines. This needs further 
confirmation through identification of the immune cells producing these cytokines.  
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8.2. RECOMMENDATIONS  
Based on the current findings, the following recommendations for future research are 
made: 
Regulatory T-cells:  Investigating the in vitro suppressive function of human Tregs in 
untreated patients with ENL. In this study, the frequency of Tregs was 
described. In addition to the reduction in percentage, it is also important to 
know if these Tregs are functionally defective or not to draw a conclusive 
conclusion. Looking into the genetic polymorphism of FOXP3 in patients with 
ENL is also another fertile area which needs future investigation. Previous 
evidence has shown that the FOXP3 genetic polymorphism is involved in the 
pathogenesis of several diseases. Therefore, the association between single 
nucleotide polymorphisms (SNPs) in the FOXP3 gene and susceptibility to 
ENL should be investigated.   
Pro-inflammatory cytokines: Delineating the cell sources of pro-inflammatory 
cytokines which have been identified as associated with ENL reaction. 
Identifying the sources of pro-inflammatory cytokines in patients with ENL 
may be useful for designing future studies aiming to block or modulate immune 
cells producing pro-inflammatory cytokines during ENL reaction.  
Immune-complex: Immune-complex formation and deposition in the skin lesions of 
ENL should be investigated by immunohistochemistry. The formation of 
immune-complex in infectious disease like ENL does not account or its 
harmful effect since immune-complex formation is part of the host immune 
response to infection. Showing defects in immune-complex clearance would 
be important evidence. Hence, future studies should measure the rate of 
immune-complex clearance.   
Longitudinal study: Longitudinal cohort studies are required to get a complete picture 
of neutrophils in the pathogenesis of ENL since the involvement of neutrophils 
in the pathogenesis of ENL are thought to be affected by the timing of sampling 
of patient materials.  To investigate the effect of the timing of sampling on 
neutrophils population in ENL patients, the time at which the first ENL reaction 
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occurs should be clearly known. Then samples should be taken within a defined 
time interval to see the changes in neutrophils population over time in one 
episode of ENL. This need a well-designed longitudinal cohort study consisting 
of lepromatous leprosy patients and following the cohort until any of the 
individuals develop ENL reaction. When some individuals develop ENL, 
samples should be collected within the pre-set time interval for investigation.  
Cytokine gene expression: Investigating the gene expression-signatures of candidate 
markers such as FOXP3, Neutrophils, IL-6, TNF-α and IFN-γ   in lepromatous 
leprosy patients with and without reactions.  This includes the search for a 
prediction tool to identify who is going to develop ENL among lepromatous 
leprosy patients.  
Inclusion of health endemic controls: Including healthy endemic controls may be 
useful to obtain additional data and to further extrapolate the results to the general 
population. Hence, it is worthwhile to include health endemic controls in future 
studies.  
8.3. THE WAY FORWARD  
Circulating T cells in ENL show several irregularities. T-cells are disturbed in 
homeostasis and skewed toward activated memory and pro-inflammatory T cell types 
with marked reduction of Tregs. This knowledge might allow specific and targeted 
therapies in the future. At present, corticosteroid and thalidomide (in some countries) 
are the only available treatments and patients always develop several side effects.  
Based on our current understanding of the disease, theoretically one could think of 
alternative treatment strategies such as cell-based therapy with ex vivo expansion of 
Tregs and subsequent infusion of these cells could potentially restore tolerance and T-
cell homeostasis in patients with ENL. However, recent findings have indicated that 
human Tregs can convert to pro-inflammatory IL-17 producing T-cells in the presence 
of specific cytokines such as  IL-1β, IL-21, IL-23 (Koenen et al., 2008). Hence, 
administration of Tregs to these patients may enhance the diseases rather than restoring 
T-cell homeostasis due to the nature of Treg plasticity. 
Therefore, control of excessive T-cell activation might pose an attractive therapeutic 
option. This could be achieved through blockage of costimulatory pathways such as 
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CD28/CD80. Blockage of CD28/CD80 has successfully been used in rheumatoid 
arthritis (Genovese et al., 2005). However, we have little information on the status of 
the expression of these costimulatory molecules in ENL. In addition, the presence of 
CD4+CD28- T-cell population should be investigated in patients with ENL since these 
cells found to secrete pro-inflammatory cytokines independent of   the CD28/CD80 
pathway. 
It might be also important to think of to interfere with T-cell trafficking into tissues 
and thereby reducing inflammation in these patients. Studies have shown that patients 
with inflammatory bowel disease and multiple sclerosis were successfully treated by 
administering Natalizumab, a humanized recombinant monoclonal antibody (Stuve et 
al., 2008). Natalizumab targets α4-integrin, which has a role in the adhesion of 
leukocytes to vascular endothelial cells, and thus inhibits leukocyte migration (Stuve 
et al., 2008). Hence, the basic mechanism of blocking leukocyte adhesion might be an 
attractive approach in patients with ENL to reduce inflammation and tissue destruction 
in the future.  
In our present work, we have shown that ENL reaction is associated with reduction of 
Tregs and increased T-cell activation.  Our findings suggest that ENL reaction is a T-
cell mediated pathology. Hence, the T-cell-mediated pathology of ENL will provide 
further insights into disease mechanisms and will potentially result in promising new 
therapeutic options. Therefore, future ENL studies should consider these fertile areas 
to improve the treatment and management of ENL.    
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INFORMATION SHEET  
 
 
 
  
 
 
 
1. Study title: The Immunopathology of Erythema Nodosum Leprosum 
(EmpaENL)  
2. Invitation paragraph  
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and to talk to 
others about the study, if you wish.   
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part.  
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
3. The purpose of the study  
The underlying cause of ENL is poorly understood. Understanding the cause of this 
condition and identifying risk factors which contribute to its development is useful 
for developing strategies to reduce the morbidity and mortality caused by ENL. This 
knowledge is crucial for the development of new and better treatments as well as 
proper management of ENL patients through improving diagnosis and treatment. In 
All Africa Leprosy,  
Tuberculosis and  
Rehabilitation Training 
centre 
Ayer Tena road 
PO Box 165. Addis Ababa.  
Ethiopia 
Tel. +251 113211334 
 
London School of Hygiene 
and Tropical Medicine  
Keppel Street, London WC1E 
7HT 
UK 
Tel. +44(0)2076127863 
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the project we are investigating the immunological changes that occur when 
lepromatous leprosy (LL) patients develop ENL reactions. The information obtained 
from this study will also be used to develop better patient treatment.    
4. Why you have been chosen? 
You are invited to participate in this study as a leprosy patient with ENL or without 
ENL.    We want to know the immunological changes that take place during the 
course of ENL and when LL patients undergo ENL reaction. In this study 45 patients 
with ENL and 30 LL patients without ENL will participate.    
5. Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given 
this information sheet to keep and be asked to sign consent form.   You are free to 
withdraw at any time, without giving a reason. A decision not to take part or to 
withdraw at any time, will not affect the standard of care you receive.  
6. What will happen to me if I take part? 
Your role in the study:  
If you agree to participate, the doctor in charge to treat your case (leprosy) will ask 
you some questions which you are expected to answer. These are:  history of 
treatment related to your current case, symptoms and time of the onset of the disease. 
In addition you will be asked your age, current address and educational status.  You 
will be asked these questions as a normal treatment procedure even if you will not 
take part in this study.  
Then you will be asked to give 50ml blood (equivalent to about 10 tea spoons or one 
and half of egg cup) which will be collected by inserting a small needle into a vein in 
your arm and one 4mm and 6mm skin biopsy samples from the diseased, part after 
receiving an anaesthetic injection.  You will be asked to return after 90 days (12 
weeks) and 180 days (24 weeks) to donate the same amount of blood. Skin biopsies 
are not required on 12 week. At the same time you will be given antileprosy 
treatment free of charge according to the national treatment guideline for leprosy (LL 
or ENL) irrespective of this study by your doctor.  
371 
   
7. What I have to do?  
You will be expected to attend the initial donation (blood and biopsy) and subsequent 
clinical investigation, blood and biopsy donations. If, for any reason you are unable 
to attend one or more of the appointments please let us know in advance.  
8.  What are the possible disadvantages and risks of taking this part? 
By participating in this research project, you may feel that it is inconvenient that you 
have to come to the hospital 3 times but you are normally expected to be followed 
for 1 year treatment for your sickness (leprosy) and come to the hospital even if you 
do not take part in this study.  
There is no major risk in participating in this research, but the minor bleeding that 
may occur during blood collection will be avoided, as the procedure is carried out by 
trained experienced health professionals on the standard good clinical practice.  
9. What are the possible benefits of taking part?  
If you participate in this research, you may not get any direct benefit but anything 
regarding your leprosy treatment case will be followed with greater care based on 
your laboratory results.  In addition, your participation is likely to help us in 
understanding the disease process of ENL which may benefit future patients by 
developing treatments for ENL reactions. 
10.  Incentives 
You will not be provided any incentive to take part in this research. However, you 
will be given 100 ETB for lunch and your travel expenses during participation in the 
project during each visit of the hospital up on the follow-up appointment given to 
you for a maximum of three times. 
11. What happens when the research study stops? 
On completing the study no further participation is required. 
12. What if there is a problem? 
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Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this 
issue is given in part 2 in this booklet.  
13. Will my taking part in the study is kept confidential? 
The information that we collect from this research project will be kept confidential. 
Information about you that will be collected from the study will be stored in a file, 
which will not have your name on it, but a code number assigned to it. Which 
number belongs to which name will be kept separately in a password protected data 
management file and it will not be revealed to anyone except the principal 
investigator and your treating physician. Your personal information will not be 
disclosed even during the reporting of the findings. Reports will be written and 
disclosed anonymously.   
14. Contact details  
Study coordinator and Principal investigator 
Edessa Negera Gobena 
Mobile: 0911880085 
AHRI, Ethiopia 
Study clinician  
 Dr. Shimelis Nigusie 
 Mobile no: 0911642060 
 ALERT Hospital, Ethiopia  
Local Study Manager (Local Supervisor)  
 Dr. Abraham Aseffa 
    Tel. +251 113211334  
    AHRI, Ethiopia 
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This completes part 1 of the information sheet. If the information in part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in part 2 before making any decision.   
Part 2 
15. What if relevant information becomes available? 
If the study is stopped for any reason, you will be told why and your care will not be 
affected by the discontinuation of the study.   
16. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will remove and destroy all your identifiable 
samples but we will need to use the data collected up to your withdrawal.  
17. What if something goes wrong? 
The London School of Hygiene and Tropical Medicine holds insurance policies 
which apply to this study. If you are harmed due to someone’s negligence, then you 
many have grounds for legal action. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been treated during the 
course of this study then you should immediately inform the local project manager 
(Abraham Aseffa), project coordinator (Edessa Negera) or the study physician 
(Shimelis Nigissie).  
18.  What will happen to any samples I give? 
As already described, during the laboratory analysis we will use your given code not 
your name for your sample. The majority of the samples are immediately used but 
some will be stored after semi-processed for further immunological assays. Any 
unused samples will be destroyed within 5 years.  The data collected will be written 
and published in peer reviewed scientific journals.  A list of publications can be 
accessed on the LSHTM website. Biopsy samples will be transferred to collaborating 
laboratories abroad (LSHTM) for immunohistochemistry since this method needs 
both expertise and advanced facilities which are not available in the country.  
19.  What will happen to the results of the study? 
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Data from this study will be analysed and published   in scientific journals but your 
identity will not be revealed.  Data will also be presented at seminars at national and 
international meetings. No information containing your name will be disclosed.  
20. Who is organizing and funding the project  
The research is funded by the Hospital and Homes of St Giles and sponsored by the 
London School of Hygiene and Tropical Medicine  
21. Who has reviewed the study?  
This study was given a favourable ethical opinion by the AHRI/ALERT Research 
Ethics committee and by the London School of Hygiene and Tropical Medicine 
Research Ethics committee.  
You will be given a copy of the information sheet and a signed consent form to 
keep.  
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INFORMED CONSENT FORM 
Full Title of Project: The Immunopathology of Erythema Nodosum Leprosum 
(Empa ENL) 
Name of the principal investigator:  Edessa Negera Gobena 
                                                                                                Please put Initial box  
1. I  Confirm that I have read and understand the participant information sheet 
dated ......….. (Version .........) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered fully. 
 
2. I understand that my participation is voluntary and I am free to withdraw at 
any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
2. I understand that sections of my medical notes and data collected during the study 
may be looked at by responsible individuals from the London School of Hygiene & 
Tropical Medicine, AHRI, regulatory authorities or from ALERT hospital, where it 
is relevant to my taking part in this research.  I give permission for these individuals 
to access my records. I agreed that my samples can be used for the intended 
research and for any investigations related to it.   
 
3. I agree for the tissue samples to be transported and used at London School of 
Hygiene & Tropical Medicine for the intended research project and related 
mentioned above. 
 
4. I agree to take part in the above study.  
 
Name of Participant  
(printed) 
 Signature/Thumbprint  Date 
Name of Person taking consent 
 
 Signature  Date 
Principal Investigator 
 
 Signature  Date 
The participant is unable to sign.  As a witness, I confirm that all the information 
about the study was given and the participant consented to taking part. 
Name of Impartial 
Witness 
(if required) 
 Signature  Date 
1 copy for participant; 1 copy for Principal Investigator; 1 copy to be kept with 
hospital notes 
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Information sheet: Amharic version 
የኢሪተማ  ኖዶሱም ለኘሮሱም ክስተትና የበሽታውን ባህሪይ ማጥናት 
 
የለንደን የሃይጅን እና የትሮፒካል ሜዲሲን ት/ቤት፣ ዩናይትድ ኪንግደም 
የአለርት ሪፈራል ሆስፒታል እና የአርማወር ምርምር ኢንስቲቲዩት 
በጥናቱ እንድሳተፋ ስለመጋበዝ 
በዚህ ጥናት ላይ እንዲሳተፋ እንጋብዘዎታለን ነገርግን በጥናቱ ከመሳተፍዎ በፊት የጥናቱ አላማና አስፈላጊነትን 
በቅድሚያ መረዳት ያስፈልገዎታል፡፡ በዚሁ መሠረት ይህ መረጃ ሰጪ ጥራዝ በሁለት ክፍሎች የተዘጋጀ ነው፡፡ 
የመጀመሪያው ክፍል የጥናቱ ዓለማና የእርሶ ለጥናቱ አስፈላጊነት በአጭሩ ይገልፃል፡፡ ክፍል ሁለት ስለጥናቱ 
አሠራርና አካሄድ በጥልቀት ያብራራል፡፡ 
ክፍል አንድ  
የጥናቱ ዓላማ 
አንዳንድ የሥጋ ደዌ በሽተኞች ኢሪተማ ኖዶሱም ለኘሮሱም በሚባል በሽታ ይጠቃሉ ፡፡ ይህ በሽታ አንዱ 
የሥጋ ደዌ አይነት ሲሆን ጠቅላላ የሰውነት ክፍሎችን በተለይም አይንና ነርቭን የሚያጠቃና ከፍተኛ 
ትኩሳትንና የመሳሰሉትን ያስከትላል፡፡ በዚህ በሽታ የተጠቁ የስጋ ደዌ ህመምተኞች ከፍተኛ የህመም ስሜት 
ይኖራቸዋል፡፡ በአንጻሩ አንዳንድ የሥጋ ደዌ በሽተኞች ለምንና በምን ምክንያት በዚህ በሽታ እንደሚጠቁ በቂ 
ጥናት አልተደረገም፡፡ ስለዚህ የዚህ ጥናት ዋና ዓላማ የበሽታውን መንስኤና ምልክቶቹን ማጥናት ነው፡፡ 
የበሽታውን መንስኤና ምክንያቶች ማወቅ ጥሩ የህክምና ስልት ለማዘጋጀትና የሥጋ ደዌ በሽተኞች በዚህ በሽታ 
እንዳይጠቁ ቀድሞ በመተንበይ መከላከል ያስችላል፡፡ 
እርሶ ለምን በዚህ ጥናት እንዲሳተፋ ተመረጡ? 
እርሶ በዚህ ጥናት ላይ እንዲሳተፋ የተመረጡበት ምክንያት የሥጋ ደዌ ህመምተኛ በመሆንዎና በጥናቱ ሊካተቱ 
የሚችሉት የሥጋ ደዌ ህመምተኞች ብቻ በመሆናቸው ነው፡፡ 
በዚህ ጥናት ላይ ለመሳተፍ የግድ ያስፈልጋል? 
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በጥናቱ ላይ ለመሳተፍ የግድ አያስፈልግም፤ በፍላጎት ላይ ብቻ የተመሠረተ ነው፡፡ በጥናቱ ላይ ለመሳተፍ 
ከወሰኑ ይህ መረጃና መስማማትዎን የሚገልጽ ቅጽ ይሰጠዎታል፡፡ መረጃውን ካነበቡና የሚጠይቁት ጥያቄ 
ካለም በመጠየቅ  በሚገባ ከተረዱ በኃላ መስማማትዎን ይገልጻሉ፡፡ 
በጥናቱ ላይ ከተሳተፍኩ ከእኔ ምን ይፈለጋል? 
በጥናቱ ላይ ለመሳተፍ ከተስማሙ 
1. መስማማተዎን በፊርማ ያረጋግጣሉ 
2. ስለ በሽታዎ አንዳንድ ጥያቄዎች ይጠየቃሉ፡፡ ይህ ጥያቄ በመደበኛ የሕክምና ጊዜ የሚጠይቅ በመሆኑ 
የዚህ ጥናት ብቻ ጥያቄ አይደለም፡፡ 
3. ስለ በሽታዎ ለማጥናት 50 ሚሊ ሊትር ደም (ግማሽ የሻይ ኩባያ ያህል) እንዲለግሱ ይጠየቃሉ፡፡ 
በተጨማሪም በበሽታው ምክንያት ከቆሰለው የቆዳዎ ክፍል 6 ሚሊሜትር እና 4 ሚሊሜትር   
ቁራጭ (ባዮፕሲ) ይወሰድና ይጠናል፡፡ አወሳሰዱ በሰለጠኑ ባለሙያዎች ስለሆነ የሚከሰት ስጋት 
አይኖርም፡፡ ደምና የባዮፕሲ ልገሳ በአጠቃላይ ለሶስት ጊዜ በየ12 ሳምንት ይሆናል፡፡ 
ከእርስዎ ምን ይጠበቃል? 
በጥናቱ ለመሳተፍ ከተስማሙ ከላይ የተገለፀውን የደምና የቆዳ ቁራጭ (ባዮፕሲ) ለሶስት ጊዜ እንዲለግሱ 
ይጠበቃል፡፡ በቀጠሮው ቀን መምጣት የማይችሉ ወይም የማይፈልጉ ከሆነ ቀድመው እንዲያሳውቁን በአክብሮ 
ትብብርዎን እንጠይቃለን፡፡ 
በጥናቱ ላይ ቢሳተፉ ጥቅማ ጥቅም አገኛለሁኝን? 
በዚህ ጥናት ላይ በመሳተፍዎ የተለየ ጥቅም በግል አያገኙም፡፡ ነገርግን የትራንስፖርትና የምሳ ወጭዎ 
ይሸፈንልዎታል፡፡ በተጨማሪም በጥናቱ ውጤት መሰረት ለበሽታዎ ልዩ ክትትል የሚያስፈልግ ከሆነ በሀኪም 
ክትትል ይደርግለዎታል፡፡ ከሁሉም በላይ ግን በዚህ ጥናት የሚገኘው ውጤት ሰለበሽታው ጥሩ ግንዛቤ 
እንዲኖረንና በሽታውን ለመቆጣጠር ጠቃሚ መረጃ ስለሚሰጠን ለህብረተሰባችን የሚያስገኘው ጥቅም ከፍተኛ 
ነው፡፡ ከሩቅ ቦታ (ክፍለሀገር) የሚመጡ ከሆነ የትራንስፖርት፣ የመኝታና የምግብ ወጭዎ ይሸፈናል፡፡ 
በተጨማሪም ቀጠሮዎ ለበሽታዎ ክትትል ወደ አለርት ሆስፒታል ከሚመጡበት ቀን ጋር አንዲጣጣም 
ይደረጋል፡፡ 
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ክፍል ሁለት 
ጥናቱ ድንገት ቢቋረጥ በበሽታዬ ህክምና ላይ ተጽዕኖ ይኖረዋልን? 
አይኖረውም፡፡ ጥናቱ ቢያልቅም ወይም ቢቋረጥ የርስዎ የህክምና እርዳታና ክትትል እንደማንኛውም ስጋ ደዌ 
ህመምተኛ ይቀጥላል፡፡ 
ከጥናቱ እራሴን ማግለል እችላለሁ? 
አዎ ይችላሉ፡፡ ከጥናቱ በፈለጉት ጊዜና ሰዓት ያለምንም ቅድመ ሁኔቴ ማቋረጥ ይችላሉ፡፡ እራስዎን ከጥናቱ 
በማግለልዎ ምክንያት ለህመምዎ የህክምና እርዳታ ከማግኘት አያግድም፡፡ እንደማንኛውም ታካሚ 
አስፈላጊውን የህክምና እርዳታ ያገኛሉ፡፡ 
እኔ የምለግሰው ናሙና ምን ይሆናል? 
የርስዎ ናሙና የተለያ ቁጥር ይሰጠዋል፡፡ በናሙናው ላይ የርስዎ ስም አይጻፍም፡፡ አብዛኛው ናሙና ወዲውኑ 
ስራ ላይ ይውላል፡፡ ጥቂት ናሙና ግን ለመጠባበቂያነትና ለከፍተኛ ምርመራ ወደ ለንደን የሀይጅንና ትሮፒካል 
ሜዲስን ት/ቤት ይላካል፡፡ ናሙናው በሚላክበት ጊዜ በልዩ ኮድ (መለያ ቁጥር) ብቻ ይሆናል፡፡ በጥናት 
የሚገኘው መረጃ በህትመት መልክ ለጤና ባለሙያና ለሳይንትስቶች ይደርሳል፡፡ ውጤት በጅምላ 
በሚገለጽበት ጊዜ የማንንም ውጤት አይወክልም፡፡ 
ጥናቱ ሲያልቅ ከእኔ ምን ይጠበቃል? 
ምንም አይጠበቅም፡፡  ጥናቱ ካለቀ የርስዎ መሳተፍ ያበቃል፡፡ ጥናቱ በሚያልቅበት ጊዜም ይነገርዎታል፡፡ 
ቅሬታ ቢኖረኝ ምን አድርጋለሁ? 
ከዚህ ጥናት ጋር በተያዘ ማንኛውንም ቅሬታ ለጥናቱ ማናጀር (ዶ/ር አብርሃም አሰፋ) ወይም ለጥናቱ 
ተመራማሪ (ለኤዴሳ ነገራ) ማመልከት ይችላሉ፡፡ 
በዚህ ጥናት መሳተፍ በሚስጥር ይያዛልን? 
አዎን ለዚህ ጥናት የሚሰበሰበው ናሙና እና የናሙና ውጤት በሚስጥር ይያዛል፡፡ ስለ እርስዎ የሚገልጽ 
ማንኛውም ነገር በናሙናም ሆነ በውጤቱ ላይ አይጻፍም፡፡ ውጤት ሲገለጽ ስም አልባ ይሆናል፡፡ ለእያንዳንዱ 
ናሙና ልዩ መለያ ቁጥር ወይም ምልክት ይሰጠዋል፡፡ የትኛው ቁጥር የማን እንደሆነ ዋና ተመራማሪው ብቻ 
ያውቃል፡፡ ስለ ናሙናዎ ውጤት ከዋና ተመራማሪው በተጨማሪ እርሶን የሚከታተለው ሀኪምም ሊያውቀው 
ይችላል፡፡ 
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ይህ ጥናት ተቀባይነትን አግኝቷል? 
ይህ ጥናት በአህሪ/አለርት የስነ-ምግባር ኮሚቴና በለንደን የሃይጅንና ትሮፒካል ሜድስን ት/ቤት የስነ-ምግባር 
ኮሚቴ ተገምግሞ ተቀባይነትን አገኝቶ ፀድቋል፡፡ 
ተጨማሪ መረጃ ከፈለጉ የሚከተሉትን ባለሚያዎች ማነጋገር ይችላሉ 
1. የጥናቱ አስተባባሪና ዋና ተመራማሪ ኢዴሳ ነገራ ጎበና ስልክ ቁ. 0911880085 
2. የጥናቱ ሀኪም ዶ/ር ሺመልስ ንጉሴ ስልክ ቁ. 0911642060 
3. የጥናቱ ማናጀር ዶ/ር አብርሃም አሰፋ ስልክ ቁ. 0113211334 
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Informed consent form: Amharic version  
የኢሪተማ  ኖዶሱም ለኘሮሱም ክስተትና የበሽታውን ባህሪይ ማጥናት 
የለንደን የሃይጅን እና የትሮፒካል ሜዲሲን ት/ቤት፣ ዩናይትድ ኪንግደም 
የአለርት ሪፈራል ሆስፒታል እና የአርማወር ምርምር ኢንስቲቲዩት 
የስምምነት መግለጫ ቅጽ  
የጥናቱ ተማራማሪ፡ ኤዴሳ ነገራ ጎበና 
እባክዎት ሳጥኑ ውስጥ ምልክት ያድርጉ 
1. ከዚህ በለይ ለተጠቀሰው ጥናት የ------------------ቀን (ቁጥር--------------) የመረጃ ወረቀት 
አንብቤ ጉዳዩን መረዳቴን አረጋግጣለሁ፡፡ 
 
2. ተሳትፎዬ በፈቃደኝነት መሆኑን እና በማንኛውም ጊዜ ምንም አይነት ምክንያት ማቅረብ 
ሳያስፈልገኝ፤ የህክምናዬ ክብካቤ ወይንም ህጋዊ መብቴ ሳይነካ ማቋረጥ እንደምችል ተረድቻለሁ፡፡  
 
3. ከእኔ የሚወሰደው ናሙና እና  የጤና መረጃ በተመራማሪዎቹና በሽታዬን በሚከታተለው ሀኪም 
መታየት እንደሚችልና የለገስኩት ናሙና ከላይ ለተገለጻው ጥናት እንዲውል ፈቅጃለሁ፡፡ 
 
4. እኔ የምለግሰው ናሙና (የቆዳ ቁራጭ) ወደ ለንደን የሀይጅንና ትሮፒካል ሜድስት ት/ቤት ተወስዶ 
ተጨማሪ ምርመራ እንዲደረግበት ፈቅጃለሁ፡፡ 
 
5. በዚህ ጥናት ለመሳተፍ በሙሉ እውቅናዬ የተስማማሁ መሆኔን አረጋግጣለሁ፡፡  
__________________________       
__________________________   __________________________ 
የተሳታፊ ስም                             ፊርማ                        ቀን  
__________________________       
__________________________   __________________________ 
የውል ተቀባይ ስም                        ፊርማ                        ቀን  
__________________________       
__________________________   __________________________ 
የጥናቱ ዋና ተመራማሪ ስም                 ፊርማ                        ቀን  
ይህ በጥናቱ የሚሳተፈው ሰው መፈረም ስለማይችል ከላይ የተዘረዘሩት መረጃዎች ለተሳታፊው 
የተሰጡና ተሳታፊውም ለመሳተፍ መስማማቱን ገለልተኛ ታዛቢ በመሆን አረጋግጣለሁ፡፡ 
__________________________       
__________________________   __________________________ 
       የገለልተኛ ታዛቢ ስም                             ፊርማ            ቀን               
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Appendix 3: Patient flow diagram and Clinical data collection sheet              
 Patient flow diagram 
 Clinical data collection sheet and enrolment criteria   
 Enrolment criteria 
 ENL patients review date (appointment date) form  
 Study participant indntification card 
 Clinical Data Collection sheet  
 Muscle testing form  
 Sensory testing form 
 Histopathology data sheet 
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Patient flow diagram 
 
Title of the study: The Immunopathology of Erythema Nodosum Leprosum  
 
 
 
 
Patient flow and Recruitment method (summary). 
1. Patients identified at Red Medical Clinic 
2. Patients informed about the study and recruited with consent. 
3. Fully history and examination by the study physician 
4. Patient sent for laboratory investigation  
5. Patient sent to physiotherapy for sensory and voluntary muscle testing 
6. Patient reviewed by the study physician  
7. Patient referred to pharmacist for treatment  
8. Patient given review date  
9. Transportation and lunch compensated ( depending on the address of the 
patient)  
 
 
  
Patient  
Red Clinic Consent  
Clinical 
examination  
Patient sent 
to 
laboratory 
Physiotherapy  
Pharmacy  
Review date  
Transportation 
and  
Home  
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            Clinical data collection sheet and enrolment criteria   
Title of the study: The Immunopathology of Erythema Nodosum Leprosum  
ALERT No. ----------------AHRI No. ---------------    Study number ------------------        
Entry Criteria:  Patient history; Patient examination; Consent form  
 
Day 0: 6mm + 4mm Skin punch Biopsy: ½ (6mm) frozen  storage (-80oc)  and 
½(6mm) in 10% formalin ( room T)   and 4mm in RNAlater (-20 oc)            
40-50mL blood sample for (ELISA, Flow cytometry, Circulating IC, 
mRNA RT-PCR) 
Week 12: 50mL blood sample for (ELISA, Flow cytometry, Circulating IC) 
Week 24:   6mm + 4mm Skin punch Biopsy: ½ (6mm) frozen  storage (-80oc)  
and ½(6mm) in 10% formalin ( room T)  and 4mm in RNAlater (-20 oc)    
40-50mL blood sample for (ELISA, Flow cytometry, Circulating IC, 
mRNA RT-PCR) 
NB: please add 2mL blood to PAXgene Blood RNA tubes and store at (-20 oc. 
 
Clinical data required: Full clinical investigation report on day 0, 12 weeks and 24 
weeks 
Date the patient enrolled in the study        dd          / mm           /yy               E.C. 
Date patient returned for follow up  
Week 12:                     dd       / mm          / yy   
Week 24   :                   dd       / mm          / yy   
Physician in charge: (Name and signature) ----------------------------------------------. 
Nurse in Charge               ‘’’                        ----------------------------------------------.         
PI in charge                     ‘’                        ------------------------------------------------. 
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ENL patients review date (appointment date) 
Please use Ethiopian Calendar (ddmmyy) 
 
 
 
 
LL patients review date (appointment date) 
Please use Ethiopian Calendar (ddmmyy) 
No Name  Study code  First visit 
 ( date)   
 Second 
review date  
3rd  review 
date  
Address  ( contact 
phone) 
       
       
       
       
       
       
       
       
       
       
       
       
 
 
 
No Name  Study 
code  
Steroid 
completion 
date  
First 
visit 
 ( date)   
 Second 
review 
date  
3rd  
review 
date  
Address  ( contact 
phone) 
        
        
        
        
        
        
        
        
        
        
        
        
ENL 
LL 
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Study participant indntification card. Project code 021 
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Clinical Data Collection sheet  
Form 1                                                  Patient ID------------------ 
                                           
 
PATIENT DETAILS PHYSICIAN 
Patient ID  
New ENL 
case 
□ 
Recurrent ENL 
case 
□ 
Chronic 
ENL case  
□ 
   
Date  __/__/__       
Gender 
Male 
□ 
Female 
□ 
Post menopause 
Yes □    No □ 
Date of birth 
__/__/_
_ 
Age  
LEPROSY DETAILS 
Date of diagnosis of 
leprosy 
__/__/__   
Ridley-
Jopling 
BB □ BL □ 
LL 
□ 
Bacterial index at 
diagnosis 
 Mean BI ____ 
Highest BI 
at any single 
site 
____   
Current BI  Mean BI ____ 
Highest BI 
at any single 
site 
____   
MB MDT Start date __/__/__   
MB MDT 
Completed 
date 
__/__/_
_ 
  
Presented with 
reaction at leprosy 
diagnosis 
NO 
□ 
YES 
□ 
TYPE 1 
□ 
ENL 
□ 
NEURI
TIS 
□ 
  
Date of onset of 
most recent T1R or 
neuritis 
__/__/__   
No previous 
T1R or 
neuritis  
□ 
   
Other illnesses  TB □ Diabetes □ HIV □ 
Other (specify) 
 
ENL DETAILS 
Duration of current 
symptoms (DAYS) 
____ 
Number of previous ENL 
episodes (if recurrent) 
0 1-4 5-9 ≥10 
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Current ENL 
treatment (drug and 
dose) 
 
Date 
started 
 
__/__/__ 
Previous ENL treatments: 
Prednisolone                
Clofazimine                   
Thalidomide 
Pentoxifylline 
Aspirin (or NSAID) 
Other (please state) 
Current symptoms Fever □ 
Skin 
lesions □ 
Other localised 
swelling (not 
skin) □ 
____________ 
Peripheral 
oedema 
□ 
Insomn
ia 
□ 
  
Anorexia 
□ 
 
 
Weight 
loss 
□ 
Nasal 
stuffiness□ 
Depression 
□ 
Malaise 
□ 
Epistax
is 
□ 
Joint 
swelling □ 
Pain symptoms Skin □ Bone □ Digits □ Testes □ Eyes □   
 
Muscles 
□ 
Lymph 
nodes □ 
Nerves □ Joints □    
Where is pain worse?  
Nerve symptoms Pain □ 
Weakness 
□ 
Reduced 
sensation □ 
Paraesthesia □ 
Hyperaesthe
sia □ 
 
New NFI 
□ 
Old NFI □      
EXAMINATION Urinalysis Protein □ 
Blood 
□ 
EHF 
Score 
___
_ 
Temperature  ___°C  Weight (kg) ______ BP /  
Type ENL skin 
lesions 
Papules 
□ 
Nodules □ Vesicles □ Bullae □ 
Pustule
s □ 
  
 
Plaques 
 □ 
Ulcerated 
□  
Necrotic  
□ 
Sub-
cutaneous 
nodules 
 □ 
EM 
like 
lesions 
 □ 
Scar 
due 
to 
ENL 
□ 
 
Size of largest 
lesion (mm) 
  
Describe 
unusual skin 
lesions such as 
EM-like 
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Number of ENL 
skin lesions 
 5 or less 
□ 
6-10 □ 11-20 □ 21-50 □ >50 □   
Number of ulcerated/necrotic 
lesions 
 
Location of ENL 
skin lesions 
Head/nec
k□ 
Trunk □ Upper limbs □ 
Lower limbs 
□ 
   
Oedema Face □ Hands □ Lower limbs □ Localised □ Specify: 
Dactylitis  Yes □ No □      
Arthritis Yes □ No □ Large joints □ 
Small joints 
□ 
   
Orchitis Left □ Right □      
Eyes  
Lagophthalmos Left □ Right □      
Conjunctivitis Left □ Right □      
Anterior uveitis Left □ Right □      
Scleritis Left □ Right □      
Episcleritis Left □ Right □      
Visual acuity Left  / Right /    
Lymphadenitis  Yes □ No □ Site/s: 
Liver tenderness Yes □ No □      
Rhinitis  Yes □ No □      
Other signs 
associated with 
ENL 
Yes □ No □ Specify: 
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                                            Patient ID---------------- 
Form 2:   For visits at weeks 12 and 24   after enrolment 
 
PATIENT DETAILS PHYSICIAN 
Patient ID  Date  __/__/__ 
ENL DETAILS 
Current 
symptoms 
No 
symptoms 
of ENL □ 
Fever □ 
Other localised 
swelling (not 
skin) □ 
____________ 
Peripheral 
oedema 
□ 
Insomn
ia 
□ 
  
Anorexia 
□ 
 
Skin 
lesions □ 
 
Weight 
loss 
□ 
Nasal 
stuffiness
□ 
Depression 
□ 
Malaise 
□ 
 
Epistax
is 
□ 
 
Joint 
swelling □ 
Pain 
symptoms 
Skin □ Bone □ Digits □ Testes □ Eyes □  
 Muscles □ 
Lymph 
nodes □ 
Nerves □ Joints □   
Where is pain worse?  
Nerve 
symptoms 
Pain □ 
Weaknes
s □ 
Reduced 
sensation □ 
Paraesthesia □ 
Hyperaesthe
sia □ 
 
New NFI 
□ 
Old NFI 
□ 
     
EXAMINATION Urinalysis Protein □ 
Blood 
□ 
EHF Score ____ 
Temperature  ___°C  Weight (kg) ______ BP /  
Type ENL 
skin lesions 
Papules □ 
Nodules 
□ 
Vesicles □ Bullae □ 
Pustule
s □ 
  
 
Plaques 
 □ 
Ulcerate
d □  
Necrotic  
□ 
Sub-
cutaneous 
nodules 
 □ 
EM 
like 
lesions 
 □ 
Scar due to 
ENL 
□ 
 
Size of largest 
lesion (mm) 
  
Describe 
unusual skin 
lesions such as 
EM-like 
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Number of 
ENL skin 
lesions 
 5 or less □ 6-10 □ 11-20 □ 21-50 □ >50 □   
Number of 
ulcerated/necrotic lesions 
 
Location of 
ENL skin 
lesions 
Head/neck
□ 
Trunk □ Upper limbs □ 
Lower 
limbs □ 
   
Oedema Face □ Hands □ Lower limbs □ 
Localised 
□ 
Specify: 
Dactylitis  Yes □ No □      
Arthritis Yes □ No □ Large joints □ 
Small 
joints □ 
   
Orchitis Left □ Right □      
Eyes  
Lagophthalmo
s 
Left □ Right □      
Conjunctivitis Left □ Right □      
Anterior 
uveitis 
Left □ Right □      
Scleritis Left □ Right □      
Episcleritis Left □ Right □      
Visual acuity Left  / Right /    
Lymphadeniti
s  
Yes □ No □ Site/s: 
Liver 
tenderness 
Yes □ No □      
Rhinitis  Yes □ No □      
Other signs 
associated 
with ENL 
Yes □ No □ Specify: 
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     Immunopathology of ENL; Histopathology data sheet 
  
               
  
AHRI  
No 
 PMN Lymphocyte
s 
Foamy 
Histiocyte
s 
Multinucleate
d Giant cells  
Eosinophil
s & must 
cells  
Granuloma  PMN 
inf. 
pattern  
Vasculit
is 
Pannicul
itis 
Lobul
ar 
vascu
litis  
Necro
sis 
Swellin
g of 
Endothe
lial 
cells  
Oedema of 
vessel 
walls  
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Immunopathology of ENL (patient follow up form)     ENL 
 
no Code ENL type at 
recruitment  
(New, chronic, 
recurrent) 
Treated before 
with steroid 
(Yes, NO) 
MDT status during sampling (Yes, No) Steroid dose on sampling date ( put the 
dose when each samples taken) 
 Remark 
1st sample 2nd  sample 3rd  sample 1st sample 2nd  sample 3rd  sample 
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Immunopathology of ENL (patient follow up form)     LL 
 
no Code LL type at 
recruitment ( new, 
defaulter, relapse)   
 
MDT status during sampling (Yes, No) Any other drugs given including steroids   Remark 
1st sample 2nd  sample 3rd  sample 1st sample 2nd  sample 3rd  sample 
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Blood and Biopsy Form (Project Code P032/12)       
 
The Immunopathology of ENL   
 
NO Date 
(ddmmyy) 
Study no ALERT 
No 
AHRI 
No 
sex Age Blood 
volume  
Biopsy  
body site 
Any remark  Name and signature of person in 
charge  
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Appendix 4: Laboratory Standard Operating Procedures (Sops) 
 Protocol 1: PBMC isolation 
 Protocol 2: PBMC freezing protocol 
 Protocol 2: PBMCs thawing  
 Protocol 4:  Reagents preparation  
 Protocol 5:  FACS staining  
 Protocol 6. RNA Extraction  
 Protocol 7: cDNA synthesis for real-time two-step RT-PCR 
 Protocol 8: Real-Time PCR  
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Protocol 1: PBMC isolation (perform under sterile condition)  
Method:  Ficoll-paque density gradient centrifugation  
Status: optimized for the intended plan in this proposal     
PBMC isolation (sing Leuocosep tubes (cat. no 227 289) 
1. Warm-up separation medium (Ficoll-Paque Plus)   to  RT 
2. Fill the Leucosep® tube with separation medium ( 15mL Ficoll-Paque) 
3. centrifuge for 1 minute  at 900 rpm  at  RT 
4. Fill  with anticoagulated blood  (25mL) 
5. Centrifuge 25 minutes at 1800 rpm   ( Break Off)  
6. Collect the plasma using pasteur pipette into cryotube and keep at -20 
7. Collect the PBMC using Pasteur pipette into another  centrifuge  tube 
8. Wash the enriched cell fraction (lymphocytes / PBMC’s) with 10 mL of 
phosphate-buffered saline (PBS), subsequently centrifuge for 10 minutes at 
1800  (Break off) 
9. Repeat washing at 1520 rpm for 10 minutes  ( break on low)  
10.  Re-suspend cells in cRPMI       Note: from here after use ice 
11.  Count the cells  
12. Make 20 million cells /mL in cRPMI 
13.  Proceed  to Freezing  
 
Protocol 2: PBMC freezing protocol 
Reagents 
A.  Complete medium (cRPMI) 
1% Pen + 1% strep + 10% FBS +88% RPMI1640 containing L-glutamine 
B. 2X freezing media 
20% DMSO + 20% FBS + 60% RPMI 
 
1. While gently swirling the tube, add drop-wise enough at 4°C 2X freezing 
medium to  
    Avoid any further mixing or agitation of the cells. 
2. Slowly remove the cell suspension and dispense 1ml per cryovial  
3. Place the cryovials in a pre-cooled StrataCooler™ that has been filled with 70% 
isopropanol according to the manufacturer’s instructions. 
4. Place the freezing container at –80oC. 
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5. After 1-3 days at –80 ˚C, vials should be transferred from StrataCooler™ units 
into standard freezer boxes  
6. Transfer the box into a liquid N2 container  if necessary  
 
Protocol 2: PBMCs thawing  
Thawing Media: RPMI 1440 (Complete RPMI with HI FBS with 200 IU Penicillin, 200 μg/mL 
Streptomycin), and 2 mM L-Glutamine) 
1. Removing cryovials from LN2 Freezer 
 Place immediately on dry Ice or Mr. Frosty equilibrated to -80°C 
2. Transfer the cryovial into the 37°C water bath soon. 
3. Hold the cryovial in the surface of the water bath with an occasional gentle “flick” 
during thawing. 
4. Do not leave cryovial unattended during the thawing process. (It is important for cell 
viability that the cells are thawed and processed quickly). 
5. When a small bit of ice remains (approximately 1 minute) in the cryovial, transfer the 
cryovial to the biosafety hood. 
6. Dry off the outside of the cryovials with a delicate task wipe before opening to prevent 
contamination. 
7. Add  1mL  Thawing Media slowly, in a drop wise manner 
8. Mix the cryovials contents by slowly pipetting up/down 3-5 times. 
9. Transfer the suspension to 50mL/15mL tube 
10. Very slowly add an additional 8 mL of Thawing Media  
11. Centrifuge at 400 x g for 10 minutes. 
12. Decant the supernatant  
13. Gently re-suspend pellet in residual media using by finger flicking the tube 
14. Repeat washing once  
15. Count the cells and adjust the cells to 106/ml 
16.  Incubate 14 -18 hrs. 
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Protocol 4:  Reagents preparation  
 A). Protocol for making 4% Paraformaldehyde (100ml)  
 For 100 ml of a 4% paraformaldehyde stock solution:  
Weigh out 4 g of paraformaldehyde, transfer powder into 50 ml conical tube (Falcon). 
1. Add 80 ml of dH2O 
2. Add 50 µl of 1 M NaOH 
3. Heat to 700C (cap on), mix frequently until complete solubilization (~10 min 
the solution should become clear 
4. Put on ice and allow the solution to cool down to ~ room temperature 
5. Adjust volume to 90 ml with ddH2O 
6. Add 1 ml of PBS 10X and mix. 
7. Filter and store at 40C. 
 
 B). Protocol penicillin solution preparation  
      Available reagent: Penicillin G sodium salt powder  
To make 100mL solution of penicillin (100,000 units/L)  
Solubility:  H2O: soluble100 mg/mL  
1. Prepare 100mL dH2O 
2. Weigh 100mg Penicillin G sodium salt powder  and add to Prepare 100mL 
dH2O 
3. filter sterilize 
4. store at -20°C for extended periods or at 2-8°C for 1 week 
Recommended for use in cell culture media at 100,000 units/L 
C). Protocol for preparation of Streptomycin solution 
 Available as streptomycin Sulfate salt 
To make 100mL solution of Streptomycin  
1. Prepare 100mL dH2O 
2. Weigh 100mg Streptomycin salt powder  and add to Prepare 1000mL dH2O 
3. filter sterilize 
4. store at -20°C for extended periods or at 2-8°C for 1 one month 
    Recommended for use in cell culture applications at 100 mg/L 
D). FACS buffer 
    FACS buffer (1x):  contains 1X PBS + 1% FCS + 0.02% sodium azide 
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Preparation (500mL
azide 
E). 10% AB serum  
10% AB serum (100mL) = 10mL AB serum + 90mL PBS  
 
Protocol 5:  FACS staining  
Extracellular and intracellular flow cytometry staining   
1. Collect cells (0.2- 1x106/ml)  and transfer into the FACS tubes 
2. Spin at 400g (1400 rpm) for 5 minutes at RT: consider the centrifuge R if rpm 
used 
3. Discard the supernatant 
4.  Resuspend in 1mL PBS 
5. Spin as above 
6. Discard the supernatant 
7. Resuspend in lmL AB serum10% in PBS (Block non-specific Fc-mediated interactions)  
8. Leave in the dark for 10 minutes at 2-8 0C or RT (Cover with aluminium foil)  
    In the meantime prepare beads for compensation controls. Compensation 
controls need extracellular single staining only 
9.  Spin as above  
10. Discard the supernatant 
11. Resuspend cells in lit bit buffer  ( approximately 50µl) 
12. Add  your extracellular antibodies  ( CD3,CD4,CD8,CD25 CD127) to the cells  
NB: the total volume shouldn’t be greater than 100 µl 
 
A. Main panel for all samples  
+ FoxP3 + 
live/dead 
 
B. Used for 10 ENL and 10LL from each time point ( 1st , 2nd and 3rd round)  
CD3 
V450 
CD4 
AH 780 
CD8 
PerCy5.5 
CD25 
PECy7 
CD127 
APC 
CD161 
PE 
 2.5µl 4.0µl 1.5µl 1.0µl 2.5µl 2.5µl 
CD3 
V450 
CD4 
AH 780 
CD8 
PerCy5.5 
CD25 
PECy7 
CD62L 
APC 
CD45RA 
PE 
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  + FoxP3 + 
live/dead 
  
C. Optional may be used if required  ( 10 samples  same as B)  
      + FoxP3 
+ live/dead 
 
13. Add live/ dead  satin:  to the final concentration of 1µl/mL)  
14. Incubate in dark at 4oC for 30 minutes 
15. Add 1mL FACS buffer 
16. Spin as above  and discard the supernatant 
17. Re-suspend cells in lit bit buffer  
Procedure 18-22 is only for surface staining.  Go to number 23 for intracellular 
staining)  
18. Add 200µl PFA (fixing the cells) 
19. Fix by keeping  in the dark at 4oC for 15 minutes 
20. Add 1mL FACS buffer 
21. Spin as above  and discard the supernatant 
22. Add 400µl FACS buffer and read 
23. Add 1 mL of Foxp3 Fixation/Permeabilization working solution to each tube and 
pulse vortex  
24.  Incubate for 60 minutes at 40c in the dark.  
25. Without washing , add 2mL of 1X permeablization buffer to each tube  
26. Spin as above  (400g, 5 minutes , room T) and discard the supernatant 
27. Re-suspend  pellets in 50 µl 1X permeablization buffer  (FoxP3 permeablization 
wash)  
28. Add your intracellular antibody (FoxP3) to the cells:  final max. volume =100µl 
(To each tube add 10µl anti-FoxP3 antibody) 
29. Incubate in dark at 4oC for 30 minutes 
30. Without washing, add 2mL 1X permeablization buffer   
31. Spin as above  and discard the supernatant 
32. Add 2mL 1x permeablization buffer   
       2.5µl 4.0µl 1.5µl 1.0µl 10 µl 10 µl 
CD3 
V450 
CD4 
AH 780 
CD8 
PerCy5.5 
CD25 
PeCy7 
CD62L 
APC 
CD45RO 
PE 
  2.5µl 4.0µl 1.5µl 1.0µl 20 2.5µl 
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33. Spin as above  and discard the supernatant 
34. Re-suspend cells in little bit buffer  
35. Add 400µl  FACS buffer  
36. Read  
Antibodies volumes/test (for 100 µl total volume)  
CD3:  2.5µl 
CD4:  5µl 
CD8: 1.25µl 
CD25: 0.625µl 
CD127: 2.5µl  
CD161: 2.5µl 
FoxP3: 10µl 
Live/dead satin: 100µl/ test  
 
For 10 reactions: working example  
 
CD3, CD127, CD161 = each 25µl each in small test tube (Eppendorf) separately  
CD4= 50µl 
CD8= 12.5µl 
CD25= 6.25µl 
FoxP3= 100 µl 
Live/dead= 1000µl 
Notice: 
It is possible to add for example 25µl of CD3 and 25µl FACS buffer. But when 
antibodies are added to each test tube, the volume added must be doubled. Instead of 
2.5 it has to be 5 µl 
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Protocol 6. RNA Extraction  
 
A). Extraction of RNA from skin punch biopsy collected from leprosy patients 
To be read in conjunction with the Category 3 code of practice  
 
Organism M.leprae There may be small numbers of live 
organisms in tissue f  from untreated patients 
Laboratory 427A 
Project supervisor 
 
Prof. Diana Lockwood  
Routes of infection 
 
Predominately by aerosol route 
Disinfectants 
 
Surfanios, freshly prepared (5%, final 
concentration), disinfection overnight 
Written by Edessa Negera  Gobena   April,  2015 
Approved by principal investigator: 
Diana Lockwood 
Date: 
Signature: 
Approved copy sent to the safety office: Date: 
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Extraction of RNA from skin biopsy collected from leprosy patients 
To be used with the RNeasy Fibrous Tissue Mini Kit 
General precautions: Apply RNase Away spray to all surfaces (work surface, tubes, 
pipettes, microcentrifuge and gloves) and wipe down. 
In CAT2 lab: 
Make DNase solution according to kit guidelines, aliquot and store at -20C. 
Before using wash buffer 2 (BR4) add 4 volumes of ethanol (96-100%, purity grade 
p.a.) to obtain a working solution. 
In CAT3 lab: 
Wear gown, gloves and sleeves. Risk of aerosol formation through use of pipettes 
and centrifugation. 
TAKE the following into class I hood: 
Large 3 polystyrene container full of ice 
Microcentrifuge 
a. Heating block 
b. Mini vortex 
c. Aerosol resistant tips and Gilson pipettes will be kept inside a plastic 
container in the isolator and transferred into the cabinet as required. These 
must be surface fumigated should they need to be removed from the cabinet. 
d. RNeasy Fibrous Tissue Mini Kit 
 RNase-free water (4ml/sample) 
 Secondary BD Hemograd closures 
 Suspension buffer (BR1) (350ul/sample) 
 Binding buffer (BR2) (300ul/sample) 
 Proteinase K (40ul/sample) 
 100% cold ethanol (350ul/sample) 
 Wash buffer 1 (BR3) (700ul/sample) 
 DNase I (10ul/sample) /DNA digestion buffer (70ul/sample) 
 Wash buffer 2 (1000ul/sample) 
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 Elution buffer (80ul/sample) 
 Purification columns and collection tubes 
CAT. III PROCEDURE 
 PROTOCOL & RISK ASSESSMENT 
RNA extraction from tissues collected from leprosy patients (ENL and LL) 
1. Tissue samples in RNAlater will be shipped to category 3 lab at LSHTM 
from Ethiopia (optional). 
2. The tissue samples are contained in cryo-tubes and sealed with sealer. The 
cryo-tubes are kept in cryo-box. 
3. Wipe tubes with 5% surftanios. Tissue samples stabilized in RNAlater 
removed with forceps and placed on suitably sized vessel containing liquid 
nitrogen and grind thoroughly with a mortar and pestle. 
Notice: any formed crystals should be removed.   
4. Transfer tissue powder and liquid nitrogen into an RNase-free, liquid-
nitrogen–cooled, 2 ml microcentrifuge tube (not supplied with the kit). Allow 
the liquid nitrogen to evaporate, but do not allow the tissue to thaw. Add the 
appropriate volume of Buffer RLT. Pipet the lysate directly into a 
QIAshredder spin column placed in a 2 ml collection tube, and centrifuge for 
2 min at full speed.  Discard the tissue nunc tubes into % surftanios. 
5. Add 590μl RNase-free water to the lysate. Then add 10μl proteinase K 
solution, and mix thoroughly by pipetting. 
6. Incubate at 55°C for 10 min. 
7. Centrifuge at 20–25°C for 3 min at 10,000 x g. 
        A small pellet of tissue debris will form, sometimes accompanied by a thin              
layer or film on top of the supernatant. 
8. Pipet the supernatant (approximately 900μl) into a new 1.5 ml or 2 ml 
microcentrifuge tube (not supplied). Discard the pellet into % surftanios. 
 
     Transferring any of the pellet. If this is unavoidable, a small amount of pelleted 
debris may be carried over   without affecting the RNeasy procedure. Hold the 
pipet tip under the thin layer or film on top of the supernatant, if present. This 
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layer will usually adhere to the outside of the pipet tip and should not be 
transferred. 
9. Add 0.5 volumes (usually 450μl) of ethanol (96–100%) to the cleared lysate. 
Mix well by pipetting. Do not centrifuge. Precipitates may be visible after 
addition of ethanol. This does not affect the procedure. 
10. Transfer 700μl of the sample, including any precipitate that may have 
formed, to an RNeasy Mini spin column placed in a 2 ml collection tube. 
Close the lid gently, and centrifuge at 20–25°C for 15 s at ≥8000 x g 
(≥10,000 rpm). Discard the flow through 5% surfatanios. 
Reuse the collection tube in step 11. 
11. Repeat step 10 using the remainder of the sample. Discard the flow-through 
into % surftanios  
Reuse the collection tube in step 12. 
12. Add 350μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge at 20–25°C for 15 s at ≥8000 x g (≥10,000 rpm) to wash the 
membrane. Discard the flow through 5% surfatanios. 
 Reuse the collection tube in step 15. 
Optional: If on-column DNase digestion is not desired, add 700μl Buffer 
RW1 instead, centrifuge for 15 s at ≥8000 x g, and discard the flow-through* 
(but not the collection tube). Proceed to step 16. 
13. Add 10μl DNase I stock solution to 70μl Buffer RDD. Mix by gently 
inverting the tube, and centrifuge briefly to collect residual liquid from the 
sides of the tube. Note: DNase I is especially sensitive to physical 
denaturation. Mixing should only be carried out by gently inverting the tube. 
Do not vortex. 
 
14. Add the DNase I incubation mix (80μl) directly to the RNeasy spin column 
membrane, and place on the benchtop (20–30°C) for 15 min. Note: Be sure to 
add the DNase I incubation mix directly to the RNeasy spin column 
membrane. DNase digestion will be incomplete if part of the mix sticks to the 
walls or the O-ring of the spin column. 
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15. Add 350μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at _8000 x g (_10,000 rpm) at 20–25°C. Discard the flow 
through  into % surftanios 
Reuse the collection tube in step 16. 
16. Add 500μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge at 20–25°C for 15 s at ≥8000 x g (≥10,000 rpm) to wash the 
membrane. Discard the flow-through into 5% suratanios 
 Reuse the collection tube in step 17 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use (see “Things to do before starting”). 
17. 15Add 500μl Buffer RPE to the RNeasy spin column. Close the lid gently, 
and centrifuge at 20–25°C for 2 min at ≥8000 x g (≥10,000 rpm) to wash the 
membrane. 
The long centrifugation dries the spin column membrane, ensuring that no 
ethanol is carried over during RNA elution. Residual ethanol may interfere 
with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from 
the collection tube so that the column does not contact the flow-through. 
Otherwise, carryover of ethanol will occur. 
18.   Optional: Place the RNeasy spin column in a new 2 ml collection tube 
(supplied), and discard the old collection tube with the flow-through. Close 
the lid gently, and centrifuge at full speed for 1 min. Perform this step to 
eliminate any possible carryover of Buffer RPE, or if residual flow-through 
remains on the outside of the RNeasy spin column after step 17. 
19. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). 
Add 30–50μl Nase-free water directly to the RNeasy spin column membrane. 
Close the lid gently. To elute the RNA, centrifuge for 1 min at ≥8000 x g 
(≥10,000 rpm) at 20–25°C. 
20. Repeat step 19 using another 30–50μl RNase-free water, or using the eluate 
from step 19 (if high RNA concentration is required). Reuse the collection 
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tube from step 19. If the expected RNA yield is >30μg, there is no need to 
repeat step 19. 
 If using the elute from step 19, the RNA yield will be 15–30% less than that 
obtained using a second volume of RNase-free water, but the final RNA 
concentration will be higher. 
21. RNA samples to be stored in a named container at -80 0C.  
Wipe tubes and box with 5% surfanios. 
22. Clear up. 
Waste to be left overnight in a waste box with lid on containing final 
concentration of 5% surfanios. Next day waste to be put in autoclave boxes 
and taken to CSU in closed metal trolley.  Hood to be swabbed down with 
5% surfanios or bombed as appropriate. 
23. Fill in log book 
24. Proceed to cDNA synthesis  
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SUMMARY PROTOCOL & RISK ASSESSMENT 
B). Extraction of RNA from blood collected from leprosy patients 
To be read in conjunction with the Category 3 code of practice 
Organism M.leprae There may be small numbers of live 
organisms in blood from untreated patients 
Laboratory 427A 
Project supervisor 
 
Diana Lockwood  
Routes of infection Predominately by aerosol route 
 
Disinfectants 
 
 
Surfanios, freshly prepared (5%, final 
concentration), disinfection overnight 
Written by Edessa N Gobena  May, 2015 
Approved by principal investigator: 
Diana Lockwood 
Date: 
Signature: 
Approved copy sent to the safety office: Date: 
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B). Extraction of RNA from blood collected from leprosy patients 
To be used with the PAXgene Blood RNA kit. 
General precautions: Apply RNase Away spray to all surfaces (work surface, tubes, 
pipettes, microcentrifuge and gloves) and wipe down. 
In CAT2 lab: 
Make DNase solution according to kit guidelines, aliquot and store at -20C. 
Before using wash buffer 2 (BR4) add 4 volumes of ethanol (96-100%, purity grade 
p.a.) to obtain a working solution. 
In CAT3 lab: 
Wear gown, gloves and sleeves. Risk of aerosol formation through use of pipettes 
and centrifugation. 
TAKE the following into class I hood: 
e. Large3 polystyrene container full of ice 
f. Microcentrifuge 
g. Heating block 
h. Mini vortex 
i. Aerosol resistant tips and Gilson pipettes will be kept inside a plastic 
container in the isolator and transferred into the cabinet as required. These 
must be surface fumigated should they need to be removed from the cabinet. 
j. PAXgene Blood RNA kit items: 
 RNase-free water (4ml/sample) 
 Secondary BD Hemograd closures 
 Suspension buffer (BR1) (350ul/sample) 
 Binding buffer (BR2) (300ul/sample) 
 Proteinase K (40ul/sample) 
 100% cold ethanol (350ul/sample) 
 Wash buffer 1 (BR3) (700ul/sample) 
 DNase I (10ul/sample) /DNA digestion buffer (70ul/sample) 
 Wash buffer 2 (1000ul/sample) 
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 Elution buffer (80ul/sample) 
 Purification columns and collection tubes 
CAT. III PROCEDURE PROTOCOL & RISK ASSESSMENT 
RNA extraction from blood collected from leprosy patients (ENL) 
25. Blood transported from hospital to Cat. 3 at LSHTM.  
Blood will be contained in a sealed unbreakable primary container and held 
within a secondary approved canister with sufficient absorbent material 
between the two to absorb any spillage according to Post Office 
transportation guidelines. 
26. In Cat. 3 room blood will be removed from canister in class 2 hood. 
Double glove procedure to be used in the first 4 stages and thereafter single 
gloves. Class 2 hood will contain tray containing absorbent material and 5% 
fresh surfanios (final concentration) from beginning to end of experimental 
protocol. 
27. PAxgene tubes containing blood will be left overnight at RT before starting 
the procedure to ensure complete lysis of blood cells. 
28. Blood centrifuged at 3000-5000g for 10 minutes at room temperature. 
Wipe tubes with 5% surftanios.  Open centrifuge buckets in hood and put in 
tubes carefully and replace bucket lids. Wipe buckets before removing from 
class 2 hood and placing in the centrifuge. 
29. Using pastette remove supernatant and add 4ml RNase free water to the pellet 
and close the tube using a fresh secondary BD Hemogard closure (supplied 
with the kit) and vortex until the pellet is visibly dissolved. 
30. Centrifuge at 3000-5000g for 10 minutes at room temperature.  
Reduce aerosol by keeping tip below surface of the water.  Waste into 5% 
surfanios. 
31. Using pastette remove entire supernatant and add 350ul resuspension buffer 
(BR1) and vortex until pellet is visibly dissolved. Waste into 5% surfanios. 
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32. Pipet sample to a 1.5ml microcentrifuge tube and add 300ul binding buffer 
(BR2) and 40ul proteinase K (PK). Mix by vortexing for 5 sec and incubate at 
55 C (heating block). 
Waste into 5% surfanios.  Wipe microcentrifuge tubes with 5% surfanios and 
continue protocol outside the hood on clean benchtop in tray containing 
absorbent paper.  Freshly prepared 5% surfanios waste bucket on bench top. 
33. Pipet the lysate directly into a PAXgene Shredder spin column (lilac) placed 
in a 2ml processing tube. 
34. Centrifuge for 3 mins at max speed in microcentrifuge (not to exceed 
20,000g). 
Waste into 5% surfanios. 
35. Transfer the entire supernatant of the flow-through fraction to a fresh 1.5ml 
microcentrifuge tube without disturbing the pellet in the processing tube. 
36. Add 300ul ethanol 96-100%, mix by vortex and centrifuge briefly (1-2sec at 
500-1000g). 
Waste into 5% surfanios. 
37. Apply 700ul sample to PAXgene spin column sitting in a 2ml processing tube 
and discard the old processing tube containing flow-through. 
38. Pipet 350ul wash buffer (BR3) into the PAXgene RNA spin column. 
39. Centrifuge for 1 min at 8000g discard flow through. 
Waste into 5% surfanios. 
40. Add 10ul DNAse I stock solution to 70ul DNA digestion buffer in a 1.5ml 
microcentrifuge tube. Mix gently by flicking the tube. 
41. Apply 10ul Dnase1 and 70ul DNA digestion buiffer (RDD) to PAXgene 
RNA spin column membrane and leave on bench top for 15 mins. 
42. Pipet 350ul wash buffer (BR3) into the PAXgene RNA spin column ande 
centrifuge for 1min at 8000g. Place the spin column in a new 2ml processing 
tube and discard the old processing tube containing flow-through in 5% 
surfanios. 
43. Pipet 500ul washing buffer 2 (BR4) to column and centrifuge for 1 min at 
8000g discard flow through. 
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Waste into 5% surfanios. 
44. Repeat step 18. 
45. Discard tube containing flow through and place the column in a new 2ml 
processing tube. Centrifuge for 1 in at 8000g 
46. Discard the processing tube containing the flow-through in 5%surfanios. 
47. Place the column in a 1.5ml microcentrifuge tube and pipet 40ul elution 
buffer (BR5) directly onto column membrane. 
48. Centrifuge for 1min at 8000g to elute the RNA. 
49. Repeat the step23 using 40ul elution buffer and the same microcentrifuge 
tube. 
50. Incubate elute at 65C for 5 min. and chill immediately on ice. 
Discard ice into 5% surfanios. 
51. RNA samples to be stored in a named container at -80 0C.  
Wipe tubes and box with 5% surfanios. 
52. Clear up. 
Waste to be left overnight in a waste box with lid on containing final 
concentration of 5% surfanios. Next day waste to be put in autoclave boxes 
and taken to CSU in closed metal trolley.  Hood to be swabbed down with 
5% surfanios or bombed as appropriate. 
53. Fill in log book 
54.  Continue cDNA synthesis  
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Protocol 7: cDNA synthesis for real-time two-step RT-PCR 
 
1. Allow the components to thaw on ice 
2. Referring to the table below, calculate the volume of components needed 
to prepare the required number of reactions. 
 
Note: Prepare the RT master mix on ice. 
 
Component  Volume / reaction  (µl) 
  
10✕ RT Buffer 2.0 
25✕ dNTP Mix (100 mM) 0.8 
10✕ RT Random Primers 2.0 
MultiScribe™ Reverse 
Transcriptase 
1.0 
RNase Inhibitor 1.0 
Nuclease-free H2O 3. 2 
Total per Reaction 10.0 
 
3. Place the 2✕ RT master mix on ice and mix gently. 
 
To prepare the cDNA RT reactions: 
 
1. Pipette 10 µL of 2✕ RT master mix into individual tube. 
2. Pipette 10 µL of RNA sample into tube, pipetting up and down two 
times to mix 
3. Seal the tubes 
4. Briefly centrifuge the tubes to spin down the contents and to eliminate 
any air bubbles. 
5. Place the plate or tubes on ice until you are ready to load the thermal 
cycler. 
 
To perform reverse transcription: 
 
1. Program the thermal cycler conditions 
 
MPORTANT! These conditions are optimized for use with the High Capacity 
cDNA Reverse Transcription Kits (by the company). 
 
Condition  Step 1 Step 2 Step 3 Step 4 
Temp. (0C)  25 37 85 4 
Time 10 min  120 min 5 min ∞ 
 
2. Set the reaction volume to 20 µL. 
3. Load the reactions into the thermal cycler 
4. Start the reverse transcription run 
 
416 
 
 
cDNA storage 
 
 
               Storage Duration Storage                            Temperature (°C) 
               Short-term (up to 24 hours before use)         2-6 
               Long term                                                   −15 to −25 
 
 
Protocol 8: Real-Time PCR  
 PCR machine: Rotor-Gene 3000 
Important points before starting 
1. The Rotor-Gene SYBR Green PCR Kit has been developed for use in a two-step 
cycling protocol, with a denaturation step at 95°C and a combined 
annealing/extension step at 60°C. This protocol will also work for primers with a 
Tm well below 60°C. 
2. For the highest efficiency in real-time PCR using SYBR Green I, targets should 
ideally be 60–200bp in length. 
3. The PCR must start with an initial incubation step of 5 minutes at 95°C to 
activate HotStarTaq Plus DNA Polymerase. 
4. We recommend a final reaction volume of 25 μl. 
5. Always start with the Mg2+ concentration as provided in 2x Rotor-Gene SYBR 
Green PCR Master Mix. 
Procedure 
1. Thaw 2x Rotor-Gene SYBR Green PCR Master Mix, template DNA or 
cDNA, primers, and RNase-free water. Mix the individual solutions. 
2. Prepare a reaction mix according to the following Table.  Due to the hot start, 
it is not necessary to keep samples on ice during reaction setup or while 
programming the Rotor-Gene cycler. 
Note: We strongly recommend starting with the Mg2+ concentration as provided in 
2x Rotor-Gene SYBR Green PCR Master Mix. 
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Component  Volume/reaction 
(μl) 
Final concentration  
2x Rotor-Gene SYBR Green 
PCR Master Mix 
6.25 1x 
Primer FW 1.0  1µm 
Primer R 1.0 1µm 
RNase-free water 3.25  
Template DNA or cDNA 
(added at step 4) 
1.0 ≤100 ng/ 
reaction 
Total reaction volume l 12  
 
3. Mix the reaction mix thoroughly, and dispense appropriate volumes into PCR 
tubes. 
4. Add template DNA or cDNA (≤100 ng/reaction) to the individual PCR tubes 
containing the reaction mix. 
For two-step RT-PCR, the volume of the cDNA added (from the undiluted RT 
reaction) should not exceed 10% of the final PCR volume. 
5. Program the Rotor-Gene cycler according to the program outlined in the 
following table   
Data acquisition should be performed during the combined annealing/extension 
step 
 
Step Time  Temperature  
PCR initial activation step 15 min 950C 
Number of cycles                   40 
Denaturation 5s 950C 
annealing 10s 600C 
extension 20s 720C 
6. Place the PCR tubes in the Rotor-Gene cycler, and start the cycling program. 
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7. Optional: Perform melting curve analysis of the PCR product(s) to verify their 
specificity and identity  (50oC to 99oC increasing by 1oC on each step. Use the 
interval between increases in temperature 30 seconds for the first step and then 5 
seconds for subsequent steps 
 
Primers  
 
Primer 
(F, forward; 
R, reverse) Sequence  (5' to 3') Length 
Tm (ºC) 
% GC 
ratio  
Amplicon  
size (bp) 
Accession 
number 
IL-10 FW TGAGAACCAAGACCCAGACA 20 63.4 50 182 
NM_000594 IL-10 RV TCATGGCTTTGTAGATGCCT 20 62.2 45 
TNF-a  FW AGCCCATGTTGTAGCAAACC 20 58.74 50.00 104 
NM_172369 TNF-a RV GCTGGTTATCTCTCAGCTCCA 21 59.24 52.38 
IL-17A FW AGACCTCATTGGTGTCACTGC 21 64.2 52.3 238 
NM_002190 IL-17A RV CTCTCAGGGTCCTCATTGCG 20 67.2 60 
IL-6 FW TTCGGTCCAGTTGCCTTCTC 20 66.5 55 193 
NM_000600 IL-6 RV TACATGTCTCCTTTCTCAGGGC 22 64.3 50 
IL-1B FW AGCCCCAGCCAACTCAATTC 20 67.4 55 380 
XM_006712496 IL-1B RV CATGGAGAACACCACTTGTTGC 22 66.6 50 
Fox P3  FW TGGAGAAGGAGAAGCTGAGTGC 22 61.99 54.55 73 
XM_011543919 FoxP3  RV ACAGATGAAGCCTTGGTCAGTGC 23 63.24 52.17 
IFN-g  FW GGCTTTTCAGCTCTGCATCG 20 59.90 55.0 172 
NM_000619 INF-g  RV TCTGTCACTCTCCTCTTTCCA 21 57.76 47.62 
IL-8 FW ACCGGAAGGAACCATCTCAC 20 59.39 55.0 104 
NM_000584 IL-8  RV AAACTGCACCTTCACACAGAG 21 58.71 47.62 
HuPO FW * GCTTCCTGGAGGGTGTCC 18 59.33 66.67 105 
NM_001002 HuPO RV * GGACTCGTTTGTACCCGTTG 20 58.86 55.00 
TGF-β FW ACATCAACGCAGGGTTCACT 20 59.89 50 264 XM_011527242 
TGF-β RV GAAGTTGGCATGGTAGCCC 20 60.03 55 
C1-qA  FW ATGGTGACCGAGGACTTGTG 20 59.68 55 276 NM_015991 
C1-qA  RV GTCCTTGATGTTTCCTGGGC 20 58.82 55 
C1-qB  FW CAGGTTGAAATCAGCATTGCC 21 58.39 47.62 163 XM_011542059 
C1-qB  RV CTGTGTCAGACGCCTCCTTTC 21 60.94 57.14 
C1-qC  FW AAGGATGGGTACGACGGACTG 21 61.56 57.14 213 NM_172369 
C1-qC  RV TTTCTGCTTGTATCTGCCCTC 21 58.01 47.62 
 
*Housekeeping gene  
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Appendix 5:  Tables for regulatory T-cell results  
Table 1.  Median percentage of CD4+T-cells, CD8+ T-cells and the median  
       percentage ratio of CD4+ to CD8+ T- cells (ENL vs LL)  
Table 2.  Median percentage of CD25 expression on CD4+ and CD8+ T-cells  
     (ENL vs LL) 
Table 3. Median percentage of FoxP3 expression on CD4+ and CD8+ T-cells  
    (ENL vs LL) 
Table 4.  Median percentage of CD4 and CD8 T-cells expressing CD25 and  
    FoxP3 (ENL vs LL) 
Table 5.   Median percentage of CD4+ and CD8+ regulatory T- cells (ENL vs LL) 
Table 6.  Median percentage of CD4 and CD8 T-cells expressing CD161 (ENL vs  
   LL) 
Table 7. Median Percentage of CD4+T-cells, CD8+ T-cells and the median  
   percentage ratio of CD4 to CD8+ T- cells (ENL before and after treatment)  
Table 8.  Median percentage of CD4 and CD8 T-cells expressing CD25 and  
   FoxP3 (ENL before and after treatment)  
Table 9. Median percentage of CD25+FoxP3+ expression on CD4 and CD8 T- 
 cells (ENL before and after treatment)  
Table 10: Median percentage of CD4+ and CD8+ Tregs (ENL before and after  
 treatment)  
11. IL-17 Producing cells (ENL before and after treatment)  
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Table 1.  Median percentage of CD4+T-cells, CD8+ T-cells and the median 
percentage ratio of CD4+ to CD8+ T- cells in the PBMCs of patients with ENL 
reaction and LL patient controls before during  and after treatment of ENL cases 
with prednisolone.   
time cell type  Patients Median (%)   P U  
H-L 
95% Confidence 
interval  
before  
 LL=31 
 ENL=46 
  
  
  
CD4+  
  
ENL  61.30 < 0.0001 153.5 -12.80 -16.20 to -9.200 
LL 49.10 
CD8+ 
  
ENL  27.00 < 0.0001 275 8.200 4.900 to 12.00 
LL 35.70 
CD4/CD8 
  
ENL  2.25 < 0.0001 174 -0.9000 -1.200 to -0.6000 
LL 1.4 
during  
 LL=31 
 ENL=46 
  
  
  
CD4+  
  
ENL  54.20 0.0235 368.5 3.800 0.5000 to 8.600 
LL 61.35 
CD8+ 
  
ENL  34.4 0.0001 250 -7.300 -10.80 to -3.400 
LL 28.3 
CD4/CD8 
  
ENL  1.7 0.001 293 0.6000 0.2000 to 1.000 
LL 2.25 
after  
  
 LL=28 
 ENL=44 
  
  
CD4+  
  
ENL  58.10 0.0033 364.5 8.050 2.600 to 13.30 
LL 64.70 
CD8+ 
  
ENL  33.35 0.0313 430 -5.400 -10.00 to -0.5000 
LL 27.2 
CD4/CD8 
  
ENL  2.14 0.0944 471 0.3700 -0.0500 to 0.8200 
LL 1.8 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 2.  Median percentage of CD25 expression on CD4+ and CD8+ T-cells in the   
PBMCs of patients with ENL reaction and LL patient controls before during   and 
after treatment of ENL cases with prednisolone 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
 
  
time cell type Patients Median 
(%) 
P U  
H-L 
 
95% Confidence 
interval 
before 
LL=31 
ENL=46 
CD4+CD25+ ENL 8.920 0.814
3 
 
690.0 
 
0.1900 -1.290 to 1.570 
LL 8.750 
CD8+CD25+ ENL 2.580 0.046
5 
521.5 0.6800 0.01000 to 
1.320 LL 3.320 
during 
LL=31 
ENL=46 
CD4+CD25+ ENL 8.170 0.897
0 
535.5 -0.08500 -1.860 to 1.660 
LL 7.140 
CD8+CD25+ ENL 3.050 0.158
2 
434.5  
0.4850 
 
-0.2200 to 1.700 LL 3.170 
after 
LL=28 
ENL=44 
CD4+CD25+ ENL 9.455 0.084
0 
484.5 -1.295 -2.660 to 0.1500 
LL 7.580 
CD8+CD25+ ENL 2.245 0.085
8 
467.0 0.4500 -0.1000 to 1.110 
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Table 3. Median percentage of FoxP3 expression on CD4+ and CD8+ T-cells in the   
PBMCs of patients with ENL reaction and LL patient controls before during   
and after treatment of ENL cases with prednisolone.   
 
 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
 
 
  
time cell type Patients 
Median 
(%) 
P U 
LH  95% confidence 
interval  
before 
CD4+FoxP3+ 
ENL 2.105 
< 0.0001 230.5 
2.380 1.540 to 3.260 
LL=31 LL 5.13 
ENL=46 
CD8+FoxP3+ 
ENL 0.585 
0.0701 538.5 
0.1800 -0.0100 to 0.380 
  LL 0.71 
during 
CD4+FoxP3+ 
ENL 3.52 
0.016 357.5 
-1.160 -2.020 to -0.290 
LL=31 LL 2.595 
ENL=46 
CD8+FoxP3+ 
ENL 0.49 
0.0108 347 
0.4850 -0.2200 to 1.700 
  LL 1.165 
after 
CD4+FoxP3+ 
ENL 4.37 0.0537 449 -
0.5950 
-1.340 to 0.0300 
LL=28 LL 3.79     
ENL=44 
CD8+FoxP3+ 
ENL 0.5 0.4817 554.5 0.0700 -0.1200 to 0.2800 
  LL 0.705     
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Table 4.  Median percentage of CD4 and CD8 T-cells expressing CD25 and FoxP3 in 
the   PBMCs of patients with ENL reaction and LL patient controls before during   
and after treatment of ENL cases with prednisolone.   
  
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time cell type Patients 
Median 
(%) 
P  U 
LH 95 % 
Confidence 
interval  
before 
CD4+CD25+FoxP3+ 
ENL 1.785 
< 0.0001 
189.5 
 
1.995 1.430 to 
2.470 
LL=31 LL 3.800  
ENL=46 
CD8+CD25+FoxP3+ 
ENL 0.4150 
0.1333 
568.0 0.1500 -0.0600 to 
0.410 
  LL 0.5900  
during 
CD4+CD25+FoxP3+ 
ENL 2.620 
0.0755 
406.0 -
0.6300 
-1.300 to 
0.09000 
LL=31 LL 2.450  
ENL=46 
CD8+CD25+FoxP3+ 
ENL 0.2800 
0.3708 
475.0 0.1050 -0.0880 to 
0.3800 
  LL 0.5150  
after 
CD4+CD25+FoxP3+ 
ENL 3.295 
  0.0003 
312.5 -1.075 -1.680 to -
0.5100 
LL=28 LL 2.220  
ENL=44 
CD8+CD25+FoxP3+ 
ENL 0.3450 0.0969 
  
472.0 0.1500 -0.0210 to 
0.4200 
  LL 0.5750  
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Table 5.   Median percentage of CD4+ and CD8+ regulatory T- cells in the   PBMCs 
of patients with ENL reaction and LL patient controls before, during   and after 
treatment of ENL cases with prednisolone.   
 
 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time cell type Patients 
Median 
(%) 
P  
U  
H-L 
95% confidence 
interval  
before 
CD4+Tregs 
ENL 1.67 
< 0.0001 
182.0 
 
1.925 
1.390 to 2.380 
LL=31 LL 3.79  
ENL=46 
CD8+Tregs 
ENL 0.3665 
0.3923 
630.0 
0.0750 
-0.1310 to 0.2610 
  LL 0.5400  
during 
CD4+Tregs 
ENL 3.21 
0.0745 
405.5 
 -0.5700 
-1.190 to 0.08000 
LL=31 LL 2.43  
ENL=46 
CD8+Tregs 
ENL 0.2340 
0.0879 
411.5 
 
0.1270 
-0.0120 to 0.3490 
  LL 0.4150  
after 
CD4+Tregs 
ENL 3.21 
0.0090 
391.5 
-0.7300 
-1.290 to -0.2200 
LL=28 LL 2.480  
ENL=44 
CD8+Tregs 
ENL 0.3425 
0.2191 509.0 0.0980 
-0.0620 to 0.3190 
  LL 0.4745  
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Table 6.  Median percentage of CD4 and CD8 T-cells expressing CD161 (IL-17 
producing TH17) in the   PBMCs of patients with ENL reaction and LL patient 
controls before during   and after treatment of ENL cases with prednisolone 
  
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
 
 
  
time cell type Patients 
Median 
(%) 
P  
U  
H-L 
95% confidence 
interval 
before 
CD4+CD161+ 
ENL 20.35 
0.0122 
473.0 
 
-4.700 
-8.100 to -1.000 
LL=31 LL 15.10  
ENL=46 
CD8+CD161+ 
ENL 7.120 
0.2807 
608.5 
1.005 
-1.110 to 2.930 
  LL 7.900  
during 
CD4+CD161+ 
ENL 14.40 
0.2891 
462.0 
 1.320 
-0.8000 to 3.700 
LL=31 LL 16.70  
ENL=46 
CD8+CD161+ 
ENL 6.140 
0.2376 
452.5 
 
1.140 
-0.9200 to 3.250 
  LL 6.350  
after 
CD4+CD161+ 
ENL 19.00 
0.8701 
601.5 
 
0.4000 
-3.300 to 4.000 
LL=28 LL 19.15  
ENL=44 
CD8+CD161+ 
ENL 7.380 
0.6358 
574.5 
0.4750 
-1.700 to 2.760 
  LL 9.290  
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Table 7. Median Percentage of CD4+T-cells, CD8+ T-cells and the median 
percentage ratio of CD4 to CD8+ T- cells in the PBMCs of patients with ENL 
reactions before during   and after treatment with prednisolone.   
Cell type Patients Median 
(%) 
P  H-L U 95% 
Confidence 
interval for HL  
CD4+ 1st  61.3  
0.0006 
 
6.800 
 
515 
 
-10.40 to -2.900 2nd  54.2 
CD4+ 1st  61.3 
 0.0234  -4.600  768.5 
 -8.300 to -
0.4000 3rd  57.25 
CD4+ 2nd  54.2 
 0.3483 
 2.200 
  
 790.0  -2.100 to 6.800 
3rd  57.25 
CD8+ 1st 27.00 
 < 0.0001   6.800  432.0 
  
 3.700 to 10.10 2nd  34.40 
CD8+ 1st  27.00 
 0.0028   6.000  678.5   2.000 to 9.800 
3rd  34.30 
CD8+ 2nd  34.40 
 840.5   -1.000  840.5 -4.800 to 2.700 
3rd   34.30 
 CD4+/CD8+ 1st  2.250 
 < 0.0001   -0.6000  439.5 
 -0.900 to -
0.300 2nd  1.700 
CD4+/CD8+ 1st  2.250 
 0.0056 
  -
0.5000 
 706.0 
  -0.800 to -
0.100 3rd  1.800 
CD4+/CD8+ 2nd  1.700 
 0.3339   0.1000  787.0   -0.100 to 0.400 
3rd  1.800 
   P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
         ENL 1st, 2nd, 3rd    (n= 46, 46, 44 for 1st, 2nd and 3rd rounds respectively) 
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Table 8.  Median percentage of CD4 and CD8 T-cells expressing CD25 and FoxP3 in 
the   PBMCs of patients with ENL reaction before during   and after 
treatment with prednisolone.   
Cell type Patients Median (%) P  HL U 95% Confidence 
interval for HL 
CD4+CD25+ 1st  8.920 0.4436 -0.4600 809.5 -1.950 to 0.8100 
2nd  8.170 
CD4+CD25+ 1st 8.920 
0.4881 0.4250 925.5 -0.9100 to 1.620 
3rd 9.455 
CD4+CD25+ 2nd 8.170 
0.1507 1.000 700.0 -0.3400 to 2.260 
3rd  9.455 
CD8+CD25+ 1st 2.580 
 0.8043   0.1300  868.5 
 -0.7800 to 0.9400 
  2nd  3.050 
CD8+CD25+ 1st  2.580 
 0.5009   -0.1950  928.0   -0.7600 to 0.4300 
3rd  2.245 
CD8+CD25+ 2nd  3.050 
 0.6385 
 -0.2700 
  
 806.0   -1.070 to 0.9400 
3rd  2.245 
 CD4+FoxP3+ 1st  2.105  < 
0.0001 
  1.405  410.5   0.8500 to 2.000 
2nd  3.520 
 CD4+FoxP3+ 1st  2.105  < 
0.0001 
  
 2.155 
 297.0   1.600 to 2.740 
3rd  4.370 
CD4+FoxP3+ 2nd 3.520 
 0.0352 0.8250 627.5 0.07000 to 1.350 
3rd 4.370 
CD8+FoxP3+ 1st  0.5850 
0.3667 0.09700 794.0 -0.1200 to 0.3200 
2nd  0.4900 
CD8+FoxP3+ 1st  0.5850 
0.8866 0.01000 994.0 -0.1500 to 0.1700 
3rd  0.5000 
CD8+FoxP3+ 
2nd 0.4900 
0.4096 -0.07000 767.0 -0.2600 to 0.1000 
3rd 0.5000 
       
   P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 9.    Median percentage of CD25+FoxP3+ expression on CD4 and CD8 T-cells 
in the   PBMCs of patients with ENL reaction before during   and after treatment 
with prednisolone.   
Cell type Patients Median 
(%) 
P  HL U 95% Confidence 
interval for HL  
CD4+CD25+FoxP3+ 1st  1.785 < 0.0001 1.040 397.5 0.6300 to 1.650 
2nd  2.620 
CD4+CD25+FoxP3+ 1st 1.785 
< 0.0001 1.550 352.0 1.080 to 2.000 
3rd 3.295 
CD4+CD25+FoxP3+ 2nd 2.620 
0.1846 0.4500 712.0 -0.2500 to 0.9100 
3rd  3.295 
CD8+CD25+FoxP3+ 1st 0.4150 
 0.6308 
 -
0.04000 
  
-0.2400 to 
0.09900 2nd  0.2800 
CD8+CD25+FoxP3+ 1st  0.4150 
 0.4931 
 -0.0600 
  
 926.5 
 -0.2700 to 
0.0900 
  
3rd  0.3450 
CD8+CD25+FoxP3+ 2nd  0.2800 
0.9042 
 0.01000 
  
 844.5 
 -0.1100 to 
0.1200 
  
3rd  0.3450 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 10: Median percentage of CD4+ and CD8+ Tregs in the   PBMCs of patients 
with ENL reaction before during   and after treatment with prednisolone. B) Trends 
in frequency of individual CD4+ and CD8+ Tregs in the PBMCs of patients with ENL 
reaction before and after treatment with prednisolone.  
Cell type Patients Median 
(%) 
P  HL U 95% Confidence 
interval for HL  
CD4+Tregs  1st  1.670 < 0.0001 1.010 348.0 0.6200 to 1.480 
2nd  2.460 
CD4+Tregs 1st 1.670 
< 0.0001 1.600 313.5 1.170 to 2.030 
3rd 3.210 
CD4+Tregs 2nd 2.460 
0.1063 0.560 713.5 -0.090 to 0.940 
3rd  3.210 
CD8+Tregs 1st 0.3665 
 0.0451  -0.1275  670.0 
 -0.3100 to -0.0010 
  2nd  0.2340 
CD8+Tregs 1st  0.3665 
 0.6904  -0.0275  1007   -0.2100 to 0.1030 
3rd  0.3575 
CD8+Tregs 2nd  0.2340 
 0.0884 
 0.1020 
  
 703.5  -0.0190 to 0.2090  
3rd  0.3575 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 11. IL-17 Producing cells in the PBMCs of patients with ENL and LL controls 
before, during and after treatment 
 
Time point  cell type patients median 
% 
P U LH 95 CI 
Before 
treatment 
  
  
  
  
  
  
  
IL-17 producing 
T cells  
  
ENL    23.10   0.0346 
  
  436.5 
  
  -4.450 
  
  -8.500 to -0.3000 
  LL   18.40 
IL-17 producing 
lymphocytes  
  
ENL 26.45 0.0059 382.5 -5.700 -9.100 to -1.700 
LL 20.60 
CD4+ IL-17+ 
  
ENL 20.35 
0.0122 
473.0 
 -4.700 
-8.100 to -1.000 
 LL 15.10 
CD8+IL-17+ 
  
ENL 7.120 
0.2807 
608.5 
1.005 
-1.110 to 2.930 
 LL 7.900 
During  
treatment 
  
  
  
  
  
  
  
IL-17 producing 
T cells  
  
ENL  16.40  0.2132 
  
 447.5 
  
  2.000  -1.500 to 5.200 
  LL  18.15 
IL-17 producing 
lymphocytes  
  
ENL  15.40  0.0954 
  
 414.5 
  
 3.200 
  
  -0.6000 to 6.500 
LL  19.70 
CD4+ CD161+ 
  
ENL 14.40 
0.2891 
462.0 
 1.320 
-0.8000 to 3.700 
 LL 16.70 
CD8+CD161+ 
  
ENL 6.140 
0.2376 
452.5 
 1.140 
-0.9200 to 3.250 
 LL 6.350 
After 
treatment  
  
  
  
  
  
  
  
IL-17 producing 
T cells  
  
ENL  13.25  0.1142 
  
497.5  
  
  2.725 -0.6700 to 6.800 
LL  16.30 
IL-17 producing 
lymphocytes  
  
ENL  12.70  0.6279 
  
 594.5 
  
  0.9550  -2.900 to 4.400 
  LL  14.80 
CD4+ CD161+ ENL 19.00 
0.8701 
601.5 
 0.4000 
-3.300 to 4.000 
 LL 19.15 
CD8+CD161+ 
  
ENL 7.380 
0.6358 
574.5 
0.4750 
-1.700 to 2.760 
 LL 9.290 
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Table 1. Memory T- cell expression on CD3+, CD4+ and CD8+ T-cells  in the 
PBMCs of ENL cases and LL control patients before, during and after treatment.   
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time cell type  Patients 
Median 
(%)   P 
 
 
U H-L 
95 % Confidence 
interval  
Before  
treatment  
ENL=35  
   LL=25 
   
  
CD3+CD45RO+ 
  
ENL  41.05 
0.0010 261.0 
 
-10.50 
 
-17.80 to -4.600 LL 28.80 
CD4+CD45RO+ 
  
ENL  52.30 < 
0.0001 159.0 
 
-20.30 
 
-27.40 to -11.90 LL 30.50 
CD8+CD45RO+ 
  
ENL  17.50 
0.3425 
 
429.0 -2.460 
 
-7.900 to 2.400 LL 15.20 
during  
treatment  
ENL=35  
   
LL=25  
  
  
CD3+CD45RO+ 
ENL  29.20 
0.8957 
 
360.0 -0.4500 
 
-7.700 to 6.400 LL 43.8 
 CD4+CD45RO+ 
ENL  45.9 
0.9966 
367.5 
-0.05 
-13.90  to 11.20 
LL 43.00 
CD8+CD45RO+  
ENL  12.55 
0.8029 
353.0 
-0.6000 
-4.460 to 4.300 
LL 13.00 
 After  
treatment  
ENL=35  
   
LL=25  
  
  
  
 CD3+CD45RO+ 
  
ENL 31.15 
0.4242 
 
2.200 
-3.600 to 8.600 
LL 32.65 458.5 
 CD4+CD45RO+ 
  
ENL 45.00 
0.5207 
470.5 
-2.500 
-10.50 to 6.100 
LL 41.80  
 CD8+CD45RO+ 
  
ENL 12.85 
0.1897 
419.5 
3.365 
-1.790 to 9.680 
LL 15.15 
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Table 2.   Median percentage of activated T-cells among  CD3+, CD4+ and CD8+ T-
cells  in the PBMCs of ENL cases and LL control patients before, during and after 
treatment.   
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
Time cell type  Patients 
Median 
(%)   P 
 
 
U HL 
95 % Confidence 
interval  
before  
 LL=25 
 ENL=35 
  
  
  
CD3+CD62L- 
  
ENL  59.15 < 
0.0001 55.50 
 
-22.40 
 
-30.00 to -17.10 LL 37.70 
CD4+CD62L- 
  
ENL  50.65 < 
0.0001 181.5 
 
-19.10 
 
-27.70 to -11.50 LL 27.10 
CD8+CD62L- 
  
ENL  71.15 < 
0.0001 
 
76.00 -27.90 
 
-34.50 to -20.20 LL 45.40 
during  
  LL=25 
 ENL=35 
  
  
  
CD3+CD62L- 
ENL  46.95 
0.7833 
 
351.5 3.095 
 
-11.10 to 17.40 LL 49.20 
CD4+CD62L- 
ENL  29.65 
0.5555 
 
318.0 3.350 
 
-6.400 to 12.60 LL 38.05 
CD8+CD62L- 
ENL  59.50 
0.3981 
 
318.0 -5.800 
 
-21.10 to 9.700 LL 49.70 
  
  LL=25 
 ENL=35 
  
  
  
  
CD3+CD62L- 
ENL 33.90 
0.1704 
  
5.650 
 
-2.800 to 13.60 LL 41.35 415.0 
CD4+CD62L- 
ENL 29.35 
0.7079 
491.0 
1.800 
-4.900 to 8.900 
LL 32.95  
CD8+CD62L- 
ENL 34.45 
 
0.0149 
 
10.10 
 
1.600 to 18.60 
LL 45.25 
335.5 
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Table 3.  Median percentage of activated memory T-cells expressed by   CD3+, CD4+ 
and CD8+ T-cells in the PBMCs of ENL cases and LL control patients before, during 
and after treatment 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time cell type  Patients 
Median 
(%)   P 
 
 
U H-L 
95 % 
Confidence 
interval  
before  
 LL=25 
 ENL=35 
  
  
  
CD3+EM 
 
ENL  26.55 
< 0.0001 100.5 
 
-18.29 
 
-22.80 to -12.80 LL 7.950 
CD4+EM ENL  24.55 
< 0.0001 68.00 
 
-18.40 
 
-23.05 to -13.50 LL 8.850 
CD8+EM ENL  16.50 
0.0083 
 
306.0 -6.690 
 
-11.45 to -2.200 LL 7.200 
during  
  LL=25 
 ENL=35 
  
  
  
CD3+EM ENL  16.80 
0.4483  
 
323.0 -2.415 
 
-7.530 to 2.810 LL 13.00 
CD4+EM ENL  11.40 
0.0284 
 
240.0 5.825 
 
0.6900 to 11.70 LL 17.60 
CD8+EM ENL  7.530 
0.8690 
 
358.0 0.2800 
 
-2.850 to 3.410 LL 8.340 
  
  LL=25 
 ENL=35 
  
  
  
  
CD3+EM ENL 7.620 
0.0409 
  
3.095 
 
0.0300 to 6.350 LL 10.44 354.5 
CD4+EM ENL 9.570 
0.2184 
414.5 
2.200 
-1.670 to 6.200 
LL 13.05  
CD8+EM 
ENL 6.490 0.5037 
 
456.5 1.100 
 
-1.680 to 4.100 
LL 8.465  
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Table 4.  Median percentage of central memory T-cells expressed by   CD3+, CD4+ 
and CD8+ T-cells in the PBMCs of ENL cases and LL control patients before, during 
and after treatment 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
 
 
  
time cell type  Patients 
Median 
(%)   P 
 
 
U H-L 
95 % Confidence 
interval  
before  
 LL=25 
 ENL=35 
  
  
  
CD3+CM 
 
ENL  13.80 
0.5354 453.5 
 
1.100 
 
-2.500 to 4.650 LL 14.60 
CD4+CM ENL  23.50 
0.0015 268.5 
 
-8.130 
 
-12.20 to -3.560 LL 14.40 
CD8+EM ENL  1.220 < 
0.0001 
 
165.0 2.340 
 
1.330 to 4.510 LL 3.530 
during  
  LL=25 
 ENL=35 
  
  
  
CD3+CM ENL  9.770 
0.0955 
 
270.0 2.400 
 
-0.6000 to 5.190 LL 12.70 
CD4+CM ENL  13.65 
0.3444 
 
312.0 3.370 
 
-2.930 to 9.200 LL 18.10 
CD8+CM ENL  1.850 
0.0696 
 
261.5 0.9250 
 
-0.090 to 1.940 LL 2.450 
  
  LL=25 
 ENL=35 
  
  
  
  
CD3+CM ENL 13.50 
0.6535 
473.0 
-1.000 
-6.310 to 2.810 
LL 13.80  
CD4+CM ENL 22.00 
0.4868 
 
-3.550  
-12.90 to 5.000 
LL 19.35 454.5 
CD8+CM 
ENL 2.660 
0.1829 
 
-0.5600 
-1.540 to 0.2100 
LL 2.015 
407.0 
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Table 5.  Median percentage of terminally differentiated  T-cells expressed by   
CD3+, CD4+ and CD8+ T-cells in the PBMCs of ENL cases and LL control patients 
before, during and after treatment 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time cell type  Patients Median (%)   P 
 
 
U H-L 
95 % 
Confidence 
interval  
before  
 LL=25 
 ENL=35 
  
  
  
CD3+ EC 
 
ENL  29.25 
0.0062 299.0 
 
-9.000 
 
-16.30 to -2.700 LL 20.00 
CD4+ 
EC 
ENL  14.00 
0.6417 465.0 
-1.000 -5.400 to 3.310 
LL 11.66 
CD8+ 
EC 
ENL  62.65 < 
0.0001 
147.5 
-25.80 
-33.20 to -17.30 
LL 39.50 
during  
  LL=25 
 ENL=35 
  
  
  
CD3+ 
EC 
ENL  43.35 
0.8160 
354.0 
2.300 
-8.600 to 10.80 
LL 37.10 
CD4+ 
EC 
ENL  22.90 
0.4953 
327.5 
-3.400 
-13.40 to 4.500 
LL 17.90 
CD8+ 
EC 
ENL  53.35 
0.5225 
330.0 
-3.600 
-14.10 to 6.500 
LL 50.20 
  
  LL=25 
 ENL=35 
  
  
  
  
CD3+ 
EC 
ENL 24.60 
0.0489 
 
8.650 
0.0 to 17.10 
LL 35.30 360.0 
CD4+ 
EC 
ENL 13.10 
0.1425 
397.0 
3.900 
-1.800 to 9.720 
LL 15.25  
CD8+ 
EC 
ENL 38.90 
0.0006 
 
14.40 
3.900 to 23.80 
LL 55.20 
304.0 
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Table 6. Median percentage of naïve T-cells among   CD3+, CD4+ and CD8+ T-cells 
in the PBMCs of ENL cases and LL control patients before, during and after 
treatment 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
time 
cell 
type  Patients Median (%)   P 
 
 
U LH 
95 % Confidence 
interval  
before  
 LL=25 
 ENL=35 
  
  
  
CD3+ 
NC 
 
ENL  27.70 
< 0.0001 111.0 
26.50 19.60 to 31.73 
LL 59.48 
CD4+ 
NC 
ENL  34.10 
< 0.0001 116.0 
25.60 17.16 to 33.50 
LL 61.54 
CD8+ 
NC 
ENL  15.35 
< 0.0001 
105.5 
31.06 
23.20 to 37.70 
LL 50.50 
during  
  LL=25 
 ENL=35 
  
  
  
CD3+ 
NC 
ENL  31.80 
0.7002 
345.0 -
2.100 
-10.60 to 7.900 
LL 32.90 
CD4+ 
NC 
ENL  45.15 
0.2947 
306.0 -
4.150 
-14.40 to 5.800 
LL 40.00 
CD8+ 
NC 
ENL  35.45 
0.8690 
358.0 
1.550 
-9.400 to 13.50 
LL 38.10 
  
  LL=25 
 ENL=35 
  
  
  
  
CD3+ 
NC 
ENL 42.90 
0.0409 
354.5 -
8.950 
-16.60 to -0.200 
LL 33.00  
CD4+ 
NC 
ENL 42.90 
0.5786 
 -
1.750 
-10.80 to 6.400 
LL 41.75 465.0 
CD8+ 
NC 
ENL 51.50 
0.0110 
 
-
14.40 
-24.60 to -2.800 
LL 32.80 
318.5 
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Table 7.  Median percentage of Memory T-cells expressed by CD3+, CD4+ and CD8+ 
T-cells in the PBMCs of ENL cases before, during and after treatment 
Cell type Patients Median 
(%) 
P  U HL 95% Confidence 
interval for HL 
CD3+CD45RO+ 1st  41.05 0.0010 354.0 -11.20 -17.60 to -4.300 
2nd  29.20 
CD3+CD45RO+ 1st 41.05 
0.0014 471.5 -9.800 -16.00 to -3.700 
3rd 31.15 
CD3+CD45RO+ 2nd 29.20 
0.7718 614.0 0.9000 -5.100 to 7.300 
3rd 31.15 
CD4+CD45RO+ 1st 52.30 
< 0.0001 164.0 -22.10 -28.60 to -14.60 
2nd 29.20 
CD4+CD45RO+ 1st 52.30 
0.0495 596.0 -8.750 -17.60 to 0.0 
3rd 45.00 
CD4+CD45RO+ 2nd 29.20 
0.0013 360.5 14.30 5.690 to 21.80 
3rd 45.00 
CD8+CD45RO+ 1st 17.50 
0.1259 504.5 -3.600 -8.300 to 0.9000 
2nd 12.55 
CD8+CD45RO+ 1st 17.50 
0.0516 562.0 -4.960 -9.660 to 0.7000 
3rd 12.85 
CD8+CD45RO+ 2nd 12.55 
0.4517 573.0 -1.335 -4.820 to 2.100 
3rd 12.85 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 8.  Median percentage of activated CD3+, CD4+ and CD8+ T-cells in the 
PBMCs of ENL cases before, during and after treatment 
Cell type Patients Median (%) P U  H-L 95% Confidence 
interval for HL 
CD3+CD62L- 1st  59.15 0.0176 431.5 -13.50 -24.60 to -2.200 
2nd  46.95 
CD3+CD62L- 1st 59.15 < 
0.0001 
233.0 -25.50 -31.60 to -17.80 
3rd 33.90 
CD3+CD62L- 2nd 29.65 
0.1231 503.5 -10.70 -22.20 to 2.700 
3rd 33.90 
CD4+CD62L- 1st 50.65 < 
0.0001 
299.5 --17.75 -28.40 to -9.200 
2nd 29.65 
CD4+CD62L- 1st 50.65 < 
0.0001 
330.5 -20.00 -28.30 to -12.60 
3rd 29.35 
CD4+CD62L- 2nd 29.65 
0.6141 595.0 -2.000 --9.800 to 6.500 
3rd 29.35 
CD8+CD62L- 1st 71.15 
0.0378 457.0 -11.70 -24.00 to -0.9000 
2nd 59.50 
CD8+CD62L- 1st 71.15 < 
0.0001 
62.50 -34.20 -40.20 to -27.70 
3rd 34.45 
CD8+CD62L- 2nd 59.50 
0.0007 347.0 -22.00 -33.30 to -10.20 
3rd 34.45 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 9. Median percentage of effector memory T cells expressed by CD3+, CD4+ 
and CD8+ T-cells in the PBMCs of ENL cases before, during and after treatment 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
  
Cell type Patients Median 
(%) 
P U  HL 95% Confidence 
interval for HL 
CD3+EM 1st  26.55 < 0.0001 256.0 -11.88 -16.74 to -6.110 
2nd  16.80 
CD3+EM 1st 26.55 
< 0.0001 85.00 -20.00 -23.68 to -16.16 
3rd 7.620 
CD3+EM 2nd 16.80 
< 0.0001 269.0 -8.200 -12.29 to -4.590 
3rd 7.620 
CD4+EM 1st 24.55 
< 0.0001 223.0 -15.54 -20.30 to -9.660 
2nd 11.40 
CD4+EM 1st 24.55 
< 0.0001 190.0 -16.23 -20.50 to -11.80 
3rd 9.570 
CD4+EM 2nd 11.40 
0.5106 566.5 -1.080 -4.840 to 2.400 
3rd 9.570 
CD8+EM 1st 16.50 
0.0024 375.5 -6.610 -10.53 to -2.390 
2nd 7.530 
CD8+EM 1st 16.50 
0.0003 418.0 -7.505 -11.30 to -3.530 
3rd 6.490 
CD8+EM 2nd 7.530 
0.4497 558.0 -0.8900 -3.400 to 1.840 
3rd 6.490 
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Table 10. Median percentage of central memory T cells expressed by CD3+, CD4+ 
and CD8+ T-cells in the PBMCs of ENL cases before, during and after treatment 
Cell type Patients Median 
(%) 
P  U H-L 95% Confidence 
interval for HL 
CD3+CM 1st  13.80 0.0014 362.5 -4.100 -6.610 to -1.400 
2nd  9.770 
CD3+CM 1st 13.80 
0.7347 745.0 0.5400 -3.430 to 4.600 
3rd 13.50 
CD3+CM 2nd 9.770 
0.0129 410.0 4.630 0.9000 to 9.490 
3rd 13.50 
CD4+CM 1st 23.50 
0.0007 347.0 -9.035 -13.30 to -4.130 
2nd 13.65 
CD4+CM 1st 23.50 
0.9281 770.5 -0.3500 -7.900 to 7.900 
3rd 22.00 
CD4+CM 2nd 13.65 
0.0234 428.5 8.600 0.9000 to 17.60 
3rd 22.00 
CD8+CM 1st 1.220 
0.0173 431.0 0.6500 0.1100 to 1.230 
2nd 1.850 
CD8+CM 1st 1.220 < 
0.0001 
374.0 1.320 0.6300 to 2.080 
3rd 2.660 
CD8+CM 2nd 1.850 
0.0980 480.5 0.6500 -0.1100 to 1.580 
3rd 2.660 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 11.  Median percentage of effector T- cells expressed by CD3+, CD4+ and 
CD8+ T-cells in the PBMCs of ENL cases before, during and after treatment 
Cell type Patients Median 
(%) 
P  U H-L 95% Confidence 
interval for HL 
CD3+EC 1st  29.25 0.0037 387.0 11.10 3.000 to 19.10 
2nd  43.35 
CD3+EC 1st 29.25 
0.3862 691.0 -3.165 -9.500 to 4.900 
3rd 24.60 
CD3+EC 2nd 43.35 
0.0024 364.5 -12.80 -22.00 to -4.900 
3rd 24.60 
CD4+EC 1st 14.00 
0.0389 458.0 7.400 0.4800 to 15.80 
2nd 22.90 
CD4+EC 1st 14.00 
0.4716 706.0 -1.625 -6.020 to 2.890 
3rd 12.1 
CD4+EC 2nd 22.90 
0.0200 423.5 -8.185 --16.40 to -0.9800 
3rd 12.1 
CD8+EC 1st 62.65 
0.0267 445.0 445.0 -21.40 to -1.300 
2nd 53.35 
CD8+EC 1st 62.65 
< 0.0001 310.0 -24.20 -33.10 to -15.50 
3rd 38.90 
CD8+EC 2nd 53.35 
0.0223 427.0 -12.40 -22.40 to -1.700 
3rd 38.90 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 12. Median percentage of naïve CD3+, CD4+ and CD8+ T-cells in the PBMCs 
of ENL cases before, during and after treatment 
Cell type Patients Median (%) P  U H-L 95% Confidence 
interval for HL 
CD3+NC 1st  27.70 0.1776 520.5 5.800 -2.470 to 13.30 
2nd  31.80 
CD3+NC 1st 27.70 < 
0.0001 
293.5 19.60 11.30 to 26.19 
3rd 42.90 
CD3+NC 2nd 31.80 
0.0030 370.0 13.60 4.700 to 22.10 
3rd 42.90 
CD4+NC 1st 34.10 
0.0011 357.0 12.10 5.300 to 20.20 
2nd 45.15 
CD4+NC 1st 34.10 
0.0022 472.0 13.80 5.700 to 20.80 
3rd 40.4 
CD4+NC 2nd 45.15 
0.7068 591.0 1.450 -8.700 to 10.50 
3rd 40.40 
CD8+NC 1st 15.35 
0.0003 324.0 17.10 7.900 to 26.30 
2nd 35.45 
CD8+NC 1st 15.35 < 
0.0001 
237.0 30.90 21.20 to 38.40 
3rd 51.50 
CD8+NC 2nd 35.45 
0.0176 419.5 11.10 1.800 to 21.80 
3rd 51.50 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 13. IL-17 Producing cells in the PBMCs of patients with ENL cases before, 
during and after treatment 
Cell type Patients Median 
(%) 
P  U HL 95% Confidence 
interval for HL  
IL-17 producing T 
cells  
1st   23.10  0.0006 
  
 512.5 
  
 -6.800 
  
 -10.50 to -2.700 
  2nd   16.40 
1st 23.10 
< 0.0001 440.5 -9.325 -13.30 to -5.700 
3rd 13.25 
2nd 16.40 
0.0859 669.5 -2.700 -5.900 to 0.4000 
3rd 13.25 
IL-17 producing T 
lymphocytes  
1st 26.45 
< 0.0001 361.0 -9.500 -12.90 to -5.800 
2nd 15.40 
1st 26.45 
< 0.0001 346.5 -11.85 -15.40 to -8.300 
3rd 12.70 
2nd 15.40 
0.1252 689.5 -2.800 -6.100 to 0.8300 
3rd 12.70 
CD4+CD161+ 1st 20.35 
< 0.0001 
395.0 -6.870 -9.730 to -3.640 
2nd 14.40 
1st 20.35 
0.2265 902.5 -1.600 -4.800 to 1.100 
3rd 18.60 
2nd 14.40 
< 0.0001 425.5 5.100 2.640 to 7.540 
3rd  18.60 
 CD8+CD161+ 
 
1st 7.120 
 0.1967  750.0  -1.170   -2.960 to 0.5700 
2nd  6.140 
1st  7.120 
 0.4511  918.0   0.6250   -1.050 to 2.500 
3rd  7.380 
2nd  6.140 
 0.0445  638.0 
 1.860 
  
  0.01000 to 3.680 
3rd  7.380 
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Appendix 7: Tables for B-cell results 
Total 1.  B Lymphocytes (CD19+) and matured B –cells (CD19+CD10-) (ENL vs 
LL) 
Table 2.  Total nave B Lymphocytes (CD19+ CD10-CD27-CD21+) expression 
(ENL vs LL) 
Table 3. Expression of activated memory (AM) B-cells (CD19+CD10-
CD27+CD21-) and tissue like memory (TLM) B –cells (CD19+CD10-CD27-
CD21-) (ENL vs LL) 
Table 4. Total B Lymphocytes (CD19+) and matured B-cells (CD19+CD10-) 
expression (ENL before and after treatment) 
Table 5.  Total nave (NB) B Lymphocytes (CD19+CD10-CD27-CD21+) and 
resting memory (RM) B -cells (CD19+CD10-CD27+CD21+) expression (ENL 
before and after treatment) 
Table 6.  Expression of activated memory (AM) B-cells (CD19+CD10-
CD27+CD21-) and tissue like memory (TLM) B -cells (CD19+CD10-CD27-
CD21-) (ENL before and after treatment) 
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Table 1.  Total B Lymphocytes (CD19+) and matured B –cells (CD19+CD10-) 
production in the PBMCs of ENL cases and LL patient controls before, during and 
after treatment of ENL cases with prednisolone.  
time Cell type  patients  Median 
(%) 
P U LH 95% confidence 
interval  
Before 
Treatment  
CD19+B 
cells  
ENL  9.490  0.3032  198.0  1.845  -2.100 to 6.960 
LL  11.55 
CD19+CD10-
B cells  
ENL  98.00  0.9132  238.0  0.0  -1.300 to 0.6000 
LL  97.25 
During 
Treatment  
CD19+B 
cells  
ENL  9.890  0.4396  53.00  2.820  -3.430 to 6.520 
LL  13.90 
CD19+CD10-
B cells  
ENL 98.95 0.1366  -0.50 -1.700 to 0.2000 
LL 98.00 
After 
Treatment  
CD19+B 
cells  
ENL  5.700  0.0004  96.00  6.020  2.800 to 9.000 
LL  11.95 
CD19+CD10-
B cells  
ENL  97.35  0.5333  215.0  0.200  -0.6000 to 1.200 
LL  98.10 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
Table 2.  Total nave B Lymphocytes (CD19+ CD10-CD27-CD21+) and resting 
memory B –cells (CD19+CD10-CD27+CD21+) expression in the PBMCs of ENL 
cases and LL patient controls before, during and after treatment of ENL cases with 
prednisolone 
time Cell 
type  
patients  Median 
(%) 
P U LH confidence interval  
Before 
Treatment  
NB  ENL  76.00  0.0377  153.5  6.750  0.6000 to 15.30 
LL  84.60 
RM  ENL  5.840  0.3731  204.0  -0.7300  -3.040 to 0.8600 
LL  4.760 
During 
Treatment  
NB ENL  64.65  0.8664  63.00  1.150  -14.80 to 15.60 
LL  64.00 
RM ENL  15.25  0.0316  31.00  -6.950  -16.04 to -0.5000 
LL  8.630 
After 
Treatment  
NB ENL  74.30  0.7759  229.5  -1.150  -10.90 to 8.700 
LL  71.55 
RM ENL  3.720  0.1301  177.0  -1.155  -3.190 to 0.2900 
LL  1.795 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 3. Expression of activated memory (AM) B-cells (CD19+CD10-CD27+CD21-) 
and tissue like memory (TLM) B –cells (CD19+CD10-CD27-CD21-) in the PBMCs 
of ENL cases and LL patient controls before, during and after treatment of ENL 
cases with prednisolone. 
time Cell type  patients  Median 
(%) 
P U LH confidence 
interval  
Before 
Treatment  
AM ENL  2.120  0.3254  200.0  -0.4950  -1.990 to 0.5200 
LL  1.425 
TLM ENL 9.280  0.0246  146.5  -3.725 -8.030 to -0.3100 
LL 4.815 
During 
Treatment  
AM ENL  3.825  0.3429  50.00  0.7900  -1.710 to 3.350 
LL  4.410 
TLM ENL  13.20  0.1326  41.00  6.390  -1.580 to 17.50 
LL  20.00 
After 
Treatment  
AM ENL  2.960  0.9487  239.0  -0.0750  -1.470 to 2.020 
LL  3.005 
TLM ENL  10.00  0.0792  167.0  -2.200  -4.740 to 0.2000 
LL  7.295 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
Table 4. Total B Lymphocytes (CD19+) and matured B-cells (CD19+CD10-) 
production in the PBMCs of ENL cases before, during and after treatment with 
prednisolone. 
Cell type Patients Median 
(%) 
P  U H-L 95% Confidence 
interval for HL 
CD19+ B -cells  1st  9.490 0.7019 149.0 0.4750 -5.440 to 4.800 
2nd  9.890 
CD19+ B- cells 1st 9.490 
0.0231 184.5 -3.925 -7.640 to -0.9300 
3rd 5.700 
CD19+ B-cells 2nd 9.890 
0.0205 68.00 -4.585 -7.820 to -0.5600 
3rd 5.700 
CD19+CD10- 1st 98.00 
0.0066 74.50 1.000 0.4000 to 2.400 
2nd 98.95 
CD19+CD10- 1st 98.00 
0.6791 276.0 0.2000 -1.000 to 1.100 
3rd 97.35 
CD19+CD10- 2nd 98.95 
0.0377 74.50 -0.9500 -2.200 to -0.1000 
3rd 97.35 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Table 5.  Total nave ( NB) B Lymphocytes (CD19+CD10-CD27-CD21+) and resting 
memory (RM)  B -cells (CD19+CD10-CD27+CD21+) expression in the PBMCs of 
ENL cases before, during and after treatment with prednisolone. 
Cell type Patients Median (%) P  U HL 95% Confidence 
interval for HL 
NB Before 76.00 0.0164 84.00 -14.05 -25.10 to -2.500 
During 64.65 
NB Before 76.00 
0.2482 239.0 -5.100 -13.10 to 3.500 
After 74.30 
NB During 64.65 
0.2569 100.0 7.400 -4.700 to 21.40 
After  74.30 
RM Before  5.840 
0.0008 56.50 8.405 3.700 to 15.87 
During  15.25 
RM Before 5.840 
0.0250 186.0 -2.185 -4.140 to -0.3600 
After 3.720 
RM During 15.25 
< 0.0001 56.50 8.405 3.700 to 15.87 
After  3.720 
 P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
Table 6.  Expression of activated memory (AM) B-cells (CD19+CD10-CD27+CD21-) 
and tissue like memory (TLM) B -cells (CD19+CD10-CD27-CD21-) in the PBMCs of 
ENL cases before, during and after treatment with prednisolone. 
Cell type Patients Median (%) P  U HL 95% Confidence 
interval for HL 
AM 1st  2.120 0.4386 136.0 0.7050 -1.190 to 2.630 
2nd  3.825 
AM 1st 2.120 
0.8538 287.5 0.1150 -1.360 to 1.420 
3rd 2.960 
AM 2nd 3.825 
0.3309 104.5 -0.6950 -2.620 to 1.000 
3rd 2.960 
TLM 1st 9.280 
0.1662 116.0 3.900 -2.000 to 7.820 
2nd 13.20 
TLM 1st 9.280 
0.8695 288.5 -0.3000 -4.900 to 2.840 
3rd 10.00 
TLM 2nd 13.20 
0.0283 71.50 -3.840 -8.280 to -0.4000 
3rd 10.00 
P= probability (significant at P≤0.05); U= Mann-Whitney U; H L= Hodges-Lehmann 
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Appendix 8: Cytokine ELISA Standard Curves and Tables  
Table 1.  Comparison of the levels of in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL and LL controls before and 
after treatment  
Table 2.   Comparison of the levels of in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL before and after treatment  
Standard curves  
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Table 1.  Comparison of the levels of in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL and LL controls before and after 
treatment  
* pg/mlL 
  
Time point  Cytokine  group  *mean ± SE  t, df  95% CI P-value 
Before 
treatment  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
TNF-α 
ENL  83.56 ± 18.82  
 t=2.629 df=67 
  -112.8 to -15.44 
 
  
0.0106 
LL  19.42 ± 10.44  
 
  
IFN-γ 
ENL  1361 ± 309.60  t=2.456 df=66 
  
 -1960 to -202.2 
  
0.0167 
LL  280.1 ± 269.80   
  
IL-1β 
ENL  29.07 ± 7.03   t=0.3989 df=75 
  
 -29.71 to 19.80 
  
0.6911 
LL  24.12 ± 10.99   
  
IL-17A 
ENL  51.38 ± 14.26  
t=3.474 df=48 
 -78.44 to -20.93 
  
0.0011 
LL  1.698 ± 1.07  
  
IL-6 
ENL  2194 ± 535.9  
t=3.8531 df=73 
 -778.6 to -23.60 
  
0.0014 
LL  1454 ± 686.7   
  
IL-8 
ENL  30775 ± 3402  
t=2.968 df=70 
 -27713 to -408.7 
  
0.0258 
LL  19463 ± 4714   
  
IL-10 
ENL  18.59 ± 4.054  
t=5.277 df=67 
 64.67 to 143.4 
  
< 0.0001 
LL  122.6 ± 23.18  
 
During 
treatment  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
TNF-α 
ENL  10.74 ± 2.786  
t=1.621 df=62 
 -6.100 to 58.43 
  
0.1101 
LL  36.91 ± 17.44   
  
IFN-γ 
ENL  340.4 ± 119.6  
t=2.720 df=62 
 132.6 to 1767 
  
0.00904 
LL  1158 ± 549.2   
  
IL-1β 
ENL  11.30 ± 3.736  
t=0.6762 df=62 
 -15.88 to 7.850 
  
0.5014 
LL  7.287 ± 4.714   
  
IL-17A 
ENL  7.119 ± 3.206  
t=0.4886 df=47 
 -15.18 to 24.91 
  
0.6274 
LL  11.99 ± 9.609   
  
IL-6 
ENL  1219 ± 376.2  t=0.06602 
df=63 
 -1234 to 1155 
  
0.9476 
LL  1179 ± 474.7   
  
IL-8 
ENL  31271 ± 3315.0  
t=2.373 df=63 
 -22481 to -1929 
  
0.0207 
LL  19066 ± 3969.0  
  
IL-10 
ENL  13.03 ± 2.55  
 t=0.3470 df=62 
  -7.199 to 10.22 
 
  
0.7298 
LL  14.55 ± 3.737 
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Time point  Cytokine  group  *mean ± SE             95% CI P-value 
After 
treatment  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
TNF-α 
ENL  25.37 ± 8.88 
 t=0.4275 df=48 
  
 -38.72 to 
25.15 
  
0.6710 
LL  18.58 ± 13.17  
 
  
IFN-γ 
ENL  328.2 ± 190.30 
 t=0.8521 df=55 
  
 -441.3 to 
1094 
  
0.3979 
LL  654.6 ± 336.40 
 
  
IL-1β 
ENL  9.598 ± 2.30  
 t=2.112 df=54 
  
 3.140 to 
120.5 
  
0.0393 
LL  71.42 ± 30.25  
 
  
IL-17A 
ENL  17.64 ± 7.96  
 t=2.098 df=48 
  
 -31.09 to -
1.568 
  
0.0377 
LL  2.876 ± 1.63  
 
  
IL-6 
ENL  1567 ± 524.00  
 t=0.1636 df=54 
  
 -1568 to 
1846 
  
0.8707 
LL  1706 ± 679.80  
 
  
IL-8 
ENL  28864 ± 3987.00  
 t=2.933 df=53 
  
 -21490 to -
395.7 
  
0.0362 
LL  18317 ± 3711.00 
 
 IL-10 
ENL  87.78 ± 22.49  
 t=3.539 df=54 
  
 -129.8 to -
35.93 
  
0.0008 
 4.908 ± 2.160  
 
  * pg/mlL 
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Table 2.   Comparison of the levels of in vitro cytokine production in culture 
supernatants of PBMCs from patients with ENL before and after treatment  
 
Cytokine  Time point *mean ± SE t, df  95% CI P-value 
TNF-α 
  
  
  
  
  
Before treatment   83.56 ± 18.82  
t=3.924 df=34 
 -130.4 to -41.42 
  
0.0004 
During Treatment   10.74 ± 2.79  
Before treatment   83.56 ± 18.82  
t=3.397 df=24 
 -155.4 to -37.93 
  
0.0024 
After treatment  25.37 ± 8.88  
During Treatment   10.74 ± 2.79 
t=1.805 df=24 
 -1.933 to 28.94 
  
0.0836 
After treatment  25.37 ± 8.88  
IFN-γ 
  
  
  
  
  
Before treatment   1361 ± 309.6   t=2.957 df=37 
  
 -1846 to -344.8 
  
0.0054 
During Treatment   340.4 ± 119.6   
Before treatment   1361 ± 309.6   t=3.027 df=28 
  
 -2424 to -467.5 
  
0.0053 
After treatment  328.2 ± 190.3   
During Treatment   340.4 ± 119.6  t=0.3971 df=28 
  
 -638.2 to 430.9 
  
0.6943 
After treatment  328.2 ± 190.3  
IL-1β 
  
  
  
  
  
Before treatment   29.07 ± 7.026   t=2.164 df=35 
  
 -40.90 to -1.304 
  
0.0374 
During Treatment   11.30 ± 3.736   
Before treatment   29.07 ± 7.026   t=2.406 df=28 
  
 -42.92 to -3.450 
  
0.0230 
After treatment  9.598 ± 2.301   
During Treatment   11.30 ± 3.736  t=0.5001 df=27 
  
 -12.60 to 7.660 
  
0.6211 
After treatment  9.598 ± 2.301  
IL-17A 
  
  
  
  
  
Before treatment   51.38 ± 14.26   t=3.290 df=24 
  
 -72.04 to -16.49 
  
0.0031 
During Treatment   7.119 ± 3.206   
Before treatment   51.38 ± 14.26  t=2.400 df=24 
  
 -62.76 to -4.732 
  
0.0245 
After treatment  17.64 ± 7.956   
During Treatment   7.119 ± 3.206  t=1.226 df=24 
  
 -7.193 to 28.23 
  
0.2322 
After treatment  17.64 ± 7.956  
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Cytokine  Time point  *mean ± SE t, df   95% CI P-value 
IL-6 
  
  
  
  
  
Before treatment   2194 ± 535.9  t=1.637 df=36   
  
 -2733 to 291.3 
  
0.1103 
During Treatment   1219 ± 376.2    
Before treatment   2194 ± 535.9 t=1.115 df=28   
  
 -3008 to 887.6 
  
0.2743 
After treatment  1567 ± 524.0    
During Treatment   1219 ± 376.2 t=0.2519 df=28 
  -1399 to 1791 
0.8029 
After treatment  1567 ± 524.0   
IL-8  
  
  
  
  
Before treatment   30775 ± 3402  t=0.2348 df=36   
  
 -8916 to 11251 
  
0.8157 
During Treatment   31271 ± 3315    
Before treatment   30775 ± 3402 t=0.7162 df=27   
  
 -19591 to 9454 
  
0.4800 
After treatment  28864 ± 3987    
During Treatment   31271 ± 3315 t=0.8823 df=27   
  
 -14416 to 5746 
  
0.3854 
After treatment  28864 ± 3987   
IL-10 
  
  
  
  
  
Before treatment   18.59 ± 4.054  t=1.591 df=36   
  
 -16.67 to 2.013 
  
0.1204 
During Treatment   13.03 ± 2.545    
Before treatment   18.59 ± 4.054 t=2.528 df=28   
  
 11.79 to 112.6 
  
0.0174 
After treatment  87.78 ± 22.49    
During Treatment   13.03 ± 2.545 t=3.244 df=28   
  
 27.54 to 121.9 
  
0.0030 
After treatment  87.78 ± 22.49    
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ELISA standard curves 
 
 
 
  
 
 
 
 
  
IL-1β 
TNF-α 
IFN-γ 
IL-7A 
IL-8 IL-10 
455 
 
 
ROC for individual cytokines  
  
 AUC=0.540 
 IFN-γ 
 AUC=0.785 
 TNF-α 
 AUC=0.703 
 IL-1β 
 
AUC=0.758 
 IL-6 
 AUC=0.665 
 IL-8 
 AUC=0.745 
 IL-17A 
 
AUC=0.290 
 IL-10 
 AUC=0.710 
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Appendix 9:  Circulating C1q ELISA Tables  
Table 1. Comparison of circulating plasma C1q in patients with ENL and LL 
controls  
Table 2. Comparison of circulating plasma C1q in patients with ENL before and after 
treatment  
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Table 1. Comparison of circulating plasma C1q in patients with ENL and LL 
controls  
Time point  Group Mean ± SE  (pg/mL) t, df  95% CI P  
Before  
treatment  
  
ENL  11698 ± 618.3   t=4.201 
df=59 
  
 4902 to 13822 
  < 0.0001  LL   21059 ± 2382 
After 
treatment  
  
ENL  22287 ± 2154   t=0.4900 
df=60 
  
 -4421 to 7290 
  
 0.6259 
  LL   23721 ± 1886  
Before 
treatment  
ENL  11698 ± 618.3 t=2.255 
df=39 439.5 to 8090 0.0298 HC  15962 ± 3011  
 
LL 21059 ± 2382 t=1.029 
df=32 -15184 to 4990 0.3110 HC  15962 ± 3011 
 
 
Table 2. Comparison of circulating plasma C1q in patients with ENL before and after 
treatment  
Time point  Mean ± SE  (pg/mL) t, df  95% CI P  
ENL 1st  11698 ± 618.3  t=5.071 
df=33 6341 to 14838 < 0.0001 ENL 3nd  22287 ± 2154  
LL 1st  21059 ± 2382 N=27 t=0.6881 
df=26  0.4975 LL 3rd   23721 ± 1886  
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Table 8.1.  Plasma anti PGL-1, LAM and Ag85 titres of patients with ENL and LL 
controls before and after treatment  
          ENL versus LL 
Antibody  time point  Pt Mean ± SE t, df 95% CI P-value 
PGL-1 
  
Before  
ENL 1.430 ± 0.1281  t=0.4653 
df=50 -0.4711 to 0.2939 
 0.6437 
  LL 1.341 ± 0.1415 
After 
ENL 1.183 ± 0.1333  t=5.268 
df=49 0.5617 to 1.255 < 0.0001 LL 2.091 ± 0.1081  
Ag85 
  
before  
ENL  1.154 ± 0.1218   t=0.1136 
df=50 
  
 -0.3864 to 0.3450 
  
 0.9100 
  LL  1.134 ± 0.1360  
after 
ENL 0.9713 ± 0.1164  t=3.508 
df=49 0.2411 to 0.8880 0.0010 LL 1.536 ± 0.1108  
LAM 
  
before  
ENL 1.191 ± 0.09790  t=0.4876 
df=50 
  
-0.3811 to 0.2322 
  
 0.6280 
  LL 1.116 ± 0.1183  
after 
ENL 1.095 ± 0.08101  t=4.258 
df=49 0.2627 to 0.7323 < 0.0001 LL 1.592 ± 0.08426  
ENL before and after treatment  
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Appendix 10:  Conferences and publication  
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World Immune Regulation Meeting (WIRM)  
    March 16-19, 2016, Davos Switzerland 
 
Titles of the abstracts   
i. T-cell regulation in Erythema Nodosum Leprosy 
Edessa Negera1,2, Anastasia Polycarpou1, Kidist  Bobosha2, Steven Walker1, Yonas 
Bekele2, Birtukam Endale2, Munir Hussien2, Rawleigh Howe2, Abraham Aseffa2, 
Hazel M. Dockrell1, Diana Lockwood1  
1 London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, 
UK ; 2 Armauer Hansen Research Institute (AHRI), Jimma Road, P. O. Box. 1005, Addis Ababa, 
Ethiopia 
 
ii. Memory T-cells and Lipid profiles of leprosy Spectrum  
Edessa Negera1,2, Anastasia Polycarpou1, Kidist  Bobosha2, Steven Walker1, 
Yonas Bekele2, Birtukam Endale2, Munir Hussien2, Rawleigh Howe2, Abraham 
Aseffa2, Hazell M. Docrell1, Diana Lockwood1  
 
1 London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, 
London, UK ; 2 Armauer Hansen Research Institute (AHRI), Jimma Road, P. O. Box. 1005, 
Addis Ababa, Ethiopia 
 
Accepted abstracts: International Leprosy congress, Beijing China 
                                      September 16-21, 2016  
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i.   A Case-control Study Investigating T-cell Regulation in Erythema Nodosum 
Leprosum  
Edessa Negera1,2, Anastasia Polycarpou1, Kidist  Bobosha2, Steven Walker1, Yonas 
Bekele2, Birtukam Endale2, Munir Hussien2, Rawleigh Howe2, Abraham Aseffa2, 
Hazell M. Docrell1, Diana Lockwood1  
1 London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, 
UK ; 2 Armauer Hansen Research Institute (AHRI), Jimma Road, P. O. Box. 1005, Addis Ababa, 
Ethiopia  
Abstract  
Background: Erythema Nodosum Leprosum (ENL) is an immune-mediated 
inflammatory complication which causes high morbidity in affected leprosy patients.  
Objective:  This study investigated the immune regulation in patients with Erythema 
Nodosum Leprosum 
Methods: A follow-up nested case-control study design was used to recruit a 46 
untreated patients with ENL reactions and 31 non-reactional lepromatous leprosy (LL) 
patient controls at ALERT hospital, Ethiopia. Blood samples were obtained before, 
during and after treatment. Peripheral blood mononuclear cells (PBMCs) were isolated 
and used for immunophenotyping of regulatory T-cells by flow cytometry.  Five 
markers were used to define CD4+ and CD8+ regulatory T-cells. The gene expression 
for FoxP3 in blood and tissue samples was used to supplement the flow cytometry 
data. Clinical and histopathological data were also obtained for each patient.  All 
patients were followed for 28 weeks.  
Results:  Patients with ENL reactions had significantly lower (1.67%) CD4+ 
regulatory T-cells than LL patient controls (3.79%) before treatment. After treatment, 
CD4+Tregulatory T-cells in the two groups were not significantly different. CD8+ 
regulatory T-cells in both groups before and after treatment were not significantly 
deferent. Patients with ENL reactions had higher CD4+ Tells and CD4+/CD8+ T-cells 
ratio than lepromatous leprosy patient controls before treatment.  The CD25 
expression on CD4+ and CD8+ T-cells were not significantly different between the two 
groups suggesting that CD25 expression is not associated with ENL reactions while 
FoxP3 expression on CD4+ T-cells was found to be associated with the reaction. The 
mRNA expression in blood and tissue samples for FOXP3 was significantly lower in 
patients with ENL reaction than in LL patient controls before treatment. After 
prednisolone treatment, the mRNA expression for FOXP3 in the blood samples from 
patients with ENL reaction did not show significant change while it is significantly 
increased in skin biopsy samples. It is possible that there is local immune regulation at 
the site of reactional lesions in these patients.  We found that corticosteroid treatment 
of patients with ENL reactions is associated with suppression of CD4+ T-cells but not 
CD8+ T-cells.  
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Conclusions: Our findings suggest that Erythema Nodosum Leprosum reaction is 
associated with reduced regulatory T-cells and increased CD4+/CD8+ T-cells ratio and 
this immune imbalance could lead to the initiation of ENL reaction in patients with 
leprosy. 
 
ii.  New Insight into the Pathogenesis of Erythema Nodosum Leprosum: Is there 
a Role of Activated Memory T-cells?  
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Background: Memory T-cells, particularly, effector memory T-cells are implicated in 
the pathogenesis of inflammatory diseases and may contribute to tissue injury and 
disease progression. Although Erythema Nodosum Leprosum (ENL) is an 
inflammatory complication, of leprosy, the role of memory T-cell subsets has never 
been studied in this patient group.  
Objective: This study investigated the kinetics of memory T-cell subsets in patients 
with ENL before and after corticosteroid treatment.  
Methods:  A case -control study design was used and a total of 35 untreated patients 
with ENL reactions and 25 non-reactional LL patient controls were recruited at 
ALERT hospital, Ethiopia. Venous blood samples were obtained before, during and 
after treatment from each patient. Peripheral blood mononuclear cells (PBMCs) were 
isolated and used for immunophenotyping of T-cell activation and memory T-cell 
subsets by flow cytometry. The kinetics of these immune cells in patients with ENL 
reactions before and after treatment were compared  with lepromatous leprosy control 
patients (LL) as well as within patients with ENL cases  at different time points.  
Results: The median percentage of CD3+, CD4+ and CD8+ T-cells expressing 
activated T-cells were significantly higher in the PBMCs from patients with ENL than 
from LL controls before treatment.  The median percentage of central and activated 
memory T-cells were significantly increased in patients with ENL reaction compared 
to LL patient controls before treatment. Interestingly, patients with ENL reactions had 
a lower percentage of naïve T-cells (28.0%) compared to LL patient controls (60.0%), 
however, after corticosteroid treatment, patients with ENL cases had a higher median 
percentage of naïve T-cells (43.0%)  than LL patient controls (33.0%). The median 
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percentage of activated T-cells (effector memory T-cells and terminally differentiated 
T-cells) were significantly increased in patients with ENL reactions (59.2%) before 
treatment compared to after treatment (33.9%).   
Conclusions: This is the first work which has shown T-cell activation and the different 
subsets of memory T-cells in untreated patients with ENL reactions. Consequently, 
this study delineates the role of T-cell activation in the pathogenesis of ENL reaction 
and challenges the long-standing dogma of immune-complex as a sole etiology of ENL 
reaction.  
iii.  Patterns of Cytokine Expression in the Blood and Skin Tissue samples 
from Patients with Erythema Nodosum Leprosum: The influence of 
Prednisolone Treatment  
Edessa Negera1,2, Anastasia Polycarpou1, Kidist  Bobosha2, Steven Walker1, Yonas 
Bekele2, Birtukam Endale2, Munir Hussien2, Rawleigh Howe2, Abraham Aseffa2, 
Hazel M. Dockrell1, Diana Lockwood1  
1 London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, 
UK ; 2 Armauer Hansen Research Institute (AHRI), Jimma Road, P. O. Box. 1005, Addis Ababa, 
Ethiopia  
Background: Erythema nodosum leprosum (ENL) is a systemic inflammatory 
complication occurring mainly in patients with lepromatous leprosy (LL) and 
borderline lepromatous (BL) leprosy. Prednisolone is used for the treatment of patients 
with ENL, although it is not efficacious in preventing reoccurrences.  This is the first 
study with good experimental design examining the effect of prednisolone on the 
kinetics of inflammatory cytokines in patients with ENL reactions. 
Objective: This study described the kinetics of pro/inflammatory and regulatory 
cytokines production and gene expression in patients with ENL reactions before and 
after prednisolone treatment. 
 Methods: A follow-up nested case-control study design was used to recruit 46 
untreated patients with ENL reactions and 31 non-reactional LL patient controls at 
ALERT hospital, Ethiopia. Blood and skin biopsy samples were obtained from each 
patient before and after treatment. To investigate the in vitro cytokine response to 
M.leprae, PBMCs from patients with ENL and LL controls were cultured with 
M.leprae whole-cell sonicates (MLWCS) in the presence of Phytohaemagglutinin 
(PHA) or left unstimulated for 6 days. The supernatants were collected and used for 
the Enzyme-linked immuno-absorbent assay (ELISA). To investigate the cytokine 
gene expression, mRNA was isolated from whole blood and skin biopsies and then 
reverse transcribed into cDNA. The mRNA copy numbers were quantified on the Light 
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Cycler using real-time PCR assays specific to TNF-α, IFN-γ, IL-β, TGF-β, IL-17A, 
IL-6, IL-8, IL-10 and HUPO. 
Results: The in vitro production of the cytokines: TNF-α, IFN-γ, IL-1β and IL-17A 
were significantly increased in untreated patients with ENL reactions before treatment. 
However, IL-10 production was significantly lower in untreated patients and 
significantly increased after treatment. The in vitro production of IL-6 and IL-8 in 
patients with ENL reactions did not show statistically significant difference before and 
after prednisolone treatment. The mRNA expression in blood and skin biopsy samples 
for TNF-α, IFN-γ, IL-1β, IL-6 and IL-17A significantly decreased in patients with 
ENL reactions after treatment. IL-10 mRNA gene expression was significantly 
increased both in blood and tissue samples after treatment.    
Conclusions: Our findings suggest that prednisolone modulates the pro/inflammatory 
cytokines studied here either directly or through suppressing the immune cells 
producing these inflammatory cytokines which need further confirmation.   
iv.  Clinico-Pathological Features of Erythema Nodosum Leprosum: A case-
control Study at ALERT Hospital, Ethiopia.  
Edessa Negera1,2, Anastasia Polycarpou1, Kidist  Bobosha2, Steven Walker1, Yonas 
Bekele2, Birtukam Endale2, Munir Hussien2, Rawleigh Howe2, Abraham Aseffa2, 
Hazel M. Dockrell1, Diana Lockwood1  
1 London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, 
UK ; 2 Armauer Hansen Research Institute (AHRI), Jimma Road, P. O. Box. 1005, Addis Ababa, 
Ethiopia  
Background: Leprosy reactions are a significant cause of morbidity. Erythema 
nodosum leprosum (ENL) is an immunological complication affecting approximately 
50% of patients with lepromatous leprosy (LL) and 10% of borderline lepromatous 
(BL) leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye 
inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of ENL 
requires immunosuppression, which is often required for prolonged periods of time 
and may lead to serious adverse effects.  
Objective:  We described the clinico-pathological features of patients with ENL 
before and after prednisolone treatment   
Materials and methods:  A case–controls study was performed at ALERT hospital, 
Ethiopia.  Forty-six patients with ENL and 30 LL controls were enrolled to the study 
and followed for 28 weeks. Clinical futures were systematically documented at each 
time point on specifically prepared forms. Blood and skin biopsy samples were 
obtained from each patient. Laboratory and histopathological investigations were used 
to supplement the clinical data  
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Results: Pain was the commonest symptoms reported (98%) by patients with ENL. 
About 80% of them had reported skin pain and more than 70% had a nerve and joint 
pains during enrolment. About 40% of these patients developed chronic ENL. The 
morphology of cutaneous lesions showed that 95.7% individuals had nodular lesions. 
More than half (52.2%) of patients with ENL had old nerve function impairment (NFI) 
while 13% had new NFI at the time of enrolment. Facial and limb oedema were the 
most reported organs involved in ENL reactions.  Before treatment dermal neutrophil 
infiltration was diagnosed in 58.8% of patients with ENL compared to 14.3% in LL 
controls. Only 14.7% of patients showed evidence of vasculitis.  
Conclusion: The most frequent site of pain due to ENL in our study was the skin 
which is explained by the fact that 95% of patients with ENL cases had skin lesions. 
More diverse cutaneous manifestations of ENL are documented in this study than 
usually used in case definition. Whenever present, flat granular polymorphonuclear 
cells infiltration with perivascular lymphocyte infiltration were diagnosed as defining 
features of ENL lesions.  The finding of chronic ENL in 40% of patients with ENL 
underline that these patients require corticosteroid treatment for extended periods. This 
implies that chronic ENL continue to be a burden for the health intuitions. Households 
affected by chronic ENL face significant economic burden and at risk of being pushed 
further into poverty.  
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Performance of general health workers in leprosy control activities at public health facilities in 
Amhara and Oromia States, Ethiopia 
Tadiye Abeje1, Edessa Negera1*, Eshetu Kebede2, Tsegaye Hailu1, Ismaile Hassen3, Tsehainesh Lema1, 
Lawrence Yamuah1, Birru Shiguti4, Melkamu Fenta5, Megersa Negasa3, Demissew Beyene1, Kidist Bobosha1 
and Abraham Aseffa1   
Abstract 
Background: Leprosy is a chronic infectious disease of public health importance and one of the leading causes of 
permanent physical disability. Nevertheless, the drop in prevalence following multidrug therapy has resulted in 
the neglect of leprosy. The annual incidence of leprosy has remained the same in Ethiopia since decades with 
more than 76 % of the reported new cases coming from Oromia and Amhara Regional States. This study was 
aimed to assess the knowledge, attitude and skill of general health workers in leprosy control activities at public 
health facilities in Oromia and Amhara Regional States. 
Methods: A cross-sectional study was conducted from September 2011 to February 2012 at different public 
health facilities in selected eight zones in Oromia and Amhara Regional States. A multistage sampling method was 
used to obtain representative samples. High and low endemic zones for leprosy were included in the study in 
both regional states. Data were collected from general health workers through a structured self-administered 
questionnaire and at on-site assessment of their performance. Baseline socio-demographic data, health workers’ 
attitude towards leprosy and their knowledge and skill in the management of leprosy were assessed. Bloom’s cut 
off point was used to describe the knowledge and practical skills of the respondents while Likert’s scale was used 
for attitude assessment. 
Result: A total of 601 general health workers responsible for leprosy control activities at public health facilities 
were included in knowledge and attitude assessment and 83 of them were subjected to practical evaluation, 
with on-site observation of how they handle leprosy patients. These included medical doctors (4 %), health 
officers and nurses with Bachelor degree in Science (27 %), clinical nurses with diploma (66 %) and health 
assistants (2.8 %). The median age of the respondents was 26.0 years and females made up of 45 %. Generally 
the knowledge and skills of the respondents were found to be poor while attitude towards leprosy was positive 
for the majority of the respondents. The result showed that 519 (86.3 %) had poor knowledge. Overall 155 
(25.8 %) of the respondents had positive attitude towards leprosy while 205 (34.1 %) had intermediate (mixed) 
attitude and 241 (40.1 %) had negative attitude to the disease. Among 83 respondents assessed for diagnosis 
of leprosy only 15(18.0 %) diagnosed leprosy correctly. Variation in knowledge and attitude indicated a 
significant difference (p < 0.05) among different health institutions, professions, gender, in-service training and 
years of experience.  
Conclusion: The current finding underlines that although leprosy control activities are integrated to the general 
health services in the country, the knowledge and skills of leprosy diagnosis, treatment and management by 
health workers was unsatisfactory. Hence, attention should be given to develop training strategies that can 
improve health worker knowledge and promote better leprosy management at public health facilities. This 
could be achieved through preservice and in-service training and giving adequate emphasis to leprosy related 
practical work and continuous follow-up.  
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